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Abstract 
Background: Schizophrenia is a pervasive and often debilitating disorder, 
although vulnerability is not easily assessed.  Cannabis has a positive relationship 
with schizophrenia. To date, it is unknown whether or not this is a causal 
relationship. Nonetheless, those with vulnerability to psychosis have displayed a 
differential sensitivity to cannabis.  
Aims: There were two main aims to this programme of research: 1) Contribute to 
discussions relating to ‘causal inference’ in the relationship between cannabis and 
psychosis. 2) Assess the reliability and validity of the Cannabis Experiences 
Questionnaire (CEQ) as a measure of psychotic vulnerability based on a 
differential sensitivity to cannabis.  
Methods: Two studies were conducted. The first was a Cross-sectional 
investigation in which two groups of cannabis users were recruited, participants 
with self-reported depression (n = 85) and participants with self-reported psychotic 
disorder (n = 48). This investigation also considered data from a community 
sample recruited as part of other research studies. These consisted of cannabis 
users (n = 861) and non-users (n = 306). These groups were compared on 
measures of schizotypy and cannabis induced experience.  
The second study was an experience sampling investigation, in which regular 
cannabis users (n = 36), submitted 7 responses per day via a mobilephone, for a 
period of 14 days.  Participants completed measures of: psychotic-like states, 
stressed states, calm states, drug consumption, stressful and pleasurable events, 
and aversive cannabis induced experience.  
Results: Cross-sectional investigation: There was no significant difference 
between cannabis users with reported depression and reported psychotic disorder 
in the disorganised or interpersonal domains of schizotypy. The cannabis-using 
groups of participants displayed a differential sensitivity to cannabis, with those 
who reported psychotic illness having significantly more aversive cannabis 
experiences than the community sample (U = 15106.5, z = 3.142, p = .002, r = 
0.10) and participants with reported depression (U = 1241.0, z = 3.746, p < .001, r 
= 0.32) . The most effective means of identifying psychotic vulnerability consisted 
of a two-step process, firstly utilising assessments of schizotypy and secondly 
assessments of aversive cannabis induced experience. 
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Experience sampling investigation: In a dose dependent fashion cannabis 
predicted increases in interpersonal (b = 0.24 95% CI 0.07 to 0.42, p = .006) and 
disorganised psychotic like experience (PLE) (b = 0.16 95% CI 0.04 to 0.27, p = 
.006). However, disorganised PLE significantly increased the odds of cannabis 
consumption (OR = 1.245 95% CI 1.045 to 1.247, p = .003).  Cannabis positively 
and significantly predicted ‘calm’ states in a dose dependent fashion (b = 0.23 
95% CI 0.07 to 0.39, p = .006). Cannabis and stressed states interacted to 
significantly predict PLEs (b = 0.33, 95% CI 0.17 to 0.49, p < .001). Aversive 
cannabis induced experience significantly predicted PLEs both within (b = 0.22, 
95% CI 0.10 to 0.33, p < .001) and between participants (b = 0.66, 95% CI 0.06 to 
1.27, p = .033). Previously documented aversive cannabis experiences 
significantly predicted propensity to experience stressed states (b  = 0.15, 95% CI 
0.05 to 0.24, p= .002). 
Conclusion: Aim 1): Within a continuum model of psychosis the results of these 
studies support three mechanisms of a cannabis-schizophrenia interaction; 
cannabis use causes schizophrenia; schizophrenia causes cannabis use; 
schizophrenia and cannabis use maintain one another. There is evidence to 
suggest psycho-social stressors interact with cannabis to induce PLEs. This may 
indicate that cannabis causes schizophrenia via a cross-sensitisation mechanism. 
At-risk groups should be warned against using cannabis as a stress coping 
mechanism. 
 Aim 2): These results confirm a differential sensitivity to cannabis in those 
vulnerable to psychotic disorder. This investigation has demonstrated that 
psychosis vulnerability can be assessed by aversive cannabis induced experience. 
This investigation has demonstrated concurrent, convergent, and predictive 
validity of the CEQ as an assessment of psychotic vulnerability. This scale could 
be useful for drug education programmes and risk assessment in recreational 
cannabis users; screening for medicinal cannabis prescription; screening for 
research trials with cannabinoids or other known psychotomimetics; and in the 
allocation of psychological intervention for cannabis dependence, and (possibly) 
stress-reduction in those with disorder or at ultra-high risk. 
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1. Background 
1.1 Introduction 
This chapter will serve to contextualise the rest of this body of work within the 
relevant literature. This investigation examines the relationship between cannabis 
and psychotic disorder, in addition to contributing to the development of a measure 
of psychotic vulnerability in cannabis users. In contextualising this research it is 
necessary to consider literature from distinct domains (e.g. scale development and 
schizophrenia). Nonetheless, this literature is pertinent in the interpretation of this 
thesis. 
 
Section 1.2.1 describes schizophrenia and some of the related psychotic 
disorders. Section 1.2.2 focuses on the schizophrenia spectrum disorder, 
schizotypal personality disorder and the non-pathological personality trait, 
schizotypy. Contained within section 1.2.2 is a sub-section which discusses the 
notion that there are time variant aspects to the purported stable personality trait of 
schizotypy. Section 1.2.3 is pertaining to assessments of vulnerability to 
schizophrenia this is separated into four subsections: environmental factors that 
increase the odds of diagnosis, genetic factors, biological markers, and 
psychological measures. 
 
One of the principal aims of this thesis is to further the development of a measure. 
Thus, to contextualise this development process, contained within Section 1.3 is 
information pertaining to the development of a measurement scale. Section 1.3.1 
contains information regarding item generation. Section 1.3.2 discusses the 
literature regarding the testing of the psychometric properties of a measure 
including reliability, validity, and factorial structure. 
 
Section 1.4 discusses the psychotomimetic and purported psychotogenic drug 
cannabis. This section provides insight into the psychological consequence of the 
pharmacology of an illicit, non-homogenous substance. Section 1.5 provides 
information about a, cannabis induced illness, which is highly related to 
schizophrenia: cannabis-induced psychotic disorder.  The relationship between 
cannabis and schizophrenia is examined in section 1.6. Contained within this 
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section are four subsections pertaining to causality between cannabis and 
psychotic disorder. Section 1.6.1 considers literature relating to cannabis use as a 
consequence of schizophrenia. In this section evidence pertaining to the ‘self-
medication hypothesis’ is considered. Section 1.6.2 considers a 3rd (common) 
factor underpinning the relationship between cannabis and schizophrenia. Section 
1.6.3 examines the evidence that both schizophrenia and cannabis interact and 
maintain one another. Section 1.6.4 assesses cannabis as an independent causal 
factor in the development of schizophrenia.  
 
Section 1.7 builds on Section 1.6.4 to explore ‘plausible’ mechanisms by which 
cannabis may cause schizophrenia. Contained within this section is an 
examination of the data pertaining to whether the drug has a dopaminergic effect 
(Section 1.7.1). Section 1.7.2 discusses the plausibility of a gene by cannabis 
interaction effect. Section 1.7.3 examines the plausibility of cannabis sensitising to 
psychotic symptoms. Section 1.7.4 examines the literature regarding cannabis and 
stress interacting to cause psychotic disorder. Section 1.8 discusses the 
relationship between cannabis, schizotypal state, and schizotypal trait. 
 
Section 1.9 serves to remind the reader of the literature contained within this 
chapter. This section also highlights the aims of this thesis and earmarks the 
subsequent sections of this thesis which serve to address these aims. 
Nonetheless, subsumed within chapters two, three, and, four are distinct aims 
related to that specific chapter. 
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1.2 Schizophrenia spectrum disorders, and schizotypal personality 
1.2.1Schizophrenia spectrum disorders descriptive features 
There are two systems of classification typically used within psychiatry one 
published by the American Psychiatric Association (APA), the Diagnostic and 
Statistical Manuals (DSM) and one published by the World Health Organisation 
(WHO) the International Classification of Diseases (ICD). At the time of writing the 
11th revision of the ICD is in a beta draft, with the last corrected update (10th 
revision) published in an online version in 2010. However, the long awaited fifth 
update of the DSM has recently been published. Due to the consistent advances 
in schizophrenia research, this thesis will primarily refer to the most recent 
diagnostic text, DSM 5 (APA, 2013a). 
 
Schizophrenia is a chronic psychological disorder that is associated with deficits in 
cognitive, social and occupational function. Schizophrenia is characterised by 
abnormalities in two (or more) of the following five domains: delusions, 
hallucinations, disorganised speech, grossly disorganised or catatonic behaviour, 
and negative symptoms (APA, 2013a, p.99). The symptoms of schizophrenia have 
been considered to disaggregate into two clusters ‘positive’ and ‘negative’ 
symptoms (APA, 2000, p.299). “The positive symptoms appear to reflect an 
excess or distortion of normal functions, whereas the negative symptoms appear 
to reflect a diminution or loss of normal functions” (APA, 2000, p.299). The 
negative symptoms include features such as affective flattening, alogia, and 
avolition.  The positive symptoms are considered to disaggregate into two further 
sub-categories: The “psychotic dimension” includes delusions and hallucinations, 
whereas the “disorganization dimension” includes disorganised speech and 
behaviour (APA, 2000, p.299).   
 
The incidence rate of schizophrenia in women is slightly lower and typically 
characterised by a later onset, than it is in men (APA, 2013a, p.102). Onset of first 
psychotic episode is typically “in the early- to mid-20s for males and in the late-20s 
for females” (APA, 2013a, p.103). Schizophrenia tends to be a chronic disorder, 
with only about 20% of people with schizophrenia having a “favourable outcome” 
and only a few of those are thought to return to pre-morbid level of function (APA, 
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2013a, p.102).  The presence of negative symptoms typically indicates a worse 
prognosis, these symptoms are often more persistent than positive ones (APA, 
2013a, p.102). About 20% of people suffering with schizophrenia have one or 
more suicide attempt, and unfortunately 5-6% of people suffering with 
schizophrenia die by suicide (APA, 2013a, p.104). 
 
Numerous different aetiologies have been proposed to explain the mechanism by 
which someone may decompensate into schizophrenia.  These various theories 
have their grounding in the psychodynamic (e.g. Fromm-Reichmann, 1948), 
behavioural (Ullman & Krasner, 1975), and cognitive models (Frith, 1992). 
Nonetheless, any adequate theory of the causes of schizophrenia must be able to 
explain the more recent wealth of data indicating that it is a heritable disorder (See 
Sullivan, 2005). The data indicate that there is plausibly a biological basis to 
schizophrenia. Further, evidence to this effect can be derived from data indicating 
that people suffering with schizophrenia display neuroanatomical abnormalities, 
specifically cortical atrophy (ventricular enlargement) (Glahn, et al.,2008). Further 
evidence for the biological basis of schizophrenia can be derived from data 
implicating psychopharmacological dysfunction. Dysfunction centralising around 
the neurotransmitter dopamine (DA) has been consistently implicated in 
schizophrenia (spectrum disorder) research.  Stemming from the observations that 
antihistamines served to calm pre-operative patients (Delay & Deniker, 1952) a 
related compound was developed, which is now commonly referred to as typical 
antipsychotics. Moreover, compounds that elicit dopamine release have been 
shown to induce psychotic like states similar to schizophrenia (Ellinwood, 1967). It 
is now known that any antipsychotic which is efficacious in treating positive 
symptoms serve to have an antagonistic effect on D2 receptors (Sanger, 2004).  
 
Dysfunction in DA activity is thought to be related to disruption to both the 
‘mesolimbic’ and the ‘mesocortical’ pathways. The mesolimbic pathway projects 
from the Ventral Tegmental Area (VTA) to the ventral striatum and the 
mesocortical pathway projects from the VTA to the frontal cortex. These have 
been referred to as the subcortical and cortical pathways respectively (Kuepper et 
al., 2010). It is thought that positive symptoms are as a consequence of 
hyperactivity of the mesolimbic DA pathway, whereas negative system are as a 
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result of a diminution of dopaminergic activity in the mesocortical pathway  (Lewis 
& Buchanan, 2002, p.62).  Nonetheless, theories of other neurotransmitter 
dysfunction have been postulated, glutamate is one such neurotransmitter that has 
been consistently implicated (Javitt, Zylberman, Zukin, Heresco-Levy & 
Lindenmayer, 1994). Despite the wealth of data indicating a biological basis to 
schizophrenia, heritability studies fail to explain all of the variance within the 
population (see Section 1.2.3). Moreover, many environmental factors have been 
implicated with an increased odds ratio of a diagnosis of psychotic disorder (see 
Section 1.2.3). Thus, although schizophrenia appears to be a heritable disorder it 
is highly influenced by environmental factors (e.g. obstetric conditions, cannabis 
etc.). 
  
There are some disorders which are very closely related to schizophrenia, known 
as the schizophrenia spectrum disorders. This cluster of disorders include 
schizophreniform disorder, schizoaffective disorder, schizotypal personality 
disorder (SPD), paranoid personality disorder and schizoid personality disorder. 
The symptoms of schizophreniform disorder are “identical” to that of schizophrenia 
(APA, 2013a, p.97). The two disorders are only distinguishable by the duration of 
disturbance; an episode of schizophreniform disorder lasts for between one and 
six months. An episode lasting shorter than this duration is given a diagnosis of 
brief psychotic disorder, whereas an episode of longer than this equates to a 
diagnosis of schizophrenia (APA, 2013a, p.97).  Approximately two thirds of 
patients with a diagnosis of schizophreniform disorder progress to develop 
schizophrenia, and one third recover within the six month period (APA, 2013a, 
p.98). 
 
Schizoaffective disorder possesses the same characteristics that are associated 
with schizophrenia. However, in addition to possessing two or more of the criteria 
for schizophrenia patients suffering with schizoaffective disorder must also display 
episodes of depression or mania for the majority of the duration of the illness 
(APA, 2013a, p.106). To distinguish schizoaffective disorder from schizophrenia 
(which is frequently associated with “mood symptoms and full mood episodes” 
(APA, 2013a, p.101)), “a major depressive episode must include pervasive 
depressed mood” (APA, 2013a, p.107).  Whereas, “to separate schizoaffective 
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disorder from a depressive or bipolar disorder with psychotic features, delusions or 
hallucinations must be present… in the absence of a major mood episode” (APA, 
2013a, p.107).   
 
Paranoid personality disorder is characterised by “a pervasive distrust and 
suspiciousness of others” (APA, 2013a, p.649). In a large epidemiological 
investigation paranoid personality disorder was the second most prevalent 
personality disorder in the cohort with 4.41% of the sample meeting criteria (Grant 
et al., 2004). However, data from the (American) national comorbidity survey 
indicates that paranoid personality disorder is prevalent in 2.3% of the population 
(Lenzenweger, Lane, Loranger & Kessler, 2007). Nonetheless, paranoid 
personality disorder was found to increase the odds of a diagnosis of 
schizophrenia or other psychotic episode by 3.2 fold. However, when controlling 
for other sociodemographic factors the increase in odds was non-significant (Pulay 
et al., 2009). This suggests that although the disorder may be related to 
schizophrenia, it is feasibly not appropriate to utilise this personality disorder as a 
prognostic indicator of schizophrenia. 
 
Schizoid personality disorder is characterised by “a pervasive pattern of 
detachment from social relationships and a restricted range of expression of 
emotions in interpersonal settings” (APA, 2013a, p.653). In a prospective cohort 
study people suffering with schizoid personality disorder were found to be less 
likely to have had a sexual relationship, less likely to be in a relationship at follow-
up, and were more likely to prefer to be on their own (Wolff & Chick, 1980). This 
disorder was shown to be prevalent in 3.13% of the general population (Grant et 
al., 2004) in one investigation and 4.9% in another (Lezenweger et al., 2007). 
Schizoid personality disorder was found to increase the odds of a diagnosis of 
schizophrenia or other psychotic episode by 3.0 (O.R.). However, as before, when 
controlling for other sociodemographic factors the increase in odds was non-
significant (Pulay et al., 2009). Thus, indicating that this disorder may also not be 
appropriate as a prognostic indicator of schizophrenia. 
 
Schizotypal personality disorder is characterised by “a pervasive pattern of social 
and interpersonal deficits marked by acute discomfort with….close relationships as 
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well as by cognitive or perceptual distortions and eccentricities of behaviour” (APA, 
2013a, p.655). Two recent epidemiological investigations estimate the prevalence 
of SPD as 3.3% (Lezenweger, et al., 2007) and 3.9% (Pulay et al., 2009). 
However, SPD is significantly more prevalent in men (Pulay et al., 2009). SPD was 
found to increase the odds of a diagnosis of schizophrenia or other psychotic 
episode by 4.7 (O.R.). Even whilst controlling for sociodemographic factors the 
odds ratio of 2.1 remained statistically significant (Pulay et al., 2009). Thus, 
indicating that out of the schizophrenia spectrum personality disorders, SPD 
displays the greatest predictive ability of schizophrenia. Moreover, medication 
which has been found to be effective in the treatment of the symptoms of 
schizophrenia, has also been used to treat the symptoms of SPD (Keshavan, 
Shad, Soloff, & Schooler, 2004). SPD has been described as the “prototypical 
schizophrenia-spectrum condition” (Fervaha & Remington, 2013, p.96). These 
observations amongst others (see Section 1.2.2) are feasibly why schizotypy has 
received a lot of focus on its relationship with schizophrenia, and the rationale for 
SPD receiving more attention than the other schizophrenia spectrum personality 
disorders in this thesis.  
 
1.2.2 Schizotypal personality: disorder and trait 
“A personality disorder is an enduring pattern of inner experience and behaviour 
that deviates markedly from the expectations of the individual’s culture, is 
pervasive and inflexible, has an onset in adolescence or early adulthood, [and] is 
stable over time” (APA, 2013a, p.645). Personality is arguably a function of 
environmental (Johnson et al., 2005) and genetic influence (Bouchard & Loehlin, 
2001). Although, as of yet precise single-nucleotide polymorphisms (SNP, see 
Section 1.2.3 for further information) influencing personality are yet to be 
established (de Moor, et al., 2012). Nonetheless, stable and enduring features of 
personality have been demonstrated in children as young as 3 years old (Caspi et 
al., 2003). Suggesting that personality traits are present from a young age, and 
they persist throughout the lifetime of the individual. 
 
A recent review by Fervaha and Remington (2013) reported converging evidence 
suggesting that people suffering with schizophrenia and people suffering with SPD 
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share common neuroanatomical abnormalities, particularly in the medial temporal 
lobe. The review also found evidence of people suffering with SPD having a larger 
pre-frontal cortex volume which, the authors suggest, may reflect a “compensatory 
neuroreserve” (p.103). This may be a factor that could explain why only a small 
minority of people suffering with SPD decompensate into schizophrenia (See 
Pulay et al., 2009). In addition to neuroanatomical similarities, SPD and 
schizophrenia also share common phenomenological, genetic, 
psychophysiological, cognitive, and pharmacological abnormalities (Siever & 
Davis, 2004). Nonetheless, assessments of SPD and assessments of a 
schizophrenia prodromal state indicate that although there is some overlap 
between the two disorders, they do display discriminant validity (Bedwell & 
Donnelly, 2005). This indicates that the disorders are distinct disease entities, 
although they are both highly related.  
 
The assessment of personality through psychometric testing has a long standing 
history with psychological research (e.g. Hathaway & Mckinley, 1940). Rather like 
many other aspects of personality, a schizotypal personality (schizotypy) can be 
assessed through self-report questionnaire. Self-reported schizotypy has 
displayed validity for both screening for SPD and assessing schizotypal traits in 
healthy participants (Raine & Benishay, 1995). However, unlike SPD, even a 
highly schizotypal personality is not pathological.  The assessment of schizotypy 
via self-reports is therefore a useful means by which to make inferences about 
schizophrenia without the need to recruit a clinical sample. Measures of 
Schizotypy are frequently used as research tools to differentiate and gradate 
psychosis-proneness in persons without psychopathology (e.g. Cohen, Buckner, 
Najolia, & Stewart, 2011). Schizotypal personality trait and research into 
schizotypal personality disorder has been described as being “of key importance in 
overcoming methodological weaknesses of schizophrenia research’ (Raine & 
Lencz, 1995, p3) as “schizotypals tend to be free of the institutionalization and 
medication confounds that impede schizophrenia research” (Raine, Lencz, & 
Mednick 1995, p. xii).  
 
Despite the advantages conveyed through the examination of personality traits 
and disorders they are not without their criticism. DSM IV-TR utilised a multiaxial 
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system in which personality disorders were considered distinct from other 
psychological disorders (APA, 2000). However, the appropriateness of 
differentiating between personality disorder (axis II) and other psychological 
conditions (axis I) as distinct has been a point of discussion (e.g. Westen & 
Shedler, 2000; Widiger, 2003). DSM 5 has subsequently moved to a non-axial 
system as “there is no fundamental difference between disorders described on 
DSM-IV’s Axis I and Axis II” (APA, 2013b, p.1). However, part of the rationale for 
this move may have been convenience “as the axis system was seen by some 
clinicians as burdensome and time consuming” (APA, 2013b, p.1). Moreover, the 
APA (2013a) acknowledges that the consideration of personality disorders in a 
non-axial model has its limitations as evinced by the inclusion of an alternative 
multiaxial model for assessment of personality disorder (p.761). 
 
Raine and Lencz (1995) pose a question related to the ‘axial debate’; “whether 
SPD is best construed as a deviation representing an exaggeration of an 
ostensibly normal personality process which places subjects at risk for 
schizophrenia, or a major disorder that is much more integrally related to 
schizophrenia itself” (p.4). With the transition to a no-axial system this question 
has not become a moot point and at present remains unresolved. Moreover, within 
the context of personality research this question is particularly poignant as it 
pertains to another long held and still active debate related to if, and how, 
someone may decompensate from a high schizotype to psychotic disorder (e.g. 
Meehl, 1962; Nelson, Seal, Pantelis & Phillips, 2013).  
 
The prevalent model within psychiatry (e.g. APA, 2000; APA, 2013a) is the 
utilisation of a categorical method differentiating between those mentally ill and 
those not. “Because of the categorical nature of the DSM …SPD is automatically 
viewed as a dichotomous entity, so that each patient either is or is not schizotypal” 
(Lencz & Raine, 1995, p.430). However, personality research has typically utilised 
a dimensional approach in which schizotypy and schizophrenia exist along a 
continuum. “Although dimensional systems increase reliability, others suggest that 
such an approach may be less useful than categorical systems for clinical practice 
and application” (Kraemer, Noda, & O’Hara, 2004 p.17). Within personality 
research a fully categorical model is rarely applied as personality research 
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typically relies on the ability to gradate or rank participants and their traits along a 
scale. 
 
There have been three principal models proposed to explain the relationship 
between schizotypy and schizophrenia: the quasi-dimensional approach (which is 
sometimes also referred to as categorical in nature e.g. Lencz & Raine, 1995, 
p.430), the “entirely” dimensional or continuum approach (Claridge & Beech, 1995 
p.194), and the fully dimensional approach .The entirely dimensional approach, 
which is influenced by personality theory (see Eysenck, 1960), suggests that 
healthy people and those suffering with schizophrenia all exist along the same 
continuum with no differentiation at the point of conversion from healthy to 
psychotic “except in a purely statistical sense” (Claridge, 1997, p.11). Evidence for 
this approach can be derived from the observation that both psychotic symptoms 
and schizotypal traits may disaggregate into a similar factorial structure (see 
Liddle, 1987; Raine & Benishay, 1995). However, it is worth noting that alternative 
factorial structures have been postulated (e.g. Mason & Claridge, 2006). High-
scoring schizotypes are at an increased risk of decompensating into psychotic 
illness (Pulay et al., 2009). This indicates a possible continuum between 
vulnerability and disorder. Nonetheless, this approach has been criticised for not 
considering “distinctions or discontinuities that might exist between symptoms and 
traits” (Claridge & Beech, 1995, p.194). This approach has become less popular in 
recent years (e.g. Nelson et al., 2013), perhaps partly due to the lack of data 
indicating the point of conversion from high schizotypy to schizophrenia, and the 
development of genetic and environmental interaction models (e.g. Réthelyi, 
Benkovits, & Bitter 2013). 
 
One alternative to the continuum model is a quasi-dimensional approach. Meehl 
(1962, 1990) was one of the central proponents of a theoretical perspective 
encompassing many aspects of the quasi-dimensional approach. Central to this 
theoretical perspective is the presence of an underlying genetic susceptibility 
conferring whether an individual is a schizotype, or to re-phrase a “schizophrenic 
phenotype” (Rado, 1960 p.87). Meehl (1990) suggests that schizotypes have a 
genetic vulberability to schizophrenia, a schizogene. Meehl (1990) determined that 
the schizogene was a dominant gene and thus, this occurs in around 10% of the 
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general population (p.26). Nonetheless, the conversion from genetic vulnerability 
(schizotaxia) to schizotype appears to be mediated and influenced by social 
factors (Meehl 1990 p.50). Meehl suggests that the form and content of a 
schizotypal trait is determined by social learning, and adverse life events, not 
heritability (Meehl 1990, p.35). Nonetheless, Meehl (1990) postulated the 
presence of a single ‘schizogene’, genetic vulnerability to psychosis was thought 
to be affected by polygenic ‘modifiers’  such as being “submissive, hyphohedonic 
[sic], anxietous, introverted, traumatized, [or] unlucky”(p.53). Although Meehl 
suggests that a schizogene is a large component of liability, nonetheless Meehl 
(1990, p.90) also suggests a scenario in which a person not carrying the gene may 
decompensate. Such a scenario is thought to only occur in instances in which the 
individual has an exorbitant amount of other (e.g. non-schizotypal) adverse 
factors.  However, decompensated ‘non-schizotypes’ are said to represent 
“genophenocopies”, as opposed to “true” cases of schizophrenia’ (p.67). 
 
Thus, to establish the relationship between schizotypy and conversion to ‘true’ 
psychotic mental illness, the quasi-dimensional approach utilises both 
dichotomous differentiations (schizogene or non-schizogene) and continuums (e.g. 
severity of symptoms, environmental modifiers).  The necessary presence of the 
schizogene in the expression of ‘true’ schizophrenia has resulted in it being 
referred to as “a discontinuous, categorical theory” (Nelson et al., 2013 p.318). 
Further evidence for the quasi-dimensional model can be derived from heritability 
studies suggesting a genetic influence on the expression of both schizophrenia 
(Gottesman, 1991) and schizotypy (Torgersen et al., 2000).  Thus, this provides 
support for the presence of a ‘schizogene’. A review of analyses assessing the 
latent structure of schizotypy suggests that the majority of the research assessed 
indicated a categorical model (Rawlings, Williams, Haslam, & Claridge, 2008). 
However, Rawlings et al. (2008) also attempted to address the shortcomings of 
the previous investigations they reviewed (i.e. small sample size, skewed data, 
biased samples etc.). Whilst attempting to control for the limitations of previous 
research Rawlings and colleagues found that the data appears to indicate a 
dimensional (continuous) distribution. This provides evidence for the presence of a 
continuum like model between schizotypy and schizophrenia, thus suggesting a 
fully dimensional model. 
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The ‘fully dimensional’ model takes influence from both Meehl’s (1990) theory and 
Eysenck’s (1960) work on personality. This model incorporates the quasi-
dimensional model, but includes another continuum related to personality (see 
Claridge & Beech, 1995, p.194). Within this model the expression of a schizotypal 
personality is descriptive of an underlying predisposition to psychotic illness. The 
expression of schizotypal personality traits are non-pathological and construct part 
of typical individual difference. Some of the factors which might affect the level of 
schizotypy have been suggested to be: ”personality traits, cognitive style 
(?creativity) [sic], nervous system type, genetic variation” (Claridge & Beech, 1995, 
p.194). Within the fully dimensional model, a schizotypal trait increases the 
individual’s vulnerability to psychosis. Nonetheless, for transition to psychotic 
mental illness, deleterious environmental factors must be present. The evidence 
which was suggested in support of the ‘entirely’ dimensional model may also apply 
to the fully dimensional model. This model explains the similar factorial structure 
between schizotypy and schizophrenia (Liddle, 1987; Raine & Benishay, 1995), 
and the increased incidence of decompensating amongst highly schizotypal 
individuals (Pulay et al., 2009). The model also explains the finding that people 
with psychotic illness tend to score highly on measures of schizotypy (Camisa et 
al.,2005). Further evidence for the fully dimensional model can be derived from the 
overlap, yet significant distinction, demonstrated between schizotypal personality 
and a psychosis prodromal state (Bedwell & Donnelly, 2005). This model may 
account for the high prevalence of psychotic-like experience in healthy populations 
(van Os, Linscott, Myin-Germeys, Delespaul, & Krabbendam, 2009) and the 
incidence of cognitive deficits in the same domains as experienced in 
schizophrenia in healthy schizotypal participants (Moritz, Andresen, Naber, Krausz 
& Probsthein 1999). 
 
Of the three models outlined, there appears to be the superior body of evidence 
for the fully dimensional model (Nelson et al., 2013). Moreover, rather than the one 
schizogene proposed by Meehl (1990), most recent research suggests a poly-
genic model with plausibly hundreds of SNPs, each conferring a slight additive risk 
(Purcell et al., 2009). This could indicate that genetic vulnerability exists at 
gradated intervals which, given the number of implicated SNPs (and the various 
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permeations of any interactions), could function similarly to a continuum. If the 
schizogene of the quasi-dimensional model (Meehl, 1990) was replaced with an 
additive poly-genic ‘continuum’, this would result in a model similar to the ‘fully 
dimensional’ approach. The relevant literature has failed to reach congruence on 
the exact nature of the relationship between psychoticism and schizotypy and the 
point at which conversion exists. Nonetheless, the relevant models concur on the 
fact that there is an inextricable link between psychotic illness and the trait of 
schizotypy.  
 
Schizotypal trait, and schizotypal state 
Schizotypy is commonly assumed to be a stable and enduring personality trait 
which has demonstrated “moderate” stability (Nestadt et al., 2010, p.1), unlike the 
symptoms of schizophrenia which are thought to “wax and wane over the lifetime 
course of a disease” (Noll, 2007, p.156). Some of the literature discussed in this 
section suggests a mechanism by which one may decompensate from schizotype 
to psychotic illness (e.g. Meehl, 1990).  However, little focus has been paid to the 
means by which each psychotic(-like) experience may influence the expression of 
schizotypy or the transition into psychotic breakdown. Moreover, there is a paucity 
of information pertaining to the factors which may influence the presence of these 
momentary psychotic-like experiences. 
 
Within an entirely dimensional model, a fully dimensional model, or (plausibly) a 
poly-genic quasi-dimensional model it is feasible that the traits and states 
demonstrated in schizophrenia (Chen, Bidwell & Norton, 2006), are also present in 
schizotypy. Within, these frameworks, if schizophrenia has state and trait 
properties, it is plausible schizotypy does as well. In addition to a schizotypal trait, 
there is also arguably a ‘schizotypal state’. Rossler, Hengartner, Ajdacic-Gross, 
Haker, & Angst (2013) determined that over a 30 year follow-up period schizotypy 
disaggregated into both state and trait factors. Miller, et al. (2002) compared two 
groups of ‘high risk’ participants, those who displayed psychotic symptoms during 
clinical interview and those who did not. Miller and colleagues administered a 
measure of schizotypy within the same battery of tests, and found that participants 
that displayed clinical symptoms also had significantly more schizotypal traits. This 
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is feasibly as a consequence of the effects of personality trait. Nonetheless, in this 
investigation assessments of symptoms and schizotypy were performed in the 
same battery. Thus, presumably the participants state may show little variance 
over such a short period of time. Hence, given that both groups were said to be 
‘high risk’ such an association may also be explained by state processes (i.e. 
elevations in symptomatology also equated to elevations in schizotypal trait). In a 
longitudinal investigation, an increase in environmental risk factors resulted in 
persistence of psychotic experience (Cougnard et al., 2007), thus, indicating that 
the persistence of schizotypal type experience is in part influenced by 
environmental factors. The very nature of environmental factors is that they are 
typically not fixed (i.e. time variant). Thus, if a time variant factor may alter 
schizotypal trait then schizotypy plausibly has a time variant component. 
 
It has been argued that the presence of a schizotypal trait is reflective of another 
state the schizophrenia prodromal (Bedwell & Donnelly, 2005). Furthermore, those 
displaying a prodromal state have been shown to display similar cognitive 
processes to those displaying a schizotypal trait (Barkus et al., 2010). Although, no 
consensus has developed suggesting schizotypy represents a psychosis 
prodromal state, schizotypal trait has been found to moderate the association 
between psychotic like (prodromal) experience and the distress caused by such 
symptoms (Kline, et al., 2012). Thus, indicating that these two factors are highly 
related, and within continuum models they are likely to represent varying 
expression of severity of the same disease process. 
 
Further, evidence for the transitory nature of schizotypy can be derived from 
observations that SPD can develop after the formative years of personality (e.g. 
after childhood see Caspi, et al., 2003). “In our clinical work we have come across 
cases where SPD has become manifest relatively later in life” (Raine & Lencz, 
1995, p.5). Moreover, some of the items used to assess schizotypy appear to infer 
that they have both permanent (e.g. “I am an odd and unusual person”, SPQ-b, 
Raine & Benishay, 1995) and momentary (e.g. “Do you ever suddenly feel 
distracted by distant sounds that you are not normally aware of?” SPQ-b: Raine & 
Benishay, 1995) elements. Additionally, some items require the experience to 
have occurred at a specific level of frequency (e.g. Do you often pick up hidden 
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threats or put-downs from what people say or do? SPQ-b: Raine & Benishay, 
1995). However, there is little information provided by the authors pertaining to 
what level of frequency is requisite for an increased vulnerability, nor, how each 
experience may individually contribute to increased psychosis proneness.  
 
However, ‘sensitisation’ may serve to explain how each psychotic-like experience 
may contribute to people decompensating (see Section 1.7.3, for further 
information). Collip, Myin-Germeys and van Os (2008) describe a plausible 
mechanism of ‘sensitisation’ in which environmental factors interact over time with 
genetic/physiological factors to bring about psychotic illness. The notion that 
environmental factors, some of which typically occur after childhood (such as 
cannabis use, see Section 1.8), serve to alter psychotic vulnerability diminishes 
the notion of the stability of schizotypy. Van Os et al., (2009) elaborates on the 
sensitisation model to suggest that the development from transitory psychotic-like 
experience, into persistent experience, and to clinical symptoms, is dependent on 
environmental risk factors. This suggests that by measuring transitory psychotic 
like experience and its persistence (frequency) this can provide information about 
both environmental and genetic factors influencing the presentation of psychotic 
illness (see Section 1.2.3 for further discussion).  
 
There is a developing body of research suggesting that schizotypy may be 
elevated by environmental factors, such as cannabis (also see Section 1.8), and 
that these heightened schizotypal states may provide a mechanism for 
decompensating into psychotic illness (van Os et al., 2009). Nonetheless, it is 
acknowledged that the majority (75-90%) of psychotic like experiences are 
typically transitory in nature and persist in only a very small proportion of people 
(van Os et al., 2009). Van Os et al., (2009) estimated that 8% of the population 
had psychotic experience, 50% of those individuals (4% of the population) had 
psychotic symptoms, and 75% of those with psychotic symptoms (3% of the 
population) decompensated into illness. Thus, this would indicate that transitory 
psychotic like states are not clinically significant in the majority of cases. However, 
in instances where these experiences are persistent then they could be indicative 
of psychotic vulnerability (van Os et al., 2009).  
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Although it appears that it is the persistent (plausibly trait-like) psychotic-like states 
which are the most clinically relevant, the momentary evaluation of psychotic-like 
phenomena is also a worthwhile endeavour. The identification of momentary 
psychotic like states may allow for an assessment of what constitutes the temporal 
boundary between a non-clinically relevant transient psychotic-like experience, 
and a more clinically relevant persistent psychotic-like experience. In the absence 
of an assessment of what constitutes a transient or persistent experience it is 
difficult to establish those at the greatest risk. Perhaps one of the most important 
contributions the assessment of transient psychotic-like states can provide is 
models of exacerbations of symptomatology in schizophrenia. With prolonged 
exposure to environmental factors which elevate or contribute to psychotic-like 
states, these psychotic-like states could plausibly become persistent (e.g. through 
sensitisation). Within a continuum model of psychosis (see Section 1.2.2, pp. 25-
31) environmental factors which increase the persistence of psychotic-like states 
are also likely to increase the incidence of psychotic symptoms and ultimately 
disorder. Thus, within such a model the evaluation of environmental factors which 
increase psychotic-like states can provide inference about the environmental 
factors influence on psychotic disorder.  
 
Due to their ‘transitory’ nature (i.e. their moment to moment variance) schizotypal 
states are difficult to measure. Traditional assessments of schizotypal personality 
are not appropriate for the measurement of schizotypal states, as the items tend to 
infer an air of permanence (e.g. “Are you so good at controlling others that it 
sometimes scares you?” OLIFE: Mason, Claridge, & Jackson, 1995 p.9) or require 
an amalgamation of previous phenomena (e.g. “Do you often feel ‘fed up’?” 
OLIFE: Mason et al., 1995 p.10). Moreover some of the most commonly used 
tools for the clinical assessment of psychotic symptoms are not appropriate for the 
assessment of a schizotypal state. For example the items from the, World Mental 
Health-Composite International Diagnostic Interview, refer to the ‘lifetime’ 
occurrence of psychotic phenomena (WMH-CIDI: Kessler & Üstün, 2004). The 
Positive and Negative Syndrome Scale (PANSS: Kay, Flazbein, & Opler, 1987), 
Brief Psychiatric Rating Scale (BPRS: Overall & Gorham, 1962) and Schedules for 
Clinical Assessment in Neruopsychiatry (SCAN: Wing et al., 1990) are all interview 
based assessments. Through the use of observations and direct questions during 
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the interview process these measures make an assessment of momentary 
symptomatology. However, they are intended for the assessment of clinical not 
sub-clinical symptoms. Therefore, although they may be adept at highlighting 
momentary exacerbations in symptomatology, they may not be adept at 
highlighting momentary exacerbations in psychotic-like symptomatology. 
 
The Structure Clinical Interview for DSM-IV Axis I disorders (SCID) has a non-
patient edition (SCID-INP) and assess “current” symptomatology, and so may be 
better suited to detecting sub-clinical schizotypal states. However, within the 
context of the measure “current” pertains to whether criteria had been “met at any 
time during the last month” (First, Gibbon, Spitzer, & Williams 2002, p.26). Thus, 
invalidating the measures use in the assessment of ‘momentary’ or transient state 
like phenomena. Such is the nature of transient phenomena that even slight 
delays in the assessment procedure may result in alterations of state, even if the 
state in question is thought to be influenced by stable processes (e.g. personality 
trait). Therefore, the use of lengthy interview based assessment may distort the 
temporal boundaries of assessments of momentary phenomena, thus making 
them inappropriate for assessments of ‘state’.  
 
Some self-report measures have been developed for the assessment of psychotic 
symptoms. The Symptoms Checklist (SCL-90-R, Derogatis, 1975) is a self-report 
measure that allows the assessment of psychotic symptoms in which the assessor 
can set the period of response (e.g. one week, one month etc.). However, the 
SCL-90-R items are related to previously experienced (as opposed to concurrently 
experienced) phenomena, and so are likely to be assessing the persistence of a 
psychotic state as opposed to a psychotic state per se. The Behaviour and 
Symptom Identification Scale (BASIS-R, Eisen, Normand, Belanger, Spiro, & 
Esch, 2004) is a self-report measure however, the anchors ranging from ‘none of 
the time’ to ‘all of the time’ are not appropriate for the momentary assessment of 
phenomena. Such a measure is likely to be inappropriate for the measurement of 
a psychotic like state as it is based on retrospective account. A retrospective 
assessment of a state is likely to be incapable of distinguishing between a rapid 
cycling state, and a ‘state’ which has greater stability. Furthermore, due to the 
undefined time frame of what constitutes ‘a state’, retrospective measures are 
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likely to encompass multiple states. Moreover, this undefinable time frame does 
not lend itself to study design assessing environmental factors which may elicit a 
schizotypal state.   
 
One such tool that has been developed for the assessment of momentary 
psychosis-like experience is the Psychotomimetic States Inventory (PSI, Mason, 
2008). An elevated score on the PSI has been documented as a result of sensory 
deprivation (Mason & Brady, 2009). Furthermore, participants that were highly 
psychosis prone scored significantly higher than those who were not. Thus, those 
who would be hypothesised to have the greatest propensity to psychotic-like 
states demonstrated such a response on the measure. Elevations on the PSI have 
also been documented after participants have been recently aroused from a 
dream in comparison to when they have been awake for approximately 6 hours 
(Mason & Wakeerley, 2012). Moreover, elevations in the PSI have been 
documented as a consequence of a cannabis challenge (Morgan, Rothwell, 
Atkinson, Mason & Curran, 2010; Schafer et al., 2012; Stokes, Mehta, Curran, 
Breen, & Grasby, 2009), a ketamine challenge (Freeman et al., 2009; Mason, 
Morgan, Stefanovic & Curran, 2008), and a salvia divinorum challenge 
(Ranganathan et al., 2012). Furthermore, following a ketamine challenge increase 
on scores on the PSI were also associated with pharmacological changes present 
in psychotic disorder (De Simoni et al., 2012). Taken together, these results 
provide strong evidence that the PSI is a sensitive and valid (see Section 1.3.2 pp. 
51-54) tool for the assessment of momentary psychotic like states. 
 
Later on in this chapter the evidence suggesting that cannabis may elevate a 
schizotypal trait and state is discussed (Section 1.8 pp. 96-99). However, prior to 
the discussion of this environmental factors influence on schizotypal state it is 
necessary to evaluate the literature pertaining to some other areas of research. As 
discussed in this section transient psychotic like experience may provide 
information about schizophrenia within several (continuum based) theoretical 
frameworks. This section has discussed the means by which a schizotypal state 
can be assessed (amongst other things). However, transient psychotic-like 
experience is non-pathological and does not provide a good prognostic indicator of 
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psychotic disorder. The next section will discuss the literature pertaining to 
assessment of vulnerability for schizophrenia. 
 
1.2.3 Assessing vulnerability to schizophrenia 
Factors that increase the odds risk 
Given the debilitating nature of the symptoms of schizophrenia and the high 
suicide rate (APA, 2013a), it is necessary to assess the extent to which psychotic 
vulnerability can be predicted and disorder ultimately prevented. One means by 
which psychotic vulnerability can be assessed is by identifying the factors which 
co-vary with (or in theory precede) a diagnosis of psychotic disorder. One factor 
that has been shown to increase the odds ratio of psychotic disorder is obstetric 
complication. In examination of epidemiological data from a Danish cohort, 
numerous obstetric complications related to behaviour (e.g. non-attendance at a 
pre-natal clinic), pathology (e.g. maternal influenza), and delivery related events 
(e.g. harmorrage during delivery, manual extraction) were shown to increase the 
odds ratio of a diagnosis (to the offspring) of schizophrenia (Byrne, Agerbo, 
Bennedsen, Eaton & Mortensen, 2007). A meta-analysis of eight studies 
concluded that three groups of obstetric complications significantly increased the 
odds ratio of schizophrenia. These were related to difficulties during pregnancy, 
difficulties during delivery, and non-standard foetal development (Cannon, Jones, 
& Murray, 2002). It should also be noted that even some seemingly innocuous 
obstetric conditions such as being born in the winter or in an urban environment 
have been implicated in an increased odds ratio of schizophrenia (Mortensen et 
al., 1999).  Prenatal stress has also been implicated in increasing the odds ratio of 
psychotic disorder. However, these effects may not be independent from the other 
aforementioned obstetric factors (See Clarke, Kelleher, Clancy, & Cannon, 2012). 
 
In addition to the broad range of obstetric complications that may increase the 
odds ratio of a diagnosis of schizophrenia, there are also factors which occur 
during childhood which may increase risk. One such example is childhood trauma. 
Heins et al. (2011) found that childhood trauma (associated with various forms of 
abuse and neglect) increased the presence of psychotic symptoms in a dose 
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dependent fashion. Moreover, Heins and colleagues found that patients with a 
psychotic disorder indicated greater exposure than their non-affected siblings. As 
the sibling group are first degree relatives they share approximately 50% of the 
genetic material with the patients. This indicates that the difference between the 
patient and sibling group is more likely to be as a consequence of environmental 
factors (as opposed to comparison with a population control group). Hence, the 
difference between the two groups further emphasises the importance of 
childhood trauma as an environmental risk factor.  
 
Further evidence comes from Arseneault et al., (2011) who conducted a 
prospective cohort investigation, and found that childhood trauma predicted 
adolescent psychotic ‘symptoms’. Other childhood factors such as peer rejection, 
IQ, the internalisation of problems, and abnormal motor development have also 
been associated with future development of schizophrenia (Cannon, Caspi et al., 
2002). Furthermore, social withdrawal in adolescence has been found to be a risk 
factor for relapse in adults (Robinson et al., 1999). The risk factors which are not 
unequivocally related to environment could plausibly be reflecting a similar 
construct to schizotypy or other ‘schizogenic’ influence (i.e. social withdrawal). 
Nonetheless, there is a good body of research or rationale to suggest that some of 
these factors are exerting an independent effect to that of schizotypy (e.g. 
childhood trauma, see Section 1.7.4).  
 
Other factors not specifically related to childhood, such as an acquired brain injury, 
have also been related to an increased odds ratio. David and Prince (2005) 
reviewed data pertaining to brain injury and psychotic symptoms and found that 
the studies indicate a broad range of purported risk with relative risks (to the 
population) spanning from 0.2 to 16.3. In Clarke et al., (2012) recent meta-analysis 
estimate that brain injury increases the odds ratio by1.65. However, the 
researchers also acknowledge that potential confounders such as substance use 
may account for at least some of this association. Such a scenario where 
substance use may result in increased incidence of traffic accident (Movig et al., 
2004), resulting in an increased likelihood of acquired brain injury, resulting in an 
increased likelihood of schizophrenia is a plausible scenario. As outlined in the 
aforementioned example identifying the independent effect of environmental 
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factors is a difficult if not impossible endeavour. Thus, an alternative approach to 
assessing a myriad of different factors is to assess a broader overarching concept, 
such as stress or the perception of stressful events, or states.   
 
Stressful events have been shown to significantly exacerbate symptomatology 
(Betensky et al., 2008; Norman & Malla, 1993) and increase incidence of relapse 
in people suffering with schizophrenia (Doering et al., 1998; Nuechterlein et al., 
1994). Moreover, different types of stressors have demonstrated such an effect. 
For example’ an adverse family environment (expressed emotion, see Brown, 
Monck, & Carstairs & Wing, 1962) has also been associated with increased odds 
of relapse (Amaresha & Venkatasubramanian, 2012). Furthermore, in comparison 
to controls people diagnosed with SPD had significantly more adverse life events 
and experienced more distress as a result of these stressors (Tessner, Mittal & 
Walker, 2011). In this same study, participants in the control groups also showed 
an increase in psychosis like symptoms as a result of stressors. Further, evidence 
for stress’ relationship with schizophrenia can be derived from evidence 
suggesting that the ability to apply coping mechanisms appears to mitigate the 
psychotomimetic effect of stress. Moreover, there is a neurophysiological 
difference in event related potentials (P300 wave) between those able to apply 
such mechanisms and those who cannot (Pallanti, Quiercioli, & Pazzagli, 1997). 
 
People suffering with schizophrenia tend to display both more emotional reactivity 
to stress than controls (Horan & Blanchard, 2003) and greater subjective stress 
(Betensky et al., 2008). Furthermore, emotional reactivity and life stressors have 
been shown to interact to increase psychotic symptoms (Docherty, St-Hilaire, 
Aakre, & Seghers, 2009).  However, it is thought that the impact of stress reactivity 
on symptomatology may be in-part mediated by familial vulnerability to depressive 
symptomatology (Kramer et al., 2012). This indicates that the relationship between 
stress reactivity and symptomatology is influenced by mood, or more specifically 
genetic vulnerability to mood disorder. This could indicate that the link between 
stress reactivity and schizophrenia is not an independent process and is in some 
way influenced by genetic factors. This may also infer that people who develop 
schizophrenia due to stress related factors are also vulnerable to mood disorder. 
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Given the subjective and loosely defined nature of what constitutes a ‘stressor’, an 
exact odds ratio for the effect of ‘stress’ is difficult to generate. Nonetheless, the 
various data indicate that stressful life events do contribute to the development of 
psychotic illness. Many of the environmental factors described herein may co-vary 
with stress and a stress response. However, within the wider context stressful 
events or psychological stressed states are considered as independent 
environmental factors (or stressors). It is thought that environmental stressors and 
innate factors may interact to cause mental illness. Such an association has been 
referred to previously as a ‘stress-diathesis’ model. Within the realms of 
schizophrenia one of the pioneers of this model was Meehl (1962). However, as 
Meehl argued and as the data still suggests genetic factors are the best predictive 
determinates of psychotic disorder. 
 
Genetic determinates of schizophrenia 
Despite the numerous environmental factors that increase the odds of psychotic 
illness, the one which appears to have the largest effect is familial history 
(Sullivan, 2005). Prior to the sequencing of the human genome (Lander et al., 
2001) familial studies were utilised to elucidate the genetic components of 
schizophrenia. A meta-analysis of familial studies was conducted by Sullivan 
(2005). From the studies Sullivan (2005) reviewed there was an increase of 9.8 in 
the odds ratio of developing schizophrenia associated with having a first degree 
relative with the disorder. However, given that families often share environments 
and thus presumably some risk factors it is difficult to disentangle the 
environmental and genetic effects. To address this, Sullivan also reviewed the 
data generated by adoption studies, which allow for separation of some of these 
factors. He found that, in cases where the adoptee had a diagnosis of 
schizophrenia there was an increase of 5 in the O.R. of the biological parents also 
having the disorder in comparison to the adoptive parents, providing even stronger 
evidence for a genetic component. 
 
Another means by which investigators have attempted to assess the heritability of 
schizophrenia is through the use of twin concordance investigations. Monozygotic 
twins share the same genetic material however dizygotic twins only share the 
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same amount of genetic material as a first degree relative. Research from within 
this domain works on the premise that sets of twins will share a similar 
environment and thus any discordance between monozygotic and dizygotic twins 
is indicative of genetic processes. Estimates from a meta-analysis of the twin 
concordance data indicate that the heritability of schizophrenia liability is 81%, and 
the effects of environment account for 11% of the variance in a diagnosis outcome 
(Sullivan, 2005). Although the data from heritability studies indicate a genetic 
influence they have been criticised as they assume “no interactions among genes 
or between gene and the environment” (Clarke et al., 2012). That is such models 
cannot assess the association between psychotic stress sensitivity and mood 
disorder vulnerability discussed earlier in this section (Kramer et al., 2012). Nor, 
can the model assess the interaction between stressful life events and psychotic 
vulnerability. Moreover, the relevant investigations often fail to adequately exert 
control over the notable differences and similarities in the familial environment 
which may predict psychotic illness (e.g. stressful life events or obstetric 
conditions). This could feasibly result in an inflated estimate of the actual genetic 
involvement. 
 
More recent studies assessing genetic vulnerability have looked at functional 
polymorphism in single nucleotides (SNPs). Some of these studies were 
‘candidate gene studies’, in which the SNPs were selected on a priori hypotheses 
(Collins, Kim, & Sklar et al., 2012). One such candidate gene is the catechol-O-
methyltransferase (COMT) gene, this gene codes for an enzyme that degrades 
catecholamines such as the neurotransmitter DA (Lachman et al., 1996; for further 
information on DA see Section 1.2.1 pp. 21-25). A functional polymorphism in the 
COMT gene has been shown to be significantly related to schizotypy (Stefanis et 
al., 2004). Thus, indicating that this SNP has convergent validity (see Section 
1.3.2 pp. 51-54) as a prognostic indicator of psychotic disorder.  However, like 
many other investigations that have assessed candidate genes (see Sullivan, 
2005 for review) these findings have been contradicted by another investigation 
which has failed to find a significant effect of the SNP (Fan et al., 2005). More than 
a thousand candidate genes have been assessed in more than a thousand 
investigations (Allen et al., 2008). However, there is rarely replication of the 
findings between the investigations and there is insufficient evidence to suggest an 
42 | P a g e  
 
effect of the eight most investigated SNP (Collins, Kim, Sklar, O’Donovan, 
Sullivan, 2012). These findings suggest that it is inefficient to assess SNP variance 
based on a priori hypotheses. Moreover, these myriad of investigation contest the 
notion of Meehl’s (1962) hypothesis of a single ‘schizogene’. If there is such a 
gene, this ‘holy-grail’ of genetics research, is as yet to be identified. 
 
More recently instead of focusing on candidate genes, assessments are being 
made in genome wide association studies (GWAS), which utilise a systematic 
interrogation of the entire genome. The GWAS consortium (Ripke et al.,2011) 
have undertaken a ‘mega-analysis’ which included more than 50,000 individuals. 
This analysis identified seven loci which are implicated in schizophrenia and 54 
significant SNPs that were subsequently confirmed in two independent samples. 
However, only approximately 6% of the variance in the data was accounted for by 
this genetic model. Indicating that the model fails to account for near to the amount 
of heritability observed in the ‘old genetics’ (familial) studies (e.g. Sullivan, 2005). 
This indicates that the model is likely to be missing other significant genetic 
determinates of diagnoses. Moreover, despite the huge number of participants 
under consideration, the GWAS consortium acknowledge that the sample is likely 
to not have sufficient power to model all of the SNPs which confer risk (p.974). 
The International Schizophrenia Consortium (Purcell et al., 2009) took an 
alternative approach to modelling the effects of SNPs. The ISC modelled the 
effects of each of the SNPs assessed with a more liberal p-value threshold 
(p<0.5). Although, this method will likely result in an increased incidence of type 
one error it does mitigate the influence of failings in statistical power. Utilising this 
technique the ISC identified 37,655 SNPs each conferring a slight additive risk. 
However, this only accounted for approximately 3% of the variance in the data.  
 
The investigations of the ISC and the GWAS consortium highlight that there is 
likely to be numerous SNP’s each conferring an additive risk. Moreover, it would 
appear that samples including vast numbers of people may be necessary to 
identify a prognostically viable genetic model. Despite the large number of 
participants and variables included in the two aforementioned GWAS they both fail 
to account for anywhere near the heritability identified in twin concordance 
investigations (e.g. 81%, Sullivan, 2005). Clarke et al. (2012) suggest that the 
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missing heritability “is likely to lie in the environment or gene-environment 
interaction” (p.597). One recent article has suggested that by combining genetic 
and epidemiological data (such as exposure to adverse environmental factors) 
may be the most proficient means to assess heritability and to account for some of 
the error term (McGrath, Mortensen, Visscher & Wray, 2013). However, such 
models have yet to be applied in a prognostic capacity. 
 
Biological markers of schizophrenia 
Although, the various investigations into genetics are very intriguing, they are yet 
to elucidate information that has any relevance in the praxis of assessing 
vulnerability. Due to what has been described as a “hypercomplex” genetic model 
(Sullivan, 2005, p.617), researchers have sought out other means to identify the 
schizophrenia genotype through examination of the phenotype. These have been 
described as biological markers, or ‘biomarkers’. According to the WHO (2001) “A 
biomarker is any substance, structure or process that can be measured in the 
body or its products and influence or predict the incidence of outcome or disease” 
(Introduction section, para. 3). A number of different bio-markers for 
schizophrenia, have been proposed, these fall within several domains including 
neuroanatomy, event related potentials, and visual processing (See Allen, Griss, 
Folley, Hawkins & Pearlson, 2009).  
 
One biomarker falling within the domain of neuroanatomy is ventricular volume. As 
discussed previously (Section 1.2.1 pp. 21-25) there is an increased incidence of 
ventricular enlargement (cortical atrophy) in patients suffering with schizophrenia. 
A recent meta-analysis found consistent enlargement in combined data from 
thirteen investigations (Kempton, Stahl, Williams, & DeLisi, 2010). This suggests 
that cortical atrophy may be a distinguishing feature between those with 
schizophrenia and those without. However, the data indicated that these effects 
are likely to be neurodegenerative. Cortical atrophy could represent a 
consequence of, rather than vulnerability to, the disorder. Consequently, 
assessments of cortical atrophy may be appropriate in identifying those suffering 
with long-term disorder. However, they are unlikely to be useful in assessment of 
vulnerability. 
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One of the most widely investigated biomarkers which falls within the domain of 
event relate potentials is the P50 suppression response. An event related potential 
is a small amount of electric current generated in response to a stimuli. These are 
measurable through an electroencephalogram (EEG) machine, the P50 is the 
most positive peak in voltage that occurs between 40 and 75 ms after stimuli (Sur 
& Sinha, 2009).The P50 suppression is one of the most widely investigated bio-
markers of schizophrenia (See Allen et al., 2009). The P50 suppression task 
purportedly assesses the brains ability to filter out irrelevant stimuli (Sur & Sinha, 
2009). A recent meta-analysis of the P50’s suppression showed a significant 
difference between patients suffering with schizophrenia and healthy controls (Su 
et al., 2010).The findings from Su et al. (2010) analyses suggest that the P50 
response may be an appropriate means of assessing vulnerability to disorder. 
 
In a search for bio-markers Benson et al. (2012) examined eye-movements in a 
number of experimental tasks assessing smooth pursuit, fixation maintenance, 
and free viewing. Patients diagnosed with schizophrenia performed significantly 
abnormally (e.g. absence of smooth pursuit) on all three tasks in question. Utilising 
this data Benson and colleagues were able to discriminate between participants 
with a high degree (87.8%) of accuracy. However, it should be noted that during 
re-test some of the patient group failed to replicate their abnormal eye movement. 
This suggests that the task may be prone to changes in environment and thus, 
may not be truly reflective of schizotaxic vulnerability. Moreover, the investigation 
assessed participants who had been ill for a substantial period of time (mean 16.9, 
SD 10.5). Thus, whether or not these findings represent a true phenotype or 
iatrogenic differences is at present unresolved. Nonetheless, the data indicates 
that with further investigation the pursuit of eye movement bio-markers may be an 
appropriate means to assess psychotic vulnerability. 
 
Despite, various biomarkers displaying promising data pertaining to their ability to 
predict schizophrenia at the moment “no biomarker currently exists” (Weickert, 
Weickert, Pillai, & Buckley, 2013 p.8). Part of the rationale for Weickert et al. 
(2013) conclusion is that bio-markers should have some clinical value. At present 
bio-markers are not as effective at diagnosing schizophrenia as a clinical interview 
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(Weickert et al., 2013). Furthermore, the prognostic capabilities of bio-markers 
have not as of yet been established, and it is feasible that some of the bio-markers 
observed may not be present prior to disease onset. Therefore, these biomarkers 
may not be useful for indicating vulnerability to schizophrenia onset.  
 
Psychological assessments of psychosis proneness 
At present there is insufficient data to generate accurate models to assess 
psychotic liability through the observation of factors that increase O.R. Neither can 
psychotic vulnerability be assessed from genetic material which is feasibly as a 
consequence of the complexity and lack of consensus emanating from the 
research within this domain. Furthermore, bio-markers although promising 
avenues of enquiry are not at present capable of being prognostic indicators. 
Thus, one of the most effective means of assessing psychotic-liability is via 
assessment of schizotypy (see Section 1.2.2 pp. 25-31). 
 
Researchers have utilised interview based assessments of a psychosis prodromal 
state to significantly predict which high risk patients decompensated (Miller et al., 
2003; Yung et al., 2006). These structured interviews have utilised assessments of 
psychotic-like phenomena. Unfortunately, these measures are unlikely to be useful 
for assessment in the general population as these investigations have utilised high 
risk help seeking participants, who are at an inherently greater risk of 
decompensating. Moreover, the psychosis prodromal phase reflects a temporary 
exacerbation in cognitive, and attenuated psychotic symptoms. Due to these 
symptoms transient nature they may not accurately reflect an individual’s inherent 
‘schizotaxic’ vulnerability. The relatively short follow-up periods of the 
aforementioned investigations (24 and 6 months respectively), and the help-
seeking status of the population, therefore suggest that this may not be an 
appropriate means to assess long-term psychotic liability in the general population.  
 
Interview methods have also been utilised in the assessment of a presumably 
more stable construct pertaining to psychotic vulnerability: schizotypy (e.g. the 
structured interview for schizotypy , SIS:  Kendler, Lieberman, & Walsh, 1989). 
Nonetheless, a limitation of interview assessments (and the aforementioned ones 
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of a psychosis prodromal state) is that they are often time consuming and costly to 
administer. Thus, interview based assessment are not appropriate for the 
widespread evaluation of vulnerability, and have more relevance when assessing 
vulnerability in people known to be at an increased risk (e.g. help-seekers). 
 
Other aspects of personality and behaviour have been evaluated for their ability to 
predict psychosis. A recent investigation has proposed that social anhedonia, 
social withdrawal, and positive psychotic like experience significantly interact in the 
siblings of people suffering with schizophrenia. This interaction has been proposed 
as a means to “contribute to a better psychosis prediction” (Velthorst et al., 
2012,p.293). Nonetheless, at present there is insufficient data to assess these 
variables as predictors of psychotic illness. Furthermore, social anhedonia and 
withdrawal are both arguably correlates or feasibly even constructs of schizotypy 
(Chapman, Chapman, & Raulin, 1976). This could suggest that the factors 
identified by Velthort et al., (2012) investigation are reflective of schizotypal 
processes as opposed to an independent influence. Thus, for the exception of the 
interaction effect this proposed model is assessing broadly similar constructs to 
other psychological means of assessing psychosis proneness (i.e. schizotypy). 
 
Given the limitations of the other methods of assessing psychotic liability, a lot of 
research has focused on the ability of self-report measures of schizotypy to predict 
psychosis. The origins of these assessments are typically rooted in either a fully 
dimensional or quasi-dimensional approach (Raine, 2006). However, there is often 
overlap between these two schools of thought with some measures utilising a 
composite of both approaches (e.g. the Schizotypal Traits Questionnaire: STQ, 
Claridge & Broks, 1984) The measures which take their influence from the quasi-
dimensional model are typically characterised by items that are similar to 
attenuated symptoms (e.g. ‘Have you ever had the sense that some person or 
force Is around you. even though you cannot see anyone?’, SPQ-b: Raine & 
Benishay, 1995). The assessment of attenuated symptoms in healthy populations 
often results in highly positively skewed data with a narrow range of responses 
(infrequent endorsement of items) (e.g Barrantes-Vidal et al., 2013). Several of 
these measures have referred to DSM criteria for the basis for the items (e.g. 
Schizotypal Personality Questionnaire, SPQ: Raine, 1991). In contrast the items 
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from the measures influenced by the dimensional model typically refer to 
“relatively mild” aspects of personality as opposed to attenuated psychotic 
symptoms (Mason, et al., 1997, p.24) e.g. Are your feelings easily hurt? 
(Psychoticism scale: Eysenck, Eysenck, & Barrett,1985).  
 
Many different measures have been utilised to assess schizotypy some of which 
have been discussed in Mason et al. (1997). A more recent review purportedly 
assesses the “most important” measures (Fonseca-Pedrero, et al., 2008, p.577). 
However, neither reviews are exhaustive,  particularly since psychosis proneness 
is still a developing area of research, with new assessments constantly being 
developed (e.g. Liu, et al., 2013) and old scales being re-developed (e.g. Gross, 
Silvia, Barrantes-Vidal, & Kwapil, 2012). 
 
As previously discussed, a diagnosis of SPD increases the risk of a diagnosis of 
schizophrenia (Pulay et al., 2009). However, of greater relevance to predicting 
disease on-set is whether the personality trait schizotypy can be used to 
differentiate between those who develop psychotic disorder and those who do not. 
Shah et al., (2012) utilised structural equation modelling to assess psychotic 
liability via three of the Chapman scales (Chapman et al., 1978; Eckblad et al., 
1982; Eckblad & Chapman, 1983). Within the model, schizotypal personality trait 
was a significant predictor of diagnosis, indicating that schizotypy accounts for a 
proportion of variance in psychotic diagnosis. Several subscales of the Schizotypal 
Personality Questionnaire (SPQ, Raine, 1991) have also been found to 
significantly predict those who will decompensate to psychotic illness (Salokangas 
et al., 2013). The data indicated that ideas of reference and lack of close 
interpersonal relationship were particularly predictive of decompensating. 
Moreover, in a ten year follow-up investigation, both positive and negative 
dimensions of schizotypy predicted the development of schizophrenia-spectrum 
disorders, in addition to both adjustment and social impairment (Kwapil, Gross, 
Silvia & Barrantes-Vidal, 2013). The data therefore indicates that despite not being 
an unequivocal indicator of psychotic liability, schizotypy may be a useful means 
for identifying potential risk to future psychotic incidence.  
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This section has focused on the means by which liability to schizophrenia 
spectrum disorder is assessed. The data presented in this section suggests 
several advantages of psychological assessments of liability over other means of 
assessing vulnerability.  The next section of this chapter will focus on the process 
by which a psychological measure is developed. This section will provide 
information on how psychological assessments of personality traits such as 
schizotypy are created, and tested for reliability, validity and factorial structure. 
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1.3 Developing and testing psychological measurement scales 
1.3.1 Measure development 
In any scientific endeavour the act of measurement is central. The precision of the 
instruments of measurement will undoubtedly affect the interpretability of data and 
any conclusions drawn. The development and refinement procedure is key to the 
precision of the measure however, this is often a long, iterative, multi-staged 
process. For example the SPQ items were derived from the diagnostic criteria 
contained within DSM III-R (APA, 1987). Reliability, validity and the factorial 
structure of the SPQ was demonstrated by Raine (1991). The most reliable of 
these items were selected to be contained within a short version of the scale the 
SPQ-b (Raine & Benishay, 1995). Through a series of investigations the SPQ and 
the SPQ-b scoring and factor structure has been further refined to create two new 
scales (Cohen, Matthews, Najolia, & Brown, 2010; Wuthrich & Bates, 2005).  
 
Sound psychometric measures are contextualised within a theoretical framework. 
This enables the assessments of the measure to have some bearing on the 
constructs they purport to measure. The importance of this is evinced by the 
longevity of the discussions of the quasi and fully dimensional models of 
schizotypy (e.g. Meehl, 1962; Nelson et al., 2013, also see Section 1.2.2).  The 
various discussions surrounding these models are not limited in their scope to 
schizotypy, similar debates are taking place within the broader context of 
personality and its relationship to psychopathology (e.g. Widiger, 2003). When 
developing a psychological measurement scale the theoretical perspective 
adopted is of importance in shaping the tool (e.g. Mason et al., 1997 p.21-3). One 
means in which theoretical perspective can alter the development of a measure is 
via item development, which is typically the first stage in the process. 
 
There are different ways in which items can be developed. One way is through 
reviews of the existing scientific literature either from full literature reviews (e.g. 
Bjordal et al., 1994) or by drawing on key texts (e.g. Poreh et al., 2006). Moreover, 
from the examination of the literature items can be generated from previously 
developed measures which are capable of assessing the same or related 
construct. For example, Doyle et al., (2013) measured subjective effects of drug 
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administration through a selection of items from; the Psychotomimetic States 
Inventory (PSI: Mason, 2008); the Clinician Administered Dissociative States 
Scale (Bremner et al, 1998); and items from a Visual Analogue Scale (VAS: 
Herbert, Johns & Doré, 1976). The advantage of ‘generating’ items from other 
measures is that the items have typically already gone through a developmental 
process and in some instances there is data pertaining to the validity. In the 
aforementioned example the PSI has been shown to be reactive to known 
psychotomimetic drugs, moreover these have been associated with physiological 
covariates (De Simoni et al., 2012). Nonetheless, the limitation of using items from 
other scales is the items may be culturally or historically bound in their relevance, 
for instance the phrase ‘muzzy’ as used by Herbert et al. (1976) may be 
ambiguous to younger participants.  
 
Another means by which items can be developed is through consultation with the 
population on which the tool is to be administered. Streiner & Norman (2002) 
suggest “whereas clinicians may be the best observers of the outward 
manifestations of a trait or disorder, only those who have it can report on the more 
subjective elements” (p.15). Focus groups and interviews with patients or the 
intended research subjects can be used to elicit a pool of items that reflect the 
subjective elements of the construct of interest (e.g. Cella et al., 1993; Nassar-
McMillan & Borders, 2002). Utilising the target population in item generation can 
elicit a rich item pool (e.g. Cella et al., 1993).  Cella et al. (1993) also adopted 
another frequently used technique in item generation, interviews with clinicians 
who have experience of interacting with, observing, and treating people from the 
population of the measures intended recipients.  
 
Most of modern psychiatry can find its origins in clinical observations (e.g. Freud, 
1953; Kraepelin, 1896). Thus clinical observations have influenced the generation 
of items which are based on symptom criteria set out in the DSM or ICD manuals 
(e.g. SPQ, Raine, 1991). However, clinical observation also directly influences 
item generation with Streiner & Norman (2003) suggesting “clinical observation is 
perhaps one of the most fruitful sources of items” (p.16).  However, clinical 
observations are subject to the interpretation of the clinician, which in part may be 
guided by; previously outlined criteria; a narrow selection of cases; or limited 
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available data. An example of where limited data has affected clinical (and 
theoretical) interpretation is the consideration of schizophrenia as premature 
dementia, dementia praecox (Kraepelin, 1896). Expert opinion has also been used 
in the process of item development. For example a Q-sort procedure with expert 
clinicians and researchers was utilised to assess the factorial structure of a 
measure (Stirling, Morris, & McCoy, 2012). However, the same criticisms which 
may apply to the use of clinical observations can be applied to the use of experts. 
 
The various phases of the development of measurement scales may involve 
several different techniques to generate items (e.g. Cella et al., 1993). Some 
measures also utilise an amalgamation of different theoretical perspectives in item 
generation. For example Rawlings and Freeman (1997) adopted items from 
measures attributed to both the dimensional and quasi-dimensional models.  Such 
an approach may elicit a broad range of ideas relevant to both clinically relevant 
and non-clinically relevant phenomena. However, the disadvantage of such an 
approach is that the absence of a clear theoretical model may result in ambiguity 
in the interpretation of data derived from such measures.  
 
1.3.2 Testing reliability and validity, and examination of the factorial 
structure 
During the development of a psychological measurement scale an important step 
is the testing of the reliability and validity of the measure. However, neither 
reliability nor validity are ever unequivocally established. Reliability and validity are 
not “inherent propert[ies] of the measure, but an an interaction of the scale, the 
group being tested, and the conditions” (Keszei, Novak, & Streiner, 2010, p.321). 
Keszei et al., (2010) outline four types of validity: face, content, criterion, and 
construct. Face validity and content validity are typically the first assessments of 
validity and they frequently take place during the item development phase. Face 
validity is the extent to which the items reflect the construct under assessment 
based on “a subjective judgement of experts” (Keszei et al., 2010, p.322). Content 
validity is the “degree to which elements of an assessment instrument are relevant 
to and representative of the targeted construct for a particular assessment 
purpose” (Haynes, Richard, & Kubany, 1995, p.239). Haynes et al., (1995) 
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recommend a 35 step process to assess content validity, however, a much more 
modest procedure has been described elsewhere (Streiner & Norman, 2003, p.19-
21). 
 
Criterion validity considers the concordance between the newly devised measure 
and a well-established measure of the same construct (see McDowell, 2006, 
p.31). This is typically assessed by performing a correlation between the two 
measures (see Keszei et al., 2010, p.321). Criterion validity may be further 
subdivided into concurrent and predictive validity, these are differentiated 
according to whether temporality can be established, i.e. whether the measure 
concurs with a current or future state. If the two measures are administered in 
close temporal proximity this is considered concurrent validity (Keszei et al., 2010, 
p.321). However, in assessments of predictive validity the new measure is 
administered in a prospective manner, typically in a follow up study design to 
assess the relationship between scores on the measure and outcome. 
 
If no appropriate measure exists capable of assessing the construct of interest 
construct validity is often utilised (Keszei et al., 2010, p.322). When assessing a 
factor which has no comparable measure validity is established through a process 
of hypothesis testing in an attempt to amass a body of evidence that suggests 
construct validity (McDowell, 2006, p.34). When attempting to establish validity in 
this manner the theoretical perspective adopted is an important consideration as 
this will effect hypothesis testing. 
 
In the development of self-report measures, there are typically three types of 
reliability considered: test-retest reliability, equivalent measures reliability and 
internal reliability (Howitt & Cramer, 2011, p.269; Keszei et al., 2010). In the 
evaluation of interview based measurement scales intra-rater and inter-rater 
reliability are important (Keszei et al., 2010). Inter- and intra- rater reliability can be 
calculated by utilising the intraclass correlation coefficient (Bartko, 1966). This 
procedure involves estimating the error between each repeated observation (or 
rating). However, this means of testing test-retest reliability is only appropriate for 
measures that assess relatively stable constructs. If the construct displays a high 
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degree of time-variance then Bartko’s (1966) method of assessing reliability will 
likely display a larger error term than the true value.  
 
Test-retest reliability refers to what extent a measure can assess a construct 
consistently across time. Equivalent measures reliability assesses the extent to 
which different formats (e.g. fonts) will elicit equivalent data. Test-retest reliability 
and equivalent measures reliability are evaluations of agreement between two 
methods. Several different methods have been proposed for the assessment of 
agreement between methods including tests of correlation, regression models and 
tests of difference, amongst others (see White & van den Broek, 2004). However, 
White and van den Broek (2004) recommend the use of the limits of agreement 
method. Nonetheless, the basic essence of these statistical procedures is to 
assess the degree to which the data are related or similar, and whether the means 
significantly differ.  
 
There is another form of reliability that assesses the internal reliability of a 
measure this is often referred to as internal consistency (e.g. Tavakol & Dennick, 
2011). Internal reliability describes the extent to which items of a measure are 
pertaining to the same related construct. Cronbach’s alpha is assessing the 
correlation between the items on the scale (Tavakol & Dennick, 2011). Typically 
the outputs generated from statistical packages will suggest items which, when 
deleted will improve the internal reliability of the measure . However, it should be 
noted that estimates derived from Cronbach’s alpha have been criticised (Cortina, 
1993). These criticisms are related to an increase in the number of items 
increasing the estimates of internal reliability.  Moreover, large estimates of alpha 
do not equate to uni-dimensionality as the presence of multiple underlying factors 
may be masked by a large number of items or correlation between the underlying 
factors (Cortina, 1993, p.100).  
 
“Factor analysis can be used to describe the underlying conceptual structure of an 
instrument” (McDowell, 2006, p.36). Factor analysis can be used to elucidate the 
underlying structure of the items of a measure. Examination of the factorial 
structure will elucidate if multiple scales or subscales are present within the 
measure. The examination of the factorial structure will allow for an assessment of 
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how many constructs are being assessed within the measure. However, factor 
analysis will not designate a name nor evaluate the ‘nature’ of such constructs. 
Nonetheless, the underlying constructs that are being assessed may be inferred 
by the grouping and the content of the items. A factor analysis may facilitate the 
identification of preferable scoring systems for a measure (e.g. Cohen et al., 2010) 
and may provide inferences to the underlying clustering of symptoms or disorders 
(see Nelson et al., 2013). Nonetheless, the results elucidated from factor analysis 
on occasion have shown variance within measures (e.g. Cohen et al., 2010; Raine 
& Benishay, 1995) and within constructs (e.g. Mason et al., 1995, p.25). 
 
This section has focused on the development of measurement scales, as 
discussed in Section 1.2.3 (pp. 37-48) such measurement scales are utilised for 
the assessment of psychotic vulnerability. Nonetheless, as discussed in Section 
1.2.3 numerous environmental factors may increase the odds of psychotic 
disorder. One possible environmental factor is cannabis, given that cannabis may 
represent one of few preventable environmental factors the relationship between 
cannabis and psychosis requires further exploration. Nonetheless, prior to the 
examination of the data pertaining to the relationship between cannabis and 
psychotic disorder, it is necessary to highlight some of the societal and 
pharmacological factors which may influence such a relationship. Consequently, 
some of the factors which may influence cannabinoid consumption are discussed 
in the next section.  
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1.4 Cannabis potency, and the British cannabis market 
Cannabis is purportedly one of the first cultivated plants (Zuardi, 2006) and 
archaeological finds of hemp textile can be dated to around 4000 BCE (Li, 1974).  
Some argue that cannabis has been used for its psychoactive effects for in excess 
of 4700 years (Jiang et al., 2007). Today cannabis is regarded as the most 
frequently used illicit substance in Britain (Home Office, 2011). An estimated 7.1% 
of the central/western European population of 15-64 year olds are thought to have 
consumed cannabis in the last 12 months (UNODC, 2011). Cannabis is not a 
homogenous drug. Indeed, the plant contains over 500 different chemical 
constituents and more than 80 of these are considered to be cannabinoids 
(Ahmed, et al., 2008; ElSohly et al., 2005; Radwan et al., 2009). Delta-nine-
tetrahydrocannabinol (∆-9-THC) is the most abundant cannabinoid and elicits the 
principal psychoactive effect (Gaoni & Mechoulam, 1964; Mechoulam & Gaoni, 
1967).  Acute intoxication with∆-9-THC has been shown to elicit psychotic-like 
experiences (Kaufmann et al., 2010 & see Section 1.5), identifying the chemical as 
a possible causal or exacerbating factor in the presentation of psychotic illness 
(see Section 1.6 for further information).  
 
Cannabidiol (CBD) is another of the major constituents of the cannabis plant (e.g. 
ElSohly et al., 2005). In contrast to ∆-9-THC, CBD appears to play a role in 
alleviating psychological disturbance. For instance, CBD has been shown to 
relieve anxiety in healthy participants (Zuardi et al., 1982) and there is evidence to 
suggest that it could plausibly improve mood (El-Alfy et al., 2010). Furthermore, in 
a randomised double-blind study, CBD treated the symptoms of schizophrenia as 
effectively as an antipsychotic but, with fewer side effects (Leweke et al., 2012). 
The alleviations of psychotic symptoms seen in the CBD group in this study were 
also significantly associated with increases in endogenous cannabinoid 
anandamide (Leweke et al., 2012). This indicates that the effects of CBD resulted 
in alteration of the endocannabinoid system, which may implicate that system in 
the efficacy of treatment response. Further evidence for the ability of CBD to 
alleviate psychotic symptoms comes from two studies showing that participants 
who consumed cannabis with low levels of CBD had significantly more ‘positive’ 
schizophrenia like symptoms than participants who typically consumed cannabis 
with CBD (Morgan & Curran, 2008; Schubart et al., 2011). Moreover, in a similar 
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study design the group that used cannabis with CBD had significantly less 
cognitive impairment, thus, feasibly inferring a neuroprotective effect of the 
cannabinoid (Morgan et al., 2012).  
 
Given the seemingly contrasting relationship ∆-9-THC and CBD have in the 
presentation of psychotic-like symptoms, the relevant proportion of each chemical 
typically consumed is of concern. The ratio of ∆-9-THC to CBD appears in part to 
be influenced by the ‘type’ (preparation) of cannabis consumed (Hardwick & King, 
2008). The vast majority of the preparations of cannabis consumed in the UK 
today falls broadly into two categories cannabis resin or herbal cannabis with a 
third preparation (cannabis oil) also detected, but much less prevalent (Hardwick & 
King, 2008).  
 
Cannabis resin is typically found as a compressed solid block or disc, but can vary 
in consistency, malleability, viscidity and colour (Scammel & Sind, 2005). 
Cannabis resin, may in fact, be further subdivided into two preparations, which 
may be indistinguishable to the naked eye after the refined cannabis product has 
been pressed (UNODC, 2009, p15). ‘Traditional cannabis resin’ is often imported 
with production generally centred in Lebanon, Morocco and Afghanistan 
(EMCDDA, 2011). ‘Herbal cannabis resin’ is a processed herbal cannabis product 
with high potency sinsemilla frequently used in production (Piljman, Rigter, Hoek, 
Golschmidt & Niesink, 2005). Although, indistinguishable to the naked eye, these 
forms of cannabis resin typically display dissimilar cannabinoid ratios (Piljman et 
al., 2005). ‘Herbal cannabis resin’ displays a profile with greater similarity to herbal 
cannabis than to ‘traditional cannabis resin’.  
 
Herbal cannabis may be further disaggregated into two groups; traditional herbal 
cannabis, and sinsemilla. Traditional herbal cannabis typically consists of 
compressed blocks of foliar and floral material (including seeds and stalks) from 
the pollinated female plants, typically originating from countries that have a climate 
capable of cultivating cannabis growth outdoors without the use of lights or heating 
equipment (Bone & Waldron, 1999; D. Potter, Clark & Brown, 2008). Meanwhile, 
sinsemilla consists of the unpollinated female plant. 
 
57 | P a g e  
 
THC is a secretion produced by glandular trichomes (tiny outgrowths from the 
epidermis of the plant), which are most abundant in the bracts of the female 
flowers (Hardwick & King, 2008; Kim & Mahlberg, 1997). Thus, the female plants 
are typically selected  as they possess larger amounts of psychoactive chemical. If 
the male plant is allowed to reach maturity it will produce pollen causing the 
female plant to divert energy away from THC production into seed production 
(Knight et al., 2012). Sinsemilla is derived from the Spanish words ‘sin’ meaning 
without and ‘semilla’ meaning seed. Recently sinsemilla has become colloquially 
referred to as ‘skunk’, the term skunk however actually refers to a specific 
cannabis strain; “this strain is said to be one of the first which combines the high 
THC content of (Cannabis sativa subspecies sativa) with the rapid growth cycle 
and yield of (Cannabis sativa subspecies indica)” UNODC, 2009, p11. 
Nonetheless, the process of categorising herbal cannabis samples can be a 
challenging endeavour to even the most adept of forensic scientists. As the 
classification of material as sinsemilla is in part determined by the environment in 
which the plant is grown (King, 2008, p, 247). 
 
Of the various preparations discussed sinsemilla typically has the highest THC to 
CBD ratio (Hardwick & King, 2008; D. Potter et al., 2008). Moreover, sinsemilla 
appears to now dominate the British cannabis market, representing the majority of 
samples seized (Hardwick & King, 2008; D. Potter et al., 2008) a fact which is 
confirmed in self-reports (Attha, 2005). Furthermore, a recent meta-analysis has 
concluded that the mean THC contained within samples of herbal cannabis has 
increased between 1970 and 2009 (Cascini, Aiello, & Di Tanna, 2012). However, a 
proportion of this variance may be attributable to the ‘freshness’ of the sample 
(Sevigny, 2013). Freshness of the sample could plausibly determine the 
conversion of THCA into THC (see Baker, Gough, & Taylor, 1982, for further 
information). However, this remains a matter of conjecture. The increase in 
freshness of cannabis can be attributed to the increase in domestic production. 
Quantifying domestic cultivation of cannabis is difficult due to the secretive nature 
of the enterprise. However, it is highly likely that this is on the increase (Hough et 
al, 2003; Lloyd & McKeganey, 2010; G. Potter, 2008; Sznitman & Olsson, 2008). 
Various sources suggest that 50% or more, of the cannabis consumed in the U.K. 
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is domestically produced (Hough et al., 2003; Leggett & Pietschman, 2008; 
Sznitman & Olsson, 2008).  
 
To conclude cannabis is the most frequently consumed drug in the UK. The 
various cannabis preparations may be indistinguishable from the naked eye. 
Nonetheless, sinsemilla is the most frequently consumed preparation with a large 
proportion of it being domestically produced. In comparison to other preparations, 
sinsemilla contains higher levels of a potentially detrimental psychotomimetic 
chemical (∆-9-THC) and lower levels of a potentially beneficial anxiolytic chemical 
(CBD). The available data also indicates that this product may be getting stronger, 
which may be due to advances in botany and selective breeding (G. Potter, 2008).  
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1.5 Cannabis and acute psychotic reaction 
Acute cannabis intoxication is associated with many pleasurable effects including 
euphoria (Ashton, 1999; 2001), relaxation (Hammersley & Leon, 2006), and 
feeling ecstatic (Barkus, et al., 2006). Nonetheless, in a small minority of users, 
cannabis intoxication is associated with a psychotic mental disorder: cannabis-
induced psychotic disorder (CIPD) (APA, 2013a, p111). In a comparison of CIPD 
and alcohol-induced psychotic disorder, CIPD elicited more ‘schizophrenia-like’ 
symptoms (Aggarwal, Banerjee, & Singh, et al., 2012).  Thus, indicating that out of 
the two disorders CIPD can be said to be more prototypical of schizophrenia. 
 
Distinguishing between a CIPD and a primary psychotic disorder can be a difficult 
task. CIPD and primary psychotic disorders yield similar assessments of positive 
symptomatology (Dawe, Geppert, Occhipinti, & Kingswell, 2011). However, those 
suffering with CIPD tend to display fewer negative symptoms (Dawe et al., 2011), 
but more ‘neurotic’ type psychopathology (e.g. anxiety and social phobia) (Rubio 
et al., 2012).  Nonetheless, the current version of the DSM (APA, 2013a) 
recommends that the two disorders are best differentiated by the duration of the 
symptoms experienced (p.113). 
 
Despite the seemingly transient effects of CIPD, it appears highly related to more 
chronic psychotic illness. In a longitudinal study of patients with a diagnosis of 
CIPD (mean follow up time 5.9 years), 44.5% patients developed a schizophrenia 
spectrum disorder (Arendt, Rosenberg, Foldager, Perto & Munk-Jørgensen, 2005). 
Moreover, 77.2% of participants went on to have another psychotic episode, while 
only 15.9% of the sample remained out of psychiatric care throughout the follow-
up period. Similar findings were also demonstrated by Komuravelli, Poole, and 
Higgo (2011) who found that the majority of participants with a diagnosis of 
substance induced disorder (assessed at follow-up) progressed to develop a 
schizophrenia spectrum disorder. Both schizophrenia spectrum disorders and 
CIPD display very similar odds rate ratios associated with a familial history of 
schizophrenia spectrum disorder (Arendt, Mortensen, Rosenberg, Pedersen & 
Waltoft, 2008). This finding led the authors to suggest that cannabis-induced 
psychosis and schizophrenia are not distinct clinical entities (p.1269). However, 
despite this emerging evidence base the latest edition of DSM still considers 
60 | P a g e  
 
cannabis induced disorder a distinct, but related condition to schizophrenia 
spectrum disorders (APA, 2013a, p.519). 
 
In addition to psychotic disorder, cannabis intoxication may also bring about 
psychotic-like experience. The administration of ∆-9-THC has been associated 
with psychotic like experience in healthy participants (Kaufmann et al., 2008). The 
effects have been shown to be different from schizophrenia, but similar to the 
psychotic prodromal phase (Koethe et al., 2006). Intravenous administration of ∆-
9-THC has been shown to transiently elicit both positive and negative psychotic-
like experience in a dose dependent fashion (D’Souza et al., 2004). Moreover, ∆-
9-THC significantly increased the presence of core-symptoms and cognitive 
deficits in participants suffering with a schizophrenia spectrum disorder (D’Souza 
et al., 2005). Delta-9-THC induced psychotic-like states are alleviated by 
antipsychotics (Kleinloog et al., 2012; Liem-Moolenaar et al., 2010). Thus, 
indicating that ∆-9-THC intoxication and endogenous psychoses (e.g. 
schizophrenia) may have similar neural substrates. 
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1.6 Cannabis and schizophrenia 
Despite the long standing (causal) relationship between cannabis and psychotic 
reaction the link between cannabis and more chronic psychotic disorder such as 
schizophrenia is less clear. That is, although there is a link between schizophrenia 
and CIPD, it is important to establish if cannabis is an independent developmental 
antecedent of schizophrenia. Perhaps most importantly there is a need to assess 
whether incidence of schizophrenia spectrum disorder may be preventable with 
the non-initiation or cessation of cannabis use.   
 
To answer this, there is a growing body of longitudinal data suggesting a 
relationship between cannabis use and chronic psychotic mental illness. 
Prospective cohort follow-up studies allow for the observation of the temporal 
relationship of the variables under consideration. A meta-analysis of some of the 
relevant cohort data has been conducted including data from a cohort of Swedish 
conscripts (Andreasson, Engstrom, Allebeck &  Rydberg, 1987), the NEMESIS 
cohort (van Os et al., 2002), the Christchurch cohort (Fergusson, Horwood & 
Swain-Campbell, 2003), and the Dunedin cohort (Arseneault et al., 2002). The 
results of the meta-analysis indicated that cannabis increased the odds ratio of 
psychotic symptoms/disorder by 2.34 times (Arseneault, Cannon, Witton, & 
Murray, 2007).  
 
However, the strengths of the conclusions drawn from this meta-analysis are 
somewhat reduced by limitations of several of the studies as reviewed by 
McLaren, Silins, Hutchinson, Mattick, and Hall (2010). For instance, they point out 
that the Swedish conscript cohort was not assessed for non-clinically relevant 
psychotic symptoms at baseline. Despite a relatively large sample of respondents 
(N>4000) the NEMESIS cohort was criticised for a low incidence of clinically 
relevant psychotic disorder (n=7), resulting in large confidence intervals.  The 
Christchurch cohort was also criticised for the means by which symptomatology 
was assessed. The Dunedin cohort investigation, however, did not have any direct 
criticisms levied against it. 
 
There are limitations associated with the more recent investigation of these 
cohorts. For instance, the Swedish conscript cohort contains more than 50,000 
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individuals. Several investigations have reported on the outcome of this cohort 
(e.g. Andreasson, et al., 1987; Zammit, Allebeck, Andreasson , Lundberg & Lewis, 
2002), the most recent of which was reported by Manrique-Garcia et al.,(2012). 
Manrique-Garcia et al. (2012) considered numerous confounders within a 
regression model (including previous diagnosis, urbanicity, cigarette smoking, 
evidence of childhood disturbance in behaviour, and social integration), and still 
showed dose-dependent relationships between cannabis use and the 
development of schizophrenia, brief psychotic episodes, and ‘other non-affective 
psychoses’. However, some of the information pertaining to childhood social 
adjustment was gathered retrospectively, and this is likely to be less precise than 
concurrent assessment. In the substantially more modest Dunedin cohort 
(N=1037) cannabis consumption before the age of 15 significantly predicted both 
schizophrenia-like symptoms and a diagnosis of schizophreniform disorder 
(Arseneault et al., 2002). However, no significant effect of cannabis consumption 
was noted on a diagnosis of schizophreniform disorder if psychotic symptoms 
assessed at the age of 11 were included in the model.  
 
The prospective cohort cannot provide unequivocal assurances of a causal model. 
With the exception of the Dunedin cohort they are frequently incapable of 
assessing baseline psychotic liability. Given that schizotypal vulnerability may be 
present from a young age (see Section 1.2.2) it is difficult to establish temporality 
of the variables (see Section 1.6.4). “An important limitation of many studies is that 
they have failed to distinguish the direction of association between cannabis use 
and psychosis” (Frisher, Crome, Martino & Croft, 2009, p.123).  The relevant 
prospective cohort studies suggest an association between cannabis and 
psychosis. However, this data can be explained by several relevant hypotheses of 
association. 
 
Gregg, Barrowclough and Haddock (2007) identified in the relevant literature, four 
hypotheses linking substance use to psychotic disorder. In addition to substance 
use causing schizophrenia Gregg and colleagues identified three additional routes 
by which substance use is linked to schizophrenia “substance use is a 
consequence of schizophrenia; …schizophrenia and substance use share a 
common origin; and … schizophrenia and substance use interact and maintain 
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each other” (p.497). Data pertaining to each of these hypotheses will be discussed 
in Sections 1.6.1 - 4. An appropriate hypothesis should be able to explain; the 
increased incidence of substance use disorder in people with schizophrenia (APA, 
2013a, p.105); the positive association between quantity of cannabis consumed 
and schizophrenia vulnerability (Zammit et al., 2002); and the association between 
cannabis consumption per se and schizophrenia (van Os et al., 2002).  
1.6.1 Cannabis use as a consequence of schizophrenia 
One alternative explanation for the association between cannabis-use and 
psychosis is that cannabis use is a consequence of schizophrenia rather than a 
cause. This notion has been expressed in several distinct versions of the self-
medication hypothesis. Edward Khantzian over the last three decades has 
developed “the most widely cited” (Kolliakou, Joseph, Ismail, Atakan & Murray, 
2011, p.337) theory of self-medication which can find its origins in the 
psychodynamic school of thought (e.g. Khantzian, 1985; Khantzian & Albanese, 
2008; Khantzian & Treece, 1977). Khantzian and Albanese (2008) suggest that 
the user may experience a beneficial effect of drugs; “[drugs] have the powerful 
effect of alleviating, removing, or changing human psychological suffering” (p. 2). 
Moreover, the authors suggested that... 
 
There is a considerable degree of specificity in a person's choice of drugs… 
Individuals navigate toward a certain drug because of what it does for 
them… he or she is drawn to one of the classes of drugs (e.g., stimulants, 
depressants, opiate analgesics) because they make the individual feel 
better than anything else (p.2).  
 
Khantzian (2012) discusses some of the factors which may reflect ‘human 
suffering’ including self-regulation, feelings, self-esteem, relationships, and self-
care. Khantzian (2012) also outlines an argument for how drug use may serve to 
alleviate the distress caused by the aforementioned factors.  
 
An alternative version of the self-medication model has been proposed suggesting 
that psychosis prone individuals are drawn to using drugs to alleviate dysphoria 
associated with adverse psychological events or mood states (Kolliakou et al., 
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2011, p.338). However, unlike Khantzian’s model this one does not indicate 
specificity of the substance of (ab)use (i.e. the substance may not make the 
participant ‘feel better than anything else’). Thus, within this model the psychosis 
prone individual drawn to using substances is more likely to indulge in poly-
substance use. In contrast to both these approaches a behavioural approach to 
self-medication has been postulated which asserts that rather than the substance 
conveying a benefit to the user, the user consumes the substance as a means of 
negating aversive events associated with absence of use, such as cravings and 
withdrawal (Blume, Schmaling & Marlatt, 2000). Nonetheless, the model of self-
medication adopted has little bearing on the hypothesis of association outlined by 
Gregg, et al., (2007) suggesting that cannabis-use is a consequence of 
schizophrenia. Their hypothesis, derived from the literature merely postulates that 
cannabis use is a consequence of the disorder and do not suggest a beneficial 
effect of the drug or negative consequence of withdrawal, just a mechanism of 
association.  
 
The onset of a chronic psychotic disorder is typically characterised by a prodromal 
state (APA, 2013a, p.102). Furthermore, individuals prone to the development of 
psychosis may exhibit traits with an affinity to psychotic symptoms (Lupay et al., 
2009). Consequently, a person who goes on to develop a psychotic disorder may 
have been experiencing prodromal symptoms for years prior to onset, and both 
clinically significant and non-clinically significant ‘symptoms’ associated with a 
schizotypal trait since early age. Khantzian suggests that the decision to self-
medicate with a particular substance of abuse is predicated upon the 
pharmacological action of the drug and its ability to alleviate symptomatology or 
psychological distress. Thus further evidence for the ‘self-medication hypothesis’ 
can be derived from the effect of CBD, which has been shown to alleviate 
psychotic symptoms with comparable efficacy (and fewer side-effect) to an 
antipsychotic (Leweke et al., 2012). Thus, there is a plausible rationale as to why 
patients prone to psychosis may choose to consume cannabis. Note though that 
this mechanism of self-medication derived from CBD does not account for the use 
of cannabis preparations such as sinsemilla which have been shown to typically 
have very low levels of CBD (Hardwick & King, 2008).  
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Further evidence for both Khantzian’s model and the model described by Kolliakou 
et al. (2011) can be derived from the research of Shoval et al. (2007). Shoval and 
colleagues found that patients comorbid for a substance use disorder and 
schizophrenia spectrum disorder displayed a trend toward lower levels of 
depression and fewer psychotic symptoms, in comparison to participants 
diagnosed with just a schizophrenia spectrum disorder. This may indicate that 
drug users with schizophrenia could be receiving an alleviation of symptoms as a 
consequence of their substance use. Moreover, Shoval and colleagues also found 
that substance use was predicted by comorbidity with anxiety disorders and 
previous suicide attempts. This could plausibly indicate that the co-morbid patients 
sought to use drugs to alleviate negative symptoms associated with the 
schizophrenia prodrome or schizotypal traits. However, several investigations 
have contradicted these findings. van Dijk, Koeter, Hijman, Kahn and van der 
Brink (2012) found no significant difference between cannabis users and non-
users suffering with schizophrenia in measures of symptoms. Similar findings have 
also been demonstrated in other cohorts (Boydell et al., 2007). Thus, indicating, 
that cannabis use may not confer a significant beneficial ‘self-medicating’ effect in 
all populations.  
 
Evidence has also been found in support of Kolliakou et al. (2011) model of self-
medication. Tosato et al. (2013) compared cannabis users and non-users that had 
been diagnosed with a psychotic disorder. The cannabis using group displayed 
fewer depressive symptoms, thus, providing evidence in support of the notion of 
cannabis use as a mechanism to alleviate dysphoria. Moreover, Tosato and 
colleagues documented no difference in pre-morbid adjustment between the 
cannabis- users and non-users. This indicates that there were no observable 
differences between the two populations. Therefore, the significant difference in 
depressive symptomatology could plausibly be attributable to cannabis use. Like 
Tosato and colleagues Katz, Durst, Shufman, Bar-Hamburger and Grunhaus 
(2010) also documented fewer depressive symptoms in cannabis users with a 
psychotic disorder in comparison to non-users. Moreover, Katz and colleagues 
reported that the cannabis using group had lower rates of social withdrawal and 
stereotyped thinking than non-users, which could implicate that cannabis is 
conferring a benefit on social skills.  
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The beneficial effect of drug use may have on a patient’s social contact found by 
Katz et al., (2010) has also been demonstrated in other investigations. Salyers & 
Meuser (2001) examined patients with a diagnosis of schizophrenia spectrum 
disorder and found that patients who did not use drugs were more likely to have 
infrequent social contact and problems in leisure than their drug or alcohol using 
counterparts. Further, evidence of the social enhancing aspects of drug use has 
been demonstrated in a qualitative investigation. Patients who had experienced a 
psychotic episode identified several motivations for use, including a need to 
conform to social norms with drug taking behaviour (Lobbana et al., 2010). This 
might suggest that the participants attempted to ‘self-medicate’ social withdrawal 
(plausibly experienced as a consequence of a schizotypal personality) by utilising 
drugs to facilitate social interaction. Further evidence of differences in personality 
between substance users and non-users can be derived from the investigation of 
Bizzarri et al., (2009) who explored self-medication with both licit and illicit 
substances in participants with a mental illness. Bizzarri and colleagues found that 
participants diagnosed with a substance use disorder displayed greater substance 
sensitivity, higher sensation-seeking personality traits, and greater incidence of 
self-medication in comparison to non-comorbid participants. These data provide 
support for the self-medication hypothesis suggesting that participants co-morbid 
with a substance use disorder utilised drugs in the alleviation of their symptoms. 
However, very few of the sample were diagnosed with a schizophrenia spectrum 
disorder (n=15 for each condition) and multiple substances not just cannabis were 
considered. Thus, although the data might suggest a differential personality profile 
between the two groups, there was too little data to suggest whether these 
differences are present in schizophrenia spectrum disorders or just 
psychopathology more generally. 
 
An alternative means by which the ‘self-medication’ hypotheses can be assessed 
is by assessing self-reported motivations for substance use. In an experience 
sampling study design the motivation for the majority of cannabis use reported 
was for the pleasurable effects (86.8%), whereas only a small (14.2%) proportion 
of cannabis use was as a coping-mechanism (Shrier, Walls, Rhoads, & Blood, 
2013). Thus, indicating that the majority of cannabis use cannot be attributable to 
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either a Khantizian or Kolliakou model of self-medication. However, this study did 
not utilise participants with a psychiatric diagnosis meaning that these individuals 
likely display a low incidence of psychosis proneness. Thus, these participants are 
not likely to be experiencing distressing symptoms that require (self-) medication, 
and so do not provide a good test of the self-medication hypothesis. Thornton et 
al. (2012) compared the motivations of participants with diagnoses of psychotic 
disorder and depression. They found no difference, between the two groups, in the 
rate cannabis was utilised as a coping mechanism or to alleviate symptoms. The 
lack of difference between the two groups suggests that they are using cannabis 
due to similar motivations. Furthermore, Gómez et al., (2013) found that patients 
who have had a first episode of psychosis did not differ from controls in their self-
report motivations for cannabis use. These findings serve to undermine 
Khantzian’s notion that psychological disorders form a unique self-medicating 
relationship with specific substances.  
 
Although, drug use may correlate with fewer negative symptoms (e.g. depression) 
and improvements in social functioning, the data do not unequivocally indicate 
self-medication. Meijer et al. (2012) documented fewer cognitive deficits in 
cannabis using patients with a psychotic disorder in comparison to non-user 
patients. Meijer and colleagues attributed the differences they observed to intrinsic 
differences between the groups. The investigators suggest that the cannabis using 
group differed as a consequence of them having a lower likelihood of 
decompensating, which has reached fruition partly as a consequence of using the 
drug. Within this model the cannabis users had fewer cognitive deficits because 
they had a lower schizotaxic loading, and had a higher rate of decompensating 
(than would be expected for their schizotaxic vulnerability) due to the causal 
effects of cannabis.  Within such a framework as that utilised by Meijer and 
colleagues the association between cannabis use, fewer negative symptoms, and 
better social functioning, may be explained by cannabis causing schizophrenia. 
 
In one of the few longitudinal investigations which has actively sought to test the 
self-medication hypothesis Henquet et al. (2005) assessed the presence of 
psychotic like symptoms at baseline (age 14 years), as a predictor of subsequent 
cannabis use at follow-up (age 24 years). There was no significant effect of 
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baseline symptoms indicating that within this cohort, participants were not 
attempting to ‘self-medicate’ attenuated psychotic symptoms with cannabis.  At 
present there is only limited available data in support of cannabis use being a 
consequence of psychotic illness. This is plausibly due to the difficulties in making 
such an assessment (see McLaren et al., 2010). Given the vast number of 
variables under consideration and the possibility of them interacting (see Section 
1.7.2) it is difficult to entirely refute the self-medication hypothesis. Moreover, 
schizophrenia could plausibly be a neurodevelopmental disorder (see Clarke et al., 
2012). If this does prove to be the case then it would be implausible to attempt to 
establish temporal priority and consequently most commonly accepted definitions 
of causality (see Section 1.6.4) of cannabis use over psychotic vulnerability. 
 
1.6.2 Common factors shared between cannabis use and schizophrenia 
Another explanatory model outlined by Gregg et al. (2007) to explain the link 
between cannabis use and schizophrenia suggests that the two share a common 
factor. This is also referred to as the 3rd factor model of association. This model 
postulates that the association between cannabis and schizophrenia is 
underpinned by a third factor which the other two variables share in common. 
When considering cannabis as a causal factor of schizophrenia one of the most 
difficult notions to dismiss is the possibility of a common factor or factors, which 
may account for the association between the two variables. One of the reasons 
why this notion is so difficult to dispel is that numerous different factors may 
underpin the association, some of which may be unobservable. In this section 
some of the possible common factors will be discussed. Nonetheless, given the 
numerous known and (in all likelihood) unknown variables that are associated with 
both schizophrenia (see Section 1.2.3) and cannabis consumption (e.g. 
availability, societal factors etc.) it is implausible to consider all of these factors. 
 
Chambers, Krystal, and Self (2001) suggest that schizophrenia and drug addiction 
may share a common aetiology in the dysregulation of dopamine and glutamate 
signalling. It is proposed that this mechanism may predicate those prone to 
schizophrenia to develop an addictive disorder more regularly than healthy 
individuals. This model may explain the association between cannabis use and 
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substance use disorder, but it fails to explain the association between incidence of 
cannabis use (i.e. non-pathological use) and psychotic disorder. A common factor 
which could plausibly increase the incidence of substance experimentation (the 
propensity to try an illicit substance) and psychotic disorder is ‘openness to 
experience’. Openness to experience is characterised by having a broad range of 
interests, and a tendency to be daring (McCrae & Costa, 1987, p.87). 
 
Ross, Lutz and Bailley (2002) found that the presence of positive schizotypal 
‘symptoms’ is predictive of an increase in openness to experience and the 
presence of negative ‘symptoms’ is predictive of a significant decrease. Indicating 
that vulnerability to schizophrenia (schizotypy) is feasibly, related in part, to the 
same mechanisms which determine the personality trait openness to experience.  
Flory, Lynam, Milich, Leukefeld and Clayton (2002) observed that cannabis abuse 
was associated with high openness to experience, as assessed by a measure of 
the five factor model of personality. Moreover, the effect of openness to 
experience being associated with cannabis abuse was not homogenous across 
substance abuse, with no such relationship established for alcohol. Thus, there 
exists converging evidence to suggest that one such common factor linking 
cannabis and the positive symptoms of schizophrenia is a propensity to be open to 
experience.  
 
Given the findings of Ross et al. (2002) it would follow reason that individuals 
displaying positive symptoms are more likely to be a drug abuser and individuals 
with more negative symptoms less so. Partial support for this comes from a study 
by Compton, Furman and Kaslow (2004), who reported that cannabis users had 
significantly fewer negative symptoms than non-users, however no significant 
difference in positive symptoms was observed. Schaub, Fanghaenel, Senn and 
Stohler (2008)found no significant difference in either positive or negative 
symptoms between moderate cannabis users, daily cannabis users or cannabis 
abstainers, thus providing no support for the theory. However, a meta-analysis of 
nine studies performed by Talamo et al. (2006) found that individuals co-morbid 
with schizophrenia and substance use disorder were significantly more likely to 
have more positive symptoms and fewer negative symptoms. In this instance 
causality is (once again) difficult to establish as the pharmacological action of the 
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substances in question (including cannabis) may independently result in the 
release of DA (see Section 1.2.1) in the human striatum (Bossong, et al., 2009) 
which in turn could elicit  more positive symptoms (Kapur, Mizrahi & Li, 2005). 
Nonetheless, taken together, these studies provide some evidence that openness 
to experience may be a shared factor between substance experimentation and 
psychotic propensity. 
  
Another example of a common factor is the presence of attention deficit 
hyperactivity disorder (ADHD) like symptoms. Cassidy, Joober, King and Malla 
(2011) found that retrospective assessments of childhood ADHD predicted inability 
to abstain from cannabis use in patients with a psychotic illness. As the presence 
of ADHD-like ‘symptoms’ were thought to precede the diagnosis of a psychotic 
disorder, it is feasible that these ‘symptoms’ may be reflective of 
neurodevelopmental differences of those able to abstain and those not. Support 
for ADHD-like ‘symptoms’ as a third factor linking psychotic disorder with cannabis 
use can be derived from investigations  that have demonstrated an association 
between childhood inattention; and a psychosis outcome (Erlenmeyer-Kimling et 
al., 2000); and drug use (van Emmerik-van Oortmerssen et al., 2012). 
Furthermore, schizotypy is a known correlate of ADHD (Keshavan, Sujata, Mehra, 
Montrose, & Sweeney, 2002). Thus, the data provides evidence in support of 
ADHD-like ‘symptoms’, acting as a common factor associating both cannabis use 
and schizophrenia. The data also indicates that such an association may plausibly 
be as a consequence of neurodevelopmental abnormalities.  
 
Evidence for many other different common factors have been suggested including; 
hedonic response influenced by ventral striatal activation (Cassidy, Lepage, 
Harvey & Malla, 2012); sensation-seeking (Zhornitsky et al., 2012); social 
anhedonia (Zhornitsky et al., 2012); and childhood abuse (Compton et al., 2004). 
However, whether or not these factors are truly independent of psychotic disorder 
and substance use is difficult to establish. For example, abnormality in ventral 
striatal activation could be a key component in the presentation of positive 
psychotic symptoms (Lewis & Buchanan, 2002). Thus, if such abnormalities are 
development antecedents of the disorder they are unlikely to exert a truly 
independent effect on drug use. Thus, in the aforementioned example it would 
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appear most plausible that this abnormality is primarily, or even causally, 
associated with schizophrenia and that the drug use association is a secondary 
effect. Nonetheless, whilst it is highly likely that cannabis use and schizophrenia 
share some common factors, this does not dispel the possible action of other 
mechanisms of association, as outlined by Gregg et al., (2007). 
 
1.6.3 Schizophrenia and cannabis synergistically maintain one another  
The third possible hypothesis outlined by Gregg et al., (2007) suggests that drug 
use and schizophrenia display a synergistic relationship wherein cannabis and 
schizophrenia can possibly prime for, and maintain, one another. Out of the four 
hypotheses suggested by Gregg and colleagues this is feasibly the most difficult to 
assess. “As yet, however, there have been no empirical investigations of 
bidirectional models” (Gregg et al., 2007, p.505). The rationale for this is that to 
assess such a relationship it is necessary to assess temporally sequenced data at 
various time points. The ability to test for such a possible hypothesis typically falls 
beyond the remit of cross-sectional research, although one novel case study may 
be able to provide limited data in support. In this instance, a 38 year old male 
patient suffering with psychotic disorder surreptitiously smoked cannabis whilst 
taking part in an imaging study (Voruganti, Slomka, Zabel, Mattar & Awad, 2001). 
During the imaging procedure the participant requested to take a break as they 
were experiencing distress. During a short break the participant used cannabis. 
The participant returned in a “relaxed and jovial” state, and completed the imaging 
procedure (p.174). However, the following day during a scheduled assessment the 
participant presented with an exacerbation of symptomatology.  
 
In Voruganti et al. (2001) case study the participant’s distress, was alleviated by 
the use of cannabis. However, despite experiencing alleviation of distress the 
following day the participant experienced an exacerbation of symptoms. This could 
plausibly indicate that cannabis provides temporary relief of distress and/or 
symptomatology. However, this relief is short lived and could come at the cost of 
exacerbation, which in turn could feasibly lead to more cannabis use. Further 
evidence for a synergistic relationship can be derived from research utilising an 
experience sampling (see Section 3.2.1) repeated measures study design. 
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Henquet et al., (2010) compared patients with a psychotic disorder with a control 
group on assessments of psychotic-like symptoms, mood, and cannabis use. They 
found that the patient group experienced significantly more psychosis-inducing 
and mood-enhancing effects of cannabis in comparison to controls. This indicates 
that the patients may be using cannabis for the mood enhancing aspects of the 
drug. However, this comes at a cost of exacerbation of symptoms. Henquet and 
colleagues describe this as feasibly underpinning a “vicious circle of deleterious 
use” (p.447). 
 
Another investigation has provided data relating to a bi-directional effect of 
cannabis and schizophrenia. Hides, Dawe, Kavanagh and Young (2006) followed 
up a group of patients who had recently experienced the onset of psychosis. 
Cannabis consumption predicted psychotic symptoms in a dose dependent 
fashion however, psychotic symptom severity in turn predicted cannabis 
consumption. This data indicates that distressing symptoms may increase the 
likelihood of cannabis use and cannabis use the likelihood of symptoms, this 
resembles the vicious deleterious circle suggested by Henquet et al., (2010). 
 
Due to the methodological difficulties associated with trying to observe the 
temporal relationship between symptomatology and cannabis use very few 
investigations have assessed this notion. Nonetheless, this hypothesis may 
explain why those who are psychosis prone may use cannabis more frequently 
than those non-prone.  
 
1.6.4 Cannabis use as a causal factor of schizophrenia 
Cannabis use has been shown to elicit psychotic-like reaction in healthy 
participants (e.g. Koethe et al., 2006) and exacerbate symptoms of people 
suffering with schizophrenia (e.g. D’Souza et al., 2005). Cannabis use is also 
associated with an acute psychotic illness, which is related to schizophrenia (see 
Section 1.5). Moreover, cannabis use has been consistently associated with a 
significantly earlier age of onset of non-cannabis induced psychotic disorder ( e.g. 
Barrigón et al., 2010; Katz et al., 2010; van Dijk et al.,2012). Furthermore, this 
effect is thought to be stronger for cannabis in comparison to other drugs of abuse 
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(Large, Sharma Compton, Slade & Neilssen, 2011). As compelling and consistent 
these findings are, they do not ‘prove’ the existence of a causal mechanism. 
 
Bradford-Hill (1965) recommended that several conditions must be satisfied in 
order for causal inference. Bradford-Hill (1965) suggests causality can be inferred 
from considering the weight of the evidence of; strength of association; 
consistency (across investigations); specificity; coherence; biological gradient; 
experimental evidence; analogy; temporality; and plausibility. “These guidelines 
provide a framework for the analysis of whether cannabis use is causally 
associated with psychosis” (McLaren et al., 2010, p.11). 
 
The epidemiological data presented in Section 1.6 suggests that there is good 
evidence for the strength of association between cannabis use and schizophrenia. 
Moreover, the association has been displayed quite consistently across the 
majority of cohort based investigations (see McLaren et al., 2010). However, one 
of Bradford-Hill’s suggested criteria is clearly not easily defined within this context. 
The criterion of specificity suggests that a given population will develop the 
disorder when introduced to the causal factor (i.e. cannabis). However, the factors 
that may constitute this population are difficult to determine (see Section 1.2.3). In 
addition to numerous different environmental and developmental factors which 
may increase the risk of a diagnosis of schizophrenia, there are plausibly 
hundreds of SNP’s each conferring an additive risk (see Section 1.2.3). Given 
these myriad of factors precisely identifying the population in which specificity can 
be demonstrated is at present impossible. Moreover, due to these numerous 
factors it is likely that schizophrenia can have multiple pathways to causation. 
Thus, even once the necessary population has been identified, there are likely to 
be incidence of the disorder which occurs in the absence of cannabis use. 
Consequently, it has been suggested that specificity should be dropped from these 
guidelines (Howick, Glasziou, & Aronson, 2009).  
 
Nonetheless, Bradford-Hill (1965) suggests that specificity may be observed by 
assessing the “specificity in the magnitude of the association” (p.297). Thus, 
specificity can be assessed by judging the magnitude in increases in O.R. in 
comparison to some of the other (feasibly) causal factors. Arseneault et al. (2002) 
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in assessments of the O.R. for psychotic like symptoms found that strong 
psychotic symptoms at 11 years old increased the O.R. 5.16 fold, however 
cannabis use by age 15 increased the O.R. 6.56 fold. However, in assessments of 
the O.R. of an outcome of schizophreniform disorder the presence of psychotic 
symptoms at age 11 had more than 5 times the magnitude of effect of cannabis 
consumption. In another investigation, cannabis dependence (O.R. 2.94) has 
demonstrated a greater O.R. on an outcome of psychotic symptoms in comparison 
to dependence on other drugs (+/- cannabis dependence) (O.R. 2.29) (Johns et 
al., 2004). Caution should be adopted in comparison of odds ratios as this will in 
some regards be dependent on the scales under assessment. However, as the 
independent variables discussed are dichotomous as opposed to continuous, the 
comparison still holds meaning (as long as the measures are viable assessments 
of the constructs). Thus, the data indicate that cannabis use may hold specificity of 
magnitude over some other constructs with regards to psychotic-like symptoms, 
but plausibly not diagnosable schizophrenia spectrum disorder.  
 
Little data is available to test the coherence for a causal relationship. Frisher, 
Crome, Martino and Croft (2009) compared estimates of the prevalence of 
cannabis use with estimates of the prevalence of schizophrenia. Frisher and 
colleagues reasoned that, if a causal model can be adopted then incidence and 
prevalence of schizophrenia should display a positive relationship with cannabis 
use. However, examination of patient records of 2.3% of the population of the U.K. 
did not elucidate such a hypothesised increase, despite this encompassing a 
period of time with a theorised increase in cannabis consumption. There was no 
significant change in incidence of schizophrenia or psychoses. In fact, the data 
indicated a decrease in the prevalence of schizophrenia and a decrease in the 
prevalence of psychoses in the latter years of the data submission period, as 
incidence of cannabis consumption increased. Further evidence against the 
presence of coherence can be derived from research with an Australian cohort. 
Degenhardt, Hall and Lynskey (2003) demonstrated no significant increase in the 
incidence of schizophrenia, and no consistent pattern of decrease in the age of 
onset, despite theorised increase in prevalence and incidence of cannabis use.  
Thus, there is no available data to suggest a coherent model of association. 
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There are however, data available suggesting a biological gradient or what may 
also be referred to as a dose-dependent effect. If cannabis causes schizophrenia 
then it would stand to reason that a greater exposure to cannabis should increase 
the odds of a diagnosis. This notion has been demonstrated in various cohort 
based studies (Henquet et al., 2005; Manrique-Garcia et al., 2012; van Os et al., 
2002).Moreover, a dose dependent effect has also been demonstrated in relation 
to within-participant variance in psychotic-like symptoms in a longitudinal 
investigation (Van Gastel, Schubart, Kahn & Boks, 2010). Furthermore, a dose 
dependent response was demonstrated in relation to frequency and onset of 
psychotic relapse in a patient group (Linszen, Dingemans, & Lenior, 1994). A 
biological gradient has also been demonstrated by Baskak et al., (2012) who 
found a negative relationship between temporal proximity to last cannabis use and 
assessments of schizotypy.  
 
However, other investigations have failed to replicate evidence of a biological 
gradient. Schaub et al. (2008) compared three groups of participants suffering with 
schizophrenia, no difference was found between those cannabis naïve, ‘moderate’ 
cannabis users, or daily cannabis users in assessments of psychotic 
symptomatology. Barrowclough, Emsley, Eisner, Beardmore, & Wykes (2013) 
compared patients with a psychotic disorder who were either cannabis users or 
users of other drugs. Barrowclough and colleagues did not document an effect of 
cannabis consumptions per se, or dose of cannabis on positive symptomatology. 
Intriguingly the cannabis using group displayed significantly fewer negative 
symptoms. Nonetheless, Barrowclough and colleagues did find a dose dependent 
effect of cannabis on assessments of functioning. Thus, this indicates that 
cannabis may confer a beneficial effect to the user, serving to dispel the notion 
that cannabis causes schizophrenia. 
  
At present the data appears to indicate that there is some evidence of a biological 
gradient in the relationship between cannabis and schizophrenia. Nonetheless, the 
significance of such a relationship is unclear due to the number and breadth of 
social (e.g. changes in maternal marital status) and genetic (e.g. child’s gender) 
factors that have been associated with cannabis use and cannabis use disorder 
(see Hayatbakhsh, Najman, Bor, O’Callaghan & Williams, 2009). Several of these 
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factors may also influence the expression of schizophrenia (see Section 1.2.3) 
thus the evidence of a dose dependent response has been brought into question. 
“Where confounding factors covary with the exposure of interest in a quantitative 
fashion (as they often will) then spurious dose–response associations will be 
apparent” (Macleod, 2007, p.405). An example of the non-independence of one of 
these factors can be derived from the prospective cohort study of Kuepper, van 
Os, Lieb, Wittchen, and van Os (2011) who found that both urbanicity and 
cannabis use interact to significantly predict psychotic symptoms. 
 
There is a body of evidence which suggests that numerous different factors may 
increase the O.R. of a psychotic disorder (see Section 1.2.3). Some of these 
factors may be seen as analogous to cannabis in the respect that they are 
environmental factors (e.g. urbanicity) which appear to increase the odds ratio of 
schizophrenia. However, these factors have not provided sufficient evidence to 
assert a causal inference (e.g. urbanicity; Pedersen & Mortensen, 2006; Vassos, 
Pedersen, Murray, Collier & Lewis, 2012). Thus, there is a body of evidence 
suggesting that analogous factors may cause schizophrenia. However, the weight 
of evidence in support of these factors as causally associated with schizophrenia 
is typically comparable to cannabis (see Clarke et al., 2012).  
 
As it would not be ethical to induce chronic illness, there is a paucity of 
experimental evidence that may provide causal inference in the relationship 
between cannabis and psychotic disorder. Nonetheless, there is a wealth of 
experimental data indicating that cannabis may cause psychotic like reaction in 
healthy participants and exacerbation of symptoms in people diagnosed with 
psychotic disorder (see Section 1.5 and also see D’Souza, Sewell, & 
Ranganathan, 2009 for review). Moreover, there are data indicating that the same 
drugs used in the treatment of schizophrenia may be proficient in ameliorating 
acute psychotic (and psychotic like) states induced by cannabis (see Crippa et 
al.,2012 for review). However, there is a vast difference between inducing and 
ameliorating temporary psychotic like states and causing chronic psychotic illness. 
The experimental evidence from temporary psychotic like states allows causal 
inferences to be made, but are far from sufficient to attribute causality to; 
schizophrenia.  
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Experimental study design is proficient at establishing temporality, there is a 
clearly demonstrated effect of ∆-9-THC preceding exacerbations in psychotic 
symptoms. However, out of the confines of the laboratory, one of the more difficult 
of Bradford Hill’s (1965) recommendations to establish is temporality. Temporal 
priority is established by examining the sequence of occurrence of events to 
ascertain which of the events precedes which. Utilising the Christchurch cohort 
Fergusson, Horwood, and Ridder, (2005) attempted to use structural equation 
modelling to account for unobserved confounders, which might include factors 
such as neurodevelopmental differences. Despite controlling for unobserved 
effects, cannabis still exerted an influence on an outcome of psychotic symptoms 
inferring between a 1.6 and 1.8 fold increase in odds. The model may even 
account for a schizotypal state (see Section 1.2.2) or gene by environment 
interaction effect in the residual (see Henquet, DiForti, Morrison, Kuepper & 
Murray, 2008). However, such a modelling technique may not elucidate time 
dynamic effects at a micro- (or macro-) level of the time dynamic under 
observation. For example, synergistic maintenance may be taking place at a 
moment to moment basis, which could result in a macro-level effect of cannabis on 
psychotic symptoms at time of assessment. Nonetheless, such a scenario is only 
likely to come to fruition where the effect of cannabis on psychotic symptoms is 
greater than the effect of psychotic symptoms on motivations to consume 
cannabis. Thus, Fergusson et al., (2005) provides a good argument for cannabis 
consumption having an independent causal effect on the presentation of psychotic 
symptoms. However, psychotic disorder was not assessed. This provides 
evidence of cannabis ‘causing’ psychotic symptoms. However, this is a finding that 
has been replicated in numerous experimental investigations (see D’Souza et al., 
2009).  
 
Some studies can provide information in regards to cannabis’ temporal priority 
over psychotic disorder. Allebeck, Adamsson, and Engström (1993) examined 
medical records to identify patients that had at some point in their lifetime received 
a diagnosis of cannabis use disorder and schizophrenia. The majority of the cases 
(69%) initiated pathological cannabis use prior to the onset of psychotic 
symptoms. These findings were supported by Sevy et al. (2010) who reported that 
the majority of patients they assessed with a dual-diagnosis of cannabis use 
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disorder and schizophrenia, had the onset of the cannabis use disorder prior to the 
onset of positive symptoms. Moreover, within this sample cannabis use was also 
associated with an increase in severity of positive symptoms. Linszen et al. (1994) 
also found that in the majority of their sample (96%) cannabis abuse preceded the 
onset of a schizophrenia spectrum disorder. The findings of Allebeck and 
colleagues, Sevy and colleagues, and Linszen and colleagues suggest; that the 
onset of a cannabis use disorder has the appropriate temporal sequencing to 
promote a psychotic disorder. However, it should be noted that, although, this 
association has been documented in cannabis abuse, this does not account for 
the association between non-pathological cannabis use and schizophrenia. 
Moreover, the aforementioned investigations have demonstrated evidence of 
priority over positive symptomatology, but not a pre-morbid state. 
  
In terms of elucidating the effect of temporal sequencing and more broadly 
causality the findings of Hambrecht & Hafner (1996; 2000) reveal an association 
which has gained some acceptance (e.g. see Gregg et al., 2007 p.505); the 
presence of multiple models of association. Hambrecht & Hafner (1996) assessed 
temporal priority in patients with a psychotic disorder. They found drug abuse 
preceded symptoms in 27.5% of cases; symptoms preceded drug use in 37.9% of 
cases; and they occurred within the same month in 34.6% of cases. These 
findings suggest that different groups of participants could plausibly have different 
models of association. This provides support for each model of association 
outlined by Gregg et al., (2007); schizophrenia as a consequence of cannabis use; 
cannabis use as a consequence of schizophrenia; and a common factor and / or 
synergistic maintenance of the factors. Although, Hambrecht & Hafner looked at 
drug use per se, the most frequently used drug in the sample was cannabis (88% 
of respondents). Hambrecht & Hafner (2000) undertook further analysis and 
elucidated that cannabis abuse typically preceded the onset of positive symptoms, 
however, the onset of prodromal symptoms disaggregated into the three groups 
described previously. By extending their investigation to assess the onset of the 
prodrome Hambrecht & Hafner have attempted to establish temporality over the 
onset of the disorder as opposed to the onset of clinically relevant symptoms. This 
adds further weight to the notion that several different models of association may 
be at work. 
79 | P a g e  
 
 
As discussed in Section 1.2.3, schizophrenia is heavily influenced by both genetic 
and developmental factors. There is also evidence suggesting schizophrenia may 
have both neurodevelopmental and neurodegenerative components, related to 
both structural and pharmacological abnormalities (Gupta & Kulhara, 2010). Thus, 
the influence of this purported “progressive neurodevelopmental disorder” may be 
exerted from a very young age (Rapoport & Gogtay, 2011, p.251). An example of 
such could be expressed in the affinity between schizophrenia and schizotypal 
personality traits which are thought to be stable from a very young age. Cannabis 
use onset will not typically occur before adolescence or early adulthood (e.g. 16 
years old; Hayatbakhsh, Williams, Bor & Najman, 2013). Thus, cannabis use 
initiation typically occurs a substantial period of time after the on-set of 
neurodevelopmental abnormalities, obstetric complications, or the formation of 
personality. If these factors that occur early in life are found to be causally related 
to the development of schizophrenia then disentangling the temporal priority of 
cannabis on disease onset becomes even more onerous. 
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1.7 ‘Plausible’ mechanisms by which cannabis might cause 
schizophrenia 
Bradford-Hill (1965) postulated several recommendations for causal inference (see 
Section 1.6.4). This section is dedicated to assessments of plausibility, the means 
by which cannabis could cause schizophrenia. Assessments of plausibility are 
however, difficult to establish in fact, Bradford-Hill suggested that plausibility “is a 
feature I am convinced we cannot demand. What is biologically plausible depends 
upon the biological knowledge of the day” (p.10). Thus, this is not a requisite of a 
causal inference and will be impart limited by inadequacies and lack of coherence 
in data pertaining; to genetic and environmental susceptibility (see Section 1.2.3 
pp. 37-49); and more broadly the aetiology of schizophrenia (see Section 1.2.1 pp. 
21-25). Nonetheless, given the available data several plausible mechanisms have 
been proposed. This section seeks to assess some of the available data pertaining 
to a selection of these mechanisms. This section will assess the plausibility of 
cannabis inducing psychotic disorder through; a dopaminergic mechanism of 
action; a gene by environment interaction effect; a sensitisation effect; and an 
interaction (cross-sensitisation) with stress. It is important to note that these 
mechanisms of action may be viewed as independent mechanism. However, the 
most likely mechanism of action consists of a combination of factors. For example, 
a genetic influence may interact with cannabis, and both cannabis and genetic 
factors may also interact with other environmental factors (e.g. stress). Through, a 
process of sensitisation this interaction of factors may result in a change in 
response amplitude and psychotic disorder. The pharmacological expression of 
these interactions of variables could be a disruption of dopaminergic function. 
 
1.7.1 Dopamine 
One plausible mechanism by which cannabis can induce both an acute psychotic 
state (i.e. D’Souza et al., 2004) and potentiate for chronic psychotic disorder 
involves the neurotransmitter dopamine. It is thought that a dysfunction in 
dopaminergic function is a central component in the expression of schizophrenia 
(see Section 1.2.1). Cannabinoids are known to elicit their principal psychoactive 
effect through the cannabinoid receptor CB1 (Pertwee, 2006). Cannabinoid 
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receptors are known to be present in many areas of the brain (Herkenham et al., 
1990). Some of these areas including the cerebellum (Picard, Amado, Mouchet-
Mages, Olié & Krebs, 2008), the basal ganglia (Perez-Costas, Melendez-Ferro, & 
Roberts, 2010), the hippocampus (Harrison, 2004) and the pre-frontal cortex 
(PFC: Salgado-Pineda et al., 2007) have previously been implicated in psychotic 
disorders.  
 
The cerebellum has been associated with dysfunction of the mesolimbic and 
mesocortical pathways (see Section 1.2.1) via its effects on the midbrain 
(Nopoulos, Ceilley, Gailis & Andreason, 2001). The basal ganglia is modulated by 
the VTA which is central to both mesolimbic and mesocortical pathways (Perez-
Costas et al., 2010). Moreover, as the PFC forms part of the cortex it is invariably 
associated with the mesocortical pathway. Thus, given the presence of the CB1 
receptors the notion that they may be modulating DAs function in these regions is 
a plausible mechanism. Consequently, a theory encompassing cannabis’ 
psychotomimetic and psychotogenic effects as mediated by dopamine has a body 
of converging evidence.  
 
There are a number of naturally occurring chemicals that bind to the CB1 receptor, 
the best known of these endogenous cannabinoids (endocannabinoid) is 
anandamide. Anandamide is thought to be metabolised more quickly than ∆-9-
THC, and to have a milder psychoactive effect (Scherma et al., 2008). 
Nonetheless, it is thought to play a crucial role in reward processing and DA 
release (Cheer, et al., 2007). In animal models, ∆-9-THC has been shown to elicit 
DA release in the medial prefrontal cortex (Chen, Paredes, Lowinson & 
Gardner,1990) and nucleus accumbens, with these effects being attenuated by a 
CB1 antagonist (Cheer, Wassum, Heien, Phillips & Wightman, 2004; Tanda, 
Pontieri & Chiara, 1997). These findings implicate a dopaminergic action of the 
endocannabinoids within humans and a dopaminergic action of ∆-9-THC within 
animal models. 
 
In human participants Bossong et al., (2009) demonstrated a dopaminergic action 
of ∆-9-THC in several human striatal sub-regions. In the case study described in 
section 1.6.3, the surreptitious consumption of cannabis resulted in an increase in 
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dopaminergic activity (Voruganti et al., 2001). Further, evidence of the 
dopaminergic action of cannabis is evinced by the ability of DA antagonists to 
alleviate the symptoms of intoxication (Liem-Moolenaar et al., 2010). Moreover, 
Greenwood et al., (In press) have demonstrated that cannabis users display N-
methyl-D-aspartate receptor (NMDAr) dysfunction. Although the NMDA-r is 
primarily associated with the neurotransmitter glutamate, antagonism of the 
NMDA-r appears to increase the availability of dopamine in the cortex (particularly 
at D1 receptors), although the mechanism by which this occurs (and indeed its 
clinical significance) remain matters of conjecture (see for example Smith et al., 
1998 and Deakin, Lees, & McKie, 2008).  
 
There is also behavioural evidence for a link between cannabis and DA activity. 
For instance, cannabis has been shown to alter attentional salience processing 
(Bhattacharyya et al., 2012), the dysfunction of which has been attributed to 
dopaminergic processes (Kapur et al., 2005). Furthermore, it is thought that 
dopaminergic activity plays a central role in addiction (Wise, 2008), and cannabis 
has been associated with psychological and physical dependence and withdrawal 
(See Maldonado, Berrendero, Ozaita & Robledo, 2011 for review).  Nonetheless, a 
recent review examining cannabis as a typical drug of dependence concluded that 
it does not display a profile of DA alteration consistent with other addictions 
(Ghazzaoui & Abi-Dargham, in press). This finding suggests that if cannabis is 
eliciting DA release then this may be occurring; in an atypical manner; in only a 
small group of users; or not on a consistent basis. 
 
Support for a cannabis dopaminergic pathway to psychotic reaction has not been 
consistently demonstrated in humans. For instance, in one post mortem 
investigation there was evidence of dopamine dysfunction in participants who had 
a provisional diagnosis of schizophrenia (Dean, Bradbury, & Copolov, 2003). 
However, there was no significant difference in DA transporter binding in controls / 
patients who had THC metabolites in their blood in comparison to those without 
recent cannabis use. Another study showed that a group of patients who had 
suffered with their first psychotic episode displaying cannabis dependence did not 
differ in their D2 receptor binding from non-cannabis using patients (Safont et al., 
2011).Chronic cannabis users also do not demonstrate a reduction of striatal 
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D2/D3 receptor availability, as would be consistent with abuse of a dopaminergic 
substance (Albrecht et al., 2013). This finding has been replicated in other 
investigations (Urban et al., 2010; 2012). However, these investigations 
demonstrated significant alterations in DA function in a subset of users who had 
initiated use prior to 18 years old. This finding may explain the lack of consensus 
in the literature relating cannabis’ effects to those of a typical drug of addiction. 
Plausibly, the findings of Urban et al (2010; 2012) indicate that age of initiation or 
duration of use may be mediating factors in the dopaminergic effect of cannabis.  
 
Results of imaging studies have also failed to support the notion of cannabis as a 
DA agonist. Neither, Barkus et al. (2011) nor, Stokes et al., (2009) found an 
elevation in striatal DA release as a result of a ∆-9-THC challenge, despite the 
presence of psychotic-like symptoms. Stokes and colleagues suggested that the 
data indicates that striatal DA release is unlikely to be the mechanism of 
association between cannabis and schizophrenia (p.186). However, in a 
subsequent re-analysis of their data Stokes et al., (2010) did elucidate evidence of 
dopaminergic activity in both frontal and temporal gyri. These areas are associated 
with decision making and auditory perception respectively (Stokes et al., 2010, 
p.1526). Alterations of dopaminergic activity in this area could explain disruptions 
in cognition and the presence of hallucinatory or delusional experience. 
Nonetheless, elevated dopaminergic activity in the cerebral cortex did not correlate 
with assessments of psychotomimetic experience. Thus, although Stokes and 
colleagues have demonstrated some evidence of dopaminergic activity as a 
consequence of cannabis, it is not yet clear whether this might be clinically 
relevant in the expression of psychotic symptoms. 
 
In a recent imaging study an inverse relationship was demonstrated in DA 
synthesis capacity in the striatum and cannabis use with cannabis users meeting 
criteria for dependence (Bloomfield et al., in press). This finding indicates that 
cannabis may serve to reduce the brains capacity to create DA within this area. It 
is thought that people suffering with schizophrenia have an increased availability 
of DA in the striatum (Kegeles et al., 2010). This may indicate that cannabis does 
elicit DA release. However, if DA release is occurring (or has occurred) it is 
unlikely that cannabis is potentiating for a sensitised dopaminergic system. 
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Therefore, this is unlikely to be the pathway to psychotic disorder. Furthermore, 
Bloomfield et al., (in press) did not find a relationship between an altered 
dopaminergic system and the presence of cannabis-induced psychotic-like 
symptoms. 
 
Research in humans implicating a dopaminergic pathway between cannabis and 
psychosis is still in its infancy (see Stokes et al., 2010, p.1521) and, as discussed 
in this section, the evidence is far from definitive. The prospect of DA release 
mediating the psychotomimetic and psychotogenic effects of cannabis is certainly 
feasible. However, even if cannabis is a DA agonist, it is not yet clear, whether this 
reflects a primary or secondary process. That is, DA release could represent the 
pharmacological expression, as opposed to the mechanism per se. Thus, other 
plausible mechanisms of action may or may not incorporate an association 
between cannabis and cortical and sub-cortical DA release.   
 
Given that genetic factors appear to be the most powerful determinates of 
psychotic disorder (see Section 1.2.3) it is feasible that those who experience the 
dopaminergic effects of cannabis already have a pre-existing vulnerability. This is 
supported by the research of Kuepper, Ceccarini et al., (2013), who found no 
dopaminergic response to a ∆-9-THC challenge in healthy controls. However, 
there was evidence of dopaminergic activity in the striatal sub-regions of patients 
and first degree relatives. This could suggest that the dopaminergic action of 
cannabis is only present in those at greatest genetic risk. This is known as a gene 
and environment interaction. 
 
1.7.2 Gene and Environment interactions 
Another plausible mechanism by which cannabis might cause schizophrenia 
involves an interaction between genes and the environment. This model suggests 
that genetic and environmental factors may interact to bring about psychotic 
disorder. As discussed in Section 1.2.3 schizophrenia appears to have a high 
degree of heritability, and yet genetic models fail to account for much of the 
variance in the data and often yield inconsistencies. These inconsistencies could 
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plausibly be attributable to the models’ inability to model an interaction between 
gene and environment.  
 
The Catechol-O-methyltransferase (COMT) gene has a functional polymorphism: 
Valine (Val) and Methionine (Met). It is thought that the genetic expression 
influences DA’s availability in the Pre-Frontal Cortex, with Val homozygotes 
presumably having the lowest synaptic DA levels, resulting in greater availability of 
DA at the receptor (Chen et al., 2004). Caspi et al., (2005) looked at genetic 
vulnerability within the COMT gene, which they found moderated the influence of 
(adolescent) cannabis use on the development of schizophreniform disorder. Once 
again utilising the Dunedin birth cohort (Arseneault et al., 2002), 953 individuals 
were genotyped. Caspi and colleagues observed no significant effect of genotype, 
or adolescent cannabis exposure per se. However, a significant interaction effect 
between the two variables was observed.  Specifically, of the early initiates into 
cannabis use 4.2% of the Met homozygotes went on to develop schizophreniform 
disorder, in contrast 13% of the Val homozygotes developed the illness. The 
adjusted O.R. of the interaction effect between adolescent cannabis use and 
geneotype showed that, whilst Met homozygotes had only a slightly elevated 
chance of developing schizophreniform disorder over cannabis abstainers (1.1 
OR), Val/Met heterozygotes were at a greater risk (2.5 OR), and carriers of two 
Val alleles were at the greatest risk (10.9 OR). This finding shows that the 
phsychotogenic effects of cannabis is moderated by the Val allele of the COMT 
gene. 
 
Further evidence of an interaction effect between the COMT gene and cannabis 
has been demonstrated in animal models (O’Tuathaigh, et al., 2012). Evidence of 
a cannabis COMT interaction effect has also been demonstrated in a naturalistic 
environment. In an ESM study Henquet et al., (2009) considered 31 patients with 
psychotic disorder and 25 healthy controls. The data from the participants were 
pooled and split into those with low schizotypy (n=14) and those with high 
schizotypy (n=42). Henquet and colleagues found that the Val carriers who were 
high schizotypes showed an increase in hallucinatory experience as a 
consequence of cannabis use. However, no such effect was found in the low 
schizotypes, or the high schizotypes who were Met homozygotes. This finding was 
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also repeated in an experimental investigation (Henquet et al., 2006), providing 
additional support for the COMT gene as a modulating factor in the psychotogenic 
effects of cannabis. However, given that this effect appears restricted to a subset 
of psychosis prone individuals it is feasible that other mechanisms may also 
explain the relationship between cannabis and schizophrenia. 
 
Several studies have failed to replicate Caspi et al. (2005) findings. One such 
study is Zammit et al. (2007) who found no significant interaction effect in a cohort 
of 493 patients with schizophrenia. The findings remained consistent even when 
participants were differentiated at age of first cannabis use. However, in this study, 
participants were differentiated on the basis of being over the age of 18 at first 
cannabis use and this information was reliant upon retrospective accounts. Caspi 
and colleagues found the most significant effect when differentiating participants 
on the basis of whether they had initiated use prior to 15 or had become monthly 
users by 18 years of age. Furthermore, the inclusion criteria were based on the 
participant’s accounts at that age. The lack of a significant interaction in this study 
could therefore be accounted for by, the adoption of a different criteria and 
retrospective assessment, in determining ‘the early onset of cannabis use’. 
 
Zammit, Owen, Evans, Heron and Lewis (2011) once again failed to replicate 
Caspi et al. (2005) findings in a prospective cohort study, cannabis use was 
assessed at age 14, with no difference in psychotic experience, after a two-year 
follow-up period, found on the basis of COMT genotype expression. However, 
cannabis use may have a neurodegenerative effect associated with chronicity of 
use (Arnone et al., 2008), which may not have been present at time of evaluation 
(age 16). Thus, this may account for the lack of significant findings in Zammit et al. 
(2011) investigation. 
 
Pelayo-Téran et al., (2010), looked at the interaction between cannabis use and 
polymorphism in the COMT gene and its effect on age of onset of psychosis. In a 
non-cannabis using control group; Val homozygotes had a significantly earlier age 
of onset; with Met homozygotes displaying a later age of onset; and heterozygotes 
displaying an intermediary profile. In the cannabis using group there was no 
significant difference on age of onset based on COMT polymorphism. Thus, the 
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data may indicate that, in this instance, the cannabis COMT interaction may serve 
to alter the delay effect conferred by two Met alleles. The research of Pelayo-
Téran and colleagues brings into question which functional polymorphism of the 
COMT gene is most susceptible to the deleterious effects of cannabis.  
 
Costas et al., (2011) also found a ‘reverse association’. They found that Met 
homozygotes had twice (2.07 OR) the probability of lifetime prevalence of 
cannabis consumption, however age of cannabis initiation was not controlled for. 
Despite age initiation being an important determining factor in Caspi et al., (2005) 
investigation. The exact effect of not differentiating participants according to early 
or late onset of use is difficult to determine. Unfortunately, this makes it difficult to 
draw comparison with the findings of Caspi and colleagues. Costas et al., (2011) 
discuss the possibility of a ‘flip-flop’ association whereby biological, environmental, 
or methodological factors may be considered the putative explanation. The 
investigations of Costas and colleagues, and Pelayo-Téran and colleagues do 
suggest a modulating effect of the COMT gene on cannabis. However, the 
‘reverse association’ of the Met allele indicates that at present our current 
understandings of the genetic factors which predispose to schizophrenia are not 
adequate. 
 
In conclusion, a gene / environment interaction based on the COMT gene and 
adolescent cannabis use does appear plausible. However, given the inability of 
subsequent studies (Costas et al., 2011; Pelayo-Téran et al., 2010; Zammit et al., 
2007; Zammit et al., 2011) to replicate Caspi et al., (2005) findings what, if any, 
interaction exists is, at this moment, difficult to establish. At present there is no 
definitive evidence mapping out specific genomes that confer susceptibility to 
schizophrenia, and research within this domain is often marred by an inability to 
replicate findings (see Section 1.2.3). Henquet et al., (2008) in a review of gene x 
cannabis (environment) interactions summarises that genetic and environmental 
influence “...are more likely to underlie the complex interactions between cannabis 
and psychosis, whereby multiple variations within multiple genes—rather than one 
single genetic polymorphism— may set an individual’s vulnerability at birth to 
develop later psychosis” (p.1117). This notion is evinced by several SNP’s 
displaying a significant interaction effect with cannabis including the NRG1 gene 
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(Han et al., 2012), the FAAH gene (Arias et al., 2010),  the  AKT1 gene (Di Forti et 
al.,2012; van Winkel, 2011), and a three-way interaction between the AKT1 gene, 
the COMT gene and cannabis (van Winkel, 2012). A cannabis gene interaction, 
possibly via a DA pathway (for example COMT SNP), is perhaps the most 
plausible model available to suggest how cannabis might cause schizophrenia. 
Nonetheless, further information is required to elucidate the mechanism by which 
each cannabis use may contribute to the expression of psychotic experience, 
psychotic symptoms and psychotic disorder. Such a mechanism has been 
proposed in sensitisation.  
 
1.7.3 Sensitisation  
Sensitisation refers to the repeated exposure to stimuli, which results in an 
enduring alteration in response amplitude. Although there is compelling evidence 
that schizophrenia is influenced by genetic factors, numerous environmental 
stressors also increase the odds ratio of decompensating (see Section 1.2.3). 
However, it is not thought that any of these factors are completely deterministic of 
psychotic disorder (Clarke et al., 2012).Van Os et al., (2009) suggests that in a 
continuum model of psychotic disorder (see Section 1.2.2); 8% of the general 
population have psychotic-like experience; 50% of them (4% of the general 
population) experience psychotic symptoms; and 75% of them (3% of the general 
population) develop psychotic disorder. Although van Os and colleagues found the 
presence of psychotic experience to be relatively common, for some people, these 
transitory experiences persist, leading to clinical relevance.  Van Os and 
colleagues suggest that repeated exposure to deleterious environmental factors in 
childhood/adolescence may be a significant contributory factor to chronic 
psychotic disorder. Given cannabis’ propensity to elicit transitory psychotic-like 
experience (see Section 1.8 & 1.6.4) exposure to cannabis may constitute one 
such environmental factor.  Van Os and colleagues suggest that this may take 
place by a process of sensitisation, defined by Collip, Myin-Germeys, and Van Os 
(2008) as “the observation that individuals who are exposed repeatedly to an 
environmental risk factor may develop progressively greater responses over time, 
finally resulting in a lasting change in response amplitude” (pp.  220-1).  
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A process has been described whereby neurochemical sensitisation, thought to be 
underpinned by the release of DA into the ventral tegmental area, plays a role in 
decompensating in vulnerable people and the course of the disorder (Lieberman, 
Sheitman, & Kinon, 1997). Lieberman et al., (1997) describe sensitisation as 
consisting of both an induction and expression phase. Lieberman and colleagues 
suggest that the induction phase is thought to be underpinned by DA release into 
the ventral tegmental area (VTA). However, a more recent review has argued that 
multiple cortical and subcortical regions (including the VTA) may be implicated as 
is the neurotransmitter glutamate at the NMDAr (Vanderschuren & Kalivas, 2000). 
Irrespective, both DA release in the VTA and inhibition of the NMDAr have been 
implicated in psychotic break down and the expression of positive and negative 
symptoms (Lieberman et al., 1997; Lisman, Pi, Zhang & Otmakhova, 2010; 
Morgan, Mofeez, Brandner, Bromley & Curran, 2004). Some of the same neural 
networks and transmitters are also thought to underpin the second phase of 
sensitisation expression (Vanderschuren & Kalivas, 2000). 
 
Lieberman et al., (1997) describe the development of schizophrenia within a three 
stage process. The first stage requires genetic vulnerability and / or 
neurodevelopmental abnormalities. The second stage occurs during adolescence 
or early adult hood wherein repeat exposure to a stressor results in repeated 
release of DA in the VTA. The third stage consists of “structural neuronal changes” 
which results in clinically relevant disorder (p.216). Although the neurochemical 
process described by Lieberman and colleagues may represent the underlying 
mechanism, the process of sensitisation can be seen expressed in behaviour, 
affect and cognition (Collip et al., 2008). 
 
Further evidence for a process of sensitisation in psychotic disorder can be 
derived from the investigation of Dominguez, Wichers, Lieb, Wittchen and van Os 
(2011), who found that the greater the persistence of sub-clinical psychotic 
experiences, the greater the transition to psychotic disorder. Moreover, this was 
found in a dose dependent fashion. Furthermore, Cougnard et al., (2007) 
elucidated an additive effect of environmental stressors that combined with 
psychotic-like experience to contribute to persistent and feasibly clinically relevant 
psychotic ‘symptoms’. A model of sensitisation could explain why schizophrenia 
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appears to have both neurodevelopmental and neurodegenerative features (Gupta 
& Kulhara, 2010). The neurodevelopmental features may be represented by 
genetic factors, and the neurodegenerative features could be as a consequence of 
sensitisation.  
 
Animal models have been shown to sensitise to cannabis. Behavioural 
sensitisation has been demonstrated as a consequence of having repeat doses of 
∆-9-THC (Cadoni, Pisanu, Solinas, Acquas & Chiara 2001; Rubino, Viganó, Massi 
& Parolaro, 2001). Furtheremore, behavioural sensitisation to ∆-9-THC has been 
found to correspond with alterations in DA transmission (Cadoni, Valentini, & 
Chiara, 2008). However, other investigations have failed to replicate these findings 
(Arnold, Topple, Hunt & McGregor, 1998; Varvel, Martin & Lichtman, 2007). The 
evidence suggesting a sensitising effect of cannabis is at present sparse. Animal 
models suggest a possible mechanism of sensitisation. However, such a response 
has not been demonstrated consistently and may not extrapolate to humans. 
 
In human subjects, cannabis users have demonstrated an increased activity in the 
ventral striatum in response to a non-drug reward (Nestor, Hester, & Garavan, 
2010). This activation significantly and positively correlated with life-time cannabis 
exposure. This indicates that cannabis may sensitise to non-cannabis related 
events: cross-sensitise. Similarly as demonstrated in Nestor et al., (2010) 
investigation, in animal models the prior administration of cannabis has been 
shown to cross-sensitise to amphetamine (Gorriti, Fonseca, Navarro & Palomo, 
1999), and morphine (Cadoni et al., 2008).  However, cannabis does not appear to 
cross sensitise with cocaine (Arnold et al., 1998).  
 
The data regarding sensitisation of cannabis in animal models is inconsistent as is 
the information pertaining to cannabis’ ability to elicit dopaminergic activity (see 
Section 1.7.1). The incongruence in the data suggests that a process of 
sensitisation may not fully explain the relationship between cannabis and 
psychotic disorder. However, there is evidence to suggest that cannabis may 
cross-sensitise to other drugs (e.g. Cadoni et al., 2008) or experimental conditions 
(Nestor et al., 2010). Due to the ethical implications, It is difficult to assess a 
mechanism of sensitisation in experimental studies utilising human subjects. 
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Within the confines of the laboratory it is difficult to observe a lasting change in 
response amplitude as a consequence of cannabis administration. However, it is 
easier to assess a process of cross-sensitisation. Through the use of statistical 
models it is possible to assess if variables may combine to elicit an effect size 
larger than the sum of the parts. Although, this may not demonstrate the 
neurological or mechanistic substrate of sensitisation it will allow for inference to 
be made as to whether response amplitude is altered as consequence of the 
presence of both factors. The interaction between these factors may be explained 
by genetic interaction processes, such as a gene x gene x cannabis interaction 
effect (van Winkel, 2012). Nonetheless, these interactions have also been taken 
as evidence for cross-sensitisation (Kuepper et al., 2010).   
 
1.7.4 Cross-sensitisation between cannabis and stress 
Sensitisation represents a plausible mechanism by which cannabis may cause 
schizophrenia. However, assessing such a mechanism is a difficult task in human 
subjects in naturalistic environments (see Section 1.7.3). Nonetheless, there is 
evidence to suggest that cannabis may cross sensitise to other rewards (Nestor et 
al., 2010) and there is also evidence to suggest that cannabis may cross-sensitise 
(interact) with stress.  
 
There is a well-established relationship between stress and psychotic disorder. For 
instance, patients suffering with Post-Traumatic Stress Disorder (PTSD) who are 
also ‘positive’ schizotypes tend to have more trauma related symptoms and a 
greater spectrum of PTSD symptomatology (Marziller and Steel, 2007).In 
comparison with positive schizotypes and controls, negative schizotypes have also 
been shown to display a significant increase of DA into the striatum as a result of 
psychosocial stress (Soliman et al., 2008). Furthermore, negative schizotypes 
have been shown to have “greater stress-induced striatal and limbic deactivation” 
(Soliman, 2011, p.184). In an experience sampling investigation (see Section 
3.2.1) patients suffering with a psychotic illness have been shown to have an 
increased stress reactivity in comparison to controls (Myin-Germeys, Van Os, 
Schwartz, Stone & Delespaul, 2001). Moreover, psychosocial stress has been 
shown to elicit DA release in the PFC in none-prone individuals (Lataster et al., 
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2011). Thus it appears that the expression and maintenance of psychotic 
symptomatology are in some part influenced by stress (see Sections 1.2.3 & 3.1 
for further discussion). However, the means by which cannabis interacts with 
stress is less clear. 
 
One of the most often cited motivations for cannabis use is the relief of dysphoria, 
this is an agent to relieve psychological distress (Gregg et al., 2007). Based on 
this premise, and the observations that cannabis has anxiolytic properties (Zuardi 
et al., 1982), it would appear that cannabis has a beneficial effect on psychological 
stress. Nonetheless, cannabis and the endocannabinoid system appears to play a 
complex role in stress related disorders (Neumeister et al., In press). Cannabis 
increases cortisol release in a dose dependent fashion in both frequent and non-
frequent users (D’Souza et al., 2008; Ranganathan et al., 2009). However, these 
affects are blunted in habitual users, which could plausibly indicate sensitisation, a 
change in response amplitude. In animal models, the endocannabinoid system 
has been shown to regulate response to aversive stimuli (Häring, Grieb, Monory, 
Lutz & Moreira 2013). If these results extrapolate to humans then stimulation of 
the cannabinoid system may result in an exaggerated response to aversive stimuli.  
 
There is emerging evidence to suggest an interaction between cannabis and 
psychological stress on a psychosis outcome. In animal models, stress was a 
necessary requisite for cannabis to elicit striatal DA release (Littleton and Maclean, 
1975; Maclean and Littleton, 1977). However, observing an interaction between 
stress and cannabis is more difficult in humans, one of the reasons being stress is 
more difficult to define and induce.  In a laboratory setting in human subjects, ∆-9-
THC significantly increased the skin conductance response in regards to intensely 
and moderately fearful faces, but not neutral faces (Fusar-Poli et al., 2010). This 
indicates that cannabis was serving to exacerbate the physiological stress 
response, but only when exposed to a psychological stressor (i.e. a fearful face). 
Cannabis and stress were interacting to result in an increase in response 
amplitude.  
 
In non-experimental investigations, urbanicity has been consistently implicated as 
a contributory factor in presentation of psychotic illness (Vassos, Pedersen, 
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Murray, Collier & Lewis, 2012). It is thought that this could be reflective of the 
presence of social processes, such as ‘social capital’ (Krabbendam & van Os, 
2005). Social capital has been shown to have a strong relationship with stress and 
stress-coping mechanisms (Gächter, Savage, & Torgler , 2011). Kuepper et al., 
(2011) in a prospective cohort study demonstrated a significant interaction effect 
between cannabis and urbanicity on the development of psychotic symptoms. 
Thus, suggesting that some of the environmental stressors conferred by an urban 
environment are interacting with cannabis consumption. This provides further 
support for the notion of a cannabis stress interaction effect. 
 
Childhood abuse or trauma is another psychological stressor which appears to 
have an independent effect on psychotic disorder (Sheffield, Williams, & Blackford, 
Heckers 2013), and interacts with cannabis on a psychosis outcome. Harley et al., 
(2010) found that both cannabis and childhood trauma contribute independently, 
and interact significantly, to predict psychotic symptoms. Houston, Murphy, 
Adamson, Stringer and Shevlin (2008), and Houston, Murphy, Shevlin, and 
Adamson (2011) found no significant main effect of cannabis on psychotic 
disorder. However, a significant interaction effect between cannabis and childhood 
trauma increased the odds of a diagnosis of psychotic disorder. This indicates that 
cannabis and psychological stressors may interact to confer a risk greater than the 
sum of the parts. However, the validity of Houston et al., (2011) findings have 
been questioned (Daly, 2011).  Daly (2011) attempted to address the 
shortcomings of previous investigations by adjusting for baseline psychotic 
symptoms. After adjustment, there was no main effect of sexual abuse, cannabis, 
and no interaction effect between the two on hallucinatory experience.  
 
In analysis of another dataset whilst controlling for baseline psychotic experience, 
Murphy, Houston, Shevlin & Adamson (2013) did demonstrate a significant 
interaction effect of cannabis and childhood trauma on psychotic disorder. This 
finding has been further replicated in independent Greek, Dutch, and English 
cohorts (Konings et al., 2012; Sideli et al., 2012), although was not replicated by 
Kuepper, Henquet, Lieb, Wittchen and van Os (2011). Taken together, these 
findings suggest that if cannabis and psychological stressors interact there are 
feasibly other factors which are important determinates of psychotic susceptibility. 
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The research of Alemany et al., (2012) may help account for some investigations 
failing to document a significant interaction effect. Alemany and colleagues 
documented no significant main effects of cannabis or childhood abuse on 
psychotic-like experience irrespective of the participant’s COMT functional 
polymorphism. However, a significant interaction effect of cannabis and childhood 
trauma was documented in all groups. The Val carriers displayed significantly 
more psychotic-like experiences as a consequence of this interaction effect, 
whereas Met homozygotes displayed significantly fewer. Vinkers et al., (2013) 
undertook a similar analysis to Alemany and colleagues. Vinkers and colleagues 
documented a significant threeway interaction effect between COMT 
polymorphism, cannabis and childhood abuse. The data also indicated that Val 
homozygotes were the most susceptible. This indicates that the interaction 
between cannabis and stress may be in part modulated by polymorphism of the 
COMT gene. 
 
Intriguingly, in a recent review of pharmacological interventions for the treatment of 
the acute effects of cannabis, propanolol (and rimonabant) were thought to be the 
most effective (Crippa, et al., 2012). Propanolol is a beta-blocker which lowers 
heart rate and has been used in the treatment of stress related disorder (Brunet et 
al., 2008). This indicates that, rather than the treatment of dopaminergic 
dysfunction associated with antipsychotic drugs, feasibly the best means of 
attenuating acute cannabis induced psychotic episode is via the amelioration of 
the physiological and psychological stressed state. This provides further evidence 
for stress playing a central role in the psychotomimetic effects of cannabis. 
 
Parakh and Basu (2013) suggest that the interaction between cannabis and 
environmental stressors is a necessary requisite in cannabis ‘causing’ psychotic 
disorder. Activation of the Hypothalamic-Pituitary-Adrenal (HPA) axis 
(physiological stress response) by cannabis may not in itself be pathological. 
However, the data indicates that feasibly, when the physiological stressed state is 
elicited in combination with a psychological stressed state this could elicit both DA 
release in cortical and subcortical regions and bring about psychotic reaction.  At 
present cross-sensitisation could represent a plausible mechanism by which 
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cannabis may cause schizophrenia (see Collip et al., 2008; Henquet et al., 2008; 
Kuepper et al., 2010; van Os et al., 2009 etc.). Nonetheless, alternative 
mechanisms have been suggested, such as that based on cognitive disruption 
(Meijer et al., 2012) or primary action of the CB1 and the cannabinoid system 
(Emrich, Leweke, & Schneider, 1997) (see Parakh & Basu, 2013 for further 
information). The discussion of these alternative mechanisms goes beyond the 
scope of this literature review. However, it is feasible that multiple different 
plausible mechanisms of association have a causal influence on psychotic 
disorder (e.g. Myin-Germeys & van Os, 2007).  
 
As discussed previously (Section 1.2.1 pp. 21-25) schizophrenia has a well-
established relationship with several other disorders. SPD is the “prototypical 
schizophrenia-spectrum condition” (Fervaha & Remington, 2013, p.96). Given that 
schizotypy has been utilised to elucidate information about schizophrenia (see 
Section 1.2.2). Schizotypy can also provide inference about the consequence of 
cannabis use on psychotic disorder. Thus, the next section will discuss the 
relationship between cannabis, schizotypal state and schizotypal trait. 
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1.8 Cannabis, schizotypal state and schizotypal trait   
In Section 1.6 various hypotheses regarding the relationship between cannabis 
and psychotic disorder were discussed. However, this association can be further 
assessed by examination of data pertaining to the relationship between cannabis 
and schizotypy. Both Schizotypal personality trait and schizotypal state are highly 
related to schizophrenia (see Section 1.2.2 pp. 25-31). Schizotypy is commonly 
viewed as a stable and enduring personality trait that is thought to reflect an 
individual’s propensity (both genetic and psychological) to develop psychotic 
disorder. This notion has led some researchers to look at the relationship between 
cannabis and schizotypy to contribute to the causal debate (e.g. Mass, Bardong, 
Kindl & Dahme, 2001). 
 
Many investigations have demonstrated a significant elevation in schizotypy in 
cannabis users in comparison to drug naïve controls (e.g. Dumas et al., 2002; 
Fridberg, Vollmer, O’Donnell & Skosnik 2011; Mass et al., 2001; Skosnik, Spatz-
Glenn & Park., 2001 etc.). Given the purported stability and early development of 
schizotypy, this may indicate that a schizotypal personality trait predisposes an 
individual to use cannabis, which is a view adopted by some investigators (Mass 
et al., 2001). However, other investigations, such as that of Bailey and Swallow 
(2004) have drawn different conclusions. Bailey and Swallow (2004) also 
documented an elevated schizotypal trait in positive, negative and disorganised 
domains in cannabis users. However, they concluded that this effect may have 
been a consequence of a schizotypal personality trait predisposing to drug 
medication, or due to the acute psychotomimetic effects of the drug. The 
interpretation of the association between cannabis and schizotypy holds relevance 
not only for the cannabis schizophrenia causality debate, but also implications for 
models of schizotypal vulnerability. 
 
As stated above, some studies have noted elevated schizotypy levels in cannabis 
users in comparison to controls. In addition, some research has demonstrated that 
current cannabis users score higher than past cannabis users on measures of 
schizotypy (Dumas et al., 2002, Skosnik et al., 2001). There may be an intrinsic 
difference between cannabis users who persist and those who cessate use. 
However, factors that underpin cessation are poorly understood (Dekker et al., 
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2008) and there is no known evidence to suggest what, if any, differences exist 
between these two groups. If there is no fundamental factor that might predict 
cessation then this could plausibly indicate that the significant difference between 
the current and past cannabis users is as a consequence of the acute effects of 
cannabis.  
 
Anglin et al. (2012) found that cannabis use prior to 14 years old predicts SPD 
independently of the presence of psychotic symptoms at baseline. This appears to 
indicate that adolescent cannabis use has temporal priority over schizotypal 
symptomatology. This implicates a causal relationship between cannabis and 
SPD. Unlike some of the other investigations Baskak et al. (2012) were capable of 
assessing the temporal relationship between cannabis and schizotypy. Baskak 
and colleagues found that former cannabis users scored significantly higher than 
cannabis-naïve participants, in positive, negative, and disorganised domains of 
schizotypy. Within the positive domain this was associated with a dose dependent 
effect. Moreover, in analysis of temporal proximity to cessation it was elucidated 
that more recent cannabis use was positively and significantly associated with 
elevations in positive and negative dimensions of schizotypy.  
 
Further evidence of cannabis’ (or more specifically Δ-9-THC) ability to elevate 
schizotypy can be derived from the research of Morgan and Curran (2008). 
Individuals’ frequently using cannabis with high levels of ∆-9-THC and no CBD (as 
assessed by hair-analysis) had significantly higher positive schizotypal traits than 
both non-users and users with ∆-9-THC and CBD in their system. The decision to 
consume cannabis containing solely Δ-9-THC or Δ-9-THC and CBD, may be 
influenced by numerous factors (e.g. geographical location: D. Potter et al., 2008). 
However, it is highly unlikely that this decision will be influenced by schizotypal 
personality, particularly considering that microscopic examination and detailed 
forensic examination is required to accurately identify preparations that contain 
CBD (see Section 1.4). Thus, it would appear that the findings of Morgan and 
Curran are as a consequence of ∆-9-THC ability to elevate schizotypy, and CBD’s 
ability to attenuate these effects.  
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Nonetheless, there are contrasting data suggesting that cannabis does not cause 
elevations in schizotypy. Schiffman, Nakamura, Earleywine and LaBrie (2005) 
found a significant difference in schizotypal trait between cannabis users and non-
users. However, Shiffman and colleagues, utilising a retrospective measure, 
elucidated that these schizotypal traits occurred significantly earlier than first 
cannabis use. Although, there are methodological limitations to retrospective 
assessment, the findings of Shiffman and colleagues appear to implicate a non-
causal relationship between cannabis and schizotypy. 
 
Fridberg et al., (2011) assessed chronic cannabis users and non-cannabis users 
on assessments of schizotypy and other non-pathological personality traits. The 
cannabis using groups scored significantly higher on assessments of schizotypy 
and, this was in a dose dependent fashion. This suggests a biological gradient, 
which is one of the requisite factors (see Section 1.6.4) to suggest that cannabis 
may cause elevations in schizotypy. Intriguingly, the cannabis using group also 
differed from controls on other aspects of personality (conscientiousness, 
agreeableness etc.). This finding may reflect intrinsic differences between 
cannabis users and non-users which predispose to cannabis use. 
 
However, the notion of intrinsic differences between cannabis users and non-users 
was not supported by the findings of Linscott (2008). He found significant 
elevations in schizotypy in cannabis users in comparison to non-users, but no 
significant difference in the latent structure of schizotypy. This finding indicates 
that the cannabis using population are exhibiting a high, but not abnormal 
schizotypal personality profile. Nonetheless, Esterberg, Goulding, McClure, and 
Compton (2009) have demonstrated that indices of cannabis, alcohol and nicotine 
use have been associated with positive and disorganised dimensions of 
schizotypy.  Thus, substance use/misuse more generally has been associated with 
schizotypy which does not indicate specificity (see Section 1.6.4).  
At present, the relationship between cannabis, schizotypal trait, and schizotypal 
state remains unresolved. Like so many other domains associated within 
schizophrenia (see Section 1.2.3, 1.6 & 1.7) the data is inconclusive. Thus, there 
is a need for further research to highlight the relationship between cannabis, 
schizotypy and schizophrenia.  
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1.9 Summary of the chapter and the aims of this body of research 
This chapter has discussed some of the relevant literature pertaining to 
schizophrenia (Section 1.2.1 pp. 21-25), schizotypal personality disorder, 
schizotypal personality trait, and a schizotypal state (all Section 1.2.2 pp. 25-37). 
This chapter has also discussed the relevant literature pertaining to assessing 
psychotic vulnerability (Section 1.2.3 pp. 37-48) and the development of a 
psychometrically sound measurement scale (Section 1.3 pp. 49-54). Section 1.4 
(pp. 55-58) has provided a summary of the status quo of the cannabis market and 
its relationship with psychotic reaction. Section 1.5 (pp. 59-60) has discussed 
some of the literature relating to cannabis-induced psychosis. This chapter also 
summarised some of the available data pertaining to a causal association between 
cannabis and schizophrenia (Section 1.6 pp. 61-79), in addition to a section 
devoted to the assessment of plausible mechanisms (Section 1.7 pp. 80-95). 
Finally, this chapter examined the data pertaining to the relationship between 
cannabis, schizotypal state and schizotypal trait (Section 1.8 pp. 96-98).  
 
This thesis contains three research chapters each of which have distinct aims. 
Chapter 2 and Chapter 3 consider data derived from distinct groups of 
participants, collected with distinct methodologies. However, further analyses of 
the data derived from both of these investigations are considered in Chapter 4. 
The aims of Chapter 2 (Section 2.1.1 p.105), Chapter 3 (Section 3.1.1 pp.164-65), 
and Chapter 4 (Section 4.1.1 p. 261) are discussed later on in the thesis. 
However, this thesis as a whole body of research possessed two primary aims. An 
assessment of whether or not the aims of the individual chapters and the thesis as 
a whole have been achieved is considered in the fifth and final chapter.  
 
The literature discussed within this chapter should serve to contextualise the 
individual chapters, along with contextualising the two principal aims of this body 
of research:  
1. To contribute to discussions relating to ‘causal inference’ in the relationship 
between cannabis and psychosis 
2. To assess the reliability and validity of a measure of psychotic vulnerability 
based on a differential sensitivity to the psychotomimetic effects of cannabis 
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The first aim of this thesis is addressed in Chapter 3, which assesses the 
temporality of various variables of interest. Within a continuum model of psychosis, 
analyses in Sections 3.3.3 (pp. 217-26), 3.3.5 (pp. 230-34) and 3.3.6 (pp. 234-38) 
assess converging evidence for the; self-medication hypothesis; a causal model of 
association; and a synergistic model of association (see Section 1.6 pp. 59-79). 
This chapter also allows for the assessment of a plausible mechanism of 
association.  The plausibility of a cannabis stress interaction effect is assessed in 
Sections 3.3.3 (pp. 217-26) and 3.3.4 (pp. 227-29). 
 
The second chapter contributes to the second primary aim of this thesis. This 
chapter tests the notion of a differential sensitivity to cannabis in those vulnerable 
to psychosis. The fourth chapter serves to fulfil the second primary aim of this 
thesis, which is achieved by assessing evidence for the predictive validity, 
convergent validity, and concurrent validity of a measure of cannabis induced 
experience. In addition, contained within the chapter are assessments of internal 
reliability and data pertaining to test-retest reliability. 
 
The previous section (1.8) of this chapter has elucidated a paucity of 
understanding about cannabis’ relationship with psychotic disorder and schizotypal 
trait. The next chapter attempts to further the understanding of cannabis’ impact 
on schizotypal trait, whilst simultaneously assessing whether psychosis proneness 
confers a differential sensitivity to cannabis.  
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2. Cannabis induced experiences, schizotypal traits and their 
relationship to self-reported diagnoses of psychotic mental 
illness and depression 
Brief overview 
This chapter is one of several research chapters contained within this thesis. This 
particular chapter seeks to further elucidate the relationship between cannabis 
use, psychotic disorder and schizotypy, whilst simultaneously assessing a 
differential sensitivity to the drug based on psychosis proneness. This aim is 
achieved by examining group differences between cannabis users; from a 
community sample; with reported depression; and with a reported psychotic 
disorder. Contained herein is a brief introduction which contextualises this 
investigation (Section 2.1 pp. 102-05). After the introduction there is a description 
of the methodology utilised in this investigation (Section 2.2 pp. 106-17). The 
results of this investigation are contained within Section 2.3 (pp. 118-45). Section 
2.3.1 (pp. 118-121) is concerned with the assessment of the assumptions of the 
subsequent analyses and Section 2.3.2 (pp. 121-125) and 2.3.3 (pp. 126-7) 
describes the participant’s characteristics. Section 2.3.4 (pp. 127-31) and 2.3.5 
(pp. 131-33) compares the groups of participants on measures of schizotypy and 
cannabis induced experience. Sections 2.3.6-8 (pp. 134-145) assesses the 
participants within a regression model to test for predictors of group-membership 
(i.e. diagnoses). The results of the investigation are discussed within Section 2.4 
(pp. 146-59).  
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2.1 Introduction 
Cannabis and psychotic disorder have a well-established link (see Section 1.6.4 
pp. 72-9), nonetheless whether cannabis causes schizophrenia is still a matter of 
debate. To assist in answering this question researchers have looked at the 
relationship between cannabis and schizotypy (e.g. Mass et al., 2001). Schizotypy 
is purportedly a stable and enduring personality trait which is thought to represent 
psychotic vulnerability (see Sections 1.2.2 pp. 25-31 & 1.2.3 pp. 45-8). Schizotypal 
trait has been shown to be elevated in current cannabis users in comparison to 
former cannabis users and people who are cannabis naïve (Dumas et al., 2002; 
Skosnik et al., 2001). However, there is data indicating that there may be state 
aspects to this purportedly stable trait (see Sections 1.2.2 & 1.8 pp. 96-8). 
 
Assessing which factors predispose individuals to psychotic disorder is a current 
and ever expanding area of research (see Section 1.2.3). One of the least 
resource intensive means of assessing psychotic vulnerability is via self-report 
assessments of schizotypy. Nonetheless, given that schizotypy may have state 
elements and cannabis may induce psychotomimetic states (see Section 1.8), 
assessments of psychosis proneness utilising schizotypy may not truly reflect 
‘schizotaxic’ liability in cannabis using populations. This is evinced from the 
frequent occurrence of psychotic like states in the healthy population and the 
infrequency that these states are clinically relevant (van Os et al., 2009). Thus, it is 
proposed that within this population other means of assessing psychotic 
vulnerability should be adopted. 
 
It has been proposed that the “genetic risk for psychotic disorder might be 
expressed in part as sensitivity to the psychotomimetic effects of cannabis” 
(Eisenberg, 2010, p.32).  There is some data which supports this notion; in a 
prospective cohort study the Genetic Risk and Outcome in Psychosis investigators 
(GROUP, 2011) compared patients with a psychotic disorder, their siblings, and 
healthy controls. In comparison to the control group, the sibling group displayed 
significantly more positive and negative aspects of schizotypy. This had a positive 
linear effect with dose of cannabis. Moreover, a similar effect was documented 
between the sibling and patient groups, but only within the domain of positive 
symptomatology. Thus, suggesting that a differential sensitivity to the 
103 | P a g e  
 
psychotomimetic effects of cannabis is partially determined by genetic 
vulnerability.  
 
In a naturalistic experience sampling investigation (see Section 3.2.1 pp. 166-70) 
Henquet et al., (2010) found that, patients suffering with a psychotic disorder had 
elevations in their positive symptoms as a consequence of cannabis use. 
However, no such relationship was demonstrated within controls. In another 
experience sampling investigation cannabis induced significantly more psychosis-
like experiences in psychosis prone participants, in comparison to those thought to 
be at a low risk (Verdoux, Gindre, Sorbara, tournier & Swendsen, 2003). In a 
further naturalistic investigation cannabis consumption induced psychotomimetic 
experience with more marked effects in those psychosis prone (Mason et al., 
2009).  
 
A measure has been developed to record and quantify cannabis induced 
experiences; the Cannabis Experiences Questionnaire (CEQ). The CEQ 
comprises of a checklist of pleasurable, aversive, and after-effects of cannabis 
intoxication. Item generation consisted of several phases (see Section 1.3.1 pp. 
49-51 for further information on item generation). Initial literature searches were 
undertaken of user’s self-report data, and clinical description of; cannabis induced 
psychosis; and amotivational syndrome. Qualitative investigation in the form of 
structured interviews were then undertaken with cannabis users (N = 62). The 
participants were asked to comment on; the familiarity of the items generated from 
the literature searches; a description of any familiar phenomena identified; any 
previous good and bad cannabis experiences and how these impact on the 
individual; any cannabis induced experiences not already generated. 
 
Although, the CEQ is typically administered as a self-report measure (e.g. 
Bloomfield, et al., in press; Stirling et al., 2008 etc.) it has also been administered 
as an interview to a clinical population (Di Forti et al., 2009). The CEQ has 
undergone several factor analyses, which have yielded two different scoring 
systems (see Stirling et al., 2008; Barkus & Lewis, 2008). Moreover, a third 
scoring system also appears to be in use, although it is unclear whether this is 
derived from statistical procedures (Greenwood et al., In press). However, the 
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most recent factor analysis on the most comprehensive dataset has yielded a 
three factor solution (Stirling unpublished data, see Appendix 1). Research has 
consistently demonstrated a highly significant relationship between aversive 
cannabis induced experiences and positive, negative, and psychotic dimensions of 
schizotypy (Barkus & Lewis, 2008; Barkus, Stirling, Hopkins & Lewis 2006; Stirling 
et al., 2008, Morris, [unpublished data]). Moreover, in a small pilot investigation, (N 
= 16) in-patients who had a diagnosis of cannabis induced psychosis had 
significantly more aversive cannabis induced experiences than a community 
sample (Stirling, 2011). 
 
The CEQ has been administered and re-administered at an approximate 2 month 
interval to a sample of 65 cannabis users. The three subscales of the CEQ 
displayed a highly significant positive correlation (all p < .001, r  > .75) (Stirling, 
unpublished data). Thus, indicating test-retest reliability. In a recent investigation 
Greenwood et al.(In press) found significant differences between short-term and 
long-term cannabis users on the CEQ. Short-term cannabis users displayed 
significantly more pleasurable and aversive cannabis experiences. This could 
indicate that these experiences may be attenuated in long term use. This may 
suggest a time variant component to this measure. However, it may reflect a 
decrease in vulnerability with time as the sample transit past the age at which 
psychotic breakdown is most common (see Section 1.2.1 pp. 21-25). Evidence for 
this can be derived from a comparison of the mean age of the short term cannabis 
users (20.9 years) and the long term cannabis users (39.9 years). 
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2.1.1 Aims of the chapter 
There is a significant positive relationship between cannabis and schizotypy. 
However, whether this relationship is causal and the significance of this particular 
association to schizophrenia remains a matter of conjecture. The literature 
indicates that people with psychotic vulnerability may display a differential 
sensitivity to cannabis. However, the utility of such an observation has yet to be 
assessed and requires further enquiry. This investigation seeks to address 
deficiencies in the literature, by fulfilling the following three aims: 
 
1. To assess variance in schizotypal trait related to cannabis use and reported 
mental illness (see Section 1.8 for rationale pp. 95-98). 
2. To assess the presence of a differential sensitivity to the psychotomimetic 
effects of cannabis in those with psychotic illness (see Section 2.1 for 
rationale pp. 101-03).  
3. To assess the utility of assessments of cannabis induced experience and 
schizotypal trait as predictors of psychotic illness in cannabis using 
populations 
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2.2 Methodology 
2.2.1 Study design 
A cross-sectional study design was utilised to compare four different groups of 
participants: a community sample of participants who were cannabis naïve 
(CSCN), a community sample of cannabis users (CSCU), a sample of cannabis 
users with a self-reported diagnosis of depression (DD), and a sample of cannabis 
users with a self-reported diagnosis of psychotic disorder (PD). A cross-sectional 
study design will allow for inferences to be made about differences in the 
populations from which the groups originate. Comparison will be drawn between 
these independent groups of respondents, on assessments of schizotypal 
personality (Section 2.3.4 pp. 127-31). Comparison will also be drawn between the 
three cannabis using groups of respondents (CSCU, DD and PD) on indices of 
cannabis use (Section 2.3.2 pp. 121-25) and cannabis induced phenomena 
(Section 2.3.5 pp. 131-33). In Sections 2.3.6-8 (pp. 134-45) the scales of the CEQ 
and the SPQ-b will be assessed as predictors of group membership. 
 
2.2.2 Participants 
Inclusion and exclusion criteria 
All participants had to be over the age of 18 to take part in the investigation. The 
criterion was used to increase homogeneity between groups, given that 
schizophrenia for example typically first presents itself “in the early- to mid-20s for 
males and in the late-20s for females” (APA, 2013a, p.103). The imposition of 
such a criterion also circumvents a possible methodological issue of obtaining 
consent. For participants under the age of 16, dual consent should be sought from 
both the participant and those with parental responsibility (BPS, 2008 p6). 
However, as this investigation utilised internet based research dual consent would 
be difficult to procure and validate.  No participant under the age of 18 years was 
recruited to the DD or PD group. However, 35 participants under 18 years old 
were recruited in cohorts 2 and 3 (see Table 1), 32 of which were in the CSCU 
group. Their data were excluded from the analysis.  
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Participants were excluded from the PD and DD groups if they self-reported a 
diagnosis of a mental illness of an unequivocally biological aetiology (e.g. 
epilepsy). As it is unclear how such mental illness may influence the expression of 
schizotypy and cannabis induced experience. Participants were also excluded if 
they had a psychological disorder of a purely exogenous origin. There was 
however, one exception applied to the PD group of substance-induced psychotic 
disorder. In addition to this exclusion criterion and the inclusion criterion outlined 
above the respondents were also subjected to further inclusion and exclusion 
criteria specific to their group status. Participants in the cannabis naïve group 
(CSCN) were excluded if they reported having ever consumed cannabis. 
 
The groups of cannabis users (CSCU, DD and PD) were subject to a further 
inclusion criterion of a minimum of one lifetime use of non-synthetic unadulterated 
(except for with tobacco) cannabis. Synthetic cannabis use and cannabis 
consumed in suspension (e.g. Sativex, GW Pharmaceuticals) were not considered 
sufficient for eligibility. Participants were eligible for inclusion in the PD group if 
they reported at any point in their lifetime receiving a diagnosis of; schizophrenia; 
schizoaffective disorder; schizophreniform disorder; delusional disorder; drug 
induced psychotic disorder; brief psychotic disorder; shared psychotic disorder or 
psychotic disorder not otherwise specified. Participants were included in the DD 
group if they reported at any point in their lifetime having received a diagnosis of 
depression. Participants were however, excluded from the DD group if they had 
received a diagnosis of any of the disorders requisite for inclusion in the PD group, 
bi-polar mood disorder, or cyclothymia. 
 
It is of importance to note that the CSCU group and CSCN groups were not 
specifically asked to document any previous mental illness. Thus, it is feasible that 
within these groups there will be a population rate incidence of mental illness, 
hence, they are referred to as a ‘community sample’. The mental illness of primary 
interest, schizophrenia, has a lifetime prevalence rate of approximately 0.3%-0.7% 
of the population (APA, 2013a, p.102). Given the large sample of respondents it is 
anticipated that in the event of several individuals being misattributed to the CSCU 
or CSCN groups this would not produce a significant effect. Moreover, the effect of 
misattributing participants to the CSCU or CSCN groups will likely result in the 
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analyses being more conservative, minimising group differences. Moreover, the 
analysis contained in Section 2.3.8 has taken further steps to control for 
incidences of unreported or undiagnosed (psychotic) mental illness. 
 
Recruitment 
Community Sample 
The two groups of community respondents (CSCN and CSCU) were derived from 
data collected from previous investigations (i.e. not as part of this PhD). A total of 
1167 participants were recruited in five different cohorts, between the years of 
2004 to 2009.  The amalgamated dataset consists of 861 individuals with 
experience of cannabis exposure and 306 without. The various cohorts, the 
recruitment strategies employed and procedure are described in greater detail 
elsewhere. Cohort one is considered in Barkus, et al., (2006); cohorts two, three 
and four are considered in Stirling et al., (2008); cohort five is considered in Morris 
(Unpublished data).  
 
Table 1 
Indicating the number of cannabis users and non-users recruited in each community 
sample cohort 
 Cannabis naïve Cannabis user Total 
Cohort 1 38 99 137 
Cohort 2 71 141 212 
Cohort 3 27 105 132 
Cohort 4 28 51 79 
Cohort 5 142 465 607 
Total 306 861 1167 
 
Cohorts one and two were recruited by posting notices requesting participants 
around a university campus. The notices invited interested individuals to contact a 
researcher for a questionnaire, which was distributed to the respondent. The paper 
questionnaires were returned anonymously in a post box on campus or via the 
mail in a pre-paid envelope.  
 
The third cohort was recruited by an email distributed by a Dutch college. The 
email directed interested individuals to an electronic version of the questionnaires 
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hosted on the college’s intranet. Within this cohort non-student respondents were 
also recruited by a snowballing technique. The participants invited people from 
within their social network to complete ‘hard copies’ of the questionnaires which 
were mailed back in pre-paid envelopes.  The fourth cohort was recruited to 
provide test-retest data on the CEQ, however, only one of their data entries is 
considered herein. Similarly to the Dutch cohort this sample utilised electronic 
methods to recruit university students. However, non-student adults were also 
recruited through various (non-online) social networking groups e.g. a film/book 
club. Irrespective of electronic or non-electronic recruitment, participants 
completed ‘hard-copies’ of the various measures.  
 
In the fifth cohort a variety of recruitment techniques were utilised. Advertisements 
were placed via a number of media including radio, mass email distribution 
systems, and web-based advertisements. Additionally (online) social network 
snowballing in the same vein as applied by Stirling, Morris and McCoy (2012) were 
employed. All participants in the fifth cohort were directed to a website which 
contained study information and a link to a web-based questionnaire, in a very 
similar manner to the method of collecting data utilised for the clinical respondents. 
 
Clinical respondents 
A total of 413 participants initiated a data entry, of those 299 participants 
progressed to the final page of the measures and thus were retained in the data 
set (see Section 2.2.6 pp. 115-17). No system of imputation was adopted 
consequently, 70 participants that had not completed all items pertaining to one of 
the scales/subscales were excluded. Of the 229 remaining participants, 22 were 
excluded as they did not report a diagnoses of depression or one of the psychotic 
disorders under consideration and 56 were excluded as they did not report a 
diagnoses of a mental illness. Please note that due to recruitment methods (i.e. 
attempts to recruit clinical respondents) these participants were not deemed 
eligible for inclusion in the community sample groups. Fifteen participants were 
excluded from the DD group as they had also reported a diagnosis of bi-polar 
mood disorder. A further three participants were also excluded, two of whom 
reported a diagnosis of epilepsy and one of whom reported heavy metal poisoning. 
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After inclusion and exclusion criteria were applied 85 participants remained in the 
DD group and 48 in the PD group.  
 
To facilitate recruitment numerous study advertisements were placed in strategic 
locations in both virtual (see Appendix 2) and physical environments (see 
Appendix 3). Advertisements were distributed to the service users of mental health 
charity the African and Caribbean Mental Health Services, Manchester. 
Advertisements were also placed in magazines/newsletters, distributed by national 
mental health charities MakingSpace, and Rethink (formerly the National 
Schizophrenia Fellowship). MakingSpace also promoted the study directly to their 
service users via their care co-ordinators. Rethink further promoted the study 
through their website, Facebook page and Twitter service. 
 
Internet based self-help and social networking website ‘Schizofriend.me’ promoted 
the study by direct messaging to their service users. Study information was also 
distributed by the research network Schizophrenia Research Forum. Discussion 
forums directed at people suffering with mental health problems (and their family 
members) ‘Psychforums.com’ and ‘Schizophrenia.com’ facilitated the posting of 
study information in their forum section. Mental health information website 
Psyweb.com promoted the study via their website alongside an article detailing the 
background of the investigation. 
 
In addition to organisations pertaining to mental illness distributing study 
information, some pertaining to drug use also helped. Drugsforum.com an 
organisation providing recreational drugs information and a medium for 
discussions posted information to their users. Two cannabis lobbying groups the 
UK Cannabis Internet Activists, and CLEAR: Cannabis Law Reform, carried study 
information on their website in addition to articles detailing the background of the 
research. 
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2.2.3 Measures 
Basic demographic information and mental health (Appendix 4) 
All participants provided basic demographic information (i.e. age and sex). Clinical 
respondents additionally provided a synopsis of their current and past mental 
health, including summary information about current and past pharmacological 
and psychological treatments and frequency of medication adherence. Each of 
these six items consisted of two parts; the first is a dichotomous, ‘Yes’ or ‘No’ 
answer e.g. ‘I am currently receiving treatment for a nervous / psychological 
disorder’; the second part is an open ended text box e.g. ‘(If previous answer was 
YES) What nervous / psychological disorder(s) are you being treated for?’ The 
only item which did not take this form was regarding medication adherence 
frequency (ie. If you are/were taking medication, did/do you take your medication 
as often as the doctor or pharmacist told you to?), which was scored on a five-
point scale ranging from ‘Rarely or never’ to ‘Always or almost always’. 
 
Schizotypal Personality Questionnaire- Brief  
All participants completed the SPQ-b (Raine and Benishay, 1995).  The SPQ-b 
contains 22-items, which represent the most reliable items from the Schizotypal 
Personality Questionnaire (Raine, 1991, Raine and Benishay, 1995). The SPQ-b 
contains statements such as ‘Sometimes I’m sure that other people can tell what 
I’m thinking’. Each item allows for only a dichotomous response either ‘Yes’ or 
‘No’. The SPQ-b provides a total schizotypy score and three subscale scores. The 
subscales contain items pertaining to cognitive-perceptual deficits, interpersonal 
deficits and deficits of (dis)organisation.  
 
The Cannabis Experiences Questionnaire (See Appendix 1 for items) 
The CEQ currently (version 8) comprises of four sections, the first records 
cannabis use history relating to; frequency of use; total amount consumed; 
environment of consumption; expenditure; age at first use; and type of cannabis 
used. The second section is in regards to drug use other than cannabis. The third 
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and fourth sections comprise a checklist of cannabis induced experiences and 
form the substantive part of the questionnaire. The third section (43-items) relates 
to the concurrent effects of the drug (experiences the participant has whilst 
intoxicated). The fourth section (12-items) is a checklist of after effects of cannabis 
(experiences the user has after initial intoxication has subsided). Various means of 
scoring the CEQ have been employed (see Barkus and Lewis, 2008; Stirling et al., 
2008). However, the current investigation will utilise the method of scoring derived 
from the most recent Principal Component Analysis (PCA) conducted by John 
Stirling in 2010. This was conducted on the largest combined database of 
respondents available. 
 
The 2010 PCA is not published elsewhere, thus the associated pattern matrix has 
been included in Appendix 1. This analysis indicated that the items disaggregated 
into three factors scoring an eigenvalue larger than two. This three factor solution 
was confirmed by the associated scree plot (see Appendix 1). The first factor 
accounted for 25.46% of variance and contained 20 items with a unique factor 
loading greater than 0.4. Three of these items originated from section four 
pertaining to the after effects. These items were labelled the aversive scale and 
contained experiences that most users would typically find unpleasant e.g. Feeling 
fearful. The second factor accounted for 10.33% of variance and contained 16 
items (> 0.4 factor loading). These items were labelled the appetitive scale and 
contained experiences that most users would typically find enjoyable e.g. Feeling 
ecstatic. The third factor accounted for 6.46% of variance and contained 10 items 
(>0.4 factor loading), 7 of which originated from the section pertaining to after 
effects. These items were labelled the intoxicated scale and contained 
experiences associated with the effects after the prominent psychoactive effects 
have subsided e.g. feeling generally slowed down. 
 
Please note that since the questionnaires original development the measure has 
evolved and as a consequence several of the cohorts described above have 
completed previous versions. The version completed by Cohort 1 and the majority 
of Cohort 2 had no section two and a substantially reduced section one thus no 
information about other drug use was collected and only minimal information about 
cannabis consumption was recorded. Cohort 3 completed a version of the CEQ 
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translated into Dutch. In this cohort due to ethical restrictions section two was not 
included as part of the questionnaire. Cohort 4 completed both sections one and 
two, however, the information contained in section two has not been retained. 
Consequently, there are only complete datasets of information from section 2 of 
the CEQ (Other drug use) for Cohorts 5 and the clinical respondents. Despite the 
CEQ now being in its eighth version throughout its development the substantive 
part of the questionnaire (the checklists of experiences) have remained consistent. 
 
2.2.4 Pilot Study 
A piloting procedure was undertaken to determine the suitability of the website 
design and item presentation. Ten participants (female n =7) were opportunistically 
recruited from a psychology student undergraduate population. These participants 
accessed the various pages of the website and completed the measures 
presented. The participants were then requested to comment on ease of access; 
ease of interpretation; clarity of presentation; and item presentation.  
 
The feedback received from the participants was broadly very positive. 
Nonetheless, as a result of the piloting additional information was added to a help 
box underneath the majority of items presented (see Figure 1). This information 
was added to help facilitate clarity of interpretation of the items.  The format of the 
display of section 2 of the CEQ (other drugs used) was also altered as a result of 
the piloting. Initially this section was displayed as a series of branched items with 
participants requested to state in separate open text boxes each drug (other than 
cannabis) that they had ever consumed. This method was deemed by the pilot 
participants to be too laborious and subsequently was replaced with a checklist of 
some of the most commonly consumed drugs (See Appendix 5). 
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Figure 1 
A screenshot of study items on the questionnaire hosting facil ity  
 
2.2.5 Procedure 
Respondents were given the opportunity of participating electronically or in a 
‘paper and pen’ format, however, none of the hard-copy data returned was eligible 
for inclusion (see Section 2.2.2 pp. 106-08). Thus, all the clinical respondents (DD 
and PD) completed the measures ‘online’ consequently only this procedure will be 
discussed. Participants were directed to the research group’s website via various 
means (see Section 2.2.2). The website, which was hosted on an internal server, 
contained; a participant study information sheet (Appendix 6); information detailing 
the background to the research (Appendix 7); information about other on-going 
research; information  about the ethical approval of the investigation (Appendix 8); 
the researchers contact details (Appendix 9); and a consent form (Appendix 10). 
 
At the bottom of the consent form was a button to affirm consent, this opened up a 
‘pop- up’ window containing the questionnaire. On the first screen of the ‘pop-up’ 
window was a notice requesting any participants who had not affirmed consent to 
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return to the previous window and do so. This page also briefly summarised some 
of the study information presented previously (Appendix 11).  Participants then 
clicked a button at the bottom of the window to open up the next page, which 
contained the items pertaining to demographic information and the mental health 
questionnaire (Appendix 4). Once this measure was completed the SPQ-b was 
presented next, with the CEQ presented last (see Appendix 1). Once these items 
were completed participants were forwarded on to a page expressing the 
researcher’s gratitude. All the submitted data was stored on an internal server, 
behind a protective firewall. 
  
 
2.2.6 Ethical considerations 
Risks and safe-guarding of participants 
The procedure was approved by the MMU research ethics committee, and was 
also granted approval by RETHINK’s ethics committee. To offer an avenue of 
support to any participant experiencing distress, a list of information groups and 
support services aimed at addiction, drug use, and mental health were presented 
on the website. Two participants reported directly to the researcher experiencing 
distressing symptoms (e.g. suicidal ideation), although they did not suggest that it 
was as a consequence of participation in the research. In these instances further 
information regarding support pertaining to those participant’s specific issues was 
forwarded on to them. 
 
Research ethics in a virtual setting 
Application of research ethics in an online setting is a complex one in which 
traditional ethical conventions may not easily be applied, one such example is the 
right to withdraw. As the participant transitioned through the process of completing 
the various measures, the participant’s data from the previous pages were 
retained in a database. Thus, allowing for the storage of partial data. There was a 
button at the bottom right of the screen which automatically erased any partial data 
submitted. However, in the instance where the participant did not press this button 
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but, instead navigates away (closes the browser) before the final page, this is 
taken as withdrawal of their data. Thus, partial data was removed from the 
dataset. 
 
In an effort to increase response rate and to promote honest and accurate 
responses participants were offered complete anonymity. However, because of 
the poorly defined notion of what constitutes a virtual identity after data submission 
participants were not offered the right to withdraw. If for instance a pseudonym is 
commonly utilised on a forum page this could reasonably be considered an 
individual’s identity, and thus asking the participants for a pseudonym is not 
appropriate. Moreover, in the event that a participant wishes to withdraw their 
data, to do so via electronic means would have resulted in them inadvertently 
identifying themselves. To further protect anonymity and confidentiality ‘cookies’ 
(small identifying pieces of information) were not sent to a participant’s computer 
as these could be used to ‘reconstruct’ the participants response (at the point of 
the data’s origin). 
 
As cookies were not utilised access to the measures could not be restricted, which 
presented a challenge for ensuring consent had been given. By simply typing in 
the URL of the hosted measure it was possible to access it without seeing the 
consent form or participant information sheet. However, several steps were taken 
to ensure that this possibility was highly improbable. The research group’s 
purpose built website acted as a gateway in-between any linked pages (e.g. 
external websites containing advertisements) and the questionnaire. This ensured 
that there was only one link to the measures posted in a public forum (that 
attached to the consent form). The URL for these measures was unmemorable 
and contained a long sequence of alphabetic characters, numbers, and 
punctuation. This URL was not distributed, placed in Google listings, or 
(knowingly) linked from another page.  Furthermore, on the first page of the hosted 
measures participants are requested not to proceed unless they have affirmed 
consent (see Appendix 11). 
 
To further ensure participant confidentiality data was stored on an in-house server. 
Via the ‘in-house’ storage of data the robust and regularly updated university 
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firewall is utilised to prevent malicious attack. However, more importantly this 
method ensures that the data is never stored outside of the EU and thus, is always 
subject to the stringent EU data protection laws. If data is stored on servers 
outside of the EU explicit consent should be sought (from the participant) and 
established prior to the exportation of data, with the exception of companies with 
licenses from the Safe Harbor Framework (International Trade Administration, 
2013). 
 
2.2.7 Statistical procedures adopted in the analysis 
In this investigation no system of imputation was utilised, this was done to ensure 
that group differences were not minimised or maximised. The results were 
generated using data analysis software SPSS 19.01 (IBM). Prior to undertaking 
meaningful analyses of the data, they were assessed for the requisite assumptions 
applicable to various statistical analyses (Section 2.3.1). As is often convention, 
the analyses contained within this investigation utilised a p-value of less than 0.05 
to indicate statistical significance. With the exception of instances when multiple 
comparisons are made in which case a Bonferroni correction is utilised to adjust 
alpha to an acceptable level. Utilising Chi2 and Kruskal-Wallis tests the various 
groups were assessed for differences in (basic) demographic data and self-
reported cannabis related behaviour (Sections 2.3.2 ). Utilising a Chi2 test 
comparison was also drawn between respondents who reported diagnoses of 
mental illness on data relating to their mental health (Section 2.3.3). 
 
Utilising Kruskal-Wallis, Jonckheere-Terpstra, and Mann-Whitney tests the four 
groups of respondents (CSCN, CSCU, DD, and PD) were compared for 
differences on assessments of schizotypy (Section 2.3.4 pp) and assessments of 
cannabis experiences (Section 2.3.5). The data was assessed in a forced entry 
multinomial regression model to assess the variables as covariates of group 
membership (2.3.6). This analysis was also utilised to elucidate any group 
differences when; an interaction between cognitive-perceptual deficits and 
aversive cannabis experiences were considered (Section 2.3.7); and undiagnosed 
or unreported mental illness is controlled for (Section 2.3.8).  
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2.3 Results 
2.3.1 Assessing the assumptions of the analyses 
This section considers the variables which must be assessed for statistical 
assumptions including; SPQ-b total score; SPQ-b cognitive-perceptual, 
interpersonal and disorganised subscales; CEQ aversive, appetitive, and 
intoxicated scales; and several indices of cannabis use. 
 
Assessing the distribution of the indices of cannabis use 
Participants responded to interval and scale items pertaining to frequency of 
cannabis use, weekly expenditure, number of lifetime uses, and age. Histograms 
were generated and the distribution of the data was examined. The results of a 
Kolmogorov-Smirnov test of distribution indicate that for all the variables under 
assessment in each of the three groups the data are significantly non-normally 
distributed (See Appendix 12). Furthermore, no transformation would correct the 
distribution due to the differences in distribution between the three groups (i.e. 
positive and negative skew). Moreover, a Levene’s test of homogeneity of 
variance indicates that for weekly expenditure and age the variances were 
significantly different for the groups under assessment (see Appendix 13). 
Therefore, analyses considering these variables will utilise non-parametric 
statistical techniques. 
 
Assessing the distribution and homoskedasticity of the schizotypal personality 
questionnaire-brief 
 
The SPQ-b consists of three subscales pertaining to cognitive-perceptual, 
disorganised, and interpersonal disruption, the sum of which provides a total score 
on the SPQ-b. The CSCN, CSCU, DD and PD group were assessed 
independently for homogeneity of variance on each of the SPQ-b subscales and 
total. In no instance did Levene’s F attain significance at < .05, thus the variances 
between the groups are presumed to be homogenous (See Appendix 15). 
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In addition to an inspection of histograms the data was tested for skewness by a 
Kolmogorov-Smirnov test. The CSCN and CSCU groups displayed significantly 
positively skewed data on all three SPQ-b subscales and total score (see 
Appendix 14).  In contrast the DD group displayed a significant negative skew on 
the cognitive-perceptual and interpersonal subscale. However, this group 
displayed a significant positive skew on the disorganisation subscale. However, 
the SPQ-b total score was not found to be non-normally distributed. The data from 
the participants who had received a diagnosis of a psychotic disorder (PD) 
displayed negatively skewed data in the three subscales and SPQ-b total score. 
 
Comparison between the four groups suggested equal homogeneity of variance, 
providing support for one of the assumptions of parametric analysis. Nonetheless, 
each of the groups submitted significantly skewed data. In this instance a 
transformation is not appropriate as the associated histograms suggest; the CSCN 
and CSCU groups have positively skewed data, the PD group displays slightly 
negatively skewed data, and the DD group submitted both positively and 
negatively skewed data. Hence, non-parametric statistical methods were utilised 
when comparing groups on these variables (section 2.3.5).  
 
Assessing the distribution and homoskedasticity of the Cannabis Experiences 
Questionnaire 
Homogeneity of variance was assessed between the cannabis using groups. The 
three groups were found to be none homogenous in the aversive, appetitive and 
intoxicated scales (Appendix 17).  Nonetheless, an assessment of the 
assumptions of normality was undertaken for the three scales of the CEQ. A 
Kolmogorov-Smirnov test was used to assess normality of distribution (Appendix 
16), in addition to an inspection of histograms in the three independent groups on 
all three of the CEQ scales. 
 
The CSCU group displayed a positive significantly non-normal skew on the 
aversive, appetitive, and intoxicated cannabis experiences scale.  The DD group 
also displayed a positive significantly non-normal skew on the aversive cannabis 
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experiences scale, and the intoxicated scale. However, the DD groups’ distribution 
on the appetitive scale was not found to be significantly non-normal and displayed 
a slightly negative skew. The PD group also displayed a positive significantly non-
normal skew on the aversive, appetitive, and intoxicated scales. Consequently the 
data are assumed to violate the assumptions requisite for parametric statistical 
analyses.  
 
Assessing the assumptions of a logistic regression model 
The SPQ-b total score, alongside the CEQ scales, was initially assessed for the 
assumptions of the multinomial logistic regression model; linearity and non- 
multicollinearity. In an alternative model the CEQ scales not found to violate 
assumptions, were also assessed with the SPQ-b’s subscales. In a logistic 
regression model the notion of a linear relationship between the ‘independent’ 
(predictor) variables is violated. “The assumption of linearity in logistic regression, 
therefore, assumes that there is a linear relationship between any continuous 
predictors and the logit of the outcome variable” (Field, 2009, p.273). Following the 
procedure described by Field (2009, p.296) the predictor variables were assessed 
for linearity with their logit values.  
 
The DD and PD groups were compared against the CSCU as the reference group. 
The non-significant p-values of the interaction between the SPQ-b total, aversive, 
and intoxicated scales and their respective log values indicate that the 
assumptions of linearity have not been violated. However, in comparison of the 
CSCU group and the DD group there was a significant relationship between the 
appetitive scale and its log indicating non-linearity between the variables (b = -
0.15, Wald χ2 (1) =  9.82, O.R.0.86, 95% CI 0.79 to 0.95, p = .002). This indicates 
that in consideration of the comparison of the CSCU and DD group the appetitive 
variable is not appropriate for a linear log regression model. However, this variable 
was not shown to have a non-linear relationship when comparing the HCU and PD 
groups. However, in comparison of the PD and DD group the interaction between 
the appetitive scale and its log was significant, suggesting a non-linear relationship 
(b = 0.19, Wald χ2 (1) = 10.37, O.R.1.22 95% CI 1.08 to 1.37, p =.001). 
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One approach to address the non-linear relationship would be to transform the 
data. However, given that the data within the PD and CSCU group indicates 
linearity (between the variable and its own log) this will necessitate the 
transformation of data that has met the assumptions. Moreover, within the context 
of a logistic regression the data is already subject to transformation. However, 
appetitive experiences are not the phenomena which are of primary interest, thus 
the scale will be dropped from regression models.  
 
Utilising group membership (CSCU, DD, & PD) as an outcome variable the 
aversive and intoxicated scales and the SPQ-b total score were assessed within a 
linear regression model for multicolinearity (Field, 2009, p.297). The associated 
tolerance and variance inflation factor (VIF) fall within the parameters 
recommended by Mernard (1995) and Myers (1990) respectively (see Appendix 
18). Moreover, the associated variance proportion table did not indicate more than 
one independent variable having a high proportion of effect on the lower 
eigenvalues (see Appendix 19). 
 
The SPQ-b subscales were also assessed in a model including the cognitive 
perceptual, interpersonal, and disorganised subscales as well as the interaction 
between the subscale and its own log. The interaction between the cognitive-
perceptual, disorganised, and interpersonal subscales and their respective log 
values were non-significant indicating that the assumptions of linearity have not 
been violated. The aversive and intoxicated scales and the SPQ-b subscales were 
also assessed within a linear regression model for multicolinearity (Field, 2009, 
p.297). The associated tolerance and variance inflation factor (VIF) fall within 
acceptable parameters (Mernard, 1995; Myers, 1990) (see appendix 20). 
Moreover, the associated variance proportion table did not indicate more than one 
independent variable having a high proportion of effect on the lower eigenvalues 
(see Appendix 21). 
 
2.3.2 Participant characteristics 
The sample consisted of 85 people who had received a (self-reported) diagnosis 
of depression (DD). The DD group had a mean age of 30 years (SD 10.83) 
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consisted of 49 males and 36 females.  The sample also contained 48 
participants, who reported receiving a diagnosis of a psychotic disorder, PD. This 
group consisted of 33 participants with a self-reported diagnosis of schizophrenia, 
6 who reported psychosis not otherwise specified, 6 who reported schizoaffective 
disorder, and 3 who reported drug (cannabis) induced psychosis. The PD group 
had a mean age of 36 years, 27 of the group were male and 21 female. 
 
The community sample of cannabis users (CSCU) (n= 861) had a mean age of 23 
years (SD 6.12), and contained 393 males, 465 females, and 3 participants who 
opted not to state their gender. The other group consisting of a community sample 
of cannabis naïve participants (CSCN) (n=306) had a mean age of 22 years (SD 
7.62), and contained 80 males, 225 females and 1 participant who did not state 
their gender. There was a significant difference in the distribution of males and 
females between the four groups (CSCU, CSCN, DD, and PD) (χ2 (3) = 48.60, 
p<.001). However, there was no significant difference in the distribution of males 
and females between the three cannabis using groups (χ2 (2) = 5.96, p=.051). 
Trend gender differences in the CSCN and CSCU groups may be due to the 
recruitment of psychology students, which have a higher proportion of females 
(Department for Education and Skills, 2007). If only the clinical respondents are 
considered (DD and PD) there was no significant association of group and gender 
(χ2 (2) = 0.24, p=.88). 
Table 2 
Indicating the number of current and former cannabis users recruited in each cohort  
Cohort / Group Current user Past user 
3 65 40 
4 30 21 
5 243 222 
Community Sample of Cannabis 
Users total 
338 283 
 
The cannabis using groups (CSCU, DD, and PD) significantly differed in the 
preparation of cannabis that they typically consumed (χ2 (6) = 74.24, p < .001) 
(Table 4). The majority of the CSCU group typically consumed sinsemilla. 
However, in the DD and PD groups traditional herbal cannabis was the most 
frequently consumed preparation.  This could potentially reflect an aversion in 
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these groups to the most commonly consumed, most potent (relative ∆-9-THC to 
CBD ratio), and theoretically most detrimental preparation; sinsemilla (D’Souza, et 
al.,2004, Hardwick & King, 2008). The participants also significantly differed in 
whether they reported that they were a current or former cannabis user (χ2 (2) = 
29.17, p < .001). The majority of the CSCU and DD group were current cannabis 
users. In contrast the majority of the PD group were former cannabis users. It is 
feasible that the psychologically deleterious effect of the substance, on the PD 
group, has resulted in a greater incidence of abstinence.  
 
No data was collected pertaining to the CSCU group’s social context of use, but 
intriguingly the PD and DD groups significantly differed. A greater proportion of the 
PD group tended to use cannabis in solely social situations more frequently than 
their counterparts. This could feasibly be as a consequence of the PD group 
utilising cannabis to mitigate the social withdrawal vulnerability conferred by their 
schizotaxic liability. Such an effect has been documented by other investigations 
(e.g. Salyers & Meuser, 2001) and is discussed in Section 1.6.1. In contrast a 
greater proportion of the DD group tended to use cannabis alone. Participants also 
documented the time of day that they tended to use cannabis. Unfortunately, the 
frequency of participants in each group is insufficient to perform a Chi2 test 
between all three groups. Nonetheless, such a test can be performed comparing 
the CSCU and PD groups (excluding the DD group). There was a significant 
association between the CSCU and PD groups on the time of day cannabis was 
used (χ2 (2) = 48.71, p < .001). The majority of participants in the PD group tended 
to use cannabis both during the day and night time, whereas the most frequent 
time of use in the CSCU group was solely at night. 
 
Participants also responded to interval and scale items pertaining to frequency of 
cannabis use, weekly expenditure, number of lifetime uses, and as discussed 
previously age. Due to the data violating assumptions (see Section 2.3.1) non-
parametric statistical methods, a Kruskal-Wallis ANOVA were employed to 
determine group differences. The p-values indicate that there are significant 
differences between the CSCU, DD and PD groups on assessment of; age; the 
frequency of their cannabis use; and weekly expenditure on cannabis; and age of 
first use (see Table 3). Despite research indicating that age of cannabis initiation 
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may be a significant determinant of psychotic mental illness, the mean ranks 
indicate that the participants in the CSCU group were initiated younger than their 
DD and PD counterparts (Arseneault et al., 2002; Veen, et al., 2004). There was 
also a significant difference between the number of self-reported lifetime uses 
between the PD and DD group.  
 
Table 3 
Comparing age and indices of cannabis use in groups of participants  
   Kruskal-Wallis 
  CSCU DD PD DF H p- value 
Age 
Mean rank 460.66 687.08 822.70 
2 114.063 <.001 
Median 21.0 27.0 33.0 
Frequency of use 
Mean rank 509.74 245.79 374.56 
2 73.352 <.001 
Median 4.0 1.0 2.0 
Weekly Expenditure 
Mean rank 389.24 529.54 464.06 
2 32.076 <.001 
Median 2.0 4.0 3.0 
Number of lifetime uses 
Mean rank 
No data 
68.64 52.45 
1 5.938 .015 
Median 1000 300 
Age of first use 
Mean rank 435.15 524.94 525.39 
2 13.961 .001 
Median 16.0 16.0 17.0 
 
The data indicates that the CSCU group used cannabis more frequently than the 
clinical respondents. However, their expenditure was substantially lower this may 
reflect an increase in price between the two data collection periods (community 
sample, 2004-9; clinical respondents, 2011-3). The PD group had significantly 
fewer lifetime uses than the DD group, which is feasibly a reflection of an adverse 
response to the drug. 
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Table 4    
Comparing further indices of cannabis use between groups of participants    
 
Group Chi
2
 DF 
CSCU (%) DD (%) PD(%)   
Type of cannabis used** 
Cannabis resin 151 (26.4) 10 (12) 8 (17)   
Sinsemilla 300 (52.5) 31 (37.3) 8 (17)   
 Traditional herbal cannabis 104 (18.2) 35 (42.2) 24 (51.1)   
 Any/Don’t know 16 (2.8) 7 (8.4) 7 (14.9)   
 Total / Test statistic 571 83 47 74.24 6 
Current or past user** 
Current 338 (54.4) 69 (81.2) 18 (37.5)   
Past 283 (45.6) 16 (18.8) 30 (62.5)   
 Total / Test statistic 621 85 48 29.17 2 
Context of use* 
Socially 
No data 
11 (12.9) 18 (38.3)   
On your own 12 (14.1) 4 (8.5)   
 Both 62 (71.3) 25 (53.2)   
 Total / Test statistic 85 47 11.43 2 
Time of day used 
Day 127 (16.5) 2 (2.4) 4 (8.3)   
Night 536 (69.6) 37 (43.5) 19 (39.6)   
 Day & Night 107 (13.9) 46 (54.1) 25 (52.1)   
 Total 770 85 48   
Frequency of cannabis use 
Everyday 140 (16.6) 45 (57) 15 (37.5)   
More than once a week 149 (17.6) 13 (16.5) 8 (20)   
About once a week 69 (8.2) 7 (8.9) 5 (12.5)   
About once or twice a month 175 (20.7) 11 (13.9) 2 (5)   
 A few times each year 168 (19.9) 2 (2.5) 5 (12.5)   
 
About once a year 71 (8.4) 1 (1.3) 3 (7.5)   
About once or twice ever 73 (8.6) 0 (0) 2 (5)   
 Total 845 79 40   
Weekly Expenditure 
<£2.50 302 (44.1) 15 (17.6) 14 (31.1)   
£2.50-£5 86 (12.6) 9 (10.6) 3 (6.7)   
 £5.01-£10 70 (10.2) 14 (16.5) 6 (13.3)   
 £10.01-£15 43 (6.3) 6 (7.1) 3 (6.7)   
 
 
£15.01-£20 72 (10.5) 9 (10.6) 9 (20.0)   
>£20 112 (16.4) 32 (37.6) 10 (22.2)   
 Total 685 85 45   
*p<.01 **p<.001      
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2.3.3 Comparing those with reported depression and those with reported 
psychotic disorder 
All clinical respondents (DD and PD) completed an additional questionnaire which 
pertained to their current and previous mental health. Those diagnosed with 
depression (DD) and those diagnosed with a psychotic disorder (PD) did not differ 
significantly in their self-assessment of currently being psychologically well (see 
table 5). However, the PD group were significantly more likely to be currently 
taking medication than the DD group (χ2 (1) = 21.10, p<.001). This is feasibly as a 
result of the PD population receiving a maintenance dose of medication, which is a 
common course of treatment for schizophrenia (NICE, 2010, p.98). The majority 
(68.8%) of the PD group had a (self-reported) diagnosis of schizophrenia. The 
data reflects the differences in the courses of the two clusters of disorders.  
Schizophrenia tends to run a more chronic course, with only “a small number of 
individuals reported to recover completely” (APA, 2013a p.102). This is evinced in 
the data with members of the PD group being significantly more likely to be 
currently receiving a non-pharmacological (psychological) treatment (χ2 (1) = 4.29, 
p=.038). Nonetheless, participants in the PD and DD group did not differ 
significantly in their previous experience of taking medication or receiving a non-
pharmacological treatment for their mental illness (see Table 5). Neither did the 
participants significantly differ in their self-reported medication adherence (Kruskal 
Wallis, U=1458, Z=-1.06, p=.29).  
 
The results of the comparisons contained within this section indicate that the two 
groups do not differ significantly in their previous experiences of medication and 
non-pharmacological intervention, on the indices under assessment. However, the 
PD group were significantly more likely to be currently taking medication and 
receiving psychological intervention. Nonetheless, there was no significant 
difference between the DD and PD group on the self-reported assessment of 
being currently psychologically well. Thus, indicating that the increased likelihood 
of current intervention in the PD group is a consequence of the chronicity of the 
disorder, as opposed to greater incidence of acute illness. 
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Table 5 
Comparing current and previous mental health of participants with reported 
depression and reported psychotic disorder  
 
Group 
 
Chi
2
 
 
Depression 
Diagnosed (%) 
Psychosis Diagnosed 
(%) 
 
Currently psychologically well? 
Yes 51 (60) 26 (54.2)  
No 34 (40) 22 (45.8)  
Total /  χ2 85 48 0.43 
Currently taking 
medication?*** 
Yes 38 (44.7) 41 (85.4)  
No 47 (55.3) 7 (14.6)  
Total /  χ2 85 48 21.10 
Currently receiving a non-
pharmacological 
treatment?* 
Yes 19 (22.6) 19 (39.6)  
No 65 (77.4) 29 (60.4)  
Total /  χ2 84 48 4.29 
Previously taken medication? 
Yes 68 (81) 35 (74.5)  
No 16 (19) 12 (25.5)  
Total /  χ2 84 47 0.75 
Previously received a non-
pharmacological treatment? 
Yes 59 (70.2) 33 (68.8)  
No 25 (29.8) 15 (31.3)  
Total /  χ2 84 48 0.03 
*p<.05 **p<.01 ***p<.001,  All degrees of freedom =1   
 
2.3.4 Cannabis use, Diagnosis and differential schizotypal trait 
Analysis contained within this section contributes to one of the primary aims of this 
chapter: To assess variance in schizotypal trait related to cannabis use and 
reported mental illness. As the data was found to be non-normally distributed (see 
section 2.3.1 and Appendices 14 & 15) a non-parametric alternative to analysis of 
variance, a Kruskal-Wallis test, was performed. The CSCN, CSCU, DD, and PD, 
groups were compared for differences on the three SPQ-b subscales and the total 
score. The four groups significantly differed in their scores on the cognitive 
perceptual subscale (H (3) = 40.92, p < .001), interpersonal subscale (H (3) = 
76.60, p < .001), disorganised subscale (H (3) = 72.31, p < .001), and SPQ-b total 
(H (3) = 79.68, p < .001) (see Table 6). 
 
A linear effect (by the definition of the phrase) between the groups is not 
hypothesised as they are categorically and substantively different. For example, 
there may be differences in schizotypal personality between the CSCN group and 
the CSCU group. However, these variances are substantively, physiologically, and 
theoretically different from the variances that will be displayed between the DD 
and PD groups. Moreover, a linear effect may presume that the differences 
128 | P a g e  
 
between the lowest scoring group and the second to lowest scoring group, is twice 
the difference of the lowest scoring group and the third lowest scoring group. 
Thus, a true linear effect between the groups would be an unreasonable 
hypothesis to address. However, some would argue that if the DD group were 
omitted with sufficient data a true linear effect may be observed within a continuum 
model of psychosis and schizotypal personality (See Section 1.2.2). Nonetheless, 
a reasonable hypothesis to test would be one asserting that the groups will display 
a distinct profile on the SPQ-b with the CSCN, CSCU, DD and PD groups scoring 
the lowest to highest in that respective order. 
 
Table 6 
Measures of central tendency on the SPQ-b by participant groups 
 
Group 
CSCN CSCU DD  PD 
Cognitive-Perceptual 
Mean (SD) 2.50 (2.3) 2.53 (2.0) 3.00 (2.1) 4.44 (1.8) 
Median 2 2 3 5 
Interpersonal 
Mean (SD) 2.87 (2.3) 2.73 (2.3) 4.74 (2.5) 4.92 (2.3) 
Median 3 2 5 5 
Disorganised 
Mean (SD) 1.54 (1.7) 1.94 (1.7) 3.15 (1.8) 3.08 (1.8) 
Median 1 2 3 3 
SPQ-b total 
Mean (SD) 6.91 (4.8) 7.20 (4.8) 10.89 (5.4) 12.44 (4.8) 
Median 6 6 11 13 
 
One means in which this notion of a distinct profile, in a distinct order can be 
tested is through a Jonckheere-Terpstra non-parametric test.  A significant trend in 
the data was noted the median score on the cognitive perceptual subscale 
significantly increased between the CSCN, CSCU, DD, and PD groups in that 
respective order, J = 235661.50, z = 3.77, r = 0.10, p  < .001. A significant trend 
indicating an increase in the median was also noted between the groups for the 
interpersonal subscale J = 240924.50, z = 4.57, r = 0.13, p  < .001, disorganised 
subscale J = 260633.50, z= 7.703, r = 0.21, p < .001, and SPQ-b total J = 
252171.00, z = 6.27, r = 0.17, p < .001. Although statistically significant the 
associated effect sizes (r) suggest only a small linear effect of group on 
schizotypal personality (Cohen, 1988). 
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Tests of difference in schizotypal trait between two groups of participants 
The groups significantly differed in the three SPQ-b subscales, and SPQ-b total. 
The results of the Jonckheere-Terpstra test suggest a distinct profile of response 
between the four groups in a distinct (hypothesised) order, albeit with only a small 
effect size. However, to make inferences pertaining to significant differences 
between specific groups the non-parametric equivalent of an independent t-test 
was performed; the Mann-Whitney test. As each pairwise comparison will utilise 
four variables, a multiple comparison (Bonferroni) adjusted alpha of < .0125 will be 
utilised. 
 
The CSCU group were tested in a pairwise comparison with the CSCN group for 
differences in the SPQ-b. The two groups did significantly differ in scores on the 
SPQ-b disorganised subscale, with the CSCU group scoring significantly higher 
than the CSCN group, see Table 6 and Table 7. Other investigations have 
demonstrated an elevated schizotypal personality score in cannabis users in 
comparison to none cannabis users (e.g. Dumas et al., 2002; Skosnik et al,. 
2001). Nonetheless, the effect size is only small accounting for 1.21% of the total 
variance. However, this was limited to solely that subscale as the two groups did 
not significantly differ in the cognitive perceptual subscale, the interpersonal 
subscale, or the SPQ-b total score.   
 
Table 7 
Pairwise comparisons of a community sample of cannabis users  and a community 
sample of non-cannabis users on assessments of schizotypy  
 
CSCN 
Mean rank 
CSCU      
Mean rank 
U Z Effect size r p-value 
Cognitive-perceptual 576.42 586.69 129413.50 -0.464 -0.01 .643 
Interpersonal 602.78 577.32 125985.00 -1.147 -0.03 .251 
Disorganised 523.83 605.38 11.3321.50 -3.719 -0.11 <.001 
SPQ-b 568.74 589.42 127064.00 -0.924 0.03 .355 
 
 
In a pairwise comparison, the DD group were assessed with the CSCU group for 
differences in the SPQ-b. The two groups did not significantly differ in the cognitive 
perceptual subscale, after a Bonferroni correction for multiple testing.  However, 
the DD group scored significantly higher than the CSCU group on the 
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interpersonal, and disorganised subscales, and SPQ-b total score (see Tables 6 & 
8). Nonetheless, the effect size indicates only a small effect accounting for 4.84%, 
3.61% and 4% of the total variance respectively. The lack of statistical difference 
in the cognitive-perceptual subscale may be as a consequence of the cannabis 
use in the CSCU group. This notion may be tested by comparing the cannabis 
naïve group (CSCN) with the DD group (U = 11088.50, z = -2.10, p < .035, r = -
0.11). The significant difference suggests that cannabis use is diminishing the 
differences between the CSCU group and the DD group, or that a Bonferroni 
correction resulted in the adoption of too conservative a p. value. 
 
Table 8 
Pairwise comparisons of a community sample of cannabis users and cannabis users 
with a reported diagnosis of depression on assessments of  schizotypy  
 
CSCU 
Mean rank 
DD 
Mean rank 
U Z Effect size r p-value 
Cognitive-perceptual 467.86 530.58 31740.50 -2.043 -0.07 .041 
Interpersonal 454.71 663.83 20414.50 -6.798 -0.22 <.001 
Disorganised 457.78 632.74 23057.50 -5.732 -0.19 <.001 
SPQ-b 456.78 642.89 22194.00 -6.003 -0.20 <.001 
 
A pairwise comparison was also performed to draw comparison between the PD 
and DD groups. The PD group scored significantly higher than the DD group on 
the cognitive perceptual subscale (see Tables 6 & 9). The effect size is within the 
boundaries of what is widely regarded as medium, accounting for 11.56% of total 
variance (Cohen, 1988). However, the two groups did not significantly differ in 
scores on the interpersonal and disorganised subscale or the SPQ-b total score. 
However, the SPQ-b total did have a small effect size accounting for 1.96% of total 
variance. 
 
Table 9 
Pairwise comparisons of cannabis users with reported diagnoses of depression and 
psychotic disorder on assessments of schizotypy  
 
DD 
Mean rank 
PD 
Mean rank 
U Z Effect size r p-value 
Cognitive-perceptual 57.34 84.11 1218.50 -3.885 -0.34 <.001 
Interpersonal 66.25 68.32 1976.50 -0.300 -0.03 .764 
Disorganised 67.44 66.23 2003.00 -0.176 -0.02 .861 
SPQ-b 62.81 74.42 1684.00 -1.671 -0.14 .095 
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Comparison was also drawn between the CSCU and PD groups. As would be 
expected (see Section 1.2.2), the PD group scored significantly higher than the 
CSCU group on the cognitive-perceptual, interpersonal and disorganised 
subscales, and the total score (see Tables 6 & 10). However, only a small effect 
size was observed with only 4%, 3.61%, 1.96%, and 4.84% of total variance 
explained respectively (Cohen, 1988). 
 
Table 10 
Pairwise comparisons of cannabis users from a community sample and cannabis 
users with reported psychotic disorder on assessments of schizotypy  
 
CSCU 
Mean rank 
PD 
Mean rank 
U Z 
Effect size 
r 
p-value 
Cognitive-perceptual 442.69 675.82 10064.50 -6.056 0.20 <.001 
Interpersonal 443.13 667.89 10445.50 -5.832 0.19 <.001 
Disorganised 446.36 609.98 13225.00 -4.281 0.14 <.001 
SPQ-b 441.59 695.56 9117.00 -6.536 0.22 <.001 
 
2.3.5 Cannabis use, Diagnosis and Cannabis Experiences 
Analysis contained within this section contributes to one of the primary aims of this 
chapter: To assess the presence of a differential sensitivity to the psychotomimetic 
effects of cannabis in those with psychotic illness. A Kruskal-Wallis test was 
performed to assess differences between the CSCU, DD, and PD groups on the 
three CEQ scales. The three groups significantly differed in their scores on the 
aversive scale (H (2) = 14.17, p < .001), and the appetitive scale    (H (3) = 14.06, 
p = .001). However, the groups did not significantly differ on the intoxicated scale 
(H (3) = 4.62, p = .101).  
 
Table 11 
Measures of central tendency on the CEQ by participant groups  
 
Group 
CSCU DD  PD 
Aversive 
Mean (SD) 14.77 (14.02) 11.44 (11.22) 22.15 (17.52) 
Median 11.00 10.00 17.00 
Appetitive 
Mean (SD) 16.88 (9.93) 20.85 (8.46) 16.92 (11.68) 
Median 17.00 21.00 12.50 
Intoxicated 
Mean (SD) 17.00 (8.82) 14.87 (7.52) 16.85 (8.70) 
Median 16.00 14.00 16.00 
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The groups were tested for group differences, by means of a linear effect (see 
Section 2.3.4) between the CSCU, DD, and PD groups in that respective order. A 
significant trend in the data was not noted in the median score of either the 
aversive scale (J = 61213.00, z = 0.62, r = 0.02, p =.532), or intoxicated scale (J = 
53908.50, z = -1.75, r = -0.06, p .079). In the assessment of the statistical 
assumptions (Section 2.3.1 pp.118-121) the appetitive scale indicated a non-linear 
effect, thus this variable will not be assessed for a linear effect between groups. 
 
Tests of difference in Cannabis Experiences between cannabis users diagnosed 
with depression and those diagnosed with a psychotic disorder 
Pairwise comparisons were performed utilising the non-parametric equivalent of 
an independent t-test; the Mann-Whitney test. The three groups of cannabis using 
respondents will be assessed for differences in their aversive, appetitive, and 
intoxicated cannabis experiences. The three scales will be tested simultaneously 
consequently a Bonferroni correction for multiple tests is applied, at p< .017.  
 
The CSCU group were tested for pairwise differences with the DD groups (see 
Tables 11 & 12). The participants did not significantly differ in their aversive 
experiences, nor their intoxicated experiences after a Bonferroni correction. 
However, the two groups did differ in their appetitive cannabis experiences with 
the DD group having significantly more pleasurable cannabis experiences than 
their counterparts in the community sample. Albeit, with only a small effect size 
accounting for only 1.44% of the total variance.  
 
Table 12 
Pairwise comparisons of a community sample of cannabis users and cannabis 
users with reported depression on assessments of cannabis induced experiences  
 
CSCU 
Mean rank 
DD 
Mean rank 
U Z Effect size r p-value 
Aversive 478.66 421.26 32152.50 -1.849 -0.06 .064 
Appetitive 463.14 578.42 27674.00 -3.713 -0.12 <.001 
Intoxicated 479.48 412.88 31439.50 -2.145 -0.07 .032 
 
The community sample of cannabis users (CSCU) were also compared to the 
group of participants who had reported a diagnosis of a psychotic disorder (PD) 
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(see Tables 11 & 13). The PD group had significantly more aversive cannabis 
experiences than the community sample. However, the effect size was small, 
accounting for only 1% of the variance in the data. The two groups did not 
significantly differ in their appetitive or intoxicated cannabis induced experiences. 
 
Table 13 
Pairwise comparisons of a community sample of cannabis users and cannabis 
users with reported psychotic disorder on assessments of cannabis induced 
experiences 
 
CSCU 
Mean rank 
PD 
Mean rank 
U Z Effect size r 
p-
value 
Aversive 448.55 570.78 15106.50 -3.142 -0.10 .002 
Appetitive 455.81 440.50 19968.00 -0.393 -0.01 .694 
Intoxicated 455.56 445.04 20186.00 -0.270 -0.01 .787 
 
 The DD group were tested for pairwise differences with the PD group (see Tables 
11 & 14). The PD group had significantly more aversive cannabis experiences 
than the DD group. The associated effect size falls within the parameters of what 
is deemed a medium effect size (Cohen, 1988), accounting for 10.24% of variance 
in the data. The converse was found in the Appetitive scale with the DD group 
reporting significantly more appetitive cannabis experiences in comparison to the 
PD group. However, with only a small effect size accounting for 4.41% of the total 
variance (Cohen, 1988). The two groups did not significantly differ in their 
intoxicated experiences associated with cannabis (see Table 14). 
 
Table 14 
Pairwise comparisons of cannabis users with reported depression and cannabis 
users with reported psychotic disorder on assessments of cannabis induced 
experiences 
 
DD 
Mean rank 
PD  
Mean rank 
U Z Effect size r p-value 
Aversive 57.60 83.65 1241.00 -3.746 -0.32 <.001 
Appetitive 73.12 56.17 1520.00 -2.438 0.21 .015 
Intoxicated 64.14 72.06 1797.00 -1.140 -0.10 .254 
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2.3.6 Covariates (predictors) of psychotic mental illness 
Assessing the CEQ scales as predictors of mental illness 
Analysis contained within this section and Sections 2.3.7 and 2.3.8 contribute to 
one of the primary aims of this chapter: To assess the utility of assessments of 
cannabis induced experience and schizotypal trait as predictors of psychotic 
illness in cannabis using populations. The data was assessed via a multinomial 
logistic regression model, utilising a forced entry method.  The three independent 
groups of cannabis users (CSCU, DD, and PD) were considered as an outcome 
variable, with the aversive and intoxicated scales as the predictor variables. This 
model will be referred to as ‘the base model’. The groups were assessed initially 
with the CSCU as the baseline category and then DD as the reference category to 
produce three separate comparisons CSCU vs PD, DD vs PD, and also 
incidentally CSCU vs DD.  Therefore, the model was computed in regards to PD 
vs reference category (CSCU or DD). This manner of running the regression 
model allows for the respective odds ratios to reflect an increase in the odds of 
membership to the PD group, i.e. a psychotic outcome. 
 
The model fitted to the data (aversive and intoxicated scales as predictors, see 
Table 15) was significantly better at predicting the data than the intercept, χ2 (4) = 
22.451, p < .001. Goodness of fit was assessed with both the Pearson (χ2 (1218) = 
1221.20, p = .47) and Deviance (χ2 (1218) = 670.664, p = 1.00) method and both 
assessments suggest a good fit of the model respectively. Cox and Snell’s R2 
indicates the model explains only 2.2% of the response data and Nagerlkerke’s R2 
indicates that the model explains 3.6% of the data. Thus, the associated pseudo 
R2 values indicate that the model may not be an accurate means of assessing 
diagnosis. 
 
Neither the aversive or intoxicated scales were significant predictors of 
membership to the CSCU in comparison to the DD group, i.e. these scales could 
not differentiate between a community sample of respondents and those 
diagnosed with depression (see Table 15). However, both the aversive (b = 0.42, 
Wald χ2 (1) = 17.06, O.R.1.04, 95% CI 1.02 to 1.07, p< .001) and intoxicated (b = -
0.45, Wald χ2 (1) = 4.93, O.R.0.96, 95% CI 0.92 to 0.995, p = .026) scales were 
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significant predictors of whether the participant was in the CSCU or PD group. 
Thus indicating that cannabis induced phenomenology may be utilised to predict 
psychotic illness. With each unit increase on the aversive scale the odds of being 
in the PD group increased by 4.3%, whereas the same increase in the intoxicated 
scale decreased the odds of being in the PD group by 4.4%.  The DD group was 
also assessed along with the PD group as outcome variables. The intoxicated 
scale did not significantly predict a diagnosis of depression or psychotic disorder. 
However, the aversive scale was a significant predictor of diagnosis (b = 0.06, 
Wald χ2 (1) = 14.24, O.R.1.06, 95% CI 1.03 to 1.09, p < .001) indicating that these 
groups may be differentiated on these experiences. Each unit increase on the 
aversive scale increased the odds of having a diagnosis of psychosis by 5.8%. 
 
 
  
Table 15 
A multinomial forced entry regression model predicting group membership as a 
function of aversive and intoxicated cannabis experiences 
 
 
Beta (SE) OR
 
P
 95% CI of O.R. 
Lower Upper 
CSCU 
Vs 
DD 
Intercept -1.855 0.235  <.001   
Aversive -0.014 0.011 0.986 .233 0.964 1.009 
Intoxicated -0.018 0.016 0.982 .278 0.951 1.014 
CSCU 
Vs PD 
Intercept -2.890 0.321  <.001   
Aversive 0.042 0.010 1.043 <.001 1.023 1.065 
Intoxicated -0.045 0.020 0.956 .026 0.918 0.995 
DD 
Vs PD 
Intercept -1.035 0.384  .007   
Aversive 0.056 0.015 1.058 <.001 1.027 1.089 
Intoxicated -0.270 0.025 0.973 .279 0.926 1.022 
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The SPQ-b subscales and the CEQ scales as predictors of psychotic illness and 
depression 
The results presented in Section 2.3.4 indicate that the three SPQ-b subscales 
may not equally contribute to predicting a diagnosis of a psychotic disorder and by 
considering the SPQ-b total score as opposed to the subscales may result in loss 
of precision. For example in pairwise comparison the cognitive perceptual 
subscale was significantly higher in the PD group in comparison to the DD group 
(U = 1218.50, z = -3.89, p < .001, r = -0.34), however the groups did not differ in 
the SPQ-b total score (U = 1684.00, z = -1.671, p = .095, r = -0.14) (see Table 9). 
Consequently, in the assessment of the SPQ-b as a predictor in a regression 
model the subscales will be considered independently (see Table 16). The 
cognitive-perceptual, interpersonal, and disorganised SPQ-b subscales were 
assessed along with the aversive and intoxicated scales in a forced entry 
multinomial regression. This model will be referred to as ‘Base + SPQ’. The 
aversive and intoxicated CEQ scales and the SPQ-b subscales were significantly 
better at predicting the data than the intercept (χ2 (10) = 138.527, p < .001). Both 
the Pearson (χ2 (1974) = 1821.210, p = .994) and Deviance (χ2 (1974) = 817.802, 
p =1.00) methods suggest a good fit of the model. Cox and Snell’s R2 indicates the 
model explains 13.0% of the response data and Nagerlkerke’s R2 indicates that 
the model explains 21.1% of the data. 
 
In comparing the CSCU and DD groups aversive cannabis experiences were 
significant predictors of group membership (b = -0.04, Wald χ2 (1) = 8.49, O.R. 
0.96, 95% CI 0.93 to 0.99, p< .004). Each unit increase on the aversive scale 
predicted a decrease of 3.8% in the odds of being a member of the DD group. The 
intoxicated scale did not significantly predict group membership. However, both 
the interpersonal (b = 0.33, Wald χ2 (1) = 30.00, O.R.1.39, 95% CI 1.23 to 1.56, p 
< .001) and disorganised (b=0.30, Wald χ2 (1) = 13.75, O.R.1.35, 95% CI 1.15 to 
1.58, p < .001) SPQ-b subscales significantly predicted a diagnosis of depression. 
A unit increase on the interpersonal and disorganised subscales predicted a 
38.5% and 34.8% increase in the odds of a diagnosis of depression. 
 
In comparison of the CSCU and PD groups aversive cannabis experiences did not 
significantly predict group membership. However, the intoxicated scale did 
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significantly predict a psychotic diagnosis (b = -0.06, Wald χ2 (1) = 6.76, O.R.0.95, 
95% CI 0.91 to 0.99, p = .009). A unit increase on the intoxicated scale predicted a 
decrease of 5.4% on the odds of a diagnosis of a psychotic disorder. The two 
groups were also significantly predicted by the cognitive-perceptual subscale (b = 
0.29, Wald χ2 (1) = 10.44, O.R.1.34, 95% CI 1.12 to 1.59, p = .001) and 
interpersonal subscale (b = 0.25, Wald χ2 (1) = 10.45, O.R.1.28, 95% CI 1.10 to 
1.49, p = .001). Each unit increase on the cognitive-perceptual and interpersonal 
subscales predicted an increase in the odds of a diagnosis of psychosis by 33.5% 
and 28.1% respectively. However, the disorganised subscale was not a significant 
predictor. 
 
In comparison of the DD and PD groups the aversive scale was a significant 
predictor of group membership (b = 0.06, Wald χ2 (1) = 11.70, O.R.1.06, 95% CI 
1.03 to 1.10, p< .001). Each unit increase on the aversive scale predicted a 6% 
increase in the odds of a psychotic diagnosis, in comparison to one of depression. 
The intoxicated scale however, was not a significant predictor. Two of the SPQ-b 
subscales were significant predictors of the outcome variable; the cognitive-
perceptual subscale (b = 0.36, Wald χ2 (1) = 10.94, O.R.1.43, 95% CI 1.16 to 1.77, 
p <.001) and the disorganised subscale (b = -0.30, Wald χ2 (1) = 5.67, O.R.0.74, 
95% CI 0.58 to 0.95, p = .017). Each unit increase on the cognitive-perceptual 
subscale predicted an increase of 42.9% in the odds of being in the PD group. 
Conversely each unit increase in the disorganised total predicted a decrease of 
26.0% in the odds of a psychotic diagnosis. Given that the SPQ-b is a measure of 
schizotypy, a trait highly linked with schizophrenia, this is an unexpected finding. 
 
The data contained within this section supports the notion of assessing the three 
SPQ-b subscales independently. In comparison of the CSCU and PD group the 
cognitive perceptual and interpersonal subscales were significant positive 
predictors of psychotic illness, but the disorganised subscale was not. In 
comparison with the DD and PD groups the cognitive perceptual subscale was a 
significant positive predictor of psychotic illness, but the disorganised subscale 
was a significant negative predictor. 
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2.3.7 Interactions between schizotypal trait and aversive cannabis 
experiences as predictors of psychotic illness 
In Section 2.3.6 there is data presented indicating that the cognitive-perceptual 
subscale of the SPQ-b may be proficient in distinguishing those participants 
diagnosed with a psychotic disorder, from a healthy population and from those 
diagnosed with depression. The analyses contained in Section 2.3.6 indicate that 
the aversive scale is a significant predictor of psychotic mental illness, when 
compared to the DD group. This section seeks to ascertain if liability to cognitive-
perceptual deficit may interact with aversive cannabis experiences to act as a 
significant predictor of psychotic mental illness (see Table 17). 
 
Table 16 
A multinomial forced entry regression model predicting group membership as a 
function of aversive and intoxicated cannabis experiences and schizotypal trait  
 
 
Beta (SE) 
Odds 
Ratio
 P
 95% CI of O.R. 
Lower Upper 
CSCU Vs 
DD 
Intercept -3.179 0.327  <.001   
Aversive -0.038 0.013 0.962 .004 .938 .988 
Intoxicated -0.026 0.017 0.974 .127 .942 1.007 
Cognitive-Perceptual -0.068 0.070 0.935 .335 .814 1.072 
Interpersonal 0.326 0.059 1.385 <.001 1.233 1.556 
Disorganised 0.299 0.081 1.348 <.001 1.151 1.579 
CSCU Vs 
PD 
Intercept -4.228 0.444  <.001   
Aversive 0.019 0.012 1.020 .105 0.996 1.044 
Intoxicated -0.055 0.021 0.946 .009 0.908 0.986 
Cognitive-
Perceptual 
0.289 0.089 1.335 .001 1.120 1.591 
Interpersonal 0.247 0.077 1.281 .001 1.102 1.488 
Disorganised -0.002 0.105 0.998 .984 0.812 1.226 
DD Vs PD 
Intercept -1.048 0.533  .049   
Aversive 0.058 0.017 1.060 .001 1.025 1.095 
Intoxicated -0.029 0.026 0.971 .255 0.924 1.021 
Cognitive-
Perceptual 
0.357 0.108 1.429 .001 1.156 1.765 
Interpersonal -0.078 0.092 0.925 .397 0.771 1.108 
Disorganised -0.301 0.126 0.740 .017 0.578 0.948 
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The aversive scale and cognitive-perceptual scale are initially centred around the 
mean value for the total of the three groups of participants.  These variables are 
then multiplied to create the interaction term. The SPQ-b subscales, the aversive 
and intoxicated CEQ scales and the interaction term between the cognitive-
perceptual scale and the aversive scale were entered into a multinomial 
regression in a forced entry fashion. This model is referred to as ‘Base + SPQ + 
X’, where X denotes the interaction term. The model fitted was significantly better 
at predicting the data than the intercept, χ2 (12) = 143.840, p < .001. The Pearson 
(χ2 (1972) = 1905.99, p = .85) and Deviance (χ2 (1972) = 812.49, p = 1.00) 
assessments suggest a good fit of the model. Cox and Snell’s R2 indicates the 
model explains 13.5% of the response data and Nagerlkerke’s R2 indicates that 
the model explains 21.8% of the data. Thus, suggesting that this model is the most 
accurate means of assessing group membership discussed so far. Nonetheless, 
the likelihood ratio test indicates that the interaction term may not in itself be 
significantly improving the model (-2LL = 817.80, χ2 (2) = 5.31, p = .070). 
 
In comparison with the community sample of cannabis users (CSCU) and those 
diagnosed with depression (DD), group membership was significantly predicted by 
aversive cannabis experiences (b = -0.39, Wald χ2 (1) = 7.07, O.R.0.96, 95% CI 
0.94 to 0.99, p = .008). Each unit increase on the aversive scale reduced the odds 
of a diagnosis of depression by 3.8%. The intoxicated scale was not a significant 
predictor of group membership.  However, both the interpersonal (b = 0.33, Wald 
χ2 (1) = 29.896, O.R.1.39, 95% CI 1.23 to 1.56, p < .001) and disorganised (b = 
0.30, Wald χ2 (1) = 13.93, O.R.1.35, 95% CI 1.15 to 1.58, p < .001) SPQ-b 
subscales were significant predictors of the groups. Each unit increase on the 
interpersonal and disorganised subscale accounted for an increase of 38.5%, and 
35.1% (respectively) in odds of a diagnosis of depression. 
 
In comparison of the community sample of cannabis users (CSCU) and those 
diagnosed with a psychotic illness (PD), diagnosis was significantly predicted by 
both aversive and intoxicated experiences (respectively, b = 0.37, Wald χ2 (1) = 
8.09, O.R.1.04, 95% CI 1.01 to 1.07, p = .004, b = -0.54, Wald χ2 (1) = 6.97, O.R. 
0.95, 95% CI 0.91 to 0.99, p = .017). Each unit increase in the aversive scale 
predicted an increase of 3.8% in the diagnosis of a psychotic illness, whereas the 
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same increase in the intoxicated scale predicted a 5.3% decrease. Both the 
cognitive perceptual and interpersonal subscales were significant predictors of 
group membership (respectively, b = 0.35, Wald χ2 (1) = 13.86, O.R. 1.43, 95% CI 
1.18 to 1.72, p <.001, b = 0.24, Wald χ2 (1) = 10.22, O.R. 1.27, 95% CI 1.10 to 
1.48, p = .001). Each unit increase in the cognitive-perceptual and interpersonal 
subscale predicted a respective increase 42.5% and 27.3% in the odds of a 
diagnosis of psychosis. There was also a significant, albeit negative interaction 
between the cognitive perceptual and aversive scales (b = -0.01, Wald χ2 (1) = 
5.19, O.R.0.99, 95% CI 0.98 to 0.99, p = .023). This indicates that a unit increase 
in the interaction term served to decrease the odds of a diagnosis of psychosis by 
0.9%. This unexpected finding will be discussed in Section 2.4.2. 
 
In comparison of the group of participants diagnosed with depression and those 
diagnosed with a psychotic disorder aversive cannabis experiences were a 
significant predictor of diagnosis (b = 0.08, Wald χ2 (1) = 16.02, O.R.1.08, 95% CI 
1.04 to 1.12, p <.001). Each unit increase on the aversive scale predicted a 7.9% 
increase in the odds of having a psychotic diagnosis. The intoxicated and 
interpersonal scales were not significant predictors, neither was the interaction 
variable. However, the cognitive-perceptual and disorganised subscales were 
significant predictors of diagnosis (respectively, b =0.42, Wald χ2 (1) = 13.60, 
O.R.1.51, 95% CI 1.22 to 1.89, p <.001, b = -0.30, Wald χ2 (1) = 5.76, O.R.0.74, 
95% CI 0.58 to 0.95, p = .016). Each unit increase of the cognitive-perceptual 
scale predicted an increase of 51.4% in the diagnosis of a psychotic illness, 
whereas the same increase in the disorganised subscale predicted a 25.9% 
decrease. 
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Table 17 
A multinomial forced entry regression model predicting group membership as a 
function of aversive and intoxicated cannabis experiences , schizotypal trait, and 
an interaction between the cognitive perceptual and aversive scales  
 
 
Beta (SE) 
Odds 
Ratio
 P
 95% CI of O.R. 
Lower Upper 
CSCU Vs 
DD 
Intercept -3.188 0.329  <.001   
Aversive -0.39 0.015 0.962 .008 0.935 0.990 
Intoxicated -0.026 0.017 0.974 .124 0.942 1.007 
Cognitive-
Perceptual 
-0.061 0.072 1.385 .396 0.817 1.083 
Interpersonal 0.325 0.060 0.941 <.001 1.232 1.556 
Disorganised 0.301 0.081 1.351 <.001 1.154 1.583 
Cog-Per * Aversive 0.000 0.005 1.000 .937 0.990 1.009 
CSCU 
Vs PD 
Intercept -4.681 0.526  <.001   
Aversive 0.037 0.013 1.038 .004 1.012 1.065 
Intoxicated -0.054 0.021 0.947 .008 0.909 0.986 
Cognitive-
Perceptual 
0.354 0.095 1.425 <.001 1.183 1.715 
Interpersonal 0.241 0.075 1.273 .001 1.098 1.476 
Disorganised 0.001 0.103 1.001 .991 0.817 1.226 
Cog-Per * Aversive -0.009 0.004 0.991 .023 0.983 0.999  
DD Vs PD 
Intercept -1.493 0.603  .013   
Aversive 0.076 0.019 1.079 <.001 1.040 1.120 
Intoxicated -0.028 0.025 0.972 .263 0.925 1.021 
Cognitive-
Perceptual 
0.415 0.113 1.514 <.001 1.215 1.888 
Interpersonal -0.084 0.092 0.919 .359 0.768 1.100 
Disorganised -0.300 0.125 0.741 .016 0.580 0.947 
Cog-Per * Aversive -0.009 0.006 0.991 .128 0.979 1.003 
Cog-Per * Aversive = cognitive-perceptual and aversive scales interaction term 
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2.3.8 Covariates of psychotic mental illness whilst controlling for incidence 
of unreported or undiagnosed mental illness in the community sample 
As discussed previously (Section 2.2.2), the participants in the community 
samples (CSCU and CSCN) were not presented with the opportunity to report any 
past or present mental illness. Thus, within this group it is feasible that some 
respondents may possess a diagnosis of a mental illness. Moreover, respondents 
in this cohort may possess an undiagnosed mental illness. Cohen et al., (2011) in 
their recent investigation differentiated their respondents according to percentile 
score on the SPQ-b (revised version). Participants scoring above the 95th 
percentile were deemed to be presenting prominent schizotypal features. Cohen 
and colleagues state their selection of participants at this percentile is…  
 
Informed by a) Meehl’s theories of schizotypy (Meehl, 1962), b) taxometric 
studies suggesting a 10% population incidence of schizotypy (Lenzenweger 
and Korfine,1992), and c) findings that over half of individuals in the top 
10% of SPQ scorers met criteria for a schizophrenia-spectrum disorder 
(Raine, 1991)( p.549). 
 
In this section a similar criteria will be applied to identify unreported or 
undiagnosed mental illness (see Table 18). All participants (CSCN, CSCU, DD, 
and PD) were considered as one group (N = 1300), each of these participants 
scores on the SPQ-b were assigned a percentile. Participants in the CSCU group 
scoring at or above the 95th percentile, a score of 17 or more, were excluded from 
analyses. To this end 42 participants were excluded from the CSCU group (thus n 
= 819).  
 
The model described in the previous Section (2.3.7) accounted for the most 
amount of variance in the data, thus, this model was re-computed with the 
remaining participants. The model included the SPQ-b subscales, the aversive 
and intoxicated CEQ scales and the interaction term between the cognitive-
perceptual scale and the aversive scale. These variables were entered into the 
model in a forced entry fashion. The variable describing the interaction term was 
not found to have an effect on the model with the likelihood ratio test indicating no 
significant effect (-2LL = 769.479, χ2 (2) =1.950, p = .377). Hence, the model was 
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re-computed with the interaction term omitted. This model is referred to as Base + 
SPQ adjusted 
  
The model fitted was significantly better at predicting the data than the intercept 
(χ2 (10) = 174.501, p < .001). Both the Pearson (χ2 (1866) = 1872.05, p = .46) and 
Deviance (χ2 (1866) =769.48, p = 1.00) assessments suggest a good fit of the 
model. Cox and Snell’s R2 indicates the model explains 16.7% of the response 
data and Nagerlkerke’s R2 indicates that the model explains 26.6% of the data. 
Thus, suggesting that this model explains the most amount of variance in the data 
than any other presented, however, this is based on fewer participants, thus less 
data. 
 
In comparison of the community sample of cannabis users (CSCU) and those 
diagnosed with depression (DD), group membership was significantly predicted by 
aversive cannabis experiences (b = -0.32, Wald χ2 (1) = 5.76, O.R.0.97, 95% CI 
0.94 to 0.99, p=.016). Each unit increase on the aversive scale reduced the odds 
of a diagnosis of depression by 3.2%. The intoxicated scale was not a significant 
predictor of group membership.  However, both the interpersonal and disorganised 
SPQ-b subscales were significant predictors, respectively, b = 0.36, Wald χ2 (1) = 
36.312, O.R.1.43, 95% CI 1.27 to 1.61, p <.001 and, b = 0.34, Wald χ2 (1) = 18.28, 
O.R.1.41, 95% CI 1.21 to 1.65, p < .001. Each unit increase on the interpersonal 
and disorganised subscale accounted for an increase of 43.0%, and 41.0% 
(respectively) in odds of a diagnosis of depression. 
 
In comparison of the community sample of cannabis users (CSCU) and those 
diagnosed with a psychotic illness (PD), diagnosis was significantly predicted by 
both aversive and intoxicated experiences (respectively, b = 0.30, Wald χ2 (1) = 
5.85, O.R.1.03, 95% CI 1.01 to 1.06, p=.016, b = -0.59, Wald χ2 (1) = 7.12, O.R. 
0.94, 95% CI 0.90 to 0.98, p = .008). Each unit increase in the aversive scale 
predicted an increase of 3.1% in the diagnosis of a psychotic illness, whereas the 
same increase in the intoxicated scale predicted a 5.7% decrease. Both the 
cognitive perceptual and interpersonal subscales were significant predictors of 
group membership (respectively, b = 0.36, Wald χ2 (1) = 16.00, O.R. 1.44, 95% CI 
1.20 to 1.72, p < .001, b = 0.30, Wald χ2 (1) = 16.02, O.R. 1.35, 95% CI 1.17 to 
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1.57, p < .001). Each unit increase in the cognitive-perceptual and interpersonal 
subscale predicted a respective increase 43.6% and 35.3% in the odds of a 
diagnosis of psychosis.  
 
In comparison of the group of participants diagnosed with depression and those 
diagnosed with a psychotic disorder aversive cannabis experiences were a 
significant predictor of diagnosis (b = 0.06, Wald χ2 (1) = 13.15, O.R.1.07, 95% CI 
1.03 to 1.10, p < .001). Each unit increase on the aversive scale predicted a 6.5% 
increase in the odds of having a psychotic diagnosis. The intoxicated and 
interpersonal scales were not significant predictors. However, the cognitive-
perceptual and disorganised subscales were significant predictors of diagnosis 
(respectively, b = 0.37, Wald χ2 (1) = 11.93, O.R.1.45, 95% CI 1.17 to 1.79, p = 
.001, b = -0.26, Wald χ2 (1) = 4.32, O.R.0.77, 95% CI 0.61 to 0.99, p = .038). Each 
unit increase of the cognitive-perceptual scale predicted an increase of 44.8% in 
the diagnosis of a psychotic illness, whereas the same increase in the 
disorganised subscale predicted a 23.6% decrease. 
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Table 18 
A multinomial forced entry regression model predicting group membership as a 
function of aversive and intoxicated cannabis experiences, schizotypal trait whilst 
controlling for unreported mental i l lness  
 
 
Beta (SE) 
Odds 
Ratio
 P
 95% CI of O.R. 
Lower Upper 
CSCU Vs 
DD 
Intercept -3.562 0.355  <.001   
Aversive -0.032 0.013 0.968 .016 0.943 0.994 
Intoxicated -0.025 0.018 0.975 .155 0.942 1.009 
Cognitive-Perceptual -0.008 0.071 0.992 .909 0.863 1.140 
Interpersonal 0.358 0.059 1.430 <.001 1.273 1.606 
Disorganised 0.344 0.080 1.410 <.001 1.205 1.651 
CSCU Vs 
PD 
Intercept -4.922 0.508  <.001   
Aversive 0.030 0.013 1.031 .016 1.006 1.056 
Intoxicated -0.059 0.022 0.943 .008 0.903 0.984 
Cognitive-
Perceptual 
0.362 0.090 1.436 <.001 1.203 1.715 
Interpersonal 0.302 0.076 1.353 <.001 1.167 1.569 
Disorganised 0.088 0.104 1.092 .396 0.891 1.338 
DD Vs PD 
Intercept -1.360 0.596  .023   
Aversive 0.063 0.017 1.065 <.001 1.029 1.101 
Intoxicated -0.034 0.026 0.967 .194 0.918 1.017 
Cognitive-
Perceptual 
0.370 0.107 1.448 .001 1.174 1.786 
Interpersonal -0.055 0.090 0.946 .541 0.793 1.129 
Disorganised -0.256 0.123 0.774 .038 0.609 0.985 
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2.4 Discussion 
2.4.1 Main findings 
Significant group differences in schizotypal trait were found between; a community 
sample of cannabis naïve participants (CSCN); a community sample of cannabis 
users (CSCU); cannabis users who had a self-reported diagnosis of depression 
(DD); and cannabis users with a self-reported psychotic disorder (PD). This finding 
was also demonstrated in a trend difference in that respective order, ranging from 
lowest to highest. In a pairwise comparison it was seen that the CSCU group 
scored significantly higher than the CSCN group on the disorganised subscale of 
the SPQ-b, but the two groups did not differ in the interpersonal or disorganised 
subscale. The DD group scored significantly higher than the CSCU group on the 
interpersonal and disorganised subscales of the SPQ-b, and also on the measures 
total score. In comparison of the PD and DD groups, the PD group only scored 
significantly higher on the cognitive-perceptual subscale. Despite the theoretical 
aetiological overlap between schizotypal personality and psychotic (schizophrenia 
spectrum) mental illness (see Raine & Lencz, 1995).Nonetheless, as would be 
expected the PD group scored significantly higher than the CSCU group on all 
three SPQ-b subscales. Taken together, these results show that cannabis use in 
the absence of mental illness is associated with high levels of reported schizotypal 
trait, within the domain of disorganised deficit. Self-reported depression and 
psychosis are associated with higher levels of interpersonal and disorganised 
schizotypal traits, in addition to increases in cognitive-perceptual deficits in those 
reporting psychosis. These analyses serve to fulfil the first aim of this chapter: To 
assess variance in schizotypal trait related to cannabis use and reported mental 
illness.   
 
The CEQ score of the cannabis using participants (CSCU, DD and PD) were also 
compared between groups.  These analyses serve to fulfil the second aim of this 
chapter: To assess the presence of a differential sensitivity to the psychotomimetic 
effects of cannabis in those with psychotic illness. There were significant group 
differences on the aversive and appetitive scales, but not on the intoxicated one.  
In pairwise comparisons the DD group had significantly more appetitive cannabis 
experiences than the CSCU group, but they differ not on the other CEQ scales. 
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The PD group scored significantly higher than the CSCU group on the aversive 
scale, but the two groups did not differ on the appetitive or intoxicated CEQ scales. 
The PD group scored significantly higher on the aversive scale, and significantly 
lower than the DD group on the appetitive scale.  However, the two groups did not 
differ in their scores on the intoxicated scale.   
 
The third aim of this chapter is fulfilled by the use of regression models: to assess 
the utility of cannabis induced experience and schizotypal trait as predictors of 
psychotic illness in cannabis using populations. To this end, scores on the 
aversive scale were found to significantly and positively predict membership of the 
PD group from the CSCU group or the DD group. The intoxicated scale was also a 
significant, but negative predictor of the PD group from the CSCU group. Taken 
together, these results indicate that psychotic illness is associated with more 
aversive, and possibly fewer intoxicated, effects of using cannabis. When 
considering scores on the SPQb and the CEQ together, a number of regression 
models were able to predict group membership (CSCU, DD or PD). The model 
which accounted for the most amount of variance from the entirety of the data set 
included; the CEQ aversive and intoxicated scales; the three SPQ-b subscales; 
and an interaction term from the CEQ aversive scale and the SPQ-b cognitive-
perceptual scale (Base + SPQ + X, Section 2.3.7).  
 
2.4.2 Implications and comparison with other research 
Comparing schizotypal trait in a community sample of cannabis users and non-
cannabis users 
Previous research has compared the schizotypal traits of cannabis users with non-
users. It has been frequently documented that non-users have a lower schizotypal 
trait than cannabis users. Several investigations have utilised the SPQ-b to define 
and measure schizotypal trait. Bailey and Swallow (2004) compared cannabis 
users and non-users, they found a significant difference in all three SPQ-b 
subscales (and total score). Cohen et al. (2011), noted that frequent cannabis 
users were more likely to score highly on both the disorganised subscale, and the 
equivalent of the cognitive-perceptual subscale. Esterberg et al., (2009) also 
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demonstrated a significant relationship between indices of cannabis use and the 
disorganised and cognitive-perceptual subscales.  
 
The current investigation has provided further evidence in support of these 
findings with a community sample of cannabis users scoring significantly higher on 
the disorganised subscale than a community sample of non-cannabis users.  
However, unlike some other investigations, there was no significant difference in 
scores on the cognitive-perceptual subscale or the interpersonal subscale. The 
rationale for this is at present unknown.  
Schizotypy and self-reported depression 
Although not one of the main research questions in this investigation, the DD 
group scored significantly higher than the CSCU group on the interpersonal, 
disorganised, and cognitive perceptual subscales. However, the differences in the 
cognitive-perceptual subscale did not remain significant after correcting for 
multiple comparisons. Lewandowski et al., (2006) demonstrated a significant 
association between both positive and negative schizotypy and depressive 
symptomatology. The DD group scored significantly higher than the cannabis 
naïve group (CSCN) on the cognitive-perceptual subscale. This may indicate that 
that the lack of a significant difference between the CSCU group and DD group on 
the cognitive-perceptual subscale may have been the result of either cannabis 
use1 or the adoption of a too conservative a p-value threshold.  
 
The group differences on the SPQ-b are consistent with findings showing that 
depressive symptoms are a positive correlate of schizotypy in both positive and 
negative dimensions (Fonseca-Pedrero, Paino, Lemos-Giráldez & Muñiz, 2011; 
Lewandowski et al., 2006; Vollema & Postma, 2002). The findings regarding the 
relationship between schizotypy and depressive symptomatology have often been 
framed within the context of schizophrenia research. Due to high incidence of 
depressive symptoms in patients diagnosed with schizophrenia, the relationship 
between schizotypy and depression has been taken as confirmatory evidence of 
schizotypy as a predictor of schizophrenia (Lewandowski et al., 2006).  
 
                                                          
1
 This does not necessarily suggest a causal association see section 1.6 for discussion.  
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Specificity of the SPQ-b 
If the SPQ-b is considered to be an assessment for vulnerability to only 
schizophrenia spectrum disorders, from the current investigation one may 
conclude that a diagnosis of depression in cannabis users may reflect a greater 
liability for psychosis than the community sample. However, in a prospective 
cohort study Breetvelt et al. (2010) found that ‘non-clinical psychotic symptoms’ 
were often associated with other psychiatric symptoms, and they also share 
common socio-demographic risk factors. Although schizophrenia and depressive 
symptoms are often co-morbid, the latter is frequently a consequence of the 
dysphoric mood associated with the former (APA, 2013a, p.102). Thus, given the 
gamut of symptoms elicited in schizophrenia spectrum disorders a more plausible 
conclusion to draw from the data is that the SPQ-b is adept at highlighting these 
symptoms, even if they originate from different mental illnesses with (presumably) 
distinct aetiological and pharmacological processes. 
  
Further evidence suggesting the SPQ-b cannot differentiate between psychotic 
liability and a broader range of psychiatric liability can be derived from the 
comparison of the DD and PD groups. The PD group scored significantly higher 
than the DD group on the cognitive-perceptual subscale. The two groups however, 
did not differ in their interpersonal or disorganised deficits, or the SPQ-b total 
score. Thus, suggesting that these groups could be differentiated on the basis of 
their scores on the cognitive-perceptual subscale, but not the other two subscales. 
This indicates that the cognitive-perceptual subscale may be the most proficient of 
the three SPQ-b subscales for the assessment of psychotic liability. However, the 
other two subscales do not demonstrate evidence of specificity, the ability to 
distinguish true incidence of psychosis proneness from false. 
 
The relationship between the SPQ-b and self-reported depression seen in this 
study may seem unremarkable considering the SPQ-b is not a clinical assessment 
tool for schizophrenia spectrum disorders, but rather a brief measure of psychosis 
proneness. Thus, one may expect that it would not be sensitive enough to 
differentiate between various clinical groups, on all subscales under consideration. 
As discussed previously, it has been frequently reported that cannabis users 
display a higher schizotypal personality profile than their non-cannabis using 
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counterparts. This could feasibly represent a reflection of the increased risk of 
psychosis associated with cannabis use (Arseneault et al., 2007).  Nonetheless, 
other psychiatric symptoms also correlate with schizotypy (Breetvelt al., 2010). 
Thus, a cannabis user with distinct psychiatric symptoms (or proneness) may 
present a schizotypal profile indistinguishable from those highly psychosis prone 
or even those with a psychotic illness, as demonstrated on the interpersonal and 
disorganised subscales. This could plausibly result in large incidence of false 
positives in assessments of psychosis proneness in cannabis users. Thus, the 
SPQ-b may not be an appropriate tool for assessing psychotic vulnerability in a 
cannabis using population. 
 
Differential cannabis sensitivity in participants with a self-reported psychotic 
disorder  
In pairwise comparisons the PD group had significantly more aversive cannabis 
experiences than the CSCU group and the DD group.  Unlike the interpersonal 
and disorganised subscales of the SPQ-b, there was no significant difference 
between the DD and CSCU groups on the aversive scale. This indicates that the 
aversive scale is not simply reflecting the iatrogenic or substantive differences 
between those afflicted with a mental illness and those not.  The notion of the 
aversive scale as a predictor of psychotic illness was further supported in the 
regression model containing just the CEQ scales (Base model), in comparison to 
both the CSCU and DD groups. However, the intoxicated scale of the CEQ was a 
significant negative predictor of the PD group in comparison to the CSCU group. 
 
A differential sensitivity to the psychotomimetic effects of cannabis as a 
consequence of psychotic vulnerability has been demonstrated by previous 
investigations (GROUP, 2011; Henquet et al., 2010; Mason et al., 2009 see 
Section 2.1). This investigation has contributed to this growing area of research 
and demonstrated a differential sensitivity to cannabis in participants with reported 
psychotic disorder. This finding supports the assertions of Eisenberg (2010) which 
propose that genetic vulnerability to psychotic disorder may be evident in 
sensitivity to cannabis. 
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Interestingly, the data indicates that the CSCU group has more intoxicated 
cannabis experiences than the PD group.  There are several plausible reasons 
why this finding may have occurred. The PD group may consistently experience 
high levels of the experiences listed in the scale as a consequence of their mental 
illness e.g. “Feeling that your thinking has been slowed down”. Thus, the effect of 
cannabis may produce a small amount of variance within the group on the scale. 
Evidence for such a notion may be derived from the groups not displaying 
homogeneity of variance. An alternative explanation is that the PD group has a 
substantive difference (possibly in their endocannabinoid system) which accounts 
for group differences in their intoxicated cannabis experiences, however, there is 
at present little data supporting this notion.    
 
Assessing predictors of psychosis 
Another regression model was computed considering the SPQ-b subscales and 
the CEQ aversive and intoxicated scales (Base + SPQ). Within this model the 
aversive scale became a non-significant predictor of the PD and CSCU groups. 
The construct assessed by the aversive scale is redundant when the SPQ-b 
subscales are considered, when comparing the PD and CSCU groups. This 
suggests that perhaps one or all of the SPQ-b subscales may be assessing a 
similar construct to the aversive scale (e.g. vulnerability). It is difficult to assess 
which subscale may be accounting for the same variance as the aversive scale, 
due to the aversive scale reflecting a breadth of psychotic symptomatology 
including experiences which are typically associated with positive (e.g. “threatened 
by an unknown force”), negative (e.g. “sad”), and disorganised psychotic-like 
experience (e.g. “disturbed in your thinking”). Moreover, the aversive scale also 
contains experiences which are not typically considered as (attenuated) primary 
psychotic symptomatology i.e. feeling “angry” and “anxious for no reason”.  
 
Intriguingly, the disorganised SPQ-b subscale was not a significant covariate of 
the PD group in comparison to the CSCU group. This may indicate that the 
disorganised subscale is considering the same underlying construct as the 
interpersonal and/or the cognitive-perceptual subscales. This might suggest that 
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the disorganised subscale is considering secondary (attenuated) symptoms, or 
that the expression of a broad range of attenuated symptoms may have a common 
aetiology. Indeed disorganised symptoms are considered to fall within the remit of 
‘positive’ symptomatology along with positive psychotic symptoms (APA, 2000, p. 
299), which are reflected in the cognitive-perceptual subscale. However, whether 
the disorganised and psychotic positive constructs represent independent 
dimensions is still a matter of debate (APA, 2000, p. 299). 
 
Furthermore, the disorganised subscale was a significant negative predictor of the 
PD group in comparison to the DD group. This finding was not anticipated, as logic 
would suggest that participants with a self-reported psychotic disorder should 
score higher on an assessment of psychosis proneness than other groups of 
respondents. This suggests that this subscale as an assessment of psychosis 
proneness lacks validity within cannabis using populations. The interpersonal 
subscale of the SPQ-b was not a significant predictor of the PD in comparison to 
the DD group. Thus, from the SPQ-b, only the cognitive-perceptual subscale was 
capable of differentiating between both; the PD and DD groups; and the PD and 
CSCU groups.  
 
Controlling for unreported/undiagnosed mental illness and the interaction between 
the cognitive-perceptual subscale and the aversive scale 
An interaction term was developed which considered the two predictors which 
appeared adept at distinguishing the PD group from both the DD and CSCU 
groups; the cognitive perceptual subscale and the aversive scale. This interaction 
term was added to a model including the SPQ-b subscales and the aversive and 
intoxicated CEQ scales (base + SPQ + X). Although the interaction variable did 
not significantly improve the model (p = .070) it was retained. Unlike the previous 
model (base + SPQ) without the interaction term this model indicated that the 
aversive scale was a significant positive predictor of the PD group compared to the 
CSCU group. However, the interaction term itself was a significant negative 
predictor of the PD group in comparison to the CSCU group. This could indicate 
that the predisposition assessed by the cognitive-perceptual subscale may interact 
with aversive cannabis experiences (or their underlying construct) to decrease the 
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propensity to psychotic reaction. However, there is no known rationale for why 
such an interaction may occur. 
 
Perhaps an explanation for the significant effect of the interaction term (in Section 
2.3.7) lies in the analysis which has attempted to control for undiagnosed or 
unreported mental illness in the CSCU group (Section 2.3.8, Base + SPQ adjusted).  
The interaction term did not significantly improve the model, however, the p-value 
is much larger than the previous mode (p = .377). Moreover, in this model the 
interaction term was not a significant covariate of group membership. Thus, Base 
+ SPQ adjusted was re-computed with the interaction term excluded, this model 
displayed the same significant covariates as the model containing the interaction 
term (Section 2.3.7 Base + SPQ + X). This included the aversive cannabis 
experiences as a significant positive predictor of the PD group in comparison to 
the CSCU. The aversive scale was not a significant covariate of the model 
assessing all of the same variables, but without the adjustment for 
unreported/undiagnosed mental illness or interaction term (Section 2.3.6 Base + 
SPQ). This could possibly indicate that the negative relationship between the PD 
group and the interaction term (Section 2.3.7 Base + SPQ + X) could feasibly be 
identifying unreported/undiagnosed mental illness.  
 
Schizotypy is a known correlate of a raft of different mental disorders, including 
anxiety (Rey, Jouvent, & Dubal, 2009), bi-polar mood disorder (Rybakowski & 
Kolonowska, 2011), autism (Dinsdale, Hurd, Wakabayashi, Elliot, & Crespi, 2013), 
and attention deficit hyperactive disorder (Keshavan, Sujata, Mehra, Montrose, & 
Sweeney, 2002). If the aversive scale is only elevated in individuals with 
schizophrenia spectrum disorders then individuals with other mental illnesses may 
develop a negative interaction term. The interaction term is generated by centering 
the participants around the group mean on the two variables and then multiplying 
the resultant scores. Thus, such a scenario may develop where an individual with 
an unreported diagnosis of depression for example may score above the mean on 
assessments of schizotypy (the cognitive-perceptual subscale), but below the 
mean on the aversive scale. This would in turn generate a negative value for the 
interaction term.  
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Self-reported depression and appetitive cannabis experiences 
Although this was not the main purpose of this investigation, one of the findings 
elucidated suggests a differential effect of cannabis on people with a diagnosis of 
depression. Participants in the DD group reported significantly more appetitive 
cannabis experiences than the CSCU group and the PD group. Moreover, 
aversive cannabis experiences were a significant negative correlate of the DD 
group in comparison to both the PD and CSCU groups. It is unlikely that the DD 
group had lower psychotic liability than the CSCU group as evinced by the former 
scoring significantly higher than the latter on two of the SPQ-b subscales. This 
may indicate a true differential effect i.e. the DD group derived more pleasure from 
cannabis than the CSCU group and had fewer aversive effects. Alternatively, this 
may plausibly reflect within group differences i.e. the DD group felt more pleasure 
than they would typically experience, which was a larger increase than the CSCU 
group. Intra-group reliability on one of the CEQ scales is assessed in Section 
4.3.3. However, inter-group reliability between the CSCU and DD group has not 
been assessed. Nonetheless, the significant difference in the appetitive scale 
indicates that the DD group could possibly be experiencing some beneficial effect 
on mood from cannabis.  
 
A review indicates that there is a relationship between the endocannabinoid 
system and depression in animal models (Serra & Fratta, 2007). However, the 
data pertaining to whether cannabis may have an anti-depressant effect is 
conflicting. Nonetheless, cannabinoids have treated the symptoms of depression 
in two case studies (Blass, 2008). At present there is insufficient data to conclude 
an antidepressant effect, “there appear to have been no formal clinical trials of 
cannabinoids in depression” (Ashton & Moore, 2011 p.255). Nonetheless, the 
current investigation provides supporting evidence of a relationship between 
cannabinoids and depression, which could suggest an antidepressant effect of 
cannabis. 
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2.4.3 Strengths and Limitations 
Web-based research has been frequently used with illicit substance users (Miller & 
Sønderlund, 2010). It is thought that web based research may serve to elicit a 
more diverse sample than traditional methods (Gosling, Vazire, Srivastava, & 
John, 2004). A recent review concluded that one of the strengths of the web based 
research reviewed “was their ability to reach hard-to-reach samples (or ‘hidden 
populations’) of illicit drug users” (Miller & Sønderlund, 2010, p.1562). In addition 
to the challenges of recruiting illicit drug users, this investigation required the 
recruitment of persons with either psychotic or depressive illness, which 
considerably reduces the population of eligible participants. Moreover, it was 
thought that the use of web-based research may improve confidentiality for 
respondents (Miller & Sønderlund, 2010, p.1557). Despite the advantages of 
internet research there are limitations. Internet based research affords the 
investigators little control over the environment in which the measures are 
completed, no control can be applied to extraneous variables (e.g. temperature, 
light, sound). Furthermore, with the development in mobile technology, the 
participant would not have necessarily been constrained to responding from a P.C. 
(see Section 3.2.1). Although, it is anticipated that the vast majority will not have 
responded from a mobile phone as the questionnaires aesthetics were not 
designed for display on a small device. Nonetheless, although these issues might 
have increased overall level of ‘noise’ (error term/residual) in the data, it is unlikely 
that they would have resulted in systematic, confounding, differences in the 
responses given by each group. Therefore, if anything, the effect sizes seen here 
might be underestimates of what may be attained under more controlled 
conditions. 
 
Two of the principal limitations of this investigation were that drug use and mental 
health history were not independently verified. This could not be performed due to 
the use of online research, the recruitment of an anonymous international sample, 
limited resources, and ethical complications (e.g. obtaining NHS ethical approval, 
along with its international equivalents).  The consequence of not independently 
verifying drug use may have resulted in participants being miscategorised as a 
cannabis user or cannabis naïve. The misallocation of respondents would likely 
result in a reduction of statistical power. Nonetheless, statistical differences 
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between the cannabis using groups and the non- cannabis groups were still noted 
despite the potential reduction of statistical power. As before, this means that the 
effect sizes may be underestimates of the true value. Moreover, anonymous 
internet research is thought to decrease social desirability and social anxiety, and 
thus feasibly increase accuracy of measurement (Johnson, 1999; though see 
Lelkes, Krosnick, Marx, Judd, & Park, 2012 for an alternative view). The anonymity 
afforded to participants in this study may have made it easier for them to make 
accurate honest responses to the items. 
 
The problem of misreporting of diagnoses may also result in the misallocation of 
respondents to groups, in all likelihood, reducing group differences. One way in 
which accuracy of group allocation can be assessed is to compare the participants 
reported diagnosis with their reported medication. In the PD group, 44 participants 
(91.6%) stated (by either using the name of the medication or brand) an 
antipsychotic that they had previously taken. In the DD group 76 participants 
(86.4%) reported by name an antidepressant that they had previously taken. 
Moreover, in several instances where participants could not state the name of the 
drug they reported the class (i.e. SSRI) or type of drug (i.e. antipsychotic).  This 
does not unequivocally mean that participants were or were not misallocated, 
given that detailed information about medication is freely available and easily 
accessible. However, it does provide reassurance that instances of misallocation 
are likely to be infrequent.  
 
The limitation of misallocation also extends to the community sample groups 
(CSCN and CSCU). The investigations that recruited these respondents did not 
specifically enquire about participants’ past and current mental health. Although no 
specific efforts were made to recruit participants with mental illness, it would be 
expected that there would be a population rate prevalence of mental illness, which 
may be exaggerated in the community sample of cannabis users (e.g. Manrique-
Garcia et al., 2011). Nonetheless, when an attempt was made to control for 
undiagnosed or unreported mental illness in the CSCU group the results produced 
were similar to when such a control was not employed (see Section 2.3.6). 
Furthermore, whilst the use of a ‘cleaner’ ‘healthy’ sample may have been 
preferable for hypothesis testing, using a large community sample reflects a 
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broader representation of the cannabis using population and thus, may be 
preferable for the generalisability of results. Moreover, the results are feasibly 
more conservative than the true difference between the groups, making the 
findings of this investigation appear even more compelling.  
 
Another limitation of the investigation is associated with the measurement of 
phenomenology of cannabis. Cannabis is known to impair cognitive functioning 
(Pope, Gruber, Hudson, Huestis & Yurgelun-Todd, 2001) including memory (Ilan, 
Smith & Gevins, 2004). Thus, it is feasible that the recall of cannabis-induced 
phenomena may be influenced by level and duration of acute intoxication. 
Nonetheless, the validity of the CEQ is evinced by the significant positive 
relationship between subscales of aversive cannabis experiences and schizotypal 
personality which has been replicated in several cohorts (Barkus et al., 2006; 
Barkus & Lewis, 2008; Morris, Unpublished data; Stirling et al., 2008). 
Furthermore, the results of this investigation may be taken as further evidence as 
convergent and discriminant validity of the CEQ as an assessment of psychotic 
vulnerability in cannabis users. Thus, although recall may be altered by 
intoxication there is substantial evidence suggesting the CEQ is a valid 
assessment nonetheless. 
 
2.4.4 Conclusion 
Being a cannabis user appears to raise schizotypal traits within the disorganised 
subscale, but not the other SPQ-b scales under assessment. The cross-sectional 
nature of the study design means the mechanisms which underpin this association 
are at present poorly understood. However, they are tested to some extent in 
Chapter 3. Cannabis users with self-reported depression displayed schizotypal 
profiles indistinguishable from cannabis users with a self-reported psychotic illness 
on two of the SPQ-b subscales. This may indicate that measures of schizotypy are 
assessing general psychiatric vulnerability as opposed to only psychotic 
vulnerability. Assessments of schizotypy may be capable of assessing schizotypal 
thinking or schizotypal behaviour; the “schizophrenic phenotype” (Rado, 1960 
p.87). However, the phenotype (the expression of certain traits) does not always 
provide inference of the aetiology of the schizotypal traits; the ‘schizotaxic’ liability. 
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One means by which psychosis proneness might be assessed is through 
measurement of differential sensitivity to cannabis (Eisenberg, 2010). This 
investigation has demonstrated that those with a self-reported psychotic illness 
displayed more aversive cannabis experiences than both a community sample and 
participants with self-reported depression. This indicates that aversive cannabis 
experiences might be a valid means of discriminating between groups of cannabis 
users. The data indicates that the differences in cannabis induced experiences 
may not just be displaying the characteristics of psychotic liability (irrespective of 
the aetiology of the disturbance), but plausibly the characteristics of schizotaxic 
vulnerability as well. Nonetheless, it must be acknowledged that aversive 
environmental factors may prime for both; aversive cannabis experiences; and 
increased psychotic vulnerability.  This notion is tested to some extent in Section 
4.3.4. Van Os et al., (2009) suggest that persistent psychotic experiences are as a 
consequence of genetic and environmental factors. Thus, it is feasible that the 
persistent psychotic like experiences assessed by the CEQ could also be 
reflective as such factors. 
 
The current investigation also provided evidence suggesting that participants with 
self-reported depression have significantly more appetitive and fewer aversive 
cannabis experiences than a community sample. This may plausibly implicate 
cannabis as having an antidepressant effect. However, it is important to note that 
the cannabis induced experiences did not necessarily occur at the same time as 
the point of mood disturbance. Thus, instead of cannabis serving to elevate mood 
in this sample, an increase in appetitive experiences may be representative of a 
dysfunctional endocannabinoid system being related to mood disturbance. This 
could indicate that drugs which bind to the CB1 receptors may be efficacious in the 
treatment of mood disorder. Nonetheless, whether a beneficial effect may be 
conferred by a CB1 agonist or antagonist remains unclear. This highlights the need 
for further research in this domain, perhaps utilising momentary assessments of 
appetitive cannabis experiences in participants currently suffering with depression. 
 
The literature reviewed in Section 1.6.4 infers that cannabis may have a causal 
effect on psychotic disorder. The literature reviewed in Section 1.7.4 provides 
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evidence of a possible interaction between cannabis and stress on psychotic 
disorder. To establish causality it is necessary to establish temporality and discuss 
plausible mechanisms. The next chapter will utilise experience sampling data to 
assess temporal priority between cannabis use and psychotic-like states. 
Furthermore, the next chapter will also examine the plausibility of a cannabis and 
stress interaction effect as a causal factor in psychotic-like states. 
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3. Cannabis use, stress, and schizotypal state: An 
experience sampling investigation 
Brief overview  
This chapter aims to test various (causal) models of association between cannabis 
and a schizotypal state. An additional aim is to assess the plausibility of cannabis 
and stress interacting to increase incidence of schizotypal states. These aims are 
achieved by examining the data from cannabis using participants.This study 
utilised a repeated measures experience sampling study design. 
 
Contained herein is a brief introduction which contextualises this investigation 
(Section 3.1 pp. 161-65). Following the introduction there is a description of the 
methodology utilised in this investigation (Section 3.2 pp. 166-205). The results of 
this investigation are contained within Section 3.3 (pp. 206-238). Section 3.3.1 (pp. 
207-213) describes the participant’s characteristics. Section 3.3.2 (pp. 214-17) 
describes the process by which the experience sampling items were validated. 
Section 3.3.3 (pp. 217-226) examines factors which predict a schizotypal state. 
Section 3.3.4 (pp. 227-29) assesses stress as a mediating influence between 
cannabis and psychosis. Section 3.3.5 (pp. 230-34) considers factors which 
predict calm and stressed states. Section 3.3.6 (pp. 234-38) examines factors 
which predict the consumption of cannabis. Section 3.4 pp. (238-258) discusses 
the implications, limitations and conclusions that can be drawn from this research. 
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3.1 Introduction 
As discussed in Section 1.6 (pp. 61-79) there is a link between cannabis use and 
schizophrenia. However, whether this is a causal relationship is still a matter of 
debate. One particular means by which investigations have sought to assess the 
relationship between cannabis and schizophrenia is through examination of the 
personality trait schizotypy. Nonetheless, this has also failed to demonstrate 
evidence of a causal relationship, partly due to the possibility of time variant, state-
like aspects to schizotypy (see Section 1.8 pp. 96-98).  A principal difficulty with 
establishing a causal relationship between cannabis and schizophrenia is that 
there is a paucity of information regarding the temporality of the variables (see 
Section 1.6.4). Various different study designs have been utilised to examine this 
relationship, including experimental laboratory design (e.g. D’Souza et al., 2004), 
longitudinal investigation (e.g. Manrique-Garcia et al., 2013) and cross sectional 
investigations (Mass et al., 2001). However, Khimy et al., (2009) highlighted that 
studies using ESM methodology may be capable of revealing the temporal 
sequence of this relationship. 
 
Experience Sampling Methodology is a naturalistic sampling technique which 
utilises repeat measurements within a close temporal proximity, typically several 
times a day for a period of days or weeks. ESM has been used in both substance 
using (Messiah, Grondin & Encrenaz, 2011) and patient populations (Oorschot et 
al., 2012). In Kimhy, Durbin and Corcoran (2009) review, four investigations were 
identified which may elucidate the relationship between cannabis and psychotic 
disorder. Verdoux, Gindre, Sorbara, Tournier and Swendsen (2003) collected data 
five times a day for a period of seven days. Verdoux and colleagues found that in 
schizotypal participants, cannabis elicited more psychosis-like experiences than in 
participants scoring lowly on measure of schizotypy. Thus, indicating a differential 
sensitivity to cannabis in a naturalistic environment, Tournier, Sorbara, Gindre, 
Swendsen and Verdoux (2003) found no significant relationship between cannabis 
consumption and an anxious state. An anxious state did not predict cannabis use, 
and cannabis use did not predict an anxious state. This suggests that cannabis 
use is not dependent on the self-medication of anxiety. However, the presence of 
anxiety disorder symptoms as assessed by cross-sectional measure significantly 
predicted cannabis use throughout the ESM period, although this finding remained 
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restricted to symptoms from with the domain of agoraphobia. In another ESM 
investigation Henquet et al., (2009) found a significant interaction between 
psychotic vulnerability, the Val allele of the COMT gene, and cannabis use on the 
presentation of hallucinations. Thus, demonstrating that cannabis use holds 
temporal priority over hallucinatory experiences. However, this is restricted to 
psychologically and genetically vulnerable individuals. Van Winkel, Henquet et al., 
(2008) found that the COMT gene moderated the effect between cannabis and 
emotional reactivity to stress in the expression of psychotic experience in patients, 
but not controls. Unlike the findings of Henquet and colleagues (2009) the 
presence of the Met allele conferred a greater risk.  These findings once again 
implicate a very complex genetic model (see Section1.2.3 pp. 37-48). 
 
Henquet et al., (2010) conducted further research within this domain and found 
that cannabis use positively predicted and held temporal priority over positive 
affect in controls and patients with a psychotic disorder alike. Moreover, cannabis 
reduced negative affect in patients, but not the control group. This could plausibly 
indicate that cannabis may confer a beneficial affect on symptomatology from 
within this domain. Nonetheless, within the patient group, but not the controls 
cannabis induced psychotic like experience. This may be as a consequence of a 
Khantzian model of self-medication of the negative symptomatology (see Section 
1.6.1 pp. 63-68), at the expense of exacerbation of positive symptomatology within 
the patient group.  Kuepper et al., (2013) found that the presence of negative 
affect and positive psychotic symptomatology significantly elevated cravings for 
cannabis within both patients with a psychotic disorder and healthy controls. This 
further implicates a self-medication model. However, within the control group the 
association between craving and consumption was significantly larger than in the 
patient group. This could reflect differences in the group’s access to cannabis, or 
suggest that within patients, rather than craving, cannabis use may be “under 
stronger guidance by other, unmeasured factors, such as fluctuating mental 
states“(p.7). When considered together the findings from previous ESM research 
are inconsistent, with cannabis seemingly maintaining (or exacerbating) some 
symptomatology, but conversely alleviating others. However, given the dearth of 
research in this area, further exploration is required. 
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In examination of plausible mechanisms by which cannabis may cause psychotic 
disorder there are inconsistencies in the data indicating a dopaminergic action of 
the drug (See section 1.7.1 pp. 80-84). In animal models, the interaction of 
cannabis and stress significantly elicited striatal DA release (Littleton & Maclean, 
1975; Maclean & Littleton, 1977). However, non-stressed conditions did not 
produce such an effect. There is evidence in humans to suggest that both 
cannabis and stress interact, which may occur through a process of sensitisation 
or cross-sensitisation (see Sections 1.7.3 pp. 88-91 & 1.7.4 pp. 91-95). However, 
at present there is also a paucity of data to this effect. 
 
Nonetheless, ESM research has also been utilised to elucidate the relationship 
between stress and psychotic symptomatology. Collip et al., (2011) found that the 
physiological stress response to adverse daily events was heightened in first 
degree relatives of patients with a psychotic disorder in comparison to controls. 
Moreover, within the sibling group psychotic experience was associated with 
physiological assessments of stress. The association between stress reactivity, 
psychotic vulnerability and psychotic symptoms have also been demonstrated in 
other cohorts (e.g. Lataster, Collip, Lardinois , van Os & Myin-Germeys 2010; 
Lataster et al., 2009). Further evidence for the effect of stress on psychotic 
symptoms can be derived from the ESM investigation of Lardinois, Lataster, 
Mengelers, van Os & Myin-Germeys (2011) who found a significant interaction 
between daily stress and childhood trauma on the intensity of psychotic 
experience. Moreover, Simons et al., (2009) have found that functional 
polymorphism within the COMT gene alters psychotic reactivity to stress within a 
healthy population. Simons and Colleagues found that Val carriers displayed 
greater paranoid symptoms in response to event stress, whereas Met carriers had 
greater paranoia associated with social-stress.  Thus, stress has been consistently 
implicated in elevations in symptomatology. However, there is a need to explore 
which domains of symptomatology are elevated by stress, and if ‘calm’ states 
serve to attenuate such symptomatology. 
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3.1.1 Aims of this chapter 
To date, the relationship between cannabis and stress on a psychotic outcome 
has not been well documented (see Section 1.7.4 pp. 91-95). Furthermore, the 
literature has demonstrated inconsistencies whilst attempting to establish the 
temporal sequence of cannabis and psychotic experience (see Section 1.6.1 pp. 
63-68). This investigation seeks to address such deficiencies in the literature. 
Previous experience sampling investigations have elucidated information about 
the association between cannabis and psychotic symptoms, and stress and 
psychotic symptoms. This investigation aims to provide evidence related to; the 
relationship between cannabis and a schizotypal state; stress/calm and a 
schizotypal state; and the interaction between cannabis, stress and psychotic-like 
experience.  Considering the repeated measures nature of this investigation it is 
possible to establish the temporal sequencing of the variables. 
 
Chapter 3 has five primary aims: 
1. To assess whether cannabis use is related to the presence of a schizotypal 
state. 
2. To assess the evidence for temporal priority in the relationship between 
cannabis and psychotic experience in a naturalistic setting.  
3. To assess the effect of a stressed and calm state on psychotic-like states 
utilising a cannabis challenge to facilitate a model of psychosis. 
4. To assess factors which may influence the consumption of cannabis (self-
medication). 
5. To assess the plausibility of an interaction between cannabis and 
psychological stressors on psychotic (like) experience. 
 
The first aim of this chapter is partially addressed by the consideration of 
scatterplots of the participant’s scores on the SSQ (Figure 9). This aim is 
addressed in more depth in analyses contained within Section 3.3.3 (pp. 217-26), 
which assesses cannabis as a covariate of a schizotypal state. Analyses provided 
in Section 3.3.3 and 3.3.6, (pp. 234-38) address the second aim by investigating 
temporality between cannabis and psychotic-like states. Respectively, these 
sections assessed cannabis as a predictor of schizotypal state, and schizotypal 
state as a predictor of cannabis consumption. 
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Analyses contained within Section 3.3.3 serves to fulfil the third aim of this 
investigation. In this section stressed and calm states are assessed as predictors 
of psychotic-like states. Thus, assessing psychosocial stress and factors which 
mitigate such stress (calmness) as a contributory factor to psychotic experience, 
utilising a cannabis model of psychosis. Aim four is addressed by assessing 
variables which increase the O.R. of cannabis consumption (Section 3.3.6). This 
aim is also addressed in Section 3.3.5 (pp. 229-34) in which evidence is assessed 
for cannabis’ ability to attenuate stressed states or induce calm states. These 
analyses are assessing aspects of the self-medication hypothesis. 
 
Aim five of the investigation is attended to in Section 3.3.3 in which a cannabis 
stress interaction variable is assessed as a predictor of a psychotic-like state. The 
fifth aim of this investigation is also addressed in Section 3.3.4 (pp. 226-29). In this 
section participants that displayed the least and most stressed states throughout 
the investigation were assessed independently for an effect of cannabis 
consumption on psychotic-like states. 
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3.2 Methodology 
3.2.1 Study Design 
Overview of Experience Sampling Methodology (ESM) 
This study utilised Experience Sampling Methodology (ESM), which is “the 
collection of self-report indices of behavior, [sic] cognition, or emotions in near real 
time in the daily lives of the participants” (Trull & Ebner-Priemer, 2009, p457). 
ESM enables the investigation of phenomena at a momentary level. In ESM 
investigations, participants typically receive multiple stimulus signals per day for 
several consecutive days (Csikszentmihalyi & Larson, 1992, p 46). Participants 
are (typically) signalled via an electronic device (signal-contingent) or temporal 
and social cues (interval-contingent), for example at meal times. However, action-
contingent data entries are also used (e.g. after eating). Signal-contingent data 
entries are typically sent “…according to a random schedule” (Csikszentmihalyi & 
Larson, 1992, p.45). This random schedule is utilised to limit participant 
anticipation of a data entry, which would invalidate the notion of a momentary 
response. The additional advantage of the randomisation of signal times is that it 
is anticipated that it will elicit variability in psychological states which are 
contingent on environmental or temporal factors.   
 
ESM is capable of circumventing some of the disadvantages of a cross-sectional 
study design. ESM is a repeated-measures ‘micro-longitudinal’ technique, which 
may enable the researcher “to demonstrate how variables are related to each 
other across time and environments, even when participants are not consciously 
aware of the association between variables” (Palmier-Claus, et al., 2011, p13). 
One of the most frequently stated benefits of ESM research over cross-sectional 
study design is the ability to research phenomena in an environment high in 
ecological validity. With regards to (certain) cross-sectional study design 
Csikizentmihalyi and Larson (1992) stated “the data are gathered in retrospect 
outside the context of the situation, thus permitting distortions and rationalizations 
to become important” (p44).  
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Non-ESM self-report measures typically rely on either a person making a 
generalised global assessment of themselves or, retrospective account. Therefore, 
they rely on subjective retrospective information which can be influenced by recall 
bias. Stone and Shiffman (2002) state that of the associated methodological 
constraints “the most vexing is the extensive memory distortion that pervades 
retrospective self-reports” (p.236). Moreover, non-ESM self-report measures 
(typically) require the participant to amalgamate any relevant phenomena 
experienced. Whereas ESM items typically refer to concurrent phenomena, they 
are set ‘in the moment’. Thus, ESM research is purportedly not marred “by the 
same motivational processes that affect standard self-reports (i.e., socially 
desirable responding or psychological defense)” (Christensen, Barrett, Bliss-
Moreau, Lebo & Kaschub, 2003, p.55).  
 
ESM in its current form has been in use since the mid 1970’s (Csikszentmihalyi, 
Larsson, & Prescott, 1977). In seminal research as well as contextual cues, 
various devices have been employed to signal the participant including pocket 
calculators (Csikszentmihalyi & Larson, 1992, p.45) pagers (Csikszentmihalyi et 
al., 1977) and wrist watches (Delle Fave & Massimini, 1992). In early ESM 
research despite an electronic device often being used to signal participants, these 
devices were not used to record the participants’ data. Instead the participant 
typically completed (paper) ‘hard copies’ of items in a booklet. However, there are 
some notable disadvantages to this method of capturing data. 
 
ESM research can place a demand on participants beyond that which is typical of 
cross-sectional research. Consequently, during the course of an ESM investigation 
it is reasonable to expect participants will miss time points for item completion. 
Distinguishing between a valid entry and one that is not may be susceptible to 
errors of inclusion or exclusion with hard-copy data capture. ESM research is the 
momentary monitoring of phenomena, if participants do not initiate their data 
entries within a specific time window then this notion is violated; “their account is 
no longer considered to represent ambulant monitoring of their experiences” 
(Palmier-Claus et al.,2011, p18). Typically, with hard-copy signal-contingent data 
capture participant’s document the time at which they initiate their response and 
this is compared to the time at which the prompt was sent / received. However, 
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without the ability to objectively assess the time at which the data was submitted 
instances of prospective or retrospective data completion cannot be ruled out.  
 
In an investigation into prospective and retrospective item completion Stone, 
Shiffman, Schwartz, Broderick and Hufford (2002) demonstrated that the 
participant’s reported compliance of 90% for paper and pen data capture was 
substantially higher than the objectively measured compliance of 11%. However, it 
should be noted that in Stone and colleagues investigation response times were 
not randomised and thus the participant was aware of the time that they were 
supposed to have responded. In the same investigation the objectively measured 
compliance using electronic data capture was 94%.  
 
Design of the current investigation 
The current investigation consisted of three phases; a pre-ESM phase; the ESM 
phase; and a post-ESM phase. The ESM phase utilised electronic data capture, 
which enabled the electronic and objective time stamping of data. Thus, errors of 
inclusion of non-momentary data or exclusion of momentary data are mostly 
negated. The current investigation utilised remote data storage, all information 
submitted by the participants was stored in a location other than the device that 
submitted it. This prevented data loss in instances of device loss and damage.  
 
An additional advantage of the use of remote data storage is it prevented the 
participant or anyone else from accessing the previously completed responses. 
This may have served to increase data validity by preventing participants adjusting 
their current response in lieu of their previous one. Furthermore, this would have 
served to assure participants that in the event of access to the device by persons 
other than themselves then there would be no breeches of confidentiality. 
Additionally, remote data storage also facilitated the ‘real-time’ monitoring of data.  
 
However, there was one principal disadvantage to the sole use of remote data 
storage, as opposed to data stored on the device, or a combination of the two. 
Remote data storage requires a means of connecting the device to the data store. 
In the current investigation this relied on a mobile phone network and thus data 
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transfer may not be possible in certain (typically remote) geographic areas. As well 
as the possibility of data loss this also may have resulted in delayed data transfer. 
The data is time stamped at the data receiver as opposed to data sender, and thus 
it is possible that errors of exclusion for non-momentary response may have 
occurred. To circumvent this methodological issue, in the current study the time of 
initiation of response was recorded (in addition to cessation).  
 
In the current investigation, the word ‘prompt’ is utilised in reference to the means 
by which participants are alerted to initiate a data entry. The word prompt is used, 
as opposed to signal, to disambiguate from reference to other uses of the word 
signal (e.g. in reference to what is also known as mobile phone reception 
strength). The current investigation also utilised a remote means of generating a 
prompt. This offered greater flexibility to altering the prompts (if necessary) 
throughout the course of the investigation. However, the principal disadvantage of 
this is in the instance when the device has little or no reception strength. In 
practice such a scenario would delay the prompt being received. This delay may 
result in the exclusion of true momentary responses (see Sections 3.2.1 & 3.2.2).  
 
One means by which the limitation of reception strength has been circumvented is 
by utilising the time at which the device receives the prompt, as opposed to 
scheduled delivery time. This should serve to avoid some instances of erroneous 
exclusion of data. Nonetheless, this could still introduce a bias by a possible 
scenario in which an area that has low signal strength is also associated with a 
psychological state in the participant. This is an unavoidable consequence of the 
sole use of remote data storage. However, it should be noted that the purported 
coverage of reception strength sufficient for data transfer in the U.K. is 99%, on 
the phone network (Orange) used in this investigation (UKmobilecoverage.co.uk, 
n.d.). Thus, instances of such a bias being introduced are thought to be rare, if 
they have occurred at all. 
 
Utilising the hardware and software outlined in Section 3.2.3 (materials) both 
equidistant interval-contingent and (pseudo)randomised signal-contingent prompts 
were sent to participants. On each of the fourteen days of the ESM phase 
participants were sent six signal-contingent prompts assessing; schizotypal state; 
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concurrent states of calm and stress; previous stressful and pleasurable events; 
and drug consumption.  
 
As the focal point of the investigation is cannabis use, the randomisation of 
responses was pertinent. Cannabis consumption is a behaviour which for some 
will occur at specific set times and set places, of which the participant may or may 
not be consciously aware. For other participants their cannabis use will form no 
discernible pattern. In order to adopt a uniform methodology, whilst still prompting 
participant’s at various temporal proximity to their cannabis use a (pseudo)-
randomising procedure is most appropriate.  
 
Nonetheless, for brevities sake only one interval-contingent data entry assessing 
aversive cannabis experiences was sent on each of the fourteen days. This data 
entry is scheduled at a pre-arranged time during the hour before the participants 
approximate bed time. At this point participants respond to a checklist of aversive 
cannabis experiences they may have experienced on that day. Although not 
strictly speaking an action-contingent measure, it does require the participant to 
have consumed cannabis at least once on that day. 
 
3.2.2 Participants 
Inclusion and exclusion criteria 
Inclusion and exclusion criteria were applied at each phase of the investigation, 
including the analyses. This procedure was adopted for several reasons firstly 
participants eligibility may fluctuate with time. Secondly, inclusion and exclusion 
criteria must not only be applied to the participants, but each individual resultant 
data entry.  
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Figure 2 
Demonstrat ing the progress of participants through the investigation  
 
 
From data derived from the pre-ESM phase, and an interview (typically via 
telephone) participants were assessed for their eligibility to continue to the ESM-
phase. Participants were assessed against various inclusion criteria; a minimum of 
18 years old; current cannabis use at a minimum frequency of twice a month; 
anticipated cannabis use (for the ESM-phase) of at least once a week; and an 
anticipated minimum of a 10 hour window, in which data may be entered, available 
each day for the majority of the ESM-phase. Various exclusion criteria were also 
applied at this stage. Participants were ineligible for the ESM-phase if they had; 
reported currently being a frequent user of recreational drugs other than cannabis, 
alcohol, caffeine and nicotine (>than once a month); a diagnoses of chronic mental 
illness (e.g. personality disorders); recent diagnosis of any mental illness (<3 
years); or lifetime diagnosis of psychotic disorder (e.g. drug induced-psychosis); 
anticipated first and last cannabis use within a 24 hour period not typically more 
than 16 hours apart.   
 
In the post-ESM phase the participant’s data was assessed against various 
exclusion criteria. As described in Section 3.2.1 ESM is a momentary assessment, 
thus only data submitted within 30 minutes of a prompt were considered eligible 
for inclusion. This cut-off is one at which “researchers typically restrict response to” 
(Scollon, Kim-Prieto, & Diener, 2003, p.18). Scollon et al., (2003) describe the use 
of a 30 minute response window as an “arbitrary cut-off” (p.18). Nonetheless, for 
uniformity of data responses exceeding the response window were excluded from 
analyses. In addition participants responding to fewer than 30% of the signal-
contingent items were excluded from the analysis, as they are thought to be less 
reliable (Henquet, et al., 2010; Wichers, et al., 2007). Furthermore, participants 
were excluded from analysis if they consumed recreational drugs other than 
Initiated ESM phase N=53 
completed phase n=36 
Initiated Pre-ESM phase N=106 
completed phase n=86 
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cannabis, caffeine, alcohol and nicotine throughout the ESM-phase. Throughout 
the ESM period the data were monitored and participants were informed if they 
were likely to be excluded from the analysis on the basis of the aforementioned 
criteria. 
 
Recruitment 
Opportunity Sampling was utilised via the distribution of study information (flyers) 
and brief presentations of study information. Study advertisements were 
distributed both in strategic locations and on an ad-hoc basis. The study 
advertisement sheet included a brief description of the investigation, the 
researcher’s contact details, and a URL linked to the pre-ESM measures (See 
Appendix 22). Study advertisements were distributed by seven shops which 
purveyed drug use paraphernalia and ‘legal highs’. Study advertisements were 
also distributed to undergraduate psychology students attending a compulsory 
lecture at Manchester Metropolitan University (MMU). This group were also 
advertised to in a virtual environment via a post on the university internal 
messaging board and notification system (Moodle). Advertisements were also 
distributed on an ad-hoc basis, to person’s who expressed an interest in the 
research topic. 
 
In addition to distributing advertisements to prospective participants, flyers were 
also distributed to participants who had initiated the ESM phase. Participants were 
requested to pass a flyer on to any person or persons over the age of 18, who they 
thought may be receptive to the idea of participating in the investigation. This 
method of advertisement distribution is one means by which participant 
snowballing was employed.  
 
Participant snowballing was also employed in a virtual environment; this was 
primarily undertaken on the social networking websites Twitter and Facebook. 
Study advertisements were distributed via a purpose built Twitter account, these 
advertisements were then ‘re-tweeted’ (forwarded on to other Twitter users) by 
various individuals and organisations. Facebook was employed to contact various 
organisers of groups or key figures in the online community. To this end study 
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advertisements were posted to virtual communities of people based in the 
appropriate geographic location which have subscribed to an interest group 
related to drug use. Advertisements were also distributed by various persons and 
organisations involved in the music industry. Participants were given the 
opportunity to complete the pre-ESM measures in either ‘hard-copy’ or online. 
Nonetheless, no ‘hard-copy’ responses were returned.  
Demographic data 
Participant demographic data is described in detail in Section 3.3.1 and in Tables 
21 and 22, by drawing comparison between those who were included in the main 
analyses with those who were not. Briefly, the final sample comprised of 36 
participants (male= 23), 21 of whom were employed, and 7 who were in education 
or training. The sample had a mean age of 27 years (SD 8.06), and started first 
using cannabis on at least a monthly basis at a mean age of 16 years (SD 2.60). 
 
3.2.3 Materials: Technical Equipment 
The current investigation utilised electronic prompt generation and data capture. 
To this end three different technologies (pieces of hardware) were utilised.  A 
messaging distribution web based programme was employed to send prompts, in 
the form of Short Messaging Service (SMS) to participants. A smartphone was 
utilised as a means of receiving prompts and submitting data. A questionnaire 
hosting programme and server were utilised for the ‘hosting’ of the measures 
(displaying the measures in an online environment), and the storage of data.  
 
Smartphone 
This investigation utilised the Orange Stockholm (which is also known as the 
Huawei U8180), a user/troubleshooting guide tailored specifically to this 
smartphone was produced for participants and this is included in Appendix 23. 
This handset was chosen because at £49.99 (per handset) this represented the 
most economical smartphone that possessed a full web browser, and the 
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possibility of 3G and Wi-Fi data transfer. In addition this handset had a lower 
resale value than the value of the remunerations on offer.  
 
Participants utilised the smartphone’s full web browser to access and complete 
items in an online environment. For this, wireless data transfer was necessary. 
The function of 3G data transfer was a sought after feature because, at the time of 
conducting the investigation, it represented the fastest (widely available) means of 
transferring data from and to a mobile phone.  However, the speed and reliability 
of the 3G network is typically not comparable with the preferable, but less widely 
available Wi-Fi networks. Hence, in the current investigation participant’s had the 
option of connecting to a Wi-Fi network if one was available, or alternatively the 
phone would default to using the fastest mobile data transfer method available 
(e.g. 3G, EDGE, etc.).   
 
For the purposes of this investigation several applications were installed on to the 
smartphone’s Android (version 2.2.2) Operating System (OS); Angry Birds 2.2.0; 
App Lock 1.32; Maxthon Mobile Browser 2.6.9; and SMS to Text 1.3.1. The only 
function of Angry Birds 2.2.0, which is a popular game, was to attempt to get 
participant’s to engage with using and carrying the device. The other applications 
provided a specific function in the data collection process.  
Maxthon Mobile Browser 
This enabled pages to be opened automatically in a ‘private’ browsing mode, 
unlike the browser which comes as standard on the OS. A private browser 
prevents the website storing information on the device such as cookies and 
temporary files, thus facilitating the preservation of confidentiality.  
App Lock 1.32  
This application was utilised to prevent participants from accessing some of the 
content on the smartphone. Participants were prevented from accessing 
applications that require data transfer (e.g. GPS services, Facebook etc.), to 
ensure that participants were not utilising the limited data allowance which was 
required to access the online measures. 
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SMS to Text 1.3.1 
This application was used to export data from the smartphone after study 
completion. This application enabled an accurate assessment of when the 
participant received a prompt for data collection, as opposed to when the prompt 
was scheduled to be sent.  
 
Messaging Distribution Facility 
SMS messages were typically used to ‘prompt’ a data entry, but in some instances 
they were also used to make contact with participants if they were un-contactable 
via a phone call. They were distributed via Meercat communications SMS web 
portal. This system allowed for the scheduling of multiple SMS’ to be sent to 
multiple recipients for any time point in the future.  
 
These text messages served a dual purpose they prompted participants, and they 
contained an embedded (hyper)link to the relevant measure (See Figure 3). In this 
instance the link contained a Uniform Resource Locator (URL), which contained a 
web page with the relevant measures displayed. These embedded URLs act in 
much the same way as hyperlink would do on a desktop PC, by clicking it a 
browser and webpage with specific content opens up on the mobile display. Each 
URL linked to a unique data set for the storage of a specific participant’s data on a 
specific measure. For each participant there were five separate URLs (webpages) 
each linking to five separate data sets. This pertains to the five different groups of 
measures or sequences of measures displayed throughout the investigation (see 
Section 3.2.6 and Table 19). 
 
Questionnaire Hosting Facilities 
LimeSurvey 1.87+ Build 8518 was installed on an ‘in-house’ server to facilitate the 
hosting (presentation in a virtual environment) of the respective measures. This 
was capable of presenting items in the various ‘question types’ necessary for this 
investigation e.g. Likert items (see Figure 4), and open ended text boxes (see 
Figure 5) etc. Participants were provided with a user guide tailored specifically to 
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completing the measures on LimeSurvey. LimeSurvey was also responsible for 
the secure storage and retrieval of data, in addition to the formulation of the 
hyperlink addresses. 
 
Figure 3  
Screen shot of smartphone displaying data entry prompts with embedded URL  
 
Random time generator 
The participant’s interval-contingent prompts were assigned according to a 
random time generator this was created on Excel (J. Cavill, personal 
communication, February 3, 2012). This generator created six randomised time 
points between personalised wake and sleep times. There was a mean interval of 
120.9 minutes (SD 60.68) between each response, and a minimum interval of 60 
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minutes.  The sampling period encompassed between ten and sixteen hours out of 
any twenty-four hour period (See Section 3.2.2).   
 
Figure 4 
Screen shot of smartphone displaying SSQ items  
 
Figure 5  
Screen shot of smartphone displaying text box data entry  
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3.2.4 Materials: Psychological Measures 
Several measures were utilised at various time points throughout the investigation. 
These measures can be differentiated into; pre-ESM measures; concurrent ESM 
measures; retrospective ESM measures; post-ESM measures; and measures 
utilised in the testing of ESM items. Several of the measures utilised in this 
investigation were either adapted versions of pre-existing measures, or developed 
specifically for the purpose of this investigation. A procedure of testing these 
measures has been taken in parallel with the current investigation.  The process of 
assessing validity and in some instances reliability of these items is described in 
Section 3.2.6, Section 3.3.2, and Appendix 29. 
Pre- ESM measures 
Cannabis Experiences Questionnaire 
The CEQ is described in detail elsewhere in this thesis (see Section 2.2.3 and 
Appendix 1). 
Schizotypal Personality Questionnaire- brief-Likert version (SPQ-b-L)  
This measure is based on adapted versions of the Schizotypal Personality 
Questionnaire (SPQ, Raine, 1991); the  Schizotypal Personality Questionnaire- 
brief (SPQ-b, Raine & Benishay, 1995); and the Schizotypal Personality 
Questionnaire- Likert version (SPQ-Lv, Wuthrich & Bates, 2005). The SPQ-b-L is 
substantially the same as the SPQ (the full version of the questionnaire described 
above). The principal difference is in the revised version instead of asking 
participants to respond dichotomously (‘Yes’ or ‘No’) responses are recorded on a 
five-point Likert scale. The Likert scale ranges from ‘Strongly disagree’ to ‘Strongly 
agree’. It is anticipated that this will encourage disclosure from the participants 
(Wuthrich & Bates, 2005). Greater variability will allow for more gradations of 
schizotypy to be identified. Furthermore, a Likert version may be more sensitive to 
identifying “high scores missed by the standard version” (Wuthrich & Bates, 2005). 
For the development of the brief version of the SPQ Raine and Benishay (1995) 
selected the 22 (of 74) of the most reliable items from the measure. These 22 
items disaggregated into three factors pertaining to cognitive-perceptual distortion 
(8 items), interpersonal distortion (8 items), and distortion of (dis)organisation (6 
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items). In the current investigation akin to the modification of the SPQ to form the 
SPQ-Lv, for brevity and variability of data, the most reliable 22 items from the 
original SPQ have been utilised with a 5 point Likert scale to form the SPQ-b-L. 
Concurrent ESM measures 
The signal-contingent measures were displayed on two pages, with concurrent 
phenomena displayed on the first and retrospective items on the second. Two 
concurrent measures were administered, between them assessing three 
constructs. DeVries (1992) recommends that “since thoughts at the time of the 
signal are the most difficult to catch, they are asked about first” (p.320). The first 
item participants are presented with is in regards to the time.  The purpose of this 
item is to place the participant in the ‘mind-set’ of considering experiences and 
psychological states that are currently occurring. Not utilised in the current 
investigation but, another consequence of utilising this item could be as a measure 
of participant’s accuracy/honesty of response. 
Schizotypal States Questionnaire (SSQ) (Appendix 25) 
As described in Section 1.2.2 the stability of schizotypy has been brought into 
question. As a consequence this investigation sought to take a measure of a 
‘schizotypal state’. The SSQ is an adapted version of the SPQ-b-Lv, with items 
amended for brevity and rubric altered to set the participant in the ‘moment’ (i.e. 
Right now I feel). For example, original SPQ-b item ‘Are you sometimes sure that 
other people can tell what you are thinking?’ has been altered to ‘Right now I feel: 
Other people can read my mind’.  Participants respond on a 5-point Likert scale, 
ranging from ‘Strongly disagree’ to ‘Strongly agree’.  This measure was adapted 
specifically for use in this investigation, the reliability and validity of this measure 
has been assessed in parallel with this investigation (Section 3.3.2). 
Concurrent states questionnaire: Stress and Calm scales (Appendix 26) 
Participant’s concurrent states of stress and calm were assessed by a 6 and 5 
item measure (respectively). Responses were recorded on a five-point Likert scale 
ranging from ‘Not at all’ to ‘Very much so’. The scales contain short (one or two 
word) statements such as ‘Chilled out’ (Calm scale) and ‘Anxious’ (Stress scale), 
which are preceded by the rubric ‘Right now I am feeling’. These items were 
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devised for the current study in discussion with John Stirling. The validity of these 
items have been discussed in Section 3.3.2, various means of scoring the scales 
have been assessed in Appendix 29. 
Retrospective ESM items 
The retrospective items were presented on a separate page after the concurrent 
ESM items.  The first item played a role in setting the participant in the mind-set of 
considering retrospective events. This consisted of a text box with the open ended 
item ‘The most noteworthy (good or bad) event that happened to me since the last 
beep [prompt] was…’ (See Figure 5). 
Event related items (Event Rating, ER; Stressful Events, SE; Pleasurable Events, 
PE) 
Immediately after the text box an item was displayed requiring an evaluation of the 
most ‘noteworthy’ event. This item (Event Rating, ER) was scored on a 5 point 
Likert scale ranging from ‘Very unpleasant’ to ‘Very pleasant’ and consisted of the 
words ‘and it was…’ 
 
Two other items were presented pertaining to previous events and these consisted 
of the consideration of ‘How many nice/stressful events have (the participants) 
experienced since the last prompt’. The items were scored on a 5 point Likert 
scale ranging from ‘none’ to ‘a lot’ participants responded to ‘Nice’ and ‘Stressful’, 
which constitute items PE (Pleasurable Events), and SE (Stressful Events) 
respectively. These items were devised for the purposes of this investigation the 
validity of these items has been examined in Section 3.3.2. 
Drug use items 
After the items pertaining to ‘events’ participants responded to a dichotomous item 
requesting the participants to consider if they had ‘…used cannabis since the last 
(prompt)?’ A positive (‘Yes’) response from the participant resulted in the 
presentation of three additional items pertaining to their cannabis use. Participants 
were asked to document ‘What type of cannabis [they had consumed]?’ 
Participants responded with one of the following options; ‘Hash (cannabis 
resin/solid)’; ‘Skunk (sinsemilla)’; ‘Traditional herbal cannabis (bush)’; ‘Cannabis 
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oil’; or ‘Don’t know’. Respondents also documented by which method of 
administration the drug was consumed either; ‘Spliff/Joint- Tobacco cannabis mix’; 
‘Blunt, Bong or Pipe- Only cannabis’; ‘Vaporiser’; or ‘Eaten’. The final item in 
pertaining to cannabis consumption was in regards to how many units of the 
participant’s standard dose had been consumed (‘How many have you had?’). The 
advantage of the participant assessing their standard dose is that in the presence 
of vast numbers of uncontrolled and immeasurable variables (see Section 1.4) a 
measure of quantity can be made. However, the dose of cannabis consumed can 
only be considered within participants, in the absence of a standard unit common 
across the sample.  
 
After the items pertaining to cannabis consumption participants were presented 
with four open text boxes, to document their consumption of drugs other than 
cannabis. There was a text box pertaining to the consumption of caffeine, tobacco, 
alcohol and any other drug, which participants were requested to respond in as 
much detail as possible. The consumption of one cigarette was considered as one 
unit, this was the only means by which nicotine was consumed. Caffeine and 
alcohol consumption were more challenging to quantify. The most commonly 
consumed caffeine substance in the sample was tea. Thus, one cup of tea formed 
the base unit (one cup of tea = one unit). Purcărea, Chi , Vica , and Fodor (2008) 
suggest that “tea usually contains about half as much caffeine per serving as 
coffee” (p.966). However, it should be noted that there is a high degree of 
variability in the ranges of caffeine between tea products (Purcărea et al., 2008). 
Thus the second most commonly consumed form of caffeine, coffee, was 
considered as two units.  Each caffeine containing carbonated drink (e.g. Coke) 
was coded as one unit, as these are thought comparable to one cup of tea. “When 
compared to previous studies, the caffeine concentration (per oz) in brewed teas 
tended to be lower than in specialty coffees and energy drinks, but similar or 
higher than carbonated sodas” (Chin, Merves, Goldberger, Sampson-Cone, & 
Cone 2008, p.704). 
 
These ‘carbonated sodas’ were differentiated from ‘energy drinks’ in the current 
investigation. A standard measure (250ml) of a popular brand of energy drink 
(Redbull) contains 80mg of caffeine. This value is higher than the range of tea 
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caffeine volumes per serving documented by Chin, Merves, Goldberger, 
Sampson-Cone & Cone (2008) (14 to 61 mg). Furthermore, in an analysis of 
various drinks available on the market it was reported that the “caffeine content for 
the majority of energy drinks included in this study was higher than the maximum 
allowed limit for cola beverages” (McCusker, Goldberger, & Cone, 2006, p.114). 
Thus, each energy drink was coded as two units. 
 
A different approach was taken to measuring the consumption of alcohol, due to 
the use of standard volumes of liquid and percentages of alcohol content, in 
addition to average data pertaining to those factors. Thus, in the instances where 
participants made reference to specific brand of alcohol beverage and/or specific 
volume, the units of alcohol (UK unit) consumed were calculated precisely. In 
instances when any of the specific information was absent or ambiguous average 
volumes and percentage of alcohol content were utilised (See Turner, 1990). 
Cannabis Experiences Questionnaire-brief (CEQ-b) 
The CEQ-b comprises of a checklist of cannabis induced experiences, this 
measure consisted of the aversive subscale of the CEQ, twenty items identified by 
the factor analysis conducted by Stirling (Unpublished data, see Section 2.2.3 and 
Appendix 1). This subscale consists of seventeen concurrent cannabis 
experiences (e.g. feeling fearful) and three after effect experiences (e.g. paranoid 
without reason). For the concurrent items participants responded to; ‘Have you 
had the following experiences today whilst using cannabis?’ For the after effect 
items participants responded to; ‘Have you had the following experiences today 
AFTER the initial effects of cannabis?’ Participant’s responded to the CEQ-b on a 
5-point Likert scale ranging from ‘Not at all’ to ‘Very much so’.  These items were 
answered once daily for the duration of the two week ESM period. 
 
Post-ESM Measures 
Quantitative Feedback Questionnaire (QFQ) 
In the post ESM phase a quantitative feedback questionnaire devised by Palmier-
Claus and Lewis (personal communication) was administered. The questionnaire 
consists of 26 items, 3 of which are related to time taken, e.g. ‘How long did it take 
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you to complete each set of questions once you started?’ These items are scored 
on a Likert scale (typically) ranging from 1 (within one minute) to 5 (5+ minutes). 
The other 23 items are related to the participant’s experience (e.g. ‘Did answering 
the questions take a lot of work?’) these are scored on a 7-point Likert scale 
ranging from ‘Not at all’ to ‘Very much so’. For brevities sake the data gleaned 
from this measure will not be considered within this thesis. 
 
Measures utilised in the testing of ESM items 
Psychotomimetic States Inventory (PSI) 
The PSI (Mason, 2008), a measure of a schizotypal state, was administered for 
the purposes of establishing concurrent validity for the SSQ. The PSI is a 48-item 
self-report measure with rubric ‘Please complete the following questions by circling 
the number that best describes your experience at the moment’. Participants 
respond to items such as ‘at the moment: you think you are being talked about’ on 
a 4-point Likert scale ranging from ‘Not at all’ to ‘Strongly’. The 48 items 
disaggregated into 6 subscales pertaining to; delusional thinking (8 items); 
perceptual distortions (10 items); cognitive disorganisation (9 items); anhedonia (7 
items); mania (6 items); and paranoia (8 items). 
Weekly Stress Inventory (WSI) 
To help establish concurrent validity with the ESM measures of stress (and 
stressful events) participants completed the WSI (Brantley et al., 2007). The WSI 
was completed twice throughout the course of the ESM period (at the end of the 
first week and again at the end of the second). The WSI is a 25 item measure 
which participants respond to on a 7-point Likert scale with items such as ‘Lost or 
misplaced something (wallet, keys)’. The WSI generates scores on two scales; the 
‘Events’ scale that documents the occurrence of stressful events; and the ‘Impact’ 
scale which assess the psychological impact of the aforementioned events. 
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3.2.5 Piloting 
Piloting of measures 
Prior to the initiation of this investigation the measures were piloted with ten 
cannabis using participants over a two week ESM investigation. Instead of using 
smartphones to record responses paper and pen methods were utilised. Prompts 
were sent in the form of text messages to participants’ own mobile phone. This 
allowed for an assessment of the measures prior to the availability of the 
hardware. As a consequence of feedback from participants after the ESM phase it 
was deemed that the effort required was not too excessive for the population. 
However, the feedback gleaned from this endeavour proved invaluable in altering 
the presentation and scoring of some items. For brevity and clarity six 
dichotomous items pertaining to previous stressful events were changed to what 
are currently items PE, and SE.  
 
To assist with the participants understanding the anchors of the SSQ were altered 
from ‘hardly at all’ to ‘definitely’, to their current notation of ‘strongly disagree’ to 
‘strongly agree’. The CEQ-b showed little variability in the data and thus a 
dichotomous (‘Yes’ or ‘No’) response was adapted to a five point Likert scale. The 
item used as a framing tool for ER previously referred to “The most important 
event…” however, several participants inferred that they did not complete the item 
because ‘nothing important had happened to them’. Thus, this item was 
subsequently changed to “The most noteworthy event…” Several participants also 
reported difficulty remembering the meanings of the words aloof, vague, and 
elusive which are contained within SSQ items. As a consequence of this feedback 
in the current investigation these words were accompanied with a brief definition 
(See Figure 4).  
 
To further increase the breadth of the information gained after the piloting phase 
an additional item was added pertaining to the preparation of cannabis consumed 
(e.g. sinsemilla, cannabis resin etc.). Furthermore, two additional options were 
added in the consideration of methods of administration of cannabis; eaten (orally 
consumed); and in a vapour form (vaporised cannabinoids). 
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Piloting of technology 
After the piloting of the measures five participants (three non-cannabis users, two 
cannabis users) assisted with the piloting of the technology. This pilot investigation 
was much the same as the current investigation. Feedback from the pilot helped to 
establish the topics included in the two ‘how to guides’ assisting with phone use 
(Appendix 23) and answering items (Appendix 24). Furthermore, many aesthetic 
aspects of the design were also adapted to facilitate ease of use. One example is 
the CSQ items were split into two tables so that the anchors could be seen at the 
same time as all of the items, reducing the need for scrolling up and down (see 
Figure 6). Moreover, the pilot study highlighted two errors (bugs) which were 
causing an unexpected reaction between the different technologies.  
 
The pilot investigation utilised drop down menus in some instances e.g. for 
selecting a method of administration of cannabis. However, drop down menus 
from time to time caused a several second delay between button press and device 
action. On occasion drop down menus also caused the browser to crash. 
Irrespective of the errors associated with this question format participants also 
documented that they took longer to respond to than other types of question. As a 
consequence in the full investigation drop down menus were replaced with other 
question formats (e.g. tick boxes).  
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Figure 6  
Screenshot of smartphone showing the CSQ anchors repeated  
 
The main error that was highlighted by this piloting phase was one attributable to 
the use of cookies. At the end of answering a questionnaire an error occurred if 
the participant did not close the browser window before exiting the web browsing 
application. When starting up a new data submission the questionnaire hosting 
facility detects that the device already has a data entry ‘session’ in progress and 
does not allow another one to commence. As a result of this in the current 
investigation participants were advised to only have one data entry browser 
window open at a time. Furthermore, the Maxthon browser was added in private 
browse mode to ensure the automatic deletion of cookies at the end of each 
session. 
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3.2.6 Procedure 
This investigation consisted of several distinct phases, the schedule of the pre-
ESM phase and ESM phase measures are considered in Table 19. 
Table 19 
Data entry schedule throughout the duration of the investigation 
Day ESM diary CEQ-b PSI WSI CEQ and SPQ-b-L 
T -1     1 
T 0 1  1   
T 1 6 1    
T 2 6 1    
T 3 6 1    
T 4 6 1 1   
T 5 6 1    
T 6 6 1    
T 7 6 1  1  
T 8 6 1    
T 9 6 1    
T 10 6 1    
T 11 6 1    
T 12 6 1    
T 13 6 1    
T 14 6 1  1  
Pre-ESM phase 
The pre-ESM phase (T-1) consisted of the completion of the CEQ and the SPQ-b-
L in addition to several other items to assess eligibility for participation in the ESM 
phase. Participants left contact details in the form of email, phone number or 
postal address and a name or pseudonym. Participants were given the opportunity 
to respond electronically (via the research group’s website) or alternatively to 
respond via ‘hard copy’ (none did so). Participants logged on to the website where 
they could read information relating to the background of the research in addition 
to a participant information sheet (PIS, see Appendix 27) and consent form 
(Appendix 28). Due to the medium of electronic participation, participants affirmed 
consent through clicking a button as opposed to a signature. 
 
Once the measures had been completed, at a future time point, the researcher 
contacted the participants by telephone or email. During this exchange the 
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respondent was provided with further information about the ESM phase of the 
investigation and an assessment was made of the participants’ eligibility for it (see 
Section 3.2.2). If the participant was receptive and eligible, a meeting (briefing 
session) was arranged. These briefing sessions were at a time most convenient to 
the participant (in some instances this was late into the evening) and a location of 
the participant’s choosing, this was typically on one of the MMU university 
campuses or in the participant’s own home. 
 
At a time prior to the meeting it is necessary for the researcher to prepare the 
equipment for use. A new ‘Pay as you go’ Subscriber Identity Module (SIM) card 
was installed, which assigns the card a new (unused) phone number. This phone 
number was then added to the messaging distribution facility database and a link 
(SMS message), with the relevant measures for the briefing session, was 
forwarded to the smartphone. The researchers contact details were then stored in 
the device for the participants’ use. The day prior to the meeting £10 worth of 
credit was added to the device. This served several functions, under the promotion 
offered by the network provider it allowed the smartphone to utilise up to 100 
megabytes (MB) of data usage (web traffic) within a 30 day period (in addition to 
400 SMS messages). This was more than sufficient for the data usage necessary 
for completion of the study (which was estimated at 11.7MB).  
 
The second purpose of the phone credit was it provided the participant with a 
means of contacting the researcher without incurring any costs. The 400 SMS 
messages and £10 of phoning credit was well above what would be required to 
contact the researcher, and thus participants were encouraged to utilise the phone 
for their personal purposes if they so wished. The rationale for this was it was 
anticipated that by utilising the device more there would be an increased chance 
that the smartphone would be in close proximity to the participant when a prompt 
was received. This also served the purpose of (feasibly) increasing the 
participants’ familiarity and engagement with the smartphone.  
 
At the briefing session (T0) participants were provided with a background to the 
research and the purposes of the study. Participants were provided with a ‘hard 
copy’ of the PIS and were asked to carefully read through it and ask the 
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researcher any questions they may have. Participants were presented with a 
consent form and if they were agreeable they affirmed their consent by signing, a 
pseudonym was once again permitted. Then the researcher and participant in 
conjunction completed the briefing document.  
 
This document was utilised for two purposes; to capture demographic information 
not considered by the other measures; and to provide a portrait of the participant’s 
anticipated schedule and cannabis use over the coming ESM period. The items 
collecting demographic data were pertaining to employment status and age at 
which the participant first became a (at least once) monthly cannabis user. The 
items pertaining to the participants schedule facilitated the construction of 
parameters by which the (pseudo)-randomised prompts could be scheduled within 
(e.g. What time do you anticipate you will wake up on each of the study days?) 
Utilising the information gleaned participants were once again assessed against 
the inclusion and exclusion criteria (Section 3.2.2 pp. 170-72). 
 
The researcher then conducted a brief training session describing how to use the 
smartphone’s functions (e.g. how to log in to a Wi-Fi network, mute the phone 
etc.), here participants were given a how to/trouble shooting phone guide 
(Appendix 23). The demonstration then progressed to describe how to use the 
phone to answer the questionnaire. The participants were then given a second 
‘how to guide’ pertaining to accessing (and answering) the measures hosted on 
the internet (Appendix 24). The participants then read through the items that were 
due to be administered six times a day, i.e. the signal-contingent measures (SSQ, 
CSQ, Event Related items, drug consumption items). Participants were given the 
opportunity to ask any questions about the items they were due to answer. Once 
any queries were satisfied participants proceeded to initiate their first unsupervised 
data entry. 
 
In addition to testing the main aims of this investigation, the validity and in some 
instances reliability of some of the signal-contingent measures were also 
assessed. Thus to assess the concurrent validity of the SSQ at T0 participants 
also completed another state measure, assessing psychotomimetic experience 
(PSI) in close temporal proximity (<3 minutes). Both these measures were 
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completed by all participants who started the ESM phase. However, participants 
could opt to submit an extra data submission at a later time point.  
 
The SSQ and PSI were administered in a randomised counterbalanced crossover 
study design to eliminate the possibility of an order effect. Dependent on which 
condition the participants were assigned to, this consisted of completing the 
signal-contingent measures prior to the PSI or vice-versa. Participants were once 
again provided with the opportunity to ask any questions. After this data entry, 
participants were presented with the interval contingent measures (CEQ-b) and 
the researcher responded to any questions about the items. Once any questions 
were answered this was the end of the briefing session. The next day the ESM 
phase of the study commenced (T1). With the exception of one participant who, 
due to unforeseen circumstances, started two days after the briefing session.  
 
After the briefing session, but before the commencement of the ESM phase 
utilising the information provided; random times were generated for the schedule 
of the interval contingent ‘prompts’. Utilising this information SMS text messages 
were scheduled to be sent via the message distribution facility for all prompts due 
on T1 to T4 (inclusive).  
 
In comparison, to some other ESM investigations, a less stringent parameter was 
applied in regards to the participant’s potential hours of response, with others 
ensuring the participants hours of response are uniform (e.g. Husky, Mazure, 
Carroll, Barry, & Petry 2008; Kimhy et al., 2006 etc.). However, given the 
population under investigation there is sufficient rationale for adapting this arbitrary 
parameter. Thus, an approach more responsive to individual need was adopted.  
 
In the current investigation participants were able to assign their own hours of 
response, and these hours of response could vary from day to day (e.g. to allow 
for a longer resting period at the weekends). Participants were also able to 
suggest times when it would be inappropriate for them to respond (e.g. whilst 
performing in a sporting event). However, few did with most preferring to utilise the 
option to mute the ‘prompt’ generating device. Despite the need to be sensitive to 
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the participant’s schedules, parameters were still assigned to ensure some 
uniformity between respondents (see Section 3.2.2). 
ESM phase 
The participant then entered the ESM phase of the investigation (T1). On every 
day of the ESM phase of the investigation the participant is sent a link to the 
signal-contingent measures six times per day, in addition to one to the (interval-
contingent) CEQ-b at around their anticipated bedtime. On the fourth study day 
(T4) participants were presented with the option of entering a second PSI 
completion, to assist with an assessment of test-retest reliability. Participants were 
presented with this opportunity at each of the six interval-contingent prompts they 
received on T4. Participants were informed that the second completion of the PSI 
was not mandatory and did not impact on their minimum data requirements, this 
questionnaire could be dismissed by the press of one button (Figure 7). 
 
Throughout the course of the ESM-phase the data was frequently monitored 
utilising the questionnaire hosting facilities. Typically prior to the fourth day of the 
‘ESM phase’ the researcher contacted the participant to enquire with regards to 
the appropriateness of the schedule. Additionally, in lieu of the participant’s data 
submitted (or not submitted) up to that time point the researcher when necessary 
provided additional guidance or support and reminded the participant of their right 
to withdraw. If the participant wished to proceed the remaining ‘prompts’ (T5 – 
T14) were scheduled on the message distribution facility. 
  
192 | P a g e  
 
Figure 7  
Screen shot of smartphone displaying item requesting a PSI completion  
 
To assist with assessing the concurrent validity of the SSQ scales, and the event 
related items (ER, SE and PE), participants performed a weekly assessment of 
stress, the WSI. On the seventh (T7) and fourteenth (T14) day’s participants were 
presented with the WSI, the completion of which was optional. On each of those 
days participants were presented with two SMS messages containing a link to the 
WSI, these were not sent within forty-five minutes of another prompt or within 
three hours of each other. 
 
Typically between three to five days since the last contact, the researcher 
contacted the participants again (typically T7 or T8). However, daily monitoring of 
the data was undertaken and thus in instances where there was a large proportion 
of missing data the participants were contacted sooner. Participants were 
contacted once more, prior to the cessation of the ESM phase (typically T12 – 14). 
After the end of the ESM phase of the investigation another meeting (de-briefing) 
was arranged with the participant. 
Post-ESM phase  
At the de-briefing the smartphone (and charger) were collected back from the 
participant, remunerations and study advertisements (to facilitate snowball 
recruitment) were distributed and both oral and written feedback from the 
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participant was sought. Oral feedback was sought according to four broad 
domains related to; the device and technology; items presented in the study; the 
methodology; and the demands placed on the participant. Written feedback was 
acquired in the form of the quantitative feedback questionnaire. 
 
The SMS messages sent from the messaging distribution facility that are stored on 
the smartphone are exported off the device. Then any of the participant’s personal 
data is removed from the smartphone, and the SIM card associated with the 
device disposed of. The participant’s data is downloaded from the questionnaire 
hosting facility and the databases are reset ready for another participant’s data. 
3.2.7 Ethical consideration 
Risks and possible harm 
The procedure was granted approval by the MMU Research Ethics Committee. 
This investigation represented no tangible risk to respondents. However, as 
participants completed items pertaining to psychotic-like symptoms and their own 
drug use there is a possibility of causing some degree of distress in certain 
sensitive individuals. To minimise this, participants were reminded throughout the 
investigation of their right not to answer any items which they found distressing. 
Participants were also informed of their right to withdraw their data at any time 
point during and up to two weeks after the completion of the ESM phase.  
 
The research group’s website contained a list of information groups and support 
services aimed at addiction, drug use and mental health for the use of any 
participant experiencing distress. This information was also included on the ‘hard-
copy’ of the participant information sheet distributed out at T 0. 
 
A more likely consequence of this methodology is that some of the participants 
found the investigation intrusive, particularly whilst trying to conduct other 
activities. To minimise the occurrence of intrusion participants were informed on 
how to mute the smartphone, or switch it off. However, participants were reminded 
not to respond to the device at any time that it may be dangerous to do so, for 
example whilst driving. Although not decreasing the inconvenience of the intrusive 
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methodology participants were remunerated for their efforts in the form of a £20 
shopping voucher. 
 
In addition to the intrusion per se of being frequently ‘prompted’ the completion of 
multiple data entries can be time consuming. Unfortunately, this is an unavoidable 
aspect of the methodology, in the current investigation several piloting phases 
were utilised to expedite item completion. These developments were typically in 
the form of adaptations to the visual display of items and the manner which data is 
input into said items. Furthermore, when appropriate (i.e. SSQ) items have been 
truncated to allow for the quickest possible response time. 
 
Confidentiality 
Due to the sensitive area of research (illegal drug use) confidentiality was 
paramount in this investigation. Therefore, several steps were taken to ensure 
confidentiality. In the pre-ESM phase only necessary contact details were 
collected and this could be in whichever medium the participant wishes to be 
contacted via. If contact is made by phone the participant is always asked whether 
it is an appropriate time to have a confidential conversation. Furthermore, 
participants were given the option to use a pseudonym throughout the 
investigation (many of whom exercised this option) thus, although not permitting 
full ‘anonymity’ (as the study requires a face to face meeting) this does serve to 
decrease the possibility of breaches of confidentiality. Nonetheless, further steps 
were taken to ensure confidentiality. In instances where the participant briefing 
session was undertaken on a university campus at no point was their name or the 
area of research (i.e. illegal drug use) reported on any of the relevant documents 
for booking a room or facilitating a visitor access on to campus.   
 
Participants were able to request not to receive ‘prompts’ to be delivered at certain 
times. In an attempt to minimise intrusion into the participant’s lives and also 
reassure them that they will not be contacted at times when they anticipate they 
will be in proximity to persons who are unaware of their drug use. Furthermore, the 
device had no (visible) identifying marks as one associated with research and is a 
model commercially available and commonly purchased. In the information stored 
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on the device itself no reference is made to cannabis or drug use, thus even in the 
instance of access by persons other than the participant this would not result in a 
breach of confidentiality or data protection.  
 
Through the use of a private browsing mode to access the measures no data is 
ever stored from the internet on to the smartphone this includes cookies, memory 
cache data etc. Thus as long as the participant does not have an active session 
running (i.e. is not currently completing the measures) it is impossible to access 
any study data from the smartphone. In the instance of an active session only the 
data due to be submitted is accessible.  All study data (including the pre-ESM 
measures) was stored on the questionnaire hosting facility prior to exportation to 
data analysis software. Only the primary investigator had access to the account on 
which the data was stored. 
 
Data was sent from the smartphone to an ‘in-house’ server, for the advantages of 
the use of an in-house server please see Section 2.2.6. Only the named 
researchers had access to data stored on the server. Once this data was 
downloaded it was stored on a password-protected computer (in a locked office) 
that only the researchers had access to.  No personal identifiers were stored with 
the data to ensure confidentiality, and individuals were, instead, identified by a 
unique identifier number.  
 
3.2.8 Analysing multilevel data 
Procedures adopted in the current study  
ESM presents a unique set of challenges when analysing the resultant data. ‘ESM 
data has a hierarchical structure in which repeated observations are nested within 
subjects’ (Kimhy et al., 2006, p224). Due to this structure (see Figure 8) typical 
‘uni-level’ tests of association, such as multiple regressions and logistic 
regressions, cannot be applied. Every participant enters multiple repeated 
observations these cannot be viewed as independent, as the observations 
associated within each respondent will in all likelihood have a greater similarity, 
than observations between respondents. Moreover, the observations submitted 
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within a participant on a specific day will in all likelihood have a greater similarity to 
other observations submitted on that day, in comparison to observations from 
other days within that participant. Consequently, multilevel modelling (MLM) is 
typically performed which takes into consideration the structure of the data i.e. the 
non-independence of observations (e.g. Henquet et al., 2010; Myin-Germeys, 
Delespaul, & Van Os, 2005; Tournier, et al., 2003; Verdoux et al., 2003 etc.). Data 
was analysed using STATA 12.1 (StataCorp). For analyses with binary outcome 
variables the Xtmelogit routine was performed. Whilst testing continuous 
dependent variables the Xtmixed command was utilised. 
 
The majority of multi-level analysis described in this thesis utilise a three level 
model; where data entries (level 3) are nested within days (level 2); and days are 
nested within participants (level 1) (see Figure 8). The modelling of the data 
structure in this manner should account for the non-independence between the 
observations. This three level structure models the relationship between multiple 
responses generated by one individual and the relationship between responses in 
any one given day. Thus, the model should be adjusted for individual differences 
between participants, and differences within participants between the events 
behaviours and states of mind associated with a particular day. To rephrase the 
third level of the model is addressing the assumption that there are ‘good days’ 
and ‘bad days’ and adjusting for this accordingly. The three level model has the 
participants at the top level of the hierarchy (level 1), and individual data entries at 
the lowest level (level 3) (see Figure 8). However, it is worthwhile noting that in 
some texts (e.g. Snijders and Bosker, 2012) the level notation is reversed with 
units at the micro-level (in Figure 8 Data entry level) being described as “level-one 
units” (p.8). 
 
However, in this thesis there are three exceptions to a three level data structure; 
the validation described with regards to the WSI (Section 3.3.2); and the analyses 
including the CEQb as an outcome variable (Section 4.3.1). These measures were 
administered on a weekly and daily basis (respectively) consequently there is no 
variability in the level three unit, making a three level analysis inappropriate. 
Analyses with these measures utilised a two level data structure where 
weeks/days (level 2) are nested within participants (level 1). The third exception 
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occurs in the instance when the third model fails to account for variance within the 
data i.e. the third data level does not alter responses. In such instances (i.e. 
Section 3.3.6) a two level model will be adopted with days constituting the lowest 
level unit within the model. 
 
Figure 8  
Showing clustered ESM data structure  
 
 
It is convention in ESM research to centre ‘continuous’ predictor variables around 
a meaningful value, this procedure is typically adopted for ease of interpretation of 
the output and to give the relevant scores a mean, or true value of 0 (Bolger and 
Laurenceau, 2013 pp37-9).  In most analyses in this investigation the grand mean 
(mean of all participants’ scores) is the most appropriate value to centre to. 
However, there is an exception, the variable ‘quantity of cannabis consumed’. As 
cannabis is the focal point of this investigation cannabis consumption per se is 
considered in most models displayed herein. To establish the presence of a ‘dose 
dependent effect’ a measure of quantity of cannabis consumed must be 
considered. Measuring cannabis consumption is very challenging (see Section 
1.4).  
 
The procedures adopted in this study to measure cannabis consumption generate 
values which represent a proxy as opposed to literal measure of cannabinoid 
absorption. Participants were requested to estimate their standard dose (e.g. one 
“spliff”) and record each time this amount was consumed. Thus, quantity of 
cannabis consumption is relative to each participant and therefore not comparable 
between participants. Consequently, an adjustment must be made to the value at 
which quantity of cannabis consumed is centred around. The most appropriate 
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value to centre to is the participant’s own mean. Thus, the value contained within 
the predictor variable will represent fluctuations within participant’s overtime. 
 
In order to generate a variable representing within participant effects initially a 
variable was created centred to the grand mean (the mean of all participants’ 
scores). Following the procedure outlined by Bolger and Laurenceau (2013) this 
variable was then split “into two (orthogonal) components: a between-subjects 
means component….and a within-subject deviations from those means 
components.” Thus, allowing for observation of the within participants effect of 
cannabis consumption. These newly created variables representing between and 
within participant effects cannot be considered within the same model as cannabis 
consumption per se. The data regarding consumption per se and quantity of 
consumption are highly related. In some instances these items may contain the 
same value, which is pertaining to the same event a consumption of (solely) one 
cannabis unit since the last data entry. If the aforementioned were considered 
within the same model this may result in collinearity. Thus, cannabis consumption 
and quantity of consumption will be considered independently from one another 
within separate models. However, this also applies to variables which require the 
presence of cannabis consumption within the model, i.e. the variable pertaining to 
the interaction between cannabis and stress (CXS). 
 
Cannabis consumption is a binary variable, whether cannabis is consumed or not. 
By multiplying a binary variable by a continuous variable it is possible to generate 
a variable that represents the interaction between its two composite parts. In this 
instance cannabis consumption is multiplied by CSQ Stress (centred) thus 
generating a variable that consists of scores on the CSQ Stress scale (only) when 
combined with cannabis use (per se). Thus when the interaction of stress and no 
cannabis consumption is considered a value of zero is assigned. By centering 
CSQ Stress around the mean value this ensures that the data set contains 
negative values, and thus the zero value does not influence the point of intercept. 
This technique of creating an interaction variable is described in Bolger and 
Laurenceau (2013, chapter 5), for use in a moderation analysis. If the newly 
created variable (cannabis x stress, CXS) is considered as a predictor in the same 
model as both cannabis consumption and CSQ Stress then the effect of the 
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interaction variable can be considered as independent of its composite parts. 
Hence, the rationale for not including the CXS variable in analyses utilising the 
variable pertaining to quantity of cannabis consumed. Unlike, the procedure 
described by Bolger and Laurenceau (2013) CXS is considered an explanatory 
variable in all levels of the analysis (both within and between participants). In the 
current investigation, CXS may be considered to reflect the effect of stress (on the 
predictor variable) when cannabis has been consumed in the moments since the 
last valid data entry. 
 
Variables which are hypothesised to contribute to the outcome variable are 
considered simultaneously within the same model, with the exception of possible 
instances of colinearity. Whilst using a multilevel hierarchical linear regression all 
explanatory variables within the model should be able to establish the effects of 
each variable on the outcome independently from one another. Thus, the inclusion 
of certain variables (i.e. alcohol consumption) although not pertaining to a specific 
hypothesis will control for the activity or behaviour and should in theory reduce the 
size of the residual. As Snijders and Bosker (2012) state  
 
Some variable, say Xq, may be omitted from the fixed part of the model. 
Part or all of this variable will then be represented by the residuals in the 
random part. If the fixed part includes some variables that are correlated 
with Xq, then the effects of the variables included will take up some of the 
effect of the variable omitted (p.157). 
 
However, in the current study stable (or relatively stable) between participant 
differences, do not need to be controlled for (e.g. age) as these between 
participant differences are inherently modelled within the data structure (level 1, 
participant level). 
 
However, the same approach cannot be adopted for the analysis utilising a binary 
outcome variable, whether cannabis has been used or not. If items not directly 
pertaining to hypotheses are included in the analysis utilising a binary outcome 
variable then this may result in miss-estimation of the other predictor variables.  
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Now suppose that a multilevel logistic or probit model has been estimated, 
and the fixed effect of some level-one [level three in the current study, the 
data entry level] variable Xr+1 is added to the model. One might think that 
this would lead to a decrease in the level-one residual variance σ2R. 
However, this is impossible as this residual variance is fixed, so that instead 
the estimates of the other regression coefficients will tend to become larger 
in absolute value and the intercept variance (and slope variances, if any) 
will also tend to become larger (Snijders and Bosker, 2012, p309). 
 
Thus, when utilising the xtmelogit routine a different strategy to analysing the data 
will have to be adopted. Initially all the relevant predictor variables will be 
considered within one model. The model will then be recomputed with any 
predictor variables identified as not achieving significance (at the 0.05 level) 
dropped from the analyses. Thus, this should help prevent mis-estimated odds 
ratios (O.R.) as a result of “[increasing] the random intercept variance and the 
effects of uncorrelated level [three] variables” (Snijders and Bosker, 2012, p321).  
 
Mis-estimation as a result of adding effects of level three variables is a 
methodological constraint that is common to all analyses that utilise regression 
and a binary outcome variable. One methodological disadvantage that is typically 
associated with most (micro) longitudinal data collection techniques such as ESM 
is the problem of missing data. The frequency of missing data elicited from ESM 
type research typically prohibits the use of other statistical procedures (than MLM) 
of modelling data structure such as that which can be applied with ANOVA and the 
related statistical procedures.  
 
In the current study missing data typically occurred in the form of missing the 
entirety of the items associated with a signal contingent prompt, referred to as unit 
missingness or non-response. This has been described as a “ubiquitous problem” 
with participants often displaying “intermittent missingness” (Rabe-Hesketh and 
Skrondal, 2012, p 278). Fortunately, utilising maximum likelihood estimation in 
instances where data is ‘Missing At Random’ (MAR) this ensures “that 
consistency…is retained for correctly specified models” and has the added 
advantage over “old-fashioned approaches to longitudinal data, such as MANOVA, 
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where subjects with any missing responses or covariates are discarded 
altogether…Using all available data does not waste information and is less 
susceptible to bias.” (Rabe-Hesketh and Skrondal, 2012, p 278). Thus, MLM is 
preferable to ANOVA related statistical procedures. However, utilising such an 
approach may introduce bias when data is not MAR, unfortunately such instances 
are difficult to identify. 
 
There were instances of missing values within data entries (item missingness), 
however, these were less frequent than non-response. Furthermore, item 
missingness did not appear to occur in any consistent patterns (See Table 20). In 
an attempt to glean information about variables which may predicate non-
compliance with the methodology or item reactivity participants that were included, 
and those that were not, were examined together for item missingness.  
 
Table 20 
Summary of missing data points of ESM data collected for both participants included 
and those not included in the main analyses  
Measure 
(number of 
items) 
Number of 
items with 
missing values 
(%) 
Responses without 
item missingness* 
(%) 
Most frequent 
pattern of 
missingness* (%) 
Minimum number 
of values in a row 
prior to prorating 
SSQ (22) 16 (73) 90 <1 15 
CSQ Stress (6) 6(100) 96 <1 4 
CSQ Calm (5) 5 (100) 96 <1 3 
Event Rating 
(1) 
n/a 90 10 n/a 
Stressful 
Events (1) 
n/a 95 5 n/a 
Pleasurable 
Events (1) 
n/a 94 6 n/a 
*Percentage of the items with missing values 
 
In instances of item missingness when these items contributed to a scale, a 
procedure of prorating was adopted. Thus, imputation was undertaken for the SSQ 
total, CSQ stress scale, and CSQ Calm scale. Prior to imputation participants must 
have attained a minimum number of values (see Table 20.). If these requirements 
were met a procedure of prorating from the mean score of the data was adopted. 
In the context of ESM research prorating using the grand mean (the mean of all 
responses for all participants on item x) or even participant mean (the mean of all 
responses on item x for the ith participant) is not appropriate as this is contrary to 
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the notion of a hierarchical data structure. If the grand mean or participant mean 
were the most appropriate value to prorate from this would invalidate the necessity 
for a multilevel analysis, as this would be based on the assumption that the mean 
of all participants data (grand mean), or all data from a given participant is the 
most related value. In the context of the assessment of variables which fluctuate 
from moment to moment, the most related data is that which is collected from the 
same person within the same time period.  Consequently, the mean of data 
collected at the same time point was utilised. For instance if one item was missing 
from day one, data entry one on the SSQ scale, the mean of all items from the 
same scale within the same data entry were pro-rated to the missing value. 
 
In this chapter (and Chapter 4) there are several figures displaying the fluctuation 
of variables over time. In all cases an inspection of all participants’ scores has 
been undertaken, however, given the volume of data it is impractical to display it 
here in its entirety. Instead, a subset of participants will be selected on the basis of 
their mean score over the ESM period, and their data for day number one (T1) will 
be displayed, this was a similar procedure to that adopted by Bolger & Laurenceau 
(2013). Participants scoring the highest within the 5th, 25th, 50th, 75th, and 95th 
percentile of the measures under assessment will be displayed graphically. 
However, the plotting of time in a figure and the utilisation of time as a variable or 
concept may introduce bias if caution is not applied.   
 
Methodological challenges of non-equidistant data entries 
Contained within this chapter there are several figures representing the fluctuation 
of the relevant ESM measures over time. It is suggested that one of the pre-
requisites for the utility of multi-level modelling is variability in the data (Snijder and 
Bosker, 2012, p153). Utilising a scatterplot it is possible to display variables 
according to time. In the instance where non-equidistant data inputs are utilised 
the creation of such a scatterplot may result in miss-estimation if each data input is 
considered as a unit of time. There are several advantages of non-equidistant 
prompts (see Section 3.2.1), however, one disadvantage is time is a proxy (rather 
like ranked data) as opposed to a true continuous variable. As a consequence of 
the limitations of utilising ranked data, for the scatterplots contained in this chapter 
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time will be considered on a scale of the number of minutes since that day’s first 
data entry, rather than ith data entry of that day.  
 
The limitations of ranked data do not only present a challenge when plotting 
responses, but may also result in miss-estimation of the statistical model. One 
means in which it is possible to circumvent this methodological limitation is to 
record the time at which participants submit their data and utilise this variable as 
the measure of time. 
 
Several analyses contained in this section have utilised items referring to the time 
period “since the last (data entry)”. Furthermore, variables which are time adjusted 
to refer to a previous as opposed to current data entry (a lagged variable) have 
been utilised. There are two types of time lagged variables utilised in this thesis, 
one which refers to the previous data entry (within the same day) this is denoted 
by the (post) superscript time – number of data entries (t-x), for example CSQ Calm 
t-1. The other type of lagged variable utilised herein is one which has had a day (24 
hour) time lag applied which is denoted by the (post) subscript Time – (number of 
days) e.g. CEQ-bT-1. By lagging data entries the effect of previous response and 
action on concurrent response can be measured, for example it is possible to 
predict the effect of a schizotypal state on future cannabis consumption.  
 
Non-equidistant time points do not just present methodological challenges for 
accurately plotting time, they can also introduce bias into analyses with both 
lagged and retrospective items. The use of these retrospective items is 
advantageous for recording both infrequent and enduring events such as cannabis 
consumption and its subsequent period of intoxication. Despite the utility of such 
items when utilised simultaneously as non-equidistant data entries they present a 
methodological challenge. One means by which this challenge can be addressed 
is to include the effect of time within the statistical model to be tested.  
 
Bolger and Laurenceau (2013) recommended “the influence of time should always 
be taken into account in your statistical model. That is time should be an explicit 
factor, or predictor, in any model of interest” (p27). The amount of minutes that 
have passed since the last data entry will be considered as a predictor in all 
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models that utilise retrospective or time-lagged items, within tables this variable is 
referred to as Time. This should help to negate the effect of the linear relationship 
between some of the predictor variables and time (e.g. amount of cannabis 
consumed since last entry and time since last entry). Consequently, it would be 
anticipated that all coefficients (betas) cited are in consideration of when the time 
difference is at a constant of zero. Thus, an attempt has been made to control for 
non-equidistant data entries. The efficacy of this adjustment (for the retrospective 
items) can be further increased by only including data points which have a 
completed response at the previous data entry. This will ensure that the time 
period in which the participant refers to does not span over two days or a non-
predetermined proportion of one day. It is important to note that other more 
sophisticated methods of accounting for non-equidistant entries have been 
reported such as the “spatial power error structure approach”, however, this 
method can currently only be administered on one platform (SAS) (Bolger and 
Laurenceau, 2013, p93).   
 
A cautionary note on causality and terminology 
Throughout this chapter reference is made to some commonly held theories, such 
as the ‘Self-Medication hypothesis’, the use of which is merely to signpost the 
relevant analyses to the reader. In the current study analyses have been 
conducted which will allow inferences to be made regarding said hypotheses, and 
the results obtained herein (in some instances) provide corroborating evidence. 
Nonetheless, all results must be considered in lieu of the literature discussed in 
the first chapter and the discussion contained within Section 3.4 and in no 
instances should be considered unequivocal support of said hypotheses.  
 
At the core of all MLM is a regression type analyses. As a consequence the 
terminology typically associated with regression analyses, specifically the phrase 
“predict”, is used throughout this thesis. However, the use of this terminology 
should not be mistaken to be an attribution of a causal inference. Establishing 
causality is very challenging (see Section 1.6) instances where causality can be 
inferred are typically reserved for studies that utilise an experimental design with 
manipulation of the dependent variables. The current study meets no such 
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requirement, as the relationships between the variables are being observed as 
opposed to directly (or indirectly) manipulated. Thus, the nature of the relationship 
between the ‘cause’ and the ‘effect’ is not established. 
 
However, one of the advantages of ESM research, as opposed to cross-sectional 
study design, is it does satisfy one of the key principles that is a pre-requisite for 
causal inference; temporal priority (see Section 1.6.4). By establishing the 
sequence of the occurrence of the variables one can observe the effect of an 
independent variable on a dependent variable at a future time point. Nonetheless, 
although temporal priority may be established on one scale there are likely several 
relevant scales of time which may influence factors. The current study does not 
establish temporal priority at micro- or macro- levels of the scale of time under-
investigation. For example, the current investigation does not measure second to 
second variability or, differences year on year. 
 
Furthermore, temporal priority is not the only consideration in establishing 
causality and once it is established there still may exist multiple plausible 
explanations for the association between the two variables. The possibility of a 
third (unmeasured) factor accounting for an association between a predictor and 
an outcome variable typically cannot be eliminated. Neither, can in some instances 
the possibility of a synergistic (self-maintaining) relationship between predictor and 
outcome. 
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3.3 Results 
The results comprise of several components the first of which sets out to describe 
the studies participant’s and their resultant data (Section 3.3.1 pp. 207 -13), in this 
section comparison is drawn between participants who were included in the final 
analysis with those who are not. Section 3.3.2 (pp. 214-17) describes briefly some 
of the analyses undertaken as means of validating the measures utilised in this 
investigation. The process of validation is described in more detail in Appendix 29. 
Section 3.2.8 (pp. 195-205) discusses the statistical procedures adopted in 
performing MLM. The main analyses are contained in sections 3.3.3 to 3.3.6 (pp. 
217-34). 
 
Section 3.3.3 relates to covariates of a schizotypal state, which will expand on the 
discussion pertaining to cannabis’ propensity to induce ‘psychosis proneness’. 
Furthermore, in this section there are also results pertaining to a stress cannabis 
interaction effect. Section 3.3.4 further explores the notion of a cannabis stress 
interaction for the most and least stressed participants in the sample. Section 3.3.5 
examines factors that co-vary with states of stress and calm which will further 
elucidate the relationship these variables have with schizotypal states. Analysis 
contained within this section will allow for inferences to be made about cannabis’ 
purported anxiolytic effect.  Section 3.3.6 assesses covariates of cannabis use, in 
this section the plausibility of the purported ‘self-medication’ of distressing 
symptoms related to psychotic disturbance is assessed.  
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3.3.1 Participant characteristics 
The current study consisted of two phases; the pre-ESM phase in which 
participants were required to complete a screening questionnaire online to assess 
their eligibility for participation; and the ESM phase.  One hundred and six 
participants began the pre-ESM measures, of those 86 participants completed the 
questionnaires. A total of 53 Participants (36 males) with a mean age of 27 years 
(SD 7.57) commenced the ESM phase of the study (for a description of inclusion 
and exclusion criteria see Section 3.2.2). After inclusion/exclusion criteria were 
applied, 36 participants (23 males) were considered in the final analysis.  
 
Research utilising Experience Sampling Methodology (ESM) typically follow 
guidelines to enhance the validity of the data. As is the procedure adopted by 
other researchers, the current study requires participants to have entered a 
minimum of 30% of the signal-contingent items, participants recording fewer than 
this figure are thought to be less reliable and thus excluded (Henquet et al., 2010; 
Wichers et al., 2007). Eleven participants recorded fewer than 25 valid signal-
contingent entries (30% of 84 opportunities for data entry) and consequently were 
not included in the main analysis. Furthermore, participants in the current study 
were required to have responded to the signal contingent prompts within a 30 
minute window to be considered valid, as any time period longer than this may no 
longer be considered a ‘momentary’ response (Scollon et al., 2003). Any 
responses outside of these 30 minutes were excluded from the analyses. The 
interval/action-contingent items (CEQ-b) were not subject to a minimum of 30% 
completion, however, all participants completed at least 3 of the 14 opportunities 
to record data. 
 
As the primary substance under investigation in this study is cannabis, participants 
were excluded if they had consumed any intoxicating substances other than 
cannabis, alcohol, nicotine and, caffeine at any point during the ESM phase. The 
frequency of alcohol, nicotine and caffeine consumption was sufficient in that it 
could be included, and thus controlled for as independent variables within the 
statistical models. Furthermore, “most joints contain tobacco” (EMCDDA, 2012, 
p119). That is to say that the majority of cannabis uses observed in this 
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investigation, and more broadly within the population; is the simultaneous use of 
cannabis and tobacco. Thus, to ensure the investigation is as naturalistic as 
possible tobacco use was permitted, as was caffeine and alcohol. 
 
However, the use of other psychoactive substances resulted in exclusion from the 
analyses. This will ensure that these chemicals do not act as potential confounding 
factors during the analyses. The instances of consumption of other psychoactive 
substances were too infrequent, and not measured precisely enough to accurately 
adjust for their effects within the analyses (i.e. include them within the statistical 
model). For example, a participant consuming a unidentifiable white powder 
described to them as a specific substance could be surreptitiously ingesting a 
number of different licit and illicit psychoactive chemical constituents (Kavanagh et 
al., 2010; Parrott, 2004).   
 
The rationale for excluding all (as opposed to a proportion of) data belonging to 
such participants is that it is difficult, if not impossible, to judge the period of 
intoxication or psychological disturbance induced. On this basis five participants 
were excluded, two for use of MDMA, one for use of amphetamine, one for use of 
“Magic mushrooms” and another for use of a combination of MDMA and cocaine. 
One other participant documented MDMA use however, they had submitted 
sufficient data (see above) prior to the event and consequently data up until that 
time point (day 8 [T 8]) was included in the main analyses. Another participant was 
also excluded from the main analyses as they had recently started a course of 
medication commonly prescribed to treat mental illness (fluoxetine). As there was 
not enough available data regarding the interaction between cannabinoids and 
SSRIs, this participant’s data cannot be considered comparable with the rest of the 
sample. 
 
There are several methods by which comparison could be drawn between the 
participants included in the final sample and those not included. Comparison could 
be made between those participants included and those that completed the 
screening phase, but did not initiate the ESM phase. Alternatively comparison 
could be drawn with a (more) general population of cannabis users by utilising the 
dataset described in Chapter 2. However, comparison will be drawn between 
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participants that completed the ESM phase and those that initiated, but did not 
complete the ESM phase. The decision to draw comparison between these two 
groups is based on cannabis’ purported propensity to elicit an ‘amotivational 
syndrome’, which is still a relevant area of research today (Barnwell, Earleywine, 
and Wilcox, 2006). Due to the demanding nature of the current study utilising a 
methodology which is not commonly applied to this population (see Kimhy et al., 
2009), it was important to ascertain if heavy cannabis use was a factor 
determining inclusion in the current study. If inclusion was partially determined by 
a ‘ceiling effect’ of intoxication or chronicity of use (i.e. those that were heaviest or 
longest standing users being less likely to complete the study) then this would bias 
the sample and reduce the generalisability of the findings from the study. 
However, it is important to note that if amotivation is a factor influencing 
participation, then this may reduce the likelihood that some members of the 
population will volunteer to initiate the pre-ESM phase. 
 
Consequently, participants who had initiated the ESM phase, but were not 
included in the main analyses were compared to those included. The 
characteristics of the participants are shown in Table 21 and Table 22. From Table 
21 it can be seen that the participants did not significantly differ by gender (χ2 (1) 
= 0.84, p = .36). Nor did the two groups of participants differ by age. Participants 
were allocated into three groups, currently employed, in education or training, and 
Not in Education Employment or Training (NEET). Participants that were included 
did not significantly differ in employment status from those who were not included 
(χ2 (2) = 0.92, p = .16).  
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Table 21 
Socio-demographic data and cannabis use information sorted by participants who 
were included in the main analyses and those who were not  
Variable  Excluded (%) Included (%) Total (%) 
Gender 
Female 4 (23.5) 13 (36.1) 17 (32.1) 
Male 13 (76.5) 23 (63.8) 36 (67.9) 
Employment status 
Student 4 (23.5) 7 (19.4) 11 (20.8) 
Employed 9 (52.9) 21 (58.3) 30 (56.6) 
NEET 4 (23.5) 8 (22.2) 12 (22.6) 
Preparation 
Hash 1 (5.9) 3 (8.3) 4 (7.6) 
Sinsemilla 14 (82.4) 31 (86.1) 45 (84.9) 
Traditional herbal 
cannabis 
2 (11.8) 2 (5.6) 4 (7.6) 
Cannabis oil 0 0 0 
Don’t know 0 0 0 
Social context 
On their own 0 0 0 
Socially 4 (23.5) 4 (11.1) 8 (15.1) 
Both 13 (76.5) 32 (88.9) 45 (84.9) 
 
A Levene (1960) test was conducted to assess homogeneity of variance of age 
and cannabis exposure as assessed prior to the ESM phase of the research. 
Neither age, expenditure, number of uses in lifetime, frequency of use, age of first 
use, nor age the participant first became a monthly cannabis user  were shown to 
have unequal variances. Due to the number of variables that would have to be 
controlled and measured (e.g. ratios of the >80 cannabinoids, mass, method of 
administration etc. see Section 1.4) it is very difficult to accurately assess 
consumption. One means in which consumption can be assessed is by taking a 
measure of several indices of factors related to consumption.  To this end, a 
measure of consumption was constituted derived from values for expenditure, 
frequency of use and number of times used, these scores were derived from the 
data of both those included and not included in the main analyses. This method of 
measuring consumption has been shown to have validity as evinced by self-
reported current ketamine users producing significantly higher mean scores in 
comparison to former users (Stirling et al., 2012). All scores on theses indices 
were converted into a percentile, to ensure that the data is normally distributed 
and not influenced by any outlying data points. These percentiles were then 
converted to a Z-score to provide ‘standardised’ scores, before the indices outlined 
previous were combined providing a measure of ‘consumption’. 
 
Independent samples t-tests were conducted to ascertain if there was a significant 
difference between the variables outlined above for those that were included, and 
those who were not included in the main analysis.  There was no significant 
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difference in self-reports of expenditure, number of lifetime uses, current frequency 
of use, or consumption. Participants did differ significantly according to self-reports 
of age of first use (p = 0.02) and there was a trend difference (p = 0.06) in the age 
at which the two groups reported becoming monthly users. These findings indicate 
that participants in the group not included were significantly more likely to initiate 
cannabis use at a younger age and the trend difference indicates that they were 
also more likely to become ‘monthly’ cannabis users earlier than those included in 
the final analyses. 
 
There is likely to be a very strong relationship between age at which cannabis use 
was initiated and age at which use at least once monthly was common place. 
Thus, given that the t-tests performed were both two tailed, and the arbitrary 0.05 
p value has been applied if the two findings are considered unilaterally this could 
result in a type 2 error, incorrectly accepting the null hypothesis. The effect size for 
age of cannabis initiation (d = 0.66) and the effect size of age of monthly cannabis 
use (d = 0.54) both exceed Cohen’s (1998) convention for a medium effect size. 
Given the lack of independence between the variables and the infeasibility of using 
a repeated measures design to collect such data the two effect sizes cannot be 
combined. Nonetheless, when considered simultaneously there could be said to 
be an effect of age with participants that were not included initiating cannabis use 
younger and becoming regular users sooner than their counterparts. 
Unfortunately, there is not enough available data to estimate what the impact of 
this group difference is, this may or may not be influential in creating a sampling 
bias. However, it is important to note that the other indices of cannabis 
consumption did not differ, at even trend significance, between the two groups.  
 
Included and excluded participants were tested for difference on other aspects of 
their cannabis use (see Table 21). Participants were asked to document the social 
context of their cannabis use, if they typically consumed cannabis either on their 
own; socially; or both on their own and socially. Participants that were included 
and those that were excluded did not significantly differ in social context of 
cannabis use (χ2 (2) = 1.39, p = .24). Nor, did participants significantly differ in the 
typical preparation of cannabis they consumed (χ2 (4) =0.70, p = .70). Assertions 
that sinsemilla is the most commonly used preparation in the U.K. (see Section 
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1.4) are borne out in the data with the vast majority of participants (84.91 %) 
reporting that it was their most frequently used cannabis preparation. 
 
The majority of the 36 participants (23 males) included in the main analyses were 
employed (see Table 21). They had a mean age of 28 (SD 8.001, minimum 18) 
and the participants typical cannabis use information is described in Table 22. Out 
of the possible total of 3024 (84 per participant) of the signal contingent-prompts 
they completed 1487 data entries, a minimum of 25 each, with a mean of 41.31 
entries each and a median of 37. The included participants recorded some 175 
entries that fell outside of the 30 minute time envelope an average of 4.86 per 
participant. In the moments preceding each data entry this group made there 
were, 734 reports of cannabis use, a mean of 20.39 per participant over the 14-
day period. Out of the 722 reports on methods of administration, 84.21% of 
cannabis uses documented were combined with tobacco and smoked, and 
15.79% was the use (through combustion) of solely cannabis. There were no 
documented uses of a vaporiser as a method of administration, neither was oral 
consumption of cannabis reported. Reports of some 1590 units of cannabis were 
documented in the investigation, which is a mean of 2.20 units per (cannabis 
using) observation. Of the interval-contingent measure (CEQ-b), which was also 
cannabis use dependent, the included participants completed 299 out of a 
possible 504 completing a mean of 8.31 entries each. 
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Table 22 
Measures of central tendency, equality of variance and t - tests of differences in  age and cannabis use information drawing comparison 
between those included and those not included in the main analyses  
 
Levene’s 
F value 
(DF) 
p. of 
F-
value 
Participants included in the main analysis Participants not included in the main analysis 
t-
value 
(DF) 
p. of 
t-
value 
Mean 
(SD) 
Within percentile Range 
Mean  
(SD) 
Within percentile Range 
25
th
 50th 75th Min Max 25th 50th 75th Min Max 
Age (years) 
0.180 
(1, 51) 
.67 
27 
(8.06) 
23 25 30 20 61 25 (6.60) 21 24 25 18 42 
1.042 
(51) 
.30 
Expenditure (£ 
per week) 
1.516 
(1, 50) 
.22 
>30 
<50 
>20 
<30 
>30 
<40 
>50 
<60 
>10 
<20 
>80 >20 <40 
>20 
<30 
>20 
<30 
>50 
<60 
<2.5 >80 
0.676 
(50) 
.50 
No. of lifetime 
uses 
2.765 
(1, 48) 
.10 
20922 
(32794
) 
1500 5785 18000 100 
1000
00 
13229 
(24639)# 
2500 6000 10000 18 
1000
00 
0.833 
(48)# 
.41 
Current 
frequency of 
use 
0.784 
(1, 51) 
.38 
>once 
a week 
< every 
day 
>once 
a week 
Every 
day 
Every 
day 
Twice 
a 
month 
Every 
day 
> once a 
week < 
everyday 
Every 
day 
Every 
day 
Every 
day 
Once 
a 
week 
Every 
day 
0.518 
(51) 
.61 
Age of first 
use (years) 
0.102 
(1, 50) 
.75 
15 
(2.12) 
14 15 16 11 20 
13 
(2.10) 
11.5 14 15 10 17 
2.349 
(50) 
.023 
Age of 
monthly use 
(years) 
0.007 
(1, 51) 
.93 
16 
(2.60) 
14.5 16.5 18 13 22 
15 
(2.46) 
13 16 17 11 18 
1.945 
(51) 
.057 
Consumption 
0.060 
(1, 47) 
.81 
0.176  
(1.98) 
-1.043 0.621 1.537 -5.072 3.419 
-0.210 
(2.28) ~ 
-
0.864 
0.133 1.576 
-
5.544 
3.046 
-
0.605 
(48) 
~ 
.59 
#One anomalous value excluded; z-score = 6.91, within the 99.99
th
 percentile. 
~ 95% confidence interval includes 0 
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3.3.2 Validating the ESM measures 
Participants were encouraged to complete the validation measures (WSI and a re-
test of the PSI). For analyses utilising the PSI, the data from those that had been 
included and those that had not, were considered in this analysis. The PSI was 
administered in a cross-sectional study design, and thus has been utilised with 
uni-level statistical procedures. Therefore, for analyses utilising this measure the 
same rigorous inclusion and exclusion criterion utilised for MLM is not adopted. 
Any participant considered eligible to commence the ESM phase of the 
investigation was also considered eligible for participation in the validation 
process. The first administration of the PSI was prior to the ESM-phase (T0, See 
Table 19) thus, all data collected at this phase was considered eligible for inclusion 
in this investigation (N=53). 
 
Validating measures of a schizotypal state 
Participants were assessed for schizotypal state utilising an adapted version of the 
SPQ-b (see Section 2.2.3).  Prior to this investigation the validity and reliability of 
such an adapted version of the SPQ-b had not been assessed. Prior to the 
commencement of the ESM phase all participants completed the SSQ and the 
PSI.  A Pearson’s r was computed to assess the relationship between the total 
score on the SSQ and the total score on the PSI. There was a strong positive 
correlation between the two variables (r = 0.63, n = 51, p < .001), furthermore the 
majority of the subscales displayed a significant positive correlation between each 
other (for correlation matrix see Appendix 29). The SSQ was also assessed for 
internal reliability displaying good internal reliability (22 items; α = 0.91). Upon 
inspection of the subscales the Cronbach’s alpha for the eight item Cognitive 
subscale (α = 0.79), the six item disorganised subscale (α = 0.76), and the eight 
item interpersonal subscale (α = 0.88) were all acceptable (Nunnally,1978). Whilst 
performing Cronbach’s alpha tests of the SSQ and subscales in no instance would 
item elimination have served to elevate alpha. 
 
On the fourth day of the study participants were requested to complete the PSI for 
a second time. Once more, the SSQ total displayed a strong positive relationship 
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with the PSI total (r = 0.82, n = 37, p < .001) and a similar relationship was found 
between the subscales (See Appendix 29). The results displayed within this 
section provide supporting evidence for convergent validity, test-retest reliability 
and internal reliability of the SSQ and its subscales. 
 
Validating momentary measures of stress and calmness 
In addition to testing the reliability and validity of the SSQ items it was also 
necessary to examine the measures of feelings of stress and feelings of calm. The 
WSI provides scores on two scales, an events scale to ascertain the number of 
stressful incidents, and an impact scale to assess the consequence of these 
events. It was anticipated that a measure of stress and one of calm would display 
convergent validity with the impact and event scale. In order to assess the 
adequacy of the measures at predicting the amount of stress a participant reports 
in one week of the ESM investigation, participants were tested to establish to what 
extent the measures under assessment co-vary with scores on the WSI.  
 
The CSQ consists of eleven items pertaining to concurrent feelings of stress, and 
concurrent feelings of calmness. The two constructs are considered as 
independent, i.e. feeling calm and feeling stress do not exist along a continuum 
and all combinations of high and low scores could potentially co-occur. For further 
information as to why this approach was adopted see Appendix 29. Therefore, the 
CSQ was considered as consisting of two independent scales, six items assessing 
stress and five items assessing calmness referred to as CSQ Stress and CSQ 
Calm respectively. 
 
This analysis was performed in-line with the procedures outlined in section 3.2.8. 
Of the participants (N=29) who completed the WSI, seventeen of them completed 
both the first and second week, consequently the WSI was completed forty-six 
times. There was no significant association between either CSQ Calm or CSQ 
Stress with the WSI Event scale (see Appendix 29). There was also no significant 
association between CSQ Calm and the WSI Impact, however, CSQ Stress did 
significantly co-vary with the scale (b = 0.21, 95% CI 0.07 to 0.35, p = .004). 
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The analysis conducted in this section provides evidence of the CSQ Stress’ ability 
to identify concurrent stress, as evinced by its covariance with weeks in which 
stressors have had a large impact on the participant’s perception of stress. This 
finding demonstrates convergent validity thus substantiating the utility of the CSQ 
Stress scale for assessing concurrent stress throughout this investigation. 
Furthermore, the findings outlined above demonstrate evidence of the 
independence of concurrent experiences of calmness and concurrent experiences 
of stress, further vindicating the approach to scoring the relevant measures (see 
Appendix 29 for further information). 
 
Validating event related items  
In addition to utilising the WSI to assist with the validation of the CSQ, the WSI 
was also used in the consideration of the validity of items associated with stressful 
and pleasurable events. Three independent retrospective items (‘Since the last 
data entry..’); one requesting the participant to rate their most important event 
(Event Rating, ER); another requesting participants report the number of 
pleasurable events (PE) that have happened; and a third enquiring as to the 
number of stressful events (SE). ER, SE and PE were not significant covariates of 
the WSI event scale (see Appendix 29), nor, did they significantly co-vary with 
scores on the WSI Impact scale. 
 
As a means of making inferences about the validity of the aforementioned items 
participants were assessed for convergent response between the ESM measures. 
It would be anticipated that the (stressful/pleasurable) evaluation of events would 
predict scores on measures of concurrent stress and concurrent calm. 
Consequently, ER, SE, and PE were tested for covariance with the CSQ scales 
(outcome variable). Concurrent measures of stress and calm were simultaneously 
administered with retrospective measures of stressful and pleasurable events, 
thus it is feasible to use data from within one data entry to observe the relationship 
between the aforementioned variables. Additionally, time was considered as a 
covariant within the model (see Section 3.2.8).  
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ER, PE, and SE, were tested as predictors of CSQ Stress and CSQ Calm 
(Appendix 29). Both ER (b = -0.42, 95% CI -0.59 to -0.24, p < .001) and SE (b = 
2.03, 95% CI  1.78 to 2.27, p < .001) were significant covariates of the CSQ Stress 
scale. A one unit increase in ER resulted in a decrease of 0.42 units of the CSQ 
stress and a unit increase in SE resulted in a 2.03 unit increase in the outcome 
variable. PE did not significantly increase scores in the CSQ Stress. However, all 
explanatory variables assessed, with the exception of time, were significant 
covariates of scores on CSQ Calm.  In assessment of CSQ Calm as the outcome 
variable; a one unit increase in ER resulted in an increase of 0.67 units (b = 0.67, 
95% CI 0.44 to 0.90, p < .001); a unit increase in SE resulted in a 1.78 unit 
decrease (b = -1.78, 95% CI -2.10 to -1.46, p < .001); and a unit increase in PE 
equated to an increase of 0.73 (b = 0.73, 95% CI 0.47 to 1.00, p < .001). These 
results provide evidence of convergent validity between measures of concurrent 
stressed and calm states, and previous stressful and pleasurable events, as well 
as an evaluation of the most important event.   
 
3.3.3 Covariates of a Schizotypal State 
The first aim of this chapter is partially fulfilled by the examination of scatterplots of 
scores on the SSQ. The aim sought to establish whether schizotypy has state like 
components that are altered by cannabis intoxication. Further evidence 
contributing to this aim is displayed later on in this section (in addition to Section 
3.3.4 pp. 227-29). The second aim of this chapter is also partially fulfilled by 
analyses considered in this section (3.3.3). The second aim of this investigation 
was to assess temporal priority in the relationship between cannabis and psychotic 
experience in a naturalistic setting. This aim is also addressed in Section 3.3.6 
(pp. 234-38), in which predictors of cannabis use are assessed. The third aim of 
this chapter sought to assess the effect of a stressed and calm state on psychotic-
like states utilising a cannabis challenge to facilitate a model of psychosis. Aim five 
of this chapter is also addressed in this section, in addition to the next section 
(3.3.4). This aim sought to assess the plausibility of an interaction between 
cannabis and psychological stressors on psychotic (like) experience. 
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Fluctuations in schizotypy over time 
In order to illustrate trends using data from individual participants, five were 
selected on the basis of their mean score on the SSQ over the ESM-phase, at the 
5th, 25th, 50th, 75th and, 95th percentile. These participant’s scores on the first day 
of the study were plotted in a graph (see Figure 9) it was anticipated that the SSQ 
would show little moment to moment variability, due to the fact that the SSQ is an 
adapted version of a measure of a trait. Nonetheless, there was variability both 
within and between participants.  
 
Figure 9  
Scatterplots of a subset of participants displaying  the variability of a schizotypal 
state over t ime 
  
Covariates of the Schizotypal States Questionnaire (SSQ) 
The analyses considered within this subsection are subsumed in Table 23. It has 
been hypothesised that stress may be a developmental antecedent of psychotic 
disorder (see section 1.2.3), to test this notion it was sought to establish what, if 
any, relationship exists between schizotypal state and concurrent perceptions of 
stress and feelings of calm. Concurrent stress as assessed by the CSQ Stress 
was a significant covariate of scores on the SSQ (b = 0.54, 95% CI 0.35 to 0.73, p 
< .001), each unit increase on CSQ stress resulted in an increase of 0.54 on the 
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SSQ total, indicating that states of stress significantly co-vary with schizotypal 
states. However, no significant relationship was observed between the CSQ Calm 
and the SSQ total (b = -0.06, 95% CI -0.20 to 0.080, p = .41). This indicates that 
concurrent feelings of calm do not serve to have an antagonistic relationship with 
stress, thus vindicating the approach taken to stress-calm dichotomy. No 
significant effect was found of ER, SE, nor PE indicating that the perception of 
previous stressful or pleasurable events does not influence a schizotypal state. 
This finding does not concur with that of Docherty et al. (2009) which suggests that 
the occurrence of potentially stressful life events predicted increases in psychotic 
symptoms in patients with a diagnosis of schizophrenia. However, the time frame 
under consideration in Docherty and colleagues investigation is not comparable to 
that of the current investigation. 
 
Within the same statistical model the effect of cannabis consumption on a 
schizotypal state was observed. Cannabis consumption per se (b = 1.04, 95% CI 
0.34 to 1.74, p = .004) was found to have a highly significant effect, with cannabis 
consumption since the previous data entry predicting a 1.04 unit increase on the 
SSQ total. The model simultaneously considered caffeine, tobacco and alcohol, 
thus the effect of cannabis on SSQ can be considered to be independent of these 
variables, none of which were significant covariates of the SSQ. The notion of an 
interaction effect can be tested by utilising the CXS variable which, considers both 
stress and cannabis consumption. The CXS variable was a significant covariate of 
the SSQ total (b = 0.33, 95% CI 0.17 to 0.49, p < .001). This indicates a significant 
interaction effect of cannabis and stress on schizotypal state, independent of the 
main effects of the variables. 
 
The other variable considered within this model was (time) minutes since last data 
entry, which was found to be statistically significant (b = -0.006, 95% CI -.010 to -
.0007, p = .026). Each unit (minute) increase from the mean score, predicted a 
decrease of 0.006 on the SSQ total. To rephrase, the further apart data entries 
were the greater likelihood of a decrease in SSQ total. This finding could be as a 
result of reactivity to the methodology, the task of having to answer questions with 
regards to schizotypy too frequently in fact could be independently influencing 
scores on schizotypy. 
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The current investigation also sought to test if the relative quantity of cannabis 
consumed rather than cannabis consumption per se was a significant covariate of 
the SSQ Total. A separate model was generated to consider the effect of quantity 
of cannabis consumed to avoid any occurrence of collinearity. As the variable CXS 
requires the consideration of cannabis consumption within the same model, CXS 
was also omitted. For brevity (and to avoid repetition) the results of this model are 
not included in the main body of this thesis and are instead displayed in Appendix 
30. A dose dependent relationship was observed within participants (b = 0.44 95% 
CI 0.125 to 0.754, p = .006), for every unit of cannabis consumed there was an 
increase of 0.44 on the SSQ total. This indicates that cannabis appears to have a 
dose dependent relationship with schizotypy, the more cannabis consumed the 
more likely a participant was to have an elevated schizotypal state.  
Table 23 
Parameter estimates for multilevel model of schizotypal state ( SSQ total) as a 
function of states of stress, states of calm, stressful events, pleasurable events, 
cannabis consumption per se and a cannabis-stress interaction 
Fixed effect (intercept, 
slopes) 
Estimate (SE) Z
 
P
 95% CI 
Lower Upper 
Intercept 14.278 1.836 7.78 <.001 10.680 17.876 
CSQ Stress 0.536 0.097 5.53 <.001 0.346 0.726 
CSQ Calm -0.058 0.070 -0.82 .412 -0.196 0.080 
Event Rating (ER) -0.127 0.207 -0.61 .539 -0.534 0.279 
Stressful Events (SE) -0.011 0.328 -0.03 .974 -0.654 0.632 
Pleasurable Events 
(PE) 
0.342 0.245 1.40 .163 -0.138 0.821 
Cannabis Consumed 1.039 0.358 2.90 .004 .337 1.741 
Cannabis X Stress 0.330 0.081 4.05 <.001 0.170 0.489 
Caffeine 0.096 0.183 0.53 .597 -0.261 -0.454 
Tobacco -0.259 0.227 -1.14 .255 -0.704 0.187 
Alcohol 0.322 0.208 1.55 .122 -0.086 0.730 
Time -0.006 0.002 -2.23 .026 -0.010 -0.0007 
Random effects ([co-
]variances) 
 Estimate (SE) ICC (%) 
95% CI 
Lower Upper 
Level 1 Intercept 118.733 28.749 83.955 73.870 190.843 
Level 2 Intercept 10.706 1.497 7.570 8.139 14.082 
 Residual 11.986 0.793  10.528 13.646 
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Covariates of the SSQ subscales 
The relationship between the aforementioned predictor variables and the SSQ can 
be further explored through the examination of the sub scales of the SSQ. The 
SSQ is based on the SPQ which consists of 3 subscales pertaining to ‘distortions’ 
within the realms of cognitive-perceptual (8 items), interpersonal (8 items), and 
disorganisation (6 items). The model described above (Table 23) was re-computed 
with the SSQ subscales considered as the out-come variables. The cognitive-
perceptual subscale is displayed in Table 24, the disorganised subscale is in Table 
25 and the interpersonal subscale is in Table 26. 
 
In further examination of the SSQ Cognitive perceptual subscale it was found that 
CSQ Stress was a significant covariate, with each unit increase on the predictor 
variable accounting for a rise of 0.22 in the outcome variable (b = 0.22 95% CI 
0.16 to 0.28, p < .001). Neither, CSQ Calm, ER nor SE produced a significant 
effect on SSQ Cognitive Perceptual scale. However, PE did have a significant 
relationship with the SSQ subscale (b = 0.21 95% CI 0.05 to 0.36, p = .009), with 
each unit increase on PE accounting for an increase of 0.21 on the subscale. This 
is in the opposite direction to that hypothesised; the rationale behind this finding is 
not clear. One feasible explanation is that the participants are considering a 
variable which appears highly related to the SSQ as a pleasurable event; cannabis 
use. Neither, caffeine, tobacco, alcohol, nor interestingly cannabis consumption 
per se had a significant effect on the cognitive perceptual subscale. Thus, no 
evidence has been found of cannabis eliciting psychotic-like states within this 
domain. Despite the significant effect of CSQ stress on subsequent SSQ cognitive 
perceptual scores, no such relationship was found between a cannabis stress 
interaction and the SSQ subscale. Furthermore, no evidence of a within participant 
dose dependent effect was found (b = 0.04 95% CI -0.06 to 0.143, p = .41). The 
lack of influence of cannabis consumption, cannabis dose, and cannabis stress 
interaction, on the cognitive perceptual scale in light of the findings in Chapter 2 
might indicate that cannabis does not induce the schizotypal features most 
predictive of psychotic vulnerability. 
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Table 24 
Parameter estimates for multilevel model of cognitive perceptual distortions 
(outcome) as a function of states of stress, states of calm, stressful events, 
pleasurable events, cannabis consumption per se and a cannabis -stress interaction 
Fixed effect (intercept, 
slopes) 
Estimate (SE) Z
 
P
 95% CI 
Lower Upper 
Intercept 4.033 0.705 5.72 <.001 2.651 5.414 
CSQ Stress 0.216 0.031 6.97 <.001 0.155 0.277 
CSQ Calm 0.033 0.023 1.45 .148 -0.012 0.077 
Event Rating (ER) -0.005 0.067 -0.07 .940 -0.137 0.127 
Stressful Events (SE) -0.011 0.106 -0.10 .919 -0.218 0.197 
Pleasurable Events 
(PE) 
0.208 0.079 2.62 .009 0.052 0.363 
Cannabis Consumed 0.055 0.117 0.47 .639 -0.174 0.283 
Cannabis X Stress 0.021 0.027 0.81 .420 -0.031 0.073 
Caffeine -0.015 0.059 -0.26 .797 -0.132 0.101 
Tobacco -0.066 0.074 -0.90 .369 -0.211 0.078 
Alcohol 0.011 0.067 0.16 .874 -0.122 0.143 
Time -0.0009 0.0008 -1.11 .269 -0.002 0.0007 
Random effects ([co-
]variances) 
 Estimate (SE) ICC (%) 
95% CI 
Lower Upper 
Level 1 Intercept 17.42 4.229 88.963 11.028 28.221 
Level 2 Intercept 0.880 0.132 4.438 0.656 1.180 
 Residual 1.309 0.085  1.152 1.486 
 
The SSQ subscale pertaining to interpersonal distortion was also tested with the 
aforementioned predictor variables. The CSQ Stress variable was a significant 
covariate of the interpersonal scale of the SSQ (b = 0.20 95% CI 0.09 to 0.30, p < 
.001), each unit increase on the CSQ scale predicted an increase of 0.20 on the 
interpersonal distortion subscale. CSQ Calm was also a significant covariate on 
the SSQ interpersonal subscale (b = -0.09 95% CI -0.16 to -0.11, p = .024), each 
unit increase on the Calm scale predicted a decrease of 0.09 on the interpersonal 
subscale. 
 
None of the other predictor variables were significant covariates of the 
interpersonal subscale, with the exception of the variables pertaining to cannabis 
use. Cannabis consumption per se was a significant covariate (b = 0.59 95% CI 
0.20 to 0.98, p = .003), cannabis use predicted an increase of 0.59 in the SSQ 
interpersonal scale. The variable accounting for a cannabis stress interaction was 
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also a significant covariate of the SSQ interpersonal subscale (b = 0.18 95% CI 
0.09 to 0.27, p < .001), each unit increase on the CXS predicted an increase of 
0.18 on the outcome. These findings indicate that interpersonal distortions appear 
to be influenced by both stress and cannabis consumption independently, and an 
interaction between stress and cannabis. In an alternative model considering 
quantity of cannabis consumption a dose dependent effect was established (b = 
0.24 95% CI 0.07 to 0.42, p = .006), with each unit of cannabis predicting a 0.25 
increase on the SSQ subscale (see Appendix 31). 
 
Table 25 
Parameter estimates for multilevel model of interpersonal distortions (outcome) as a 
function of states of stress, states of calm, stressful events, pleasurable events, 
cannabis consumption per se and a cannabis-stress interaction 
Fixed effect (intercept, 
slopes) 
Estimate (SE) Z
 
P
 95% CI 
Lower Upper 
Intercept 6.067 0.764 7.94 <.001 4.569 7.565 
CSQ Stress 0.196 0.053 3.71 <.001 0.092 0.300 
CSQ Calm -0.087 0.039 -2.26 .024 -0.163 -0.011 
Event Rating (ER) 0.029 0.114 0.25 .803 -0.196 0.254 
Stressful Events (SE) 0.007 0.180 0.04 .971 -0.347 0.360 
Pleasurable Events 
(PE) 
-0.170 0.134 -1.26 .207 -0.433 0.094 
Cannabis Consumed 0.587 0.198 2.96 .003 0.198 0.975 
Cannabis X Stress 0.177 0.045 3.92 <.001 0.088 0.265 
Caffeine 0.052 0.101 0.51 .607 -0.146 0.250 
Tobacco -0.142 0.125 -1.13 .257 -0.388 0.104 
Alcohol 0.112 0.115 0.97 .330 -0.114 0.338 
Time -0.002 0.001 -1.41 .157 -0.005 0.0008 
Random effects ([co-
]variances) 
 Estimate (SE) ICC (%) 
95% CI 
Lower Upper 
Level 1 Intercept 20.291 5.001 75.505 12.518 32.893 
Level 2 Intercept 2.836 0.432 10.511 2.103 3.823 
 Residual 3.747 0.250  3.287 4.272 
 
The predictor variables utilised in the previous analyses were tested with the SSQ 
disorganised subscale as an outcome. CSQ Stress was a significant covariate of 
the disorganised subscale (b = 0.14 95% CI 0.07 to 0.20, p < .001). Each unit 
increase on CSQ Stress scale predicted a 0.14 increase on the disorganised 
subscale. Item ER was found to be a significant covariates of the SSQ 
disorganised subscale (b = -0.15 95% CI -0.29 to -0.004 p = .045). Similarly, PE 
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was also found to be a significant covariate of SSQ disorganised scale (b = 0.30 
95% CI 0.13 to 0.46, p = .001). A unit increase on ER predicted a 0.15 decrease 
on the SSQ disorganisation subscale. The more unpleasant the most significant 
event was the more likely a participant is to have a decrease in the SSQ subscale. 
However, a one unit increase in PE predicted a significant 0.33 increase in the 
disorganisation subscale, this was not anticipated. As discussed previously this 
could be as a consequence of the participant considering cannabis consumption 
or activities surrounding cannabis consumption (e.g. socialising) as pleasurable.  
 
Alcohol consumption was also a significant covariate of the SSQ disorganisation 
scale (b = 0.20 95% CI 0.06 to 0.35, p = .006), each unit accounting for an 
increase of 0.20 in the outcome variable. Alcohol consumption has been shown to 
be an antecedent of psychotic episode (APA, 2013a, p.502), and is known to elicit 
psychotic symptoms during withdrawal (APA, 2013a, p.499). The effect of alcohol 
within the statistical model is considered independent of cannabis, however, given 
that the sample were all cannabis users the possibility of an interaction between 
cannabis and alcohol at a neuropharmacological level cannot be excluded. Thus, it 
is difficult to extrapolate these findings to non-cannabis using populations. 
Nonetheless, other investigations have also noted a relationship between alcohol 
consumption and elevations in schizotypal trait (Esterberg et al., 2009). The 
number of minutes that had elapsed since the last data entry was also found to be 
a significant covariate of the SSQ disorganised subscale (b = -0.003 95% CI -
0.004 to -0.001, p = .002). Each minute (unit) increase above the mean predicted 
a reduction of 0.002 on the subscale. This finding indicates that as the study 
requires a greater intensity (data entries x time) of response this corresponds to an 
elevation of scores on the disorganisation scale of the SSQ.  
 
Cannabis consumption per se was also a significant covariate of the 
disorganisation subscale (b = 0.41 95% CI 0.16 to 0.66, p = .001), with the 
independent variable predicting a 0.41 unit increase in scores on the SSQ 
disorganisation subscale (see Section 3.4 for further discussion). A significant 
effect of a cannabis and stress interaction was also observed (b = 0.12 95% CI 
0.07 to 0.18, p < .001), with each increase of a unit on the CSQ stress scale when 
combined with cannabis use per se predicting an increase of 0.12 in the 
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disorganisation subscale. In an alternative model quantity of cannabis consumed 
was a significant covariate of the disorganised subscale (within participants) (b = 
0.16 95% CI 0.04 to 0.27, p = .006), each unit of cannabis consumed predicted an 
increase of 0.16 on the outcome variable (see Appendix 32). 
 
Table 26 
Parameter estimates for multilevel model of distortions of disorganisation (outcome) 
as a function of states of stress, states of calm, stressful events, pleasurable events, 
cannabis consumption per se and a cannabis-stress interaction 
Fixed effect (intercept, 
slopes) 
Estimate (SE) Z
 
P
 95% CI 
Lower Upper 
Intercept 4.164 0.562 7.40 <.001 3.061 5.266 
CSQ Stress 0.137 0.034 4.06 <.001 0.071 0.203 
CSQ Calm -0.008 0.025 -0.30 .761 -0.056 0.041 
Event Rating (ER) -0.147 0.073 -2.01 .045 -0.291 -0.004 
Stressful Events (SE) -0.012 0.115 -0.11 .916 -0.238 0.214 
Pleasurable Events 
(PE) 
0.295 0.086 3.43 .001 0.127 0.464 
Cannabis Consumed 0.410 0.127 3.24 .001 0.162 0.659 
Cannabis X Stress 0.122 0.029 4.25 <.001 0.066 0.179 
Caffeine 0.062 0.065 0.96 .338 -0.065 0.188 
Tobacco -0.047 0.080 -0.58 .559 -0.204 0.110 
Alcohol 0.202 0.074 2.75 .006 0.058 0.346 
Time -0.003 0.0009 -3.16 .002 -0.005 -0.001 
Random effects ([co-
]variances) 
 Estimate (SE) ICC (%) 
95% CI 
Lower Upper 
Level 1 Intercept 11.096 2.696 80.823 6.891 17.864 
Level 2 Intercept 1.089 0.178 7.931 0.790 1.501 
 Residual 1.544 0.105  1.351 1.764 
 
In this section a stressed state was a significant positive covariate of a schizotypal 
state and the three subscales. Furthermore, the CSQ Calm was a significant 
negative covariate of the interpersonal subscale of the SSQ. However, the CSQ 
Calm did not significantly predict scores on the SSQ total score, the cognitive-
perceptual subscale and the disorganised subscale. This indicates that stress 
serves to elevate schizotypal states within several domains, however states of 
calm can only attenuate this effect within a restricted area of psychotic experience. 
There is also evidence herein suggesting the consumption of cannabis serves to 
predict scores on measures of a schizotypal state, indicating that cannabis 
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consumption holds temporal priority and thus could ‘cause’ a schizotypal state. 
Cannabis consumption per se was a covariate of the SSQ total, SSQ interpersonal 
subscale, and the SSQ disorganised subscale. The quantity of cannabis 
consumed within participants was also a covariate of the same SSQ subscales, 
indicating a dose dependent effect. 
 
The quantity of caffeine, tobacco and alcohol consumed does not have a 
significant effect on scores on the SSQ total nor subscales, with the exception 
being alcohol’s ability to predict scores on the disorganised subscale. SE was not 
a significant covariate of the SSQ or its subscales, whilst ER was capable of 
predicting scores on the interpersonal subscale in a negative fashion (as ER 
increases scores on the subscale decrease). However, the small beta value and p-
value may indicate only a slight association between the variables. Unexpectedly, 
PE had a positive relationship with the disorganised subscale and interpersonal 
subscale. The rationale for the nature of this relationship is at present unclear, but 
could plausibly reflect an association between cannabis and pleasurable 
experiences. An effect of (time) proximity of data entries has also been noted in 
this section, the closer data entries were together predicted an elevation in the 
disorganised subscale, which produced a significant effect on the SSQ total score. 
It is hypothesised that the relationship between schizotypy and time may be as a 
result of reactivity to the methodology, this notion will be discussed further in 
Section 3.4. 
 
Moreover, in this section there is evidence of a cannabis stress interaction term 
being a significant positive covariate of a schizotypal state, thus indicating that 
these factors may interact in the presentation and maintenance of transient 
experience. Whilst stress and cannabis consumption per se are controlled for the 
interaction variable CXS significantly predict scores on the SSQ total, SSQ 
interpersonal subscale and SSQ disorganised subscale. The notion of a stress 
interaction moderating the relationship between cannabis and psychotic-like 
experience will be further tested in the next section. 
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3.3.4 Assessing stress as a mediator of the relationship between cannabis 
and schizotypal states 
Aim five of this chapter is addressed within this section (as well as Section 3.3.3). 
This aim sought to assess the plausibility of an interaction between cannabis and 
psychological stressors on psychotic (like) experience. To further elucidate the 
relationship between a schizotypal state and stress the sample was split into 
tertiles (three quantiles) each containing 12 participants (see Table 27). 
Participants were split according to their mean score (participant mean) on the 
CSQ Stress scale over the duration of the study, for the purposes of the analysis 
comparison will be drawn between the upper and lower tertile. Consequently, the 
two groups can be said to consist of individuals who have had the highest mean 
stressed states in comparison to those that have had the lowest, respectively. 
Thus, herein analyses are performed to establish whether cannabis consumption 
significantly co-varies with scores on the SSQ total and its subscales in both of the 
groups.  
 
In the lower tertile CSQ Stress did not significantly co-vary with scores on the SSQ 
total, whereas the upper tertile did (b = 0.81 95% CI 0.47 to 1.15, p < .001) with 
each unit increase in the independent variable predicting an increase of 0.86 on 
the SSQ total. This finding may indicate that there is a threshold of concurrent 
stress which must be attained prior to an effect on schizotypal state. However, 
given that participants were differentiated on the basis of their CSQ Stress mean 
score, it is feasible that the non-significant finding may be due to a small effect 
size and reduced statistical power rather than no relationship between the 
variables. The CSQ Calm scale was not a significant covariate of a schizotypal 
state in either tertile, neither were the items ER, SE and PE. 
 
The interaction between stress and cannabis can be explored through the 
comparison of the two tertiles on the ability of cannabis consumption (per se) to 
predict scores on the SSQ. In the lower tertile group there was not a significant 
effect of cannabis on SSQ Total. The same was not found in the upper tertile 
group cannabis consumption in the moments prior to a data entry was a significant 
covariate of the SSQ Total (b = 2.81 95% CI 1.01 to 4.61, p = .002). For the upper 
tertile consuming cannabis in the moments prior to a data entry predicted an 
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increase of 2.8 on SSQ total score, whereas in the lower tertile cannabis use not a 
significant covariate. This finding indicates that cannabis consumption predicts a 
schizotypal state in the participants’ who experienced the highest states of stress, 
but not those who experienced the lowest. 
 
In section (3.3.3) the results presented demonstrate a significant positive 
relationship between the cannabis stress interaction variable and the SSQ 
interpersonal subscale, disorganised subscale and total score. This indicates that 
in the current study a proportion of disturbance within the domains of the 
aforementioned subscales may be attributable to an interaction effect between 
cannabis and stress. This section sought to explore this relationship further. Thus, 
contained with this section is convergent data indicating; participants that had 
higher states of stress during the ESM period appeared to be affected by the 
(psychologically) deleterious effects of cannabis; whereas those who experienced 
the lowest states of stress did not appear to be affected by cannabis. Therefore 
the data indicates further support for a cannabis stress interaction contributing to a 
psychotic state. Thus, herein is data suggesting a stress interaction ‘moderating’ 
the relationship between cannabis and psychotic-like experience. These findings 
will be discussed in further detail in Section 3.4.  
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Table 27 
Parameter estimates for multilevel model of a schizotypal state (SSQ total, outcome)  
as a function of states of stress, states of calm, stressful events, pleasurable events, 
cannabis consumption per se and a cannabis -stress interaction, for the participants 
that have had the lowest and highest stressed states 
Fixed effect (intercept, 
slopes) 
Tertile Estimate (SE) Z
 
P
 95% CI 
Lower Upper 
Intercept 
L 8.065 1.850 4.36 <.001 4.439 11.690 
U 19.976 3.836 5.21 <.001 12.458 27.494 
CSQ Stress 
L 0.283 0.207 1.36 .173 -0.124 0.689 
U 0.812 0.174 4.66 <.001 0.470 1.153 
CSQ Calm 
L 0.006 0.086 0.07 .948 -0.162 0.174 
U 0.115 0.170 0.67 .501 -0.219 0.448 
Event Rating (ER) 
L 0.095 0.204 0.47 .640 -0.304 0.494 
U 0.136 0.523 0.26 .795 -0.890 1.161 
Stressful Events (SE) 
L -0.253 0.398 -0.64 .525 -1.034 0.527 
U -0.249 0.703 -0.35 .723 -1.626 1.128 
Pleasurable Events 
(PE) 
L 0.311 0.273 1.14 .254 -0.223 0.846 
U 0.291 0.617 0.47 .637 -0.917 1.500 
Cannabis consumed 
L 0.518 0.352 1.47 .141 -0.171 1.208 
U 2.813 0.918 3.06 .002 1.014 4.613 
Caffeine 
L 0.025 0.178 0.14 .888 -0.323 0.373 
U 0.373 0.503 0.74 .458 -0.612 1.359 
Tobacco 
L 0.019 0.284 0.07 .946 -0.537 0.576 
U -0.622 0.514 -1.21 .226 -1.629 0.385 
Alcohol 
L -0.260 0.193 -1.35 .178 -0.639 0.119 
U 0.723 0.538 1.34 .179 -0.332 1.778 
Time 
L -0.0001 0.003 -0.06 .953 -0.005 0.005 
U -0.014 0.008 -1.87 .061 -0.294 0.0007 
Random effects ([co-]variances) Tertile Estimate (SE) 
ICC 
(%) 
95% CI 
Lower Upper 
Level 1 Intercept 
Lower 41.128 16.531 80.516 18.707 90.421 
Upper 169.007 71.391 79.848 73.849 386.779 
Level 2 Intercept 
Lower 5.173 1.026 10.127 3.507 7.630 
Upper 18.858 5.063 8.910 11.143 31.917 
 Residual 
Lower 4.780 0.461  3.956 5.775 
Upper 23.796 2.982  18.614 30.419 
L= Lower U= Upper 
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3.3.5 Covariates of concurrent states of stress and calm 
This section serves to address the fourth aim of this chapter; to assess factors 
which may influence the consumption of cannabis. Given cannabis’ purported 
anxiolytic effect, stressed and calm states could plausibly be determinates of 
cannabis consumption. Nonetheless, this aim is considered in greater depth in 
Section 3.3.6 in which factors that predict cannabis consumption are considered.  
Fluctuations in states of stress and calm over time  
In order to illustrate trends using data from individual participants, five participants 
were selected on the basis of their mean score on the CSQ Stress scale over the 
ESM-phase, at the 5th, 25th, 50th, 75th and, 95th percentile.  These five participant’s 
data on the CSQ scales (stress and calm) for day one are displayed in Figure 10.  
An advantage of plotting participant’s scores on the various measures is that it is 
possible to observe the relationship between two variables over a period of time, 
such as that displayed in Figure 10. The relevant scatterplots broadly show, that 
when CSQ Stress scores increase CSQ Calm tends to decrease and vice versa. 
The items display both within and between participant variability.  
 
Figure 10  
Scatterplots of a subset of participants displaying  the variability of CSQ Stress and 
CSQ Calm over time 
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Covariates of the Concurrent States Questionnaire (CSQ): Stress scale 
The analysis contained within this subsection is displayed in Table 28. Concurrent 
states of stress appear to influence a participant’s schizotypal state. However, it is 
important to establish what, if any, variables influence concurrent feelings of stress 
and calm. The SSQ total score was a significant covariate of the CSQ Stress scale 
(b = 0.09 95% CI 0.06 to 0.11, p < .001), each unit increase on the SSQ total 
predicted an increase of 0.09 on the outcome. This provides further evidence of a 
relationship between stress and schizotypal states. There was also a significant 
relationship between the CSQ calm (predictor) and the CSQ stress (b = -0.32 95% 
CI -0.37 to -0.27, p< .001), in the direction anticipated, a unit increase in CSQ calm 
served to predict a decrease of 0.32 on the Stress scale. Both ER and SE were 
significant covariates of concurrent states of stress (ER; b = -0.16 95% CI -0.32 to 
-0.004, p = 0.044, SE; b = 1.31 95% CI 1.08 to 1.54, p < .001). A one unit increase 
in ER accounted for a decrease of 0.16 in CSQ stress and a unit increase in SE 
predicted an increase of 1.31 in the outcome. In the direction anticipated previous 
stressful events and ER predicted concurrent feelings of stress. However, 
pleasurable events did not influence the presence of concurrent stress. 
 
Cannabis use per se was found to have no relationship with concurrent stress. 
Neither did quantity of cannabis consumed within participants which was 
considered in a different model (b = -0.04 95% CI 0.16 to 0.08, p = .551). This 
non-significant finding indicates that cannabis is not capable of attenuating 
feelings of stress. If the model of ‘self-medication’ described by Kolliakou et al 
(2011) and Khantzian were to be accepted (see Section 1.6.1) one may expect a 
significant relationship would have been observed here. However, nicotine use 
was a significant covariate of the CSQ Stress (b = 0.20 95% CI 0.03 to 0.38, p = 
.020), for every unit (cigarette) of tobacco used scores on the outcome variable 
increase by 0.20. Due to the nature of MLM analysis the participant’s previous 
responses have been adjusted for, consequently, the effect of nicotine on CSQ 
stress should be viewed as independent of previous stress, and previous nicotine 
use. Consequently, this finding is not likely to be an artefact of prior stress priming 
for both nicotine use and concurrent stress. Thus this could plausibly indicate an 
independent effect of nicotine on stress. 
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Table 28 
Parameter estimates for multilevel model of states of stress (outcome) as a function 
of schizotypal state, calm, stressful events, pleasurable events and cannabis 
consumption per se  
Fixed effect (intercept, 
slopes) 
Estimate (SE) Z
 
P
 95% CI 
Lower Upper 
Intercept 2.254 0.339 6.64 <.001 1.589 2.918 
SSQ total 0.088 0.013 7.01 <.001 0.064 0.113 
CSQ Calm -0.321 0.024 -13.14 <.001 -0.367 -0.273 
Event Rating (ER) -0.162 0.080 -2.01 .044 -0.320 -0.004 
Stressful Events (SE) 1.308 0.118 11.11 <.001 1.078 1.539 
Pleasurable Events (PE) 0.005 0.094 0.05 .957 -0.179 0.189 
Cannabis consumed -0.063 0.140 -0.45 .653 -0.336 0.211 
Caffeine -0.069 0.071 -0.97 .330 -0.208 0.070 
Tobacco 0.203 0.088 2.31 .021 0.031 0.375 
Alcohol 0.067 0.081 0.82 .410 -0.092 0.226 
Time -0.002 0.001 -2.14 .032 -0.004 -0.0002 
Random effects ([co-
]variances) 
 Estimate (SE) ICC (%) 
95% CI 
Lower Upper 
Level 1 Intercept 3.712 0.999 50.705 2.190 6.291 
Level 2 Intercept 1.805 0.233 24.663 1.402 2.325 
 Residual 1.803 0.117  1.588 2.047 
 
Covariates of the CSQ: Calm scale 
The previous section described the relationship between the aforementioned 
predictor variables and measures of concurrent stress, this section will assess the 
variables as covariates of concurrent feelings of calm (Table 29). There was no 
significant effect of SSQ total on CSQ Calm, this further vindicates the approach 
taken to scoring the CSQ. However, there was a significant effect of concurrent 
feelings of stress on concurrent feelings of calm (b =-0.55 95% CI -0.63 to -0.47, 
p<.001). Each unit increase on CSQ Stress scale predicted a decrease of 0.55 on 
the CSQ Calm scale. The items pertaining to previous events were all significant 
covariates of concurrent feelings of calm (ER; b = 0.37 95% CI 0.15 to 0.58, p = 
.001, SE; b = -0.57 95% CI -0.90 to -0.24, p = .001, PE; b = 0.51 95% CI 0.27 to 
0.76, p < .001). A unit increase in ER and PE served to predict an increase of 0.37 
and 0.51 in SSQ Calm respectively, the same increment increase in SE was 
related to a decrease of 0.57. These findings suggest the validity of the event 
related items. 
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Cannabis consumption per se was a significant covariate of the CSQ Calm (b = 
0.60 95% CI 0.23 to 0.97, p = .002), use in the time period prior to a data entry 
predicted a 0.60 increase in concurrent feelings of calm. This finding may be 
explained by cannabis’ ability to induce feelings of calm corroborating cannabis’ 
purported anxiolytic effect (Zuardi et al.,1982), and (feasible) improvement to 
mood (El-Alfy et al., 2010). In an alternative model these findings were replicated 
in a dose dependent fashion within participants, (b = 0.23 95% CI 0.07 to 0.39, p = 
.006), each unit of cannabis consumed predicted an increase of 0.23 in CSQ Calm 
(see Appendix 33). 
 
No other substance examined produced a significant effect, including nicotine. 
However, a significant effect of minutes since last data entry was observed, (b = -
0.004 95% CI -0.006 to -0.001, p = .006) each minute (unit) increase above the 
mean resulted in a decrease of 0.004 in concurrent feelings of calm. As discussed 
previously, this finding may be interpreted to be as a result of reactivity to the 
methodology, the longer the time difference in between each data entry the less 
calm the participant feels. Perhaps the reduction in feelings of calm may be as a 
result of anticipation of an impending data entry. 
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This section has examined factors predicting concurrent states of stress, in which 
there was no evidence of cannabis’ ability to attenuate stressed states. However, 
analyses in this section suggest that previous cannabis consumption significantly 
predicts calm states, furthermore, a dose dependent effect was established. This 
finding supports the notion of cannabis as an anxiolytic, thus providing evidence 
for Khantzian’s model of self-medication (see Section 1.6.1). As evidenced by the 
use of cannabis conferring some benefit on the user in eliciting calm like states. 
 
3.3.6 Covariates of cannabis use  
This section fulfils the second aim of this investigation: to assess temporal priority 
in the relationship between cannabis and psychotic experience in a naturalistic 
setting. This aim is fulfilled by examination of factors which predict cannabis 
consumption. However, information contained in Section 3.3.3 also serves to fulfil 
Table 29 
Parameter estimates for multilevel model of states of calm (outcome) as a function 
of schizotypal state, stress, stressful events, pleasurable events, and cannabis 
consumption per se 
Fixed effect (intercept, 
slopes) 
Estimate (SE) Z
 
P
 95% CI 
Lower Upper 
Intercept 13.083 0.492 26.61 <.001 12.119 14.047 
SSQ total -0.024 0.017 -1.42 .155 -0.058 0.009 
CSQ Stress -0.552 0.042 -13.04 <.001 -0.635 -0.469 
Event Rating (ER) 0.367 0.109 3.36 .001 0.153 0.581 
Stressful Events (SE) -0.569 0.169 -3.38 .001 -0.900 -0.239 
Pleasurable Events 
(PE) 
0.514 0.125 4.11 <.001 0.269 0.760 
Cannabis consumed 0.598 0.189 3.16 .002 0.226 0.969 
Caffeine -0.036 0.097 -0.37 .711 -0.225 0.154 
Tobacco -0.013 0.119 -0.11 .912 -0.247 0.221 
Alcohol 0.119 0.110 1.08 .279 -0.097 0.334 
Time -0.004 0.001 -2.85 .004 -0.006 -0.001 
Random effects ([co-
]variances) 
 Estimate (SE) ICC (%) 
95% CI 
Lower Upper 
Level 1 Intercept 8.102 2.039 60.090 4.948 13.267 
Level 2 Intercept 1.742 0.312 12.917 1.226 2.473 
 Residual 3.640 0.238  3.202 4.138 
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this aim. This section also serves to address the fourth aim of this chapter; to 
assess factors which may influence the consumption of cannabis. Given cannabis’ 
purported anxiolytic effect (see Section 1.4 pp.55-58) this aim is also considered in 
Section 3.3.5.  
 
The SSQ and the CSQ scales are concurrent measures, which were administered 
simultaneously with several retrospective measures (ER, SE, PE, and items 
pertaining to drug consumption).  If a time lag of one data entry is applied to the 
concurrent measures it is possible to observe their effects on retrospective items 
or in this case prior action of consuming cannabis.   
Covariates of cannabis consumption per se 
As discussed previously analyses with a dichotomous outcome variable were 
computed once with all covariates and for a second time with only the significant 
predictor variables. Values from the variables that were deemed pertinent to 
hypotheses testing are displayed in Table 30, and when not significant (at the 0.05 
level) refer to the first of the two models, these are the SSQ (and all subscales) 
and the CSQ stress scale. Apart from these exceptions the values generated by 
the second model are the ones which are displayed in the text and Tables 30 and 
31. 
 
As anticipated time was a significant covariate of cannabis consumption, as the 
amount of time between each data entry increased by a minute the odds of using 
cannabis increased by 0.4% (OR =1.004 95% CI 1.001 to 1.007, p = .012). 
However, SE did not predict cannabis use, suggesting that cannabis users were 
not consuming cannabis as a result of stressful events. Both ER and PE 
significantly increased the odds of cannabis consumption (respectively; O.R. =1.68 
95% CI 1.32 to 2.12, p < .001; O.R. = 1.89 95% CI 1.43 to 2.04, p < .001). Thus, 
indicating for every unit increase in PE that had occurred in the moments 
proceeding a data entry the odds of having consumed cannabis were 89% higher, 
and for every unit increase on ER the odds of using cannabis increased by 68%. 
 
Caffeine consumption in the moments proceeding a data entry significantly 
increased the odds that cannabis would be used in the same time frame (OR 
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=1.60 95% CI 1.26 to 2.04, p < .001).For every unit of caffeine consumed (1 cup of 
tea) the odds of having used cannabis in the same time frame increased by 60%. 
Whereas, tobacco use significantly reduced the odds of cannabis use (OR = 0.51 
95% CI 0.39 to 0.67, p < .001), for each unit of tobacco used (1 cigarette) the odds 
of having used cannabis in the same time frame decrease by 49%. The inferences 
that can be drawn from the data regarding the relationship between cannabis, 
caffeine and tobacco are feasibly explained by co-occurring behaviours (e.g. 
drinking a cup of tea every time cannabis is consumed, or replacing cannabis use 
with tobacco use) as opposed to causality.  
 
Table 30 
Parameter estimates for multilevel model of cannabis consumption per se (outcome) 
as a function of a schizotypal state, states of stress, stressful events, and 
pleasurable events 
Fixed effect (intercept, 
slopes) 
O.R. (SE) Z
 
P
 95% CI 
Lower Upper 
Intercept 0.981 0.294 -0.06 .949 0.545 1.765 
*SSQ total 
 T-1
 1.034 0.049 0.71 0.478 0.943 1.133 
*CSQ Stress
 T-1
 1.016 0.040 0.39 0.694 0.940 1.100 
Event Rating (ER) 1.675 0.203 4.25 <.001 1.321 2.124 
Pleasurable Events 
(PE) 
1.892 0.272 4.44 <.001 1.427 2.507 
Caffeine 1.602 0.197 3.85 <.001 1.260 2.038 
Tobacco 0.513 0.070 -4.90 <.001 0.392 0.669 
Time 1.004 0.002 2.50 .012 1.0009 1.007 
Random effects ([co-
]variances) 
Estimate (SE) Median OR ICC (%) 
95% CI 
Lower Upper 
Level 1 1.636 0.280 4.763 44.621 1.170 2.288 
Level 2 0.182 0.580 1.189 0.550 0.0003 95.392 
*Computed from previous model  
 
Analysis within this section will allow inferences to be made regarding the ‘self-
medication’ hypothesis described by Kollikaou et al., (2011) or Khantizian, by 
assessing (see Section 1.6.1) whether distressing states of mind (stress) or 
psychotic-like states at the previous data entry alter the odds of cannabis 
consumption prior to the next data entry. CSQ Calm T-1 and CSQ Stress T-1 did not 
significantly alter the odds ratio of cannabis consumption. The lack of relationship 
with CSQ Stress T-1 does not provide any corroborating evidence of the self-
medication hypothesis (see Section 1.6.1). Concurrent feelings of stress did not 
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increase the odds of cannabis use, and concurrent feelings of calm did not 
decrease the odds of cannabis use. This section also sought to assess if a 
schizotypal state predicts cannabis use. Scores on the SSQ total T-1 did not 
significantly increase the odds ratio associated with cannabis use (Table 30).  
 
To ascertain if the scores on the SSQ subscales would be a significant covariate 
of cannabis consumption, the model was re-computed utilising the subscales (see 
Table 31) as opposed to the grand total. Please note that a two level model was 
utilised as the third level failed to yield an intra-class correlations (ICC) value 
indicating that this level of the model is not accounting for variability in the data. 
Thus, suggesting that cannabis consumption remained stable within participants 
between days, i.e. participants did not tend to consume more on one day in 
comparison to another. One of the three SSQ subscales was found to have a 
significant effect. For each unit increase on the SSQ disorganised T-1 subscale the 
odds of cannabis being consumed since the last data entry increased by 14% (OR 
= 1.25 95% CI 1.05 to 1.25, p = .003). This finding concurs with the notion that a 
proportion of cannabis use could be attributable to individuals attempting to 
attenuate some of their distressing symptoms. Thus, within this domain of 
schizotypy there is some evidence of cannabis ‘causing’ a schizotypal state. 
 
In this section some of the factors predicting cannabis consumption have been 
described. Caffeine and tobacco use are both significant covariates of cannabis 
consumption per se, which feasibly may represent, co-occurring behaviours 
associated with cannabis use and abstinence of cannabis use. States of stress 
and states of calm did not significantly increase or decrease the odds of future 
cannabis consumption. Consequently, this does not provide evidence in support of 
distress predicting an increase in cannabis consumption. Drug consumption as a 
means of mitigating psychological distress is a central component of Khantzian’s 
model and the model described by Kollikaou et al., (2011). Thus, the lack of 
relationship observed between these variables does not support the self-
medication hypotheses described.  
  
238 | P a g e  
 
Table 31 
Parameter estimates for multilevel model of cannabis consumption per se (outcome) 
as a function of a schizotypal state, states of stress, states of calm, stressful 
events, pleasurable events, and a cannabis -stress interaction 
Fixed effect (intercept, 
slopes) 
O.R. (SE) Z
 
P
 95% CI 
Lower Upper 
Intercept 0.905 0.249 -0.36 .718 0.528 1.553 
*SSQ inter 
 T-1
 0.926 0.044 -1.64 .101 0.844 1.015 
SSQ dis 
 T-1
 1.141 0.051 2.93 .003 1.045 1.247 
*SSQ cog 
 T-1
 0.931 0.061 -1.09 .275 0.819 1.058 
*CSQ Stress
 T-1
 1.010 0.042 0.26 .791 0.933 1.096 
Event Rating (ER) 1.718 0.208 4.46 <.001 1.355 2.179 
Pleasurable Events 
(PE) 
1.824 0.256 4.27 <.001 1.384 2.402 
Caffeine 1.642 0.203 4.01 <.001 1.288 2.094 
Tobacco 0.499 0.069 -5.05 <.001 0.381 0.654 
Time 1.004 0.002 2.60 .009 1.001 1.007 
Random effects ([co-
]variances) 
Estimate (SE) Median OR ICC (%) 
95% CI 
Lower Upper 
Level 1 1.470 0.253 39.630 4.062 1.049 2.059 
*Computed from previous model  
 
The most important data contained in this section pertaining to the ‘self-
medication’ hypotheses is that describing a schizotypal states’ propensity to 
predict future cannabis consumption. Participant’s total scores on the SSQ did not 
indicate any evidence for the ‘self-medication hypothesis’. However, further 
examination of the subscales suggests that distortion of (dis)organisation 
increases the odds of cannabis consumption. Thus, the findings provide evidence 
that psychological distress within this domain significantly and positively increases 
the odds of cannabis consumption. The relationship between distortion of 
disorganisation and cannabis consumption may be most meaningful when 
considered in parallel with the finding indicating cannabis consumption significantly 
co-varies with scores on the disorganised (and interpersonal) subscale. These 
findings when considered in parallel may represent a synergistic relationship 
between cannabis and distortion of disorganisation. This notion will be discussed 
in greater detail in the next section. 
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3.4 Discussion 
3.4.1 Main findings 
The current investigation found supporting evidence of cannabis consumption 
holding temporal priority over increases in schizotypal state, within the domains of 
interpersonal distortion and disorganisation. This finding was also demonstrated in 
a dose dependent fashion. Stress (as measured by the CSQ Stress scale) was 
also a significant covariate of a schizotypal state in all three of the subscales under 
assessment, thereby supporting the notion that stress may be an antecedent for 
psychotic like experiences and their persistence (see Section 1.2.3 pp. 37-48). 
Support was found for a state of calmness decreasing psychotic-like states. 
However, this only occurred with one of the three subscales under assessment, 
interpersonal deficits. 
 
Sections 3.3.5 (pp. 230-34) and 3.3.6 (pp. 234-38) elucidated information on what 
is commonly referred to as the ‘self-medication hypothesis’. In examination of 
stress as a predictor of cannabis consumption no evidence was found of a 
relationship, thus not supporting the notion of psychological distress within this 
domain predicating cannabis use. However, some support was found for self-
medication. Psychological distress within the domain of distortions of 
disorganisation significantly and positively predicted cannabis use. However, no 
significant effect was found in the other SSQ subscales.  Previous cannabis 
consumption (since the last prompt) did not significantly predict decreases in 
concurrent stress. Thus, no evidence was found for cannabis having an efficacious 
self-medication effect on states of stress, as would be consistent with self-
medication models. Nonetheless, cannabis consumption significantly co-varied 
with an increase in states of calm. Furthermore, a dose dependent effect was 
established. Thus, providing support for the self-medication hypothesis and the 
efficacy of cannabis as an anxiolytic. 
 
A stressed state significantly predicted increases in schizotypal state, and calm 
states significantly predicted decrease within the interpersonal domain. This 
indicates that within a continuum model (utilising a cannabis model of psychosis) 
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stressed and calm states may be determinates of the presentation of psychotic 
symptomatology. 
The notion of a cannabis stress interaction effect mediating the relationship with 
psychotic experience was also tested in this investigation.  A cannabis and stress 
interaction variable significantly co-varied with increase in a schizotypal state 
within the domain of interpersonal distortion and disorganisation, thus providing 
support for an interaction between environmental factors on psychotic states. 
Moreover, when participants were differentiated on the basis of their concurrent 
stress, cannabis consumption within the high stress group significantly co-varied 
with schizotypal state. However, in the low stress group cannabis did not 
significantly predict schizotypy. These findings indicate that cannabis and stress 
interact to cause elevations in psychotic-like states, and the presence of both 
factors may be a necessary requisite for the factors to exert an influence. 
 
3.4.2 Implications and comparison with other research 
Schizotypy is commonly considered a stable and enduring personality trait (see 
Section 1.2.2 pp. 31-37). Nonetheless, in the current investigation several 
variables under examination were significant predictors of (variance in) a 
schizotypal state. The relationship between a schizotypal state and trait is poorly 
understood. Moreover, there is even less information pertaining to how a 
schizotypal state may infer risk for diagnosable mental illness. 
 
Rössler, Hengartner, Ajdacic-Gross, Haker and Angst (2013) stated “to date, we 
are still uncertain whether liability to sub-clinical psychosis represents either 
transient and occasion-specific states or a stable dispositional trait” (pp1-2). 
Rössler and colleagues in a 30 year follow up investigation found that the 
proportion of variance in symptomatology attributable to state and trait varies over 
the course of a person’s life.  Nonetheless, Hodgekins et al. (2012) was able to 
distinguish healthy controls from a patient group recovering from psychosis with a 
state measure of schizotypy, not dissimilar from that used in the current 
investigation. Chen et al. (2006) in a review of trait and state markers of 
schizophrenia concluded that “distinguishing enduring trait markers from transient 
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state markers for schizophrenia… is helpful for developing neurobiologically and 
psychologically based intervention strategies” (p.431). 
 
One construct which co-varied with schizotypal state was concurrent stress. There 
is a compelling body of evidence suggesting that psychosocial stressors play a 
role in the presentation of psychosis (see Sections 1.2.3 & 3.1). The current 
investigation provides corroborating evidence for this notion with concurrent stress 
significantly co-varying with scores on all three domains of schizotypal state under 
assessment.  The results therefore support the notion of a diathesis-stress model, 
whereby psychosocial stressors function as an antecedent (along with 
vulnerability) to the development of psychotic disorder (Zubin and Spring, 1977). 
Additionally, the inverse relationship was observed, with concurrent feelings of 
calm (CSQ Calm scale) predicting a decrease within the interpersonal domain. 
 
Despite the lack of data pertaining to the mechanism by which one 
decompensates from schizotypal state to schizophrenia, the relationship between 
schizotypal state and concurrent stress indicates that stress could potentially 
contribute to the development of psychotic disorder. Whereas, feelings of calm 
may serve to (independently) reduce the potential for decompensating. This 
finding may have wide reaching implications possibly indicating that stress 
reduction therapies in addition to interventions to increase psychological ‘positivity’ 
may have a beneficial effect on the primary symptoms of schizophrenia sufferers. 
Mindfulness exercises in people with psychosis have been shown to reduce 
symptomatology (Chadwick, Taylor, & Abba, 2005; Chadwick, Hughes, Russell, 
Russell, & Dagnan 2009) and enhance “ability to respond mindfully to stressful 
internal events” (Langer, Cangas, Salcedo, & Fuentes, 2012, p.105). In a recent 
meta-analysis mindfulness exercises were also found to be effective at reducing 
anxiety and stress (Khoury et al., 2013). 
 
Cannabis consumption was shown to significantly co-vary with a schizotypal state. 
Moreover, a dose dependent effect was established. The results suggest that 
cannabis can serve to independently elevate scores within the interpersonal 
domain. The literature indicates a relationship between cannabis consumption and 
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schizotypal personality (e.g. Dumas et al., 2002; Skosnik et al., 2001). However, 
the nature of this association is poorly understood.  
 
The observed relationship between cannabis and schizotypal state appears at 
odds with the assertions of Mass et al., (2001) who suggest that highly schizotypal 
individuals are more prone to using cannabis. Mass and colleagues state that   
“schizotypal subjects seem to be more likely to use cannabis than the general 
population. Therefore, cannabis use may be a vulnerability indicator for 
schizophrenia” (p.209). The results of this investigation indicate that cannabis use 
may be a contributory factor, as opposed to vulnerability indicator. Mass and 
colleagues concluded that “schizotypal features… within the cannabis group were 
related to the drug consumption per se rather than to acute intoxication effects” 
(p212). 
 
The current investigation allows inferences to be drawn regarding the association 
between schizotypy and cannabis. The results appear to indicate that cannabis 
consumption (acute intoxication) serves to elevate a schizotypal state. There is 
supporting evidence for this notion in the literature with an inverse relationship 
demonstrated between completion of measures of schizotypy and temporal 
proximity with cannabis use; the closer the time period to last cannabis use the 
more schizotypal traits were observed (Baskak et al., 2012). Moreover, in an 
experimental study design scores on the PSI were significantly increased as a 
result of a cannabis challenge (Mason et al., 2009). Furthermore, Skosnik et al. 
(2001) found that current cannabis users exhibited a higher schizotypal personality 
trait than past users. 
 
The current investigation demonstrated a significant association between cannabis 
and schizotypal state within the domains of interpersonal deficits and 
disorganisation, but not within the domains of cognitive-perceptual deficits. Despite 
temporal priority being established the notion of synergistic maintenance cannot 
be dismissed wherein psychotic like states prime for and maintain cannabis use, 
and vice versa. Within the domain of deficits of organisation, reported behaviour 
consistent with ‘self-medication’ was observed. Disorganisation as a sub-factor of 
a schizotypal state co-varied with future cannabis use. Indicating that the 
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participants’ decision as to whether or not to consume cannabis may be in some 
part based on the occurrence of psychotic-like disorganisation. Nonetheless, 
disorganised states are in some part influenced by prior cannabis use. Thus, 
within the domain of disorganisation there is evidence suggesting synergistic 
maintenance, whereby disorganisation may be a symptom of- and a primer for- 
cannabis use. Interestingly, within Chapter 2 (Section 2.3.4) participants that were 
cannabis users displayed significantly more disorganised schizotypal traits than 
their cannabis naïve counterparts. Taken together the data support the notion that 
a proportion of the association between schizotypy and cannabis is as a 
consequence of the user self-medicating disorganised psychotic-like 
symptomatology. 
 
In the current investigation there was no evidence that cannabis consumption co-
varies with psychotic-like states within the realm of cognitive-perceptual distortion. 
This suggests that, within the time frame observed at least, in habitual users, 
cannabis does not influence psychotic-like response within this domain. However, 
it is noteworthy that the sample under consideration was not anticipated to display 
high vulnerability in comparison to the population. Thus these effects may be a 
differentiating factor between a healthy and unhealthy sample. The data 
considered in Chapter 2 suggests that the cognitive-perceptual construct is the 
only SPQ-b subscale capable of differentiating psychotic populations. This finding 
provides further evidence that in healthy cannabis users this domain of schizotypy 
is not elevated.  
 
The transient psychotic-like states observed in this investigation did not appear to 
be pathological, nor did they result in conversion in the current sample. 
Nonetheless, the notion that cannabis use may act as an independent 
developmental antecedent of psychotic illness is supported, particularly for 
symptoms related to interpersonal deficits. Previous cannabis consumption 
predicted interpersonal deficits but, previous interpersonal deficits did not predict 
future cannabis consumption. 
 
The current investigation provides data implicating stress as component of the 
relationship between cannabis and psychosis. A cannabis stress interaction effect 
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was a significant predictor of a schizotypal state within the domains of 
interpersonal deficit and disorganisation. Moreover, cannabis consumption was a 
significant predictor of a schizotypal state in the participants who experienced the 
highest states of stress, but not in the ones who experienced the lowest. These 
findings suggest the possibility of an interaction effect with stress and cannabis in 
the development of psychotic illness.  
 
Stress and cannabis appear to have a complex, but nonetheless well 
substantiated relationship. In animal models cannabinoids have been shown to 
increase the release of adrenocorticotropic hormones and glucocorticoids; a 
physiological stress response (See Brown & Dobs, 2002 for review). Moreover, the 
endocannabinoid system is thought to play a role in the regulation of a stress 
response. Hill and McEwen (2010) summarised in a recent review “...it is 
becoming increasingly apparent that the endocannabinoid system is an integral 
regulatory force on HPA [Hypothalamic-Pituitary-Adrenal] axis activation and 
stress responsivity” (p.795). Endocannabinoid systems regulation of a stress 
response is thought to occur via GABAergic, glutamatergic and monoaminergic 
transmission (Häring, Grieb, Monory, Lutz, & Moreira, 2013). Furthermore, the 
endocannabinoid system has also been implicated in stress related disorders. A 
dysfunctional endocannabinoid system as a result of “…abnormal CB1 receptor-
mediated anandamide signalling is implicated in the etiology of PTSD” 
(Neumeister, et al., in press). 
 
There is also data available suggesting an interaction effect between cannabis and 
stress on a psychosis outcome. Within animal models a cannabinoid stress 
interaction effect has been demonstrated, ∆-8-THC did not elicit striatal DA release 
under ‘normal’ (non-stressed) conditions. However, under ‘stressful’ conditions (no 
food for 24 hours) striatal DA was released and behavioural changes occurred 
(Littleton and Maclean, 1975; Maclean and Littleton, 1977).  This may go some 
way to explain some of the contradictory data pertaining to cannabis’ ability to elicit 
DA release in humans (see Section 1.7.1 pp. 80-84). 
 
In human subjects D’Souza et al., (2008) and Ranganathan et al., (2009) 
demonstrated increased heart rate (tachycardia) and serum cortisol release as a 
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consequence of a ∆-9-THC challenge. These physiological changes occurred 
simultaneously with psychotomimetic effects and perceptual alterations. However, 
the physiological and the aversive psychological effects were blunted in habitual 
users in comparison to controls. In epidemiological data from an American sample 
Houston et al., (2008: 2011), identified an interaction between childhood sexual 
trauma and cannabis use on a psychosis outcome. Cannabis use alone was not a 
significant predictor of psychotic illness. In a Greek and Dutch sample an 
interaction effect was also observed between childhood maltreatment and 
cannabis use on a psychosis outcome (Konings et al., 2012). 
 
When the results from the current investigation are considered in light of the 
research outlined above (and in Sections 3.1 & 1.7.4) a developing picture of an 
interaction between stress and cannabis emerges. This interaction could plausibly 
be responsible for some cases of psychotic illness. Although, the mechanisms by 
which such an interaction effect could ‘cause’ mental illness are still a matter of 
debate (see Henquet et al., 2008). One proposed mechanism which the current 
investigation appears to support (in part) is one of ‘cross-sensitisation’. 
Sensitisation is not (typically) considered as a unitary aetiological theory of 
schizophrenia, but rather a means by which environmental factors may interact 
with genetic ones (e.g. Henquet et al., 2008; Van Winkel, Henquet et al., 2008). 
Collip et al., (2008) state “Sensitization refers to the observation that individuals 
who are exposed repeatedly to an environmental risk factor may develop 
progressively greater responses over time, finally resulting in a lasting change in 
response amplitude” (pp. 220-1). 
 
Both stress and cannabis may independently play a role in the sensitisation 
processes (see Section 1.7.3). The interaction effect outlined by previous 
investigations, and the current investigation, indicates that if such a sensitisation 
process was to occur then it is plausible that these processes are interacting i.e. 
cross-sensitisation. Van Winkel, Stefanis and Myin-Germeys (2008) state “The 
neurobiological substrate of sensitization may involve dysregulation of the 
hypothalamus-pituitary-adrenal axis, contributing to a hypothesized final common 
pathway of dopamine sensitization in mesolimbic areas and increased stress-
induced striatal dopamine release” (p.1095). Therein is a plausible mechanism 
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(supported in part by the current study), in which cannabis, stress and genetic 
factors may interact to cause psychotic- like states, psychotic symptoms and 
eventually psychotic disorder. 
 
Nonetheless, the variable nature of cannabis and the myriad of different effects 
elicited from numerous cannabinoids cannot be ignored. Despite indications that 
cannabis and stress may interact to the detriment of psychological wellbeing, the 
data also indicated that cannabis elicited feelings of calm. This appears to support 
the assertions that cannabis has an anxiolytic effect (Zuardi et al., 1982). 
Nonetheless, the complex relationship between cannabis and stress means that 
for most users (in the UK at least) this is not a viable anti-anxiety aid. Most 
consumers of cannabis in the UK will not have access to the equipment necessary 
for determining cannabinoid ratios, nor are they likely to be accurately informed of 
ratios at point of sale (see Section 1.4). It is likely that the calming effect of 
cannabis is as a consequence of the actions of CBD (see Section 1.4). Thus, in 
the absence of reliable cannabinoid levels it does not appear that cannabis is 
appropriate for use in ‘self-medication’ of anxiety. 
 
The current investigation indicates that the greatest risk to the deleterious effects 
of cannabis occurs during high periods of stress. However, in a recent meta-
analysis examining risk-factors for cannabis consumption, stress-coping was 
frequently cited as a motivation for cannabis use (Hyman and Sinha, 2009). Given 
the relatively low prevalence of schizophrenia in comparison to the relatively high 
prevalence of cannabis use this would appear to suggest that; the most debilitating 
of the deleterious effects of a cannabis stress interaction are reserved for those at 
the greatest genetic risk. Further investigation is required to identify genes which 
confer risk of the development of psychosis (Sullivan, 2005). Nonetheless, the 
available data indicates that at risk groups (e.g. first degree relatives, those 
displaying bio-markers etc.) should be warned against utilising cannabis as a 
stress coping mechanism. This could be adopted within advertisement campaigns 
focused on the prevention of harm within this population 
 
The findings of this investigation have implications for research, theoretical 
development, and feasibly illness prevention. Despite the advantages of this 
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investigation it is not absent of limitations. The next section will focus on the 
limitations of this investigation and the implications of these limitations on the 
interpretation of the findings.  
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3.4.3 Limitations 
Representativeness and generalisability 
Two limitations which are pervasive in many methodological approaches, of which 
this study is not an exception, are a self-selecting bias and participant attrition. 
ESM research places demands on the participants above what is typical within 
cross-sectional investigation. The participants are required to attend to prompts 
numerous times throughout the day. Moreover, the pseudo-randomised prompts 
are designed to capture various psychological states in a variety of environments, 
whilst a variety of activities are being conducted. Thus, in their very nature they 
are designed to interrupt participants in their daily activities. The prompts may also 
distract people other than the participant or cause the participant to feel 
stigmatised due to the sensitive area of research. As a consequence, the nature of 
the methodology may further exacerbate the limitations of a self-selecting bias and 
attrition. “The difficult nature of these tasks might lead certain types of individuals 
to be over- or underrepresented in ESM studies” (Scollon et al., 2003, p.14). Thus 
a self-selecting bias has the influence of reducing the generalisability of the results 
from the sample to the wider population. Moreover, the relatively low N although 
sufficient for an ESM investigation reduces the generalisability of the findings.  
 
The issue of participant attrition has been addressed to some extent in the current 
investigation. Section 3.3.1 compares two samples from the population; 
participants who were included in the final sample; and those who initiated the 
ESM phase, but were not included. Age of cannabis use initiation was significantly 
earlier in participants that were not included in the final sample. Nonetheless, the 
mean age of first initiation of those included in the final sample was only two years 
higher than their counterparts, and age of regular cannabis use was only one year 
more. Moreover, the mean age of initiation for both groups falls within the 
parameters of what appears to be an age associated with increased lifetime risk of 
psychotic illness (Arseneault et al., 2002). Age of initiation aside all of the other 
indices under assessment indicated no significant differences between the two 
groups. This suggests that attrition did not cause additional biases within the final 
sample.  
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Nonetheless, the exhaustive steps taken to promote a viable research alliance 
between researcher and participant may have gone some way towards reducing 
bias as a result of attrition. Ciskszentmihalyi and Larson (1992) suggest that ESM 
is an appropriate methodology “...provided that a viable research alliance can be 
established” (p.48). Scollon et al., (2003) suggest that an “effective way of 
ensuring participant cooperation is to gain participant trust” (p.15). One means by 
which this can be established is discussed by DeVries (1992, p319), wherein the 
briefing and debriefing session form a part of developing a research alliance. 
 
In this investigation participants were briefed and de-briefed in a location and time 
of their choosing. At these sessions (and prior via telephone and email) there was 
the facility for comprehensive discussion with a researcher regarding the 
background to the investigation and how the investigation is situated within the 
wider programme of research. Participants frequently commented that these 
discussions helped to allay their concerns regarding; findings which unduly portray 
them or cannabis in a negative light; and the sharing of information with the police. 
Furthermore, participants were contacted at several time points throughout the 
investigation and were provided with the opportunity to contact a researcher 
(virtually) 24-hours a day for the duration of their ESM-phase. The researcher’s 
duties also extended to providing full technical assistance for all apparatus used in 
the investigation.  
 
There are other aspects of the current investigation which limit the generalisability 
of the sample. For instance, the use of technology within the study design and 
recruitment procedure may have served to reduce the likelihood of participation 
from populations with less confidence or experience of using technology. The 
factors which may influence the use of technology are broad and wide ranging, but 
include age (Czaja et al., 2006), ethnicity (Office of Communications, 2013), 
economic status (Hsieh, Rai & Keil, 2006), and level of education (Sun & Metros, 
2011).  
 
The restrictive geographic range from which participants were recruited may have 
also reduced the variance between the participants, and perhaps most importantly 
this could have served to reduce the preparations of cannabis available to the 
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participants. D. Potter et al., (2008) reported that particular preparations of 
cannabis (i.e. cannabis resin) occurred more frequently in certain geographic 
locations this appeared most pervasive in samples collected from areas in close 
proximity to a port. Nonetheless, the proportions of the various preparations of 
cannabis consumed by the sample are similar to the proportions documented 
within the population. In the Home Office potency study 81% of samples seized 
were sinsemilla, 16% cannabis resin, and 3% traditional herbal cannabis 
(Hardwick & King, 2008). In the current investigation 86.1% of participants 
reported typically using sinsemilla, 8.3% cannabis resin, and 5.6% traditional 
herbal cannabis. 
 
Measurement and study duration 
Another limitation of the study relates to the quality of the data submitted. A multi-
site investigation into ESM, lasting for seven days, did not observe any effects of 
duration of ESM phase on compliance (Johnson et al., 2009). Nonetheless, Stone, 
Kessler, and Haythornthwaite (1991) state that “problems of declining data 
quality…have been documented to occur between 2 and 4 weeks in some diary 
investigations” (p.592). The current investigations ESM phase lasted for fourteen 
days. However, it is anticipated that the exhaustive steps taken to develop a 
research alliance may have mitigated (some of) the potential for declining data 
quality. 
 
Another limitation which may influence the quality of data is one of validity. Of 
particular concern is the assessment of quantity of cannabis consumed. 
Cannabinoid consumption quantity and ratios are dependent on a myriad of 
variables (see Section 1.4). The current investigation allowed for little control over 
these variables. There are ethical, legal, and pragmatic reasons which would 
prohibit ESM study designs in which participants are either given controlled doses 
of cannabinoids, or in which participants provide samples of the cannabis they 
consumed. Moreover, such assessments may have reduced ecological validity, 
making this a less ‘naturalistic’ investigation. The current investigation utilised 
retrospective self-report, albeit from a relatively short period of time (see Section 
3.2.3). This assessment may be limited in its accuracy and will not provide 
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information relating to specific cannabinoids. Future, research within the domain 
could be conducted in locations with less stringent controls on cannabis use, e.g. 
Amsterdam, Holland. An open (i.e. non-secretive) cannabis market would enable 
the researcher to procure samples of the same cannabis as that consumed by the 
participant and subject it to analyses of cannabinoid ratios.  
 
In psychological research there is often a ‘trade-off’ between the accuracy of 
measurement and control of variables, and the utilisation of a naturalistic setting. 
The current investigation has attempted to strike a reasonable balance, between 
naturalistic research and precision of measurement. Nonetheless, precision of 
measurement is not only a limitation of items pertaining to quantifiable substances, 
but psychological constructs as well.  
 
The measures utilised in the current investigation were either constructed or 
adapted specifically for this investigation. The advantage of such an approach is 
that it has allowed for the assessment of constructs for which alternative measures 
may not be appropriate for an intensive ESM study design (e.g. utilising the 48 
item PSI for six-fold daily assessment of schizotypal state), or instances where 
there was no alternative ESM measure (e.g. CEQ). The disadvantage of using 
such an approach is the measures in question had not been assessed for their 
validity, prior to this investigation. Evidence of concurrent validity was established 
for the measures of concurrent stress (CSQ Stress scale) and schizotypal state 
(SSQ) and to a lesser extent the event related items (ER, SE, and PE). Thus, 
there are now appropriate measures for future ESM investigations to utilise in the 
assessment of these constructs. Nonetheless, the efficacy of measurement and 
process of validation for the stress, calm and event related constructs can be 
further improved through the use of objective physiological measures of stress (i.e. 
cortisol).  
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Modelling of time 
One limitation of the current investigation is the consideration of time within the 
statistical model. Unfortunately, the linear relationships between the incremental 
units of time are not modelled. To assess the effect of time the current 
investigation considered the number of minutes that had passed since the last 
prompt (centred around the mean), in doing so variance in time between prompts 
is considered within the model. The utilisation of the variable in this manner in 
theory (see Section 3.2.6) should adjust the betas of the (other) independent 
variables under consideration so that they are differentiated from the effect of time.  
However, this is not the optimum solution as it does not consider time as a linear 
variable throughout the ESM period only between prompts. 
 
Bolger and Laurenceau (2013) recommend “…the influence of time should always 
be taken into account in your statistical model. That is time should be an explicit 
factor, or predictor, in any model of interest” (p27). Bolger and Laurenceau, 
suggest the “spatial power error structure approach” (p.93) as a preferable solution 
to the modelling of time. However, this method can currently only be administered 
on one platform (SAS). The advantage of this approach over the one utilised is 
that a linear relationship between a variable on a macro-scale of the level 2 (see 
Figure 8) unit can be established. For example, the current investigation can 
adjust for the linear effect of time on the quantity of cannabis consumed, between 
prompts. Whereas the approach described by Bolger and Laurenceau within the 
current investigation could adjust for the linear effect of time on the quantity (or 
accumulative effect) of cannabis consumed, from initiation to cessation of the ESM 
phase (day 1-14). 
 
The current investigation has attempted to adjust for the limitations in the 
approach taken to the measurement of time. A three level data structure inherently 
models one conceptual element of time (the day level unit). Furthermore, signal-
contingent data is only considered within the analysis if there is a valid entry at the 
previous prompt, within that day. Thus, ensuring that the time gap between 
responses do not fall outside of pre-determined parameters. 
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Retrospective assessment 
The current investigation utilised some items (e.g. ‘Have you used cannabis since 
the last [prompt]?) and measures (e.g. CEQb) which are pertaining to 
retrospective information. This may be seen as a limitation of the research. The 
rationale for the use of these retrospective items (not including the CEQ-b) is to 
attempt to capture information pertaining to events or drug consumption since the 
last data entry. If the typical method of consumption of cannabis is considered (i.e. 
smoking) from the moment the substance is exhaled (unless more is consumed) 
the participant is no longer currently using cannabis. Thus, a concurrent cannabis 
use item is fraught with poorly defined temporal boundaries, and this may not 
capture concurrent intoxication. Thus, in this instance retrospective items are the 
most accurate means of assessing the variable in question. 
 
The use of the CEQ-b as a retrospective measure was based on the 
impracticalities associated with administering it by other means, for example set ‘in 
the moment’ or ‘since the last prompt’. According to feedback from the pilot 
investigation these approaches would likely result in little variability in the data. In 
addition to making reference to concurrent experiences of intoxication the CEQ-b 
makes reference to after-effects, thus, setting the measure ‘in the moment’ is not 
plausible. Administering the CEQ-b six-fold daily pertaining to phenomena ‘since 
the last prompt’ would be unsuitable. As it would exceed the maximum time of 2-3 
minutes recommended for completion of each data entry (Palmier-Claus, et al., 
2011, p.14). 
 
Retrospective items are common place within ESM research (See Christensen et 
al., 2003) nonetheless, the use of retrospective items are often subject to 
limitations. Christensen et al. (2003) recommend that retrospective items “should 
not be used for experiences that are susceptible to retrospective memory bias 
(e.g. emotions, subjective well-being, or any experiences that are quick to decay)” 
(p.60). Thus, in the current investigation (with the exception of the CEQb) the 
items typically refer to tangible and objectively quantifiable constructs. Even the 
items pertaining to stressful or pleasurable events are not in reference to the 
frequency of a self-determined pre-defined intensity of experience (i.e. How many 
very stressful events have you experienced since the last prompt?). Instead, 
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participants were given the specific instruction to document both minor and major 
stressors, thus reducing the possibility of recall bias. Moreover, this method of 
collecting data is considered preferable to (some) cross-sectional approaches as 
“the time of reference is much shorter than with global reports” (Scollon et al., 
2003, p.22). 
 
Experience Sampling Methodology 
A limitation which is particularly pertinent to retrospective items and is fairly 
ubiquitous amongst ESM research is that of ‘scaling’. Within the current 
investigation the participants ‘prompts’ occurred within a relatively short period of 
time of each other (mean 120.9 minutes, SD 60.68). Nonetheless, this may have 
resulted in the participants developing a unique scaling based on that time frame. 
Scollon et al. (2003) outline a case in which scaling may contribute to bias in 
response; 
 
The threshold for what is considered an angry state, for example, might be 
lower when one considers the past few hours as opposed to the past week. 
Additionally, participants might rate their present state in reference to their 
previous states (e.g., Compared to my other reports, how happy am I right 
now?). Thus, the meaning of momentary reports might change compared to 
between-subject responses. These are empirical questions that, 
unfortunately, have not received much attention thus far (pp. 22-3). 
 
Experience sampling research does however hold advantages over (typical) cross-
sectional research. Experience sampling research is typically capable of making 
inferences about two of the prerequisites for causality, temporal priority and 
concomitant variation. Kenny (1979) states “Three commonly accepted conditions 
must hold for a scientist to claim that X causes Y; 1. time precedence; 2. 
relationship; 3. nonspuriousness” (p.3).  However, Kenny describes a scenario in 
which although temporal priority is established, previous responses on the 
dependent variable may have influenced the independent variable. Within the 
context of the literature outlined in Section 1.6., such a relationship may be as a 
result of synergistic maintenance. Kenny (1979) states: 
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For X to cause Y, X must precede Y in time... To see this let X cause Y with 
a lag in time, and we then have, Xt causes Yt+k where the subscript refers to 
time with k > 0. Note that Yt+k cannot cause Xt since this would violate time 
precedence. (It is true, however, that Yt could cause Xt+k.) (p.3) 
 
ESM and cross-sectional research alike are capable of establishing the second of 
the conditions of causality, relationship (concomitant variation) (Kenny, 1979). 
Several analyses herein suggest a relationship between variables, however, the 
consideration of whether a relationship is significant or not is based on the 
selection of an arbitrary, yet commonly utilised value of 0.05. Kenny (1979) 
suggests “in judging whether two variables are related, it must be determined 
whether the relationship could be explained by chance” (p.5). Although the 0.05 
value is utilised to discriminate between related variables and chance occurrence 
this does not guarantee against making a type 1 or type 2 error. 
 
The third condition of causality, nonspuriousness, cannot be established in this 
instance. Kenny (1979) states “For a relationship between X and Y to be 
nonspurious, there must not be a Z that causes both X and Y such that the 
relationship between X and 2Y vanishes once Z is controlled” (p.5). In the current 
investigation the notion of the possibility of a variable Z cannot be eliminated. Such 
a variable could be responsible for explaining any significant relationships between 
the predictor variables and outcome variables in the analyses contained herein.  
 
The participants perspective 
Methodological reactivity is whereby the act of measuring a construct serves to 
influence a participant’s response. A method for assessing methodological 
reactivity has been proposed a (see Johnson et al., 2009). However, the same 
approach was also suggested for assessing reliability (Palmier-Claus et al., 2011).  
Where the distinction between concluding either methodological reactivity or 
unreliability is arbitrary as the results would be equivocal, thus neither approaches 
have been adopted. However, modelling time as a function of minutes since last 
response elucidated significant variance in several measures which co-varied with 
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intensity of response rate.  This may indicate methodological reactivity. Reactivity 
is typically framed within the context of the participant consciously subverting the 
data. Within the context of this investigation it would appear that intensity of 
response independently (and feasibly unconsciously) alters a participant’s 
schizotypal state, within the domain of distortions of (dis)organisation; concurrent 
stress; and concurrent calmness.     
 
As much as possible an attempt was made to adhere to recommendations for 
reducing reactivity. DeVries and Delespaul (1992) suggest “randomizing the 
occurrence of [prompts] throughout the day minimizes subject reactivity” (p.100). 
In the current investigation only the CEQ-b was not sent according to a pseudo-
randomised schedule. Delespaul (1992) recommends that “small devices usually 
create less reactivity” (p.363). In the current investigation, a small device was 
utilised. Further attempts were made to reduce reactivity by only administering a 
minimal number of items. Moreover, it was anticipated that adaptations to item 
structure, aesthetics and response format as a result of several piloting phases 
would also reduce reactivity. Nonetheless, it is not known if methodological 
reactivity may have influenced the quality of data submitted, this is a limitation of 
this investigation which cannot be addressed. However, it is worthwhile noting that 
the analyses conducted were sensitive enough to elucidate instances of reactivity 
itself. 
 
There are of course ethical considerations associated with methodological 
reactivity and although within the current investigation many different aspects of 
ethics have been considered, methodological reactivity was not one of them. This 
could have been measured through other means by utilising the QFQ data. 
However, this was beyond the scope of this investigation. Nonetheless, it is 
recommended that future investigations within this domain monitor participants 
before, after and feasibly even during the ESM period for methodological 
reactivity.  
 
Despite recommendations that a small device reduces reactivity, in de-briefing 
sessions the most frequently criticised aspect of the study by the participants was 
the smartphone. Fiscal constraints limited the investigation to a narrow selection of 
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apparatus which could have been utilised. As a consequence participants utilised 
a smartphone with a relatively small display size for a touch screen phone (58 mm 
x 45 mm). At the de-briefing participants often commented that a phone with more 
reliable functionality and a larger screen would have made participation easier. It is 
difficult to assess the impact this may have had as there are no available data 
comparing ESM on various smartphones. Nonetheless, this may have feasibly 
reduced participant response rate. However, due to the steps taken to ensure a 
viable research alliance the smartphone may not have been detrimental to data 
quality. Moreover, despite the limitations of the technology this method may still 
have been preferable to the alternative of paper and pen methods (Stone et al., 
2002).  
 
3.4.4 Conclusions 
Kimhy et al., (2009) highlighted the paucity of research conducted utilising ESM 
with cannabis users. Perhaps, the relative paucity of research with this population 
may be partially attributable to researchers’ concerns about the participants’ ability 
to follow study protocol. In the current investigation the majority of the equipment 
(smartphone) was returned (9/12) and the majority of the participants were eligible 
for inclusion in the main analyses (36/53). Nonetheless, the data indicates that the 
participants may have experienced some reactivity to the methodology. This 
investigation has examined the temporal and concomitant relationship between 
cannabis consumption, schizotypal state, stress, and calmness. Participants 
submitted, into a smartphone, self-report assessments six times a day for a period 
of fourteen days. The analysis of the resultant data has elucidated findings which 
have wider reaching implications than the mere context of this investigation. 
 
This investigation indicates schizotypy consists of state, as well as trait, elements 
which are influenced by stress and calmness. This implicates stress-reduction 
exercises as a possible treatment of psychotic symptoms. Cannabis consumption 
appears to exert some influence on a schizotypal state, particularly within the 
domains of interpersonal distortion. However, distortion in organisation appears to 
implicate a system of synergistic maintenance. No evidence was found for 
cannabis eliciting psychotic-like states from within the cognitive-perceptual 
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domain. However, a cannabis-stress interaction effect was identified this could 
implicate a system of cross-sensitisation. It appears that the greatest risk to the 
deleterious effects of cannabis occurs during high periods of stress. At risk groups 
who are cannabis users should be warned against using the drug as a coping-
mechanism. 
 
Whether via a cross-sensitisation process or not the current study implicates a 
stress and cannabis interaction as an antecedent of psychotic illness. The 
relationship between the endocannabinoid system and the Hypothalamic-Pituitary-
Adrenal (HPA) axis cannot be ignored, and neither can the relationship between 
stressful life events and psychosis. The data implicating cannabis as being 
capable of eliciting DA striatal release has been conflicting (see Section 1.7.1). 
Perhaps, it is only in instances when ∆-9-THC is combined with psychological 
stressors that striatal DA release occurs. Psychological stressors (in addition to 
genetic factors) could feasibly mediate the relationship between cannabis and 
psychosis. Both psychological stressors and cannabis use serve to activate the 
HPA axis. The presence of a cannabis induced physiological stress state when 
accompanied with psychological stressors, could serve to combine with genetic 
factors to induce psychotic illness. Placing stress as a central component of the 
relationship between cannabis and psychosis could feasibly account for; mixed 
laboratory findings; association in epidemiological data; and within person 
variability in response to cannabis. This interaction effect may prove to be a 
valuable line of enquiry in elucidating the relationship between cannabis and 
psychosis. 
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4. The development of the Cannabis Experiences 
Questionnaire for assessment of psychotic vulnerability  
Brief Overview 
This chapter aims to examine evidence for the convergent, discriminant, 
concurrent and predictive validity of the aversive scales of the CEQ as an 
assessment of psychotic vulnerability, in addition to assessing the internal 
reliability and providing inference about the test-retest reliability of the measure. 
These aims are achieved by drawing on the data discussed in Chapters 2 and 3. 
 
Section 4.1 sumarises the findings from Chapters 2 and 3 which are also relevant 
to this chapter. Following the introduction there is a brief description of the 
methodology utilised in this investigation (Section 4.2). A more extensive 
discussion of methodologies is considered elsewhere in this thesis (Sections 2.2 & 
3.2). The results of this investigation are contained within Section 4.3. Section 
4.3.1 considers covariates of the aversive scale adapted for the purposes of an 
ESM investigation. Section 4.3.2 considers the aversive scale and the SPQ-b-L 
(see Section 3.2.4) administered at T0 (see Table 19) as predictors of schizotypal 
and stressed states throughout the ESM period. Section 4.3.2 tests the internal 
consistency of the aversive scale within the CSCU, DD and PD groups. Section 
4.3.3 employs the SPQ-b and the CEQ to discriminate between the three 
aforementioned groups. Section 4.4 contains the discussion of findings, 
implications, limitations, and conclusions from this chapter. 
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4.1 Introduction 
A review and introduction to previous research with the CEQ is considered in 
Section 2.1. This section will make reference to the results of the two previous 
research chapters (Chapter 2 & 3) to elucidate information about the CEQ as a 
measure of psychotic vulnerability.  The CEQ disaggregates into three 
independent scales (Section 2.2.3 & Appendix 1). The scale which appears most 
relevant to psychosis proneness (e.g. Stirling et al., 2008) contains twenty items; 
seventeen concurrent effects and three after effects. The items consider a range 
of psychotomimetic phenomena, which could feasibly represent attenuated 
positive psychotic (e.g. feeling threatened by an unknown force), disorganised 
(e.g. disturbed in your thinking), and negative (e.g. depressed) symptomatology. 
 
Section 2.3.5 considers group differences in the aversive scale. Cannabis users 
with a self-reported diagnosis of a psychotic disorder (PD) scored significantly 
higher than both a community sample (CSCU) and a sample with a self-reported 
diagnosis of depression (DD) (Tables 13 & 14). The aversive scale was also 
assessed for covariance with a self-reported diagnosis of psychosis (Section 
2.3.6). The aversive scale was a significant covariate of the PD group in 
comparison to the DD group, and the CSCU group when unreported or 
undiagnosed mental illness is being controlled for (Section 2.3.8) or seemingly 
being controlled for (Section 2.3.7). However, it would appear that in comparison 
of the CSCU and PD groups the SPQ-b subscales and the aversive scale may be 
assessing a similar underlying factor (see Table 16).  
 
This chapter will utilise the data set derived from Chapter 3 to provide further 
information about the aversive scale of the CEQ. An examination of a daily 
measure of aversive cannabis experiences (CEQ-b) will be performed to assess 
the scale as both a predictor and an outcome of a schizotypal state (Section 
4.3.1). That section will also assess whether the CEQ-b predicts schizotypal states 
as a consequence of within or between participant variance. The data described in 
Chapter 3 will also be utilised to assess the CEQ’s aversive scale as a predictor of 
schizotypal states (Section 4.3.2). Furthermore, this data will be used to assess 
the aversive scale and the SPQ-b as predictors of a stressed state.   
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This chapter will also utilise the data described in Chapter 2 to assess the internal 
reliability of the aversive scale in; a community sample of cannabis users (CSCU); 
cannabis users with a self-reported diagnosis of depression (DD); and cannabis 
users with a self-reported diagnosis of a psychotic disorder (PD) (Section 4.3.3). 
This chapter will conclude by utilising the data from Chapter 2 to assess the CEQ 
and the SPQ-b as predictors of psychotic illness (Section 4.3.4). This section will 
utilise a discriminant function analysis (DFA) to assess whether the participants 
group status (CSCU, DD or PD) can be predicted from their data. To facilitate 
interpretation of which investigation has contributed data to this chapter please 
refer to Figure 11. 
 
Figure 11 
Demonstrating which datasets have contributed to the analyses contained within 
chapter 4 
 Chapter 2 Chapter 3 
 
  
Chapter 4 Section 4.3.3 Section 4.3.1 
 Section 4.3.4 Section 4.3.2 
4.1.1 Aims of this chapter 
Information contained within the literature review, discussing the development of a 
measurement scale, is particularly pertinent to this chapter (Section 1.3), which 
had two primary aims: 
1. To assess evidence for the reliability of the aversive scale of the CEQ as an 
assessment of psychotic vulnerability. 
2. To assess evidence for the convergent, concurrent and predictive validity of 
the aversive scale of the CEQ.  
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4.2 Methodology 
The discussion of the methodology and analytical procedures associated with 
Chapter 3 are contained within Section 3.2. As stated within this section, the 
assessment of cannabis experiences in the ESM investigation was slightly 
different to that of the other variables. The CEQ-b is an adapted version of the 
aversive scale of the CEQ. The principal adaptation being that the CEQ-b has a 
much shorter time of reference than the CEQ items. The CEQ-b items refer to 
cannabis induced phenomena experienced in a 24-hour period, whereas the CEQ 
refers to experiences over the participant’s lifetime. 
 
It is important to note that because of the CEQ-b’s period of reference (previous 
24-hours) it was administered in a slightly different manner to the other ESM 
items. The CEQ-b was administered with the participant’s last response of the day, 
within one hour of their predicted bed time. The items of the CEQ-b were 
pertaining to cannabis experiences the participant had experienced within a 24 
hour period. This is the same sampling period as the assessment of the other 
variables. Thus, the CEQ-b should not be presumed to have temporal priority, 
except in instances where a time lag has been applied.  
 
The discussion of the methodology considered for analyses conducted in Sections 
4.3.3 and 4.3.4, is in Section 2.2. However, unlike the data considered in Chapter 
2, the data analysed within this chapter utilised data analysis software STATA 12.1 
(StataCorp).  
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4.3 Results 
4.3.1 Covariates of aversive cannabis experiences: An ESM investigation  
Fluctuations in daily assessments of aversive cannabis experiences 
A subset of five participants were selected on the basis of their mean score on the 
CEQb over the ESM-phase, at the 5th, 25th, 50th, 75th and, 95th percentile, see 
Figure 12. These participant’s scores on the CEQ-b were then mapped over the 
duration of the 14 days investigation. The CEQ-b displayed variability both 
between participants and in the majority of the cases within participants. 
Figure 12 
Scatterplots of a subset of participants displaying the va riability of aversive cannabis 
experiences over t ime 
  
Covariates of the Cannabis Experiences Questionnaire-Brief 
Analyses contained within this subsection are contained within Table 32. The SSQ 
total was a significant covariate of the CEQ b (b = 0.17 95% CI 0.11 to 0.23, p < 
.001), each unit increase in the SSQ total co-varies with a 0.17 increase on the 
CEQ b. This finding indicates that schizotypal states co-vary with aversive 
cannabis experiences, suggesting a possible link between psychotic illness and 
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these experiences. Furthermore, the CSQ Stress scale was a significant covariate 
of the CEQ b (b = 0.23 95% CI 0.06 to 0.41, p = .009), each unit increase of 
concurrent stress co-varies with an increase of 0.23 on the CEQb. This suggests a 
relationship between states of stress and aversive cannabis experiences, 
however, it cannot be ascertained as to which of these variables possesses 
temporal priority. Consequently, it may be deemed that aversive cannabis 
experiences are influenced by stress, or, aversive cannabis experiences may be 
influencing stress. Nonetheless, this finding provides convergent validity and 
further evidence for the utility of the CEQb.  
 
The cannabis-stress interaction variable was also a significant covariate of the 
CEQb (b = 0.40 95% CI 0.22 to 0.57, p < .001), each unit increase on the CSQ 
stress scale when combined with cannabis co-varies with an increase of 0.40 on 
the CEQ-b. This finding indicates that there is a relationship between the stress-
cannabis interaction effect and aversive cannabis induced experiences. As 
discussed previously this does not infer temporal priority consequently numerous 
explanations of the finding may be possible. The cannabis-stress interaction may 
be influencing the aversive cannabis experiences or the experiences may in turn 
be promoting the cannabis-stress interaction. Nonetheless, this finding provides 
further corroborating evidence of a cannabis and stress interaction effect. 
 
Cannabis consumption per se was also considered within this model, which was a 
significant covariate of the CEQb (b = 0.81 95% CI 0.10 to 1.52, p = .026). This 
finding could plausibly indicate that an increase in incidence of consumption could 
increase the propensity to experience aversive cannabis experiences. However, in 
an alternative model the quantity of cannabis consumed (within participants) did 
not significantly co-vary with the CEQb (b = 0.22 95% CI -0.10 to 0.53, p = .18). 
Neither, were, SSQ Calm, ER, SE, or PE significant covariates of the CEQb. 
However, caffeine consumption per se co-varies with a reduction of scores on the 
CEQ-b (b = -0.42 95% CI -0.80 to -0.04, p = .028). Each unit of caffeine consumed 
(1 cup of tea, ½ cup of coffee) co-varies with a decrease of 0.42 on the CEQ-b. 
Tea has been shown to lower post-stress cortisol and induce greater subjective 
relaxation, which may explain the relationship between caffeine and the CEQb 
(Steptoe et al., 2007).  
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Daily Aversive cannabis experiences as a covariate of a schizotypal state 
One means of assessing the CEQ-b’s utility as an assessment of psychosis 
proneness is to assess it as a covariate of a schizotypal state. As discussed in 
Section 4.2 the CEQ-b is administered at the end of every day and the measure is 
in reference to that day’s cannabis experiences (i.e. today have you had the 
following experiences). Consequently temporal priority between the variables 
cannot be established through conventional means. Nonetheless, the CEQ-b’s 
ability to co-vary with measures of schizotypal states is informative.   
 
The analysis described within this section is very similar to that displayed in Table 
23 and discussed in Section 3.3.3, thus the relevant table is contained within 
Table 32 
Parameter estimates for multilevel model of daily assessments of aversive cannabis 
experiences (outcome) as a function of schizotypal states of stress, states of calm, 
stressful events, pleasurable events, cannabis consumption per se and a cannabis -
stress interaction 
Fixed effect (intercept, 
slopes) 
Estimate (SE) Z
 
P
 95% CI 
Lower Upper 
Intercept 3.091 0.693 4.46 <.001 1.733 4.449 
SSQ total 0.169 0.029 5.73 <.001 0.111 0.227 
CSQ Stress 0.232 0.088 2.62 .009 0.059 0.405 
CSQ Calm 0.078 0.064 1.22 .224 -0.047 0.202 
Event Rating (ER) 0.068 0.218 0.31 .754 -0.359 0.496 
Stressful Events (SE) 0.463 0.320 1.44 .149 -0.165 1.091 
Pleasurable Events 
(PE) 
-0.242 0.239 -1.01 .312 -0.712 0.227 
Cannabis X Stress 0.395 0.087 4.52 <.001 0.224 0.567 
Cannabis consumed 0.809 0.363 2.23 .026 0.097 1.520 
Caffeine -0.421 0.192 -2.19 .028 -0.797 -0.044 
Tobacco -0.424 0.238 -1.79 .074 -0.890 0.041 
Alcohol 0.226 0.223 1.01 .310 -0.211 0.663 
Time 0.003 0.003 0.94 .345 -0.003 0.008 
Random effects ([co-
]variances) 
 Estimate (SE) ICC (%) 
95% CI 
Lower Upper 
Level 1 Intercept 3.941 0.534 52.801 3.021 5.141 
 Residual 3.726 0.108  3.521 3.943 
266 | P a g e  
 
Appendix 34. The most notable difference between these models is the 
significance value of PE has decreased dramatically from .163 to .007. The 
rationale for this decrease is not known. Nonetheless, the CEQ-b was a significant 
covariate of the SSQ total (b =0.29 95% CI 0.16 to 0.42, p<.001) each unit 
increase on the CEQ-b co-varies with an increase of 0.29 on the SSQ total. This 
finding indicates that the cannabis experiences documented at the end of the day 
significantly predicts schizotypal states throughout the day. However, without 
establishing temporal priority this finding cannot be considered causal, 
nonetheless, this provides convergent evidence of the validity of the CEQ-b at 
identifying potentially pathological experiences. 
  
Temporal priority between the CEQ-b and the other variables under consideration 
cannot be established through conventional means. However, one means in which 
it is possible to establish temporal priority and to consider the duration of 
disturbance is by lagging the CEQ-b variable by a day (CEQ-bT-1). The CEQ-b was 
administered at equidistant time points consequently no additional procedures 
need to be adopted to control for time differences between days. However, as 
discussed (see Section 3.2.8), time since last data entry will be considered within 
the model. For brevity and to avoid repetition this analysis is not contained within a 
table (see Appendix 35). The CEQ-b T-1 was a significant predictor of a schizotypal 
state total (b = 0.23, 95% CI  0.12 to 0.34, p < .001). In this instance temporal 
priority can be established: the CEQ-b was capable of predicting schizotypal 
states that occurred on the following day. This finding provides further evidence for 
the utility of the CEQ-b at predicting experiences which may indicate susceptibility 
to psychotic illness, thus providing evidence of the measures predictive validity. 
 
Further, examination of the lagged variable was undertaken to model between and 
within participant effects. To this end CEQ-b T-1 was split into two orthogonal 
components this procedure has been described in Section 3.2.8 and in Bolger and 
Laurenceau (2012, p.78). These variables were recomputed into the previous 
model described, the output is identical to that contained in Appendix 35, with the 
exception of the variance predicted by the CEQ-b T-1. Both within (b = 0.22, 95% CI 
0.10 to 0.33, p < .001) and between (b = 0.66, 95% CI 0.06 to 1.27, p = .033) 
participant effects of the CEQ-b T-1 were significant positive predictors of 
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schizotypal state. Each unit increase from the participants mean score predicted a 
0.22 unit increase on the SSQ total score. Each unit increase above the samples 
mean predicted a 0.66 unit increase on the SSQ total score. 
 
4.3.2 Schizotypal trait and the Aversive scale as covariates of momentary 
experience 
The full length CEQ and the SPQ-b-L were completed prior to the briefing session. 
These measures were not administered as ESM items, but as cross-sectional 
measures. Nonetheless, the aversive scale of the CEQ and the cognitive-
perceptual, disorganised, and interpersonal subscales of the SPQ-b-L can be 
considered as covariates within a multilevel model. The SPQ-b-L is assessing a 
personality construct and the aversive scale could also feasibly be assessing a 
stable construct (see Section 2.4). Some of the momentary variables under 
assessment may be influenced by these stable constructs, thus to observe the 
effect of these constructs it is necessary to omit some variables. Schizotypal state, 
states of calm, states of stress, the interaction term considering stress (CXS) and 
perception of events may all be influenced by schizotypal traits and the same 
constructs that promote aversive cannabis phenomena. Thus, the variables 
pertaining to these momentary phenomena will be omitted. 
 
Schizotypal state (SSQ total) was assessed as an outcome variable (see Table 
33). Given that schizotypal trait and state are likely to be highly related the SPQ-b 
subscales were not considered within the initial model in order to assess the 
aversive scale independently. The model considered the consumption of cannabis, 
alcohol, caffeine and tobacco, time, and the aversive scale. The aversive scale 
was not a significant predictor of a schizotypal state (b = 0.09, 95% CI -0.37 to 
0.55, p = .71) (see Appendix 36). The model was re-computed with the three SPQ-
b subscales included as predictors. The cognitive-perceptual subscale of the SPQ-
b was a significant predictor of a schizotypal state (b = 0.75, 95% CI 0.01 to 1.48, 
p = .046), however, the disorganised and interpersonal subscales were not.  
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Table 33 
Parameter estimates for multilevel model of a schizotypal state (outcome) as a 
function of aversive cannabis experiences, schizotypal trait and cannabis 
consumption per se 
Fixed effect (intercept, 
slopes) 
Estimate (SE) Z
 
P
 95% CI 
Lower Upper 
Intercept 14.202 1.866 7.61 <.001 10.544 17.859 
Aversive scale -0.026 0.253 -0.10 .917 -0.521 0.468 
SPQ: Cog-per 0.745 0.374 1.99 .046 0.0121 1.477 
SPQ: inter -0.186 0.419 -0.044 .657 -1.008 0.635 
SPQ: dis -0.651 0.524 -1.24 .214 -1.677 0.376 
Cannabis consumed 0.812 0.357 2.28 .023 0.113 1.512 
Caffeine 0.139 0.198 0.70 .484 -0.250 0.527 
Tobacco 0.107 0.243 0.44 .661 -0.370 0.583 
Alcohol 0.270 0.224 1.21 .227 -0.168 0.709 
Time -0.005 0.003 -1.93 .053 -0.01 0.0001 
Random effects ([co-
]variances) 
 Estimate (SE) ICC (%) 
95% CI 
Lower Upper 
Level 1 Intercept 118.673 28.711 80.932 73.861 190.673 
Level 2 Intercept 13.108 1.710 8.939 10.151 16.927 
 Residual 14.851 0.909  13.172 16.744 
 
Stress is thought to be a contributory factor in the presentation of psychotic illness 
(see Section 1.2.3 pp. 37 -40), and presented in Sections 3.3.3 (pp. 217-26) and 
3.3.4 (pp. 227-229) there is evidence of an interaction between cannabis and 
stress on schizotypal state. Thus, stressed states (CSQ stress) were assessed as 
an outcome variable, of the aforementioned predictor variables (Table 34). The 
aversive scale was a significant and positive predictor of the amount of concurrent 
stress documented throughout the ESM period (b = 0.15, 95% CI 0.05 to 0.24, p = 
.002). However, neither the cognitive-perceptual, interpersonal, or disorganised 
subscales were significant predictors of stress. This provides some supporting 
evidence of the predictive validity of the CEQ.  
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Table 34 
Parameter estimates for multilevel model of a stressed state (outcome) as a function 
of Aversive cannabis experiences,  schizotypal trait  and cannabis consumption per se 
Fixed effect (intercept, 
slopes) 
Estimate (SE) Z
 
P
 95% CI 
Lower Upper 
Intercept 2.267 0.359 6.32 <.001 1.564 2.969 
Aversive scale 0.147 0.048 3.04 .002 0.053 0.242 
SPQ: Cog-per 0.008 0.0714 0.11 .914 -0.132 0.148 
SPQ: inter -0.047 0.080 -0.59 .556 -0.204 0.110 
SPQ: dis -0.048 0.102 -0.47 .638 -0.248 0.152 
Cannabis consumed -0.427 0.167 -2.56 .011 -0.755 -0.100 
Caffeine 0.011 0.093 0.012 .904 -0.171 0.193 
Tobacco 0.431 0.114 3.77 <.001 0.207 0.655 
Alcohol 0.014 0.105 0.13 .897 -0.193 0.220 
Time -0.001 0.001 -0.81 .419 -0.003 0.001 
Random effects ([co-
]variances) 
 Estimate (SE) ICC (%) 
95% CI 
Lower Upper 
Level 1 Intercept 3.738 1.061 33.837 2.143 6.521 
Level 2 Intercept 4.139 0.459 37.467 3.330 5.144 
 Residual 3.170 0.191  2.817 3.567 
 
4.3.3 Assessments of internal reliability of the Aversive scale 
The aversive scale of the CEQ was assessed for internal reliability with the three 
groups of cannabis users discussed in Chapter 2; a community sample (CSCU); a 
sample with a self-reported diagnosis of depression (DD); a sample with a self-
reported diagnosis of a psychotic disorder (PD). The aversive scale displayed 
good internal reliability in the CSCU group (Cronbach’s α = .932), DD group 
(Cronbach’s α = .917) and the PD group (Cronbach’s α = .939). Thus, the 
measure indicated a small amount of error variance in the three groups 
(respectively, 13.14%, 15.91%, & 11.83%). In the CSCU group no item deletion 
would have served to elevate alpha (see Appendix 37). In the DD group the 
deletion of two items may have served to elevate alpha, however, the largest 
increase is very small (0.002) (see Appendix 37). In the PD group the deletion of 
three items may have served to elevate alpha, however, the largest increase is 
also very small (0.002). This indicates that group identity (CSCU, DD, or PD) 
appears to have little effect on the internal reliability of the aversive scale. Despite 
270 | P a g e  
 
the PD group and the CSCU group presumably having differences in 
neuropharmacology they both respond consistently within groups on the CEQ. 
Unfortunately, there are insufficient participants within the PD group to assess the 
factorial structure of the CEQ. However, the assessments of Cronbach’s alpha do 
not indicate that any of the items have been misallocated to the scale. 
4.3.4 Using the Cannabis Experiences Questionnaire and the Schizotypal 
Personality Questionnaire-brief to predict psychotic illness 
Utilising the data reported in Chapter 2, a discriminant function analysis (DFA) was 
performed. Whilst using a linear DFA the analysis tests a linear combination of 
variables to model group classification. However, as described in Section 2.3.1 the 
data do not meet the requisite assumptions necessary for parametric statistical 
procedures. The principle limitation of using non-parametric DFA is that the 
canonical discriminant coefficients are based on parametric assumptions (linear 
estimation), and thus cannot be computed. Nonetheless, a non-parametric 
discriminant function analysis utilising the Kth nearest neighbour (KNN) method 
was administered.  
 
The KNN method (in this instance) predicts group membership from the 
membership of the nearest data point. The aversive and intoxicated scales of the 
CEQ, and the SPQ-b subscales were considered within the model. The Euclidean 
distances between the participant’s data points on the aforementioned measures 
will be utilised to calculate their nearest neighbour in (Euclidean) geometric space. 
In this investigation the two nearest neighbours will be utilised to calculate the 
group classification. In the instance of a tie between the two nearest neighbours, 
the tie will be decided by selecting the neighbour with the closest proximity to the 
dependent variable.  In the presentation of the results both the true value 
classification will be considered as will the leave-one-out (LOO) method. The LOO 
method considers the results “where the observation in question is omitted and its 
result is predicted from the rest of the data” and thus is more conservative than the 
true value classification (StataCorp, 2011, p203). 
 
The results of the DFA classification table (Table 35) indicate that the model 
computed in the most conservative estimation (LOO) correctly classified 98.14% of 
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the HCU group, 32.94 % of the DD group and 16.67% of the PD group. The total 
error rate value for this model was 11.33%, thus the model correctly classified 
participants 88.67% of the time (Table 36). At the least conservative estimates (i.e. 
not utilising the LOO method) the model correctly classified 94.77% of the HCU 
group, 94.12% of the DD group and 83.33 % of the PD group. This produced an 
error rate of 8.30%, correctly assigning participants 91.70% of the time. 
 
Table 35 
kth nearest neighbour discriminant function analysis assessing group membership as 
a function of the SPQ-b and aversive and intoxicated cannabis induced experiences 
True Group (%) 
Classified Group (%) 
HCU DD PD 
  All data LOO All data LOO All data LOO 
CSCU 
All 
816 
(94.77) 
 45 (5.23)  0  
LOO  
845 
(98.14) 
 14 (1.63)  2 (0.23) 
DD 
All 5 (5.88)  80 (94.12)  0  
LOO*  53 (62.35)  28 (32.94)  3 (3.53) 
PD 
All 3 (6.25)  5 (10.42)  40 (83.33)  
LOO  29 (60.42)  11 (22.92)  8 (16.67) 
Total 824 927 130 53 40 13 
Observed % 82.90 93.26 13.08 5.33 4.02 1.31 
Predicted % 86.62 8.55 4.83 
*One participant unclassified  
 
Table 36 
Count error rate of kth nearest neighbour discriminant function analysis  
 
Count error rate 
CSCU DD PD Total 
All % 6.74 15.15 24.07 8.30 
LOO % 1.86 66.67 83.33 11.33 
Predicted % 86.62 8.55 4.83  
 
The data presented in Sections 2.3.4 and 2.3.6 suggests that the cognitive-
perceptual subscale of the SPQ-b is adept at identifying those who have had a 
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psychological disturbance. The data presented in Sections 2.3.5 and 2.3.6 
suggests the aversive scale may be adept at distinguishing between those who 
have and have not had a psychotic mental illness. This suggests that one feasible 
means of identifying people with a psychotic disorder may be to administer the 
SPQ-b to initially identify psychological disturbance. Those who are affirmatively 
identified could be differentiated into psychotic (or not) by the use of the aversive 
scale. To test this notion a KNN DFA with the three SPQ-b subscales as 
independent variables was conducted. This test was performed with a 
dichotomous outcome variable differentiating between participants who were in the 
community sample of cannabis users (CSCU) and those that have reported a 
diagnosis of mental illness (DD and PD) (Table 37). The predicted category was 
saved as a variable and only those participants predicted to suffer with mental 
illness were re-computed in the next model. The second model utilised the 
aversive scale of the CEQ to differentiate between participants who had been 
diagnosed with a psychotic illness and the participants still left in the model (CSCU 
and DD). The more conservative LOO model will be presented. 
 
Table 37 
Table displaying discriminant function analyses predicting psychopathology per se  as 
a function of schizotypal personality  
Mental illness 
Classified  
No Yes Total 
True value 
No 837 (97.21) 24 (2.79) 861 
Yes 110 (82.71) 23 (17.29) 133 
Error rate (%) 2.787 82.707 13.481 
Observed % 95.27 4.73  
Predicted % 86.62 13.38  
 
Table 38 
Table displaying discriminant function analyses predicting psychotic disorder as a 
function of aversive cannabis experiences 
Psychotic mental illness 
Classified  
No Yes Total 
True value 
No 17 (70.83) 7 (29.17) 24 
Yes 6 (26.09) 17 (73.91) 23 
Error rate (%) 29.167 26.087 27.660 
Observed % 48.94 51.06  
Predicted % 51.06 48.94  
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Table 38 indicates that the proportion (relative percentage) of correctly assigned 
data is lower than the previous approach of considering all predictor variables in 
one model. However, the number of participants correctly assigned to the PD 
group has increased from 16.67% of the sample (8), to 35.42% of the sample (17). 
Suggesting that by administering the SPQ-b to identify those ill and those not ill, 
before using the aversive subscale to identify those psychotic or not is a more 
accurate means of assessing group membership. 
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4.4 Discussion 
4.4.1 Main findings 
This chapter utilised data derived from the investigation described in Chapter 3 to 
elucidate information about the CEQ. The aversive scale of the CEQ was utilised 
to assess cannabis experiences that had occurred within a 24 hour period (CEQ-
b). The aversive cannabis experiences were assessed as an outcome variable of 
events and states that had occurred in the previous 10-16 hours (Section 4.3.1, 
Table 32). A schizotypal state, (psychotomimetic phenomena) was a significant 
positive covariate of the CEQ-b. An assessment of concurrent stress was also a 
significant positive covariate as was the interaction term from the measure of 
stress and cannabis consumption. Aversive cannabis experiences (CEQ-b) 
significantly and positively co-varied with the items most related to psychosis 
proneness. This provides evidence of concurrent and convergent validity of these 
aversive cannabis experiences as assessments of psychosis proneness. 
 
The CEQ-b was also found to be a significant positive predictor of future (>8 hours 
<23 hours) schizotypal state. The aversive cannabis experiences were found to 
hold temporal priority over momentary increases in psychotomimetic experience, 
indicating that the CEQ-b has predictive validity. Moreover, both the within and 
between participant effects of the CEQ-b were found to be significant positive 
predictors of future schizotypal state. This indicates that the CEQ-b could plausibly 
be assessing both; pharmacological vulnerability (see Section 2.4.4) as seen in 
the significant between participant differences; and environmental risk factors as 
demonstrated by significant within participant effects. 
 
The aversive scale (CEQ full version) was assessed as a predictor of a schizotypal 
state and was not found to be a significant covariate. However, the cognitive-
perceptual subscale of the SPQ-b was. This indicates that the CEQ may not be 
appropriate for the assessment of proneness to momentary increases in 
psychotomimetic phenomena. However, given that these experiences commonly 
occur and it is the persistence of experience which appears most clinically 
relevant, this finding may not indicate an absence of predictive validity (van Os et 
al., 2009). Nonetheless, the aversive scale was a significant predictor of self-
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reported states of stress. This indicates that the aetiology of aversive cannabis 
induced experience may be common or related to stress liability/evaluation.   
 
This chapter also utilised data from Chapter 2. The aversive scale of the CEQ 
displayed good internal reliability (all α > .9) in the cannabis users; from a 
community sample (CSCU); with self-reported depression (DD); and with self-
reported psychotic illness (PD). A discriminant function analysis was utilised to 
assess the various measures ability to predict group membership (CSCU, DD or 
PD) from the participant’s data. The CEQ aversive and intoxicated scales and the 
SPQ-b subscales, correctly predicted 88.67% of group membership. However, the 
most effective means identified of discriminating those with psychotic illness 
involved a two-step process: first utilising the SPQ-b subscales to differentiate 
those who have received a diagnosis of a mental illness, and then subsequently 
using the aversive scale of the CEQ to identify those with psychotic illness. 
 
4.4.2 Implications and comparison with other research 
Experience Sampling and the Cannabis Experiences Questionnaire- brief version 
The CEQ-b significantly and positively co-varied with a schizotypal state, 
concurrent perception of stress and an interaction term between concurrent stress 
and cannabis consumption. Propensity for schizotypal states have been shown to 
be increased in psychosis prone cannabis users (Mason et al., 2009). Stressful life 
events have been shown to predict increases in psychotic symptoms in patients 
(Docherty et al., 2009). Moreover, in Sections 3.3.3 and 3.3.4 there is data 
indicating that a cannabis stress interaction effect may be a contributing factor to 
psychotic like experience. Therefore, this indicates convergent validity for the 
CEQ-b as an assessment of psychosis proneness.  
 
The CEQ-b was a significant predictor of schizotypal states that occurred the 
following ESM study day (>8 hours <23 hours). One of the pre-requisites for 
causality, temporal priority can be established here (Bradford-Hill, 1965). However, 
it may be possible that schizotypal states are priming for aversive cannabis 
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experiences. Nonetheless, this finding indicates the predictive validity of the CEQ-
b as an assessment of proneness to psychotic like experience.  
 
This investigation also demonstrated that both within and between participant 
effects of the CEQ-b were significant predictors of schizotypal states the following 
day. The between participant significant effect of the CEQ-b provides some 
evidence in support of the test-retest reliability of the CEQ. The significant 
relationship of, between participant variance and schizotypal state indicates that 
despite within participant variance the measure still accounts for a significant 
proportion of the variance in schizotypal state. 
 
Prior to this investigation it was unclear as to whether aversive cannabis 
experiences represent stable ‘schizotaxic’ vulnerability or aversive environmental 
factors, or both. The significant effect of the within participant differences indicates 
that there are plausibly environmental factors which influence aversive cannabis 
induced experiences relationship with future schizotypal states. The relationship 
documented between the CEQ-b and stress, suggests that this could be one 
environmental factor which may prime for aversive cannabis induced experience 
and schizotypal state. In an ESM investigation another factor (emotional reactivity) 
has been shown to interact with stress to correlate with positive psychotic 
symptoms in patients with psychotic illness and their relatives (Lataster et al., 
2010). However, Lataster et al. (2010) also found that emotional-reactivity to 
stress tended to cluster in families which could suggest genetic factors. 
 
The between participant significant effect of the aversive scale indicates that a 
stable construct may influence the relationship between the predictor and future 
psychotic-like experience. An increased sensitivity to the psychotomimetic effects 
of cannabis has been documented to have a familial link with psychotic illness 
(GROUP, 2011) and aversive cannabis experiences occur most frequently in 
those psychosis prone (Barkus, et al., 2006; Stirling et al., 2008). Henceforth, it is 
likely that a proportion of the between participant variance is as a consequence of 
a genetic component. Nonetheless, there are feasibly relatively stable 
environmental factors which may account for some of the effect (e.g. urbanicity, 
see Krabbendam & van Os, 2005).  However, the significant within and between 
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participant effects of the CEQ-b appears to indicate that the measure reflects both 
environmental and genetic processes. 
 
Experience sampling and the aversive scale of the cannabis experiences 
questionnaire (full version)  
The aversive scale (administered prior to the ESM phase) was not found to be a 
significant predictor of schizotypal state. However, the cognitive-perceptual 
subscale of the SPQ-b was. This provides evidence of the predictive validity of the 
cognitive-perceptual subscale, but not the aversive scale. Section 2.3.4 suggests 
that of the three SPQ-b subscales the cognitive-perceptual one is most adept at 
identifying self-reported psychotic illness, these results support that notion. 
Moreover, other research has demonstrated that highly schizotypal cannabis users 
have displayed elevated psychotic like experience (Mason et al., 2009). The non-
significant relationship between the aversive scale and schizotypal state indicates 
that the measure cannot significantly predict the propensity to momentary 
psychotic-like experience. However, this does not discount the scales proficiency 
in feasibly; assessing propensity to more enduring clinically relevant psychotic 
symptoms; or assessing other related momentary constructs.  
 
The CEQ aversive scale was however, a significant predictor of a stressed state. 
This implicates that the expression of aversive cannabis induced phenomena may 
share a common aetiology with reactivity to stressors, and/or a stressful 
environment. Collip et al., (2013) demonstrated that individuals with persistent 
psychotic experiences had higher levels of reactivity to stress in comparison to 
individuals with transient psychotic experiences. One review concluded that 
“aberrant emotional reactivity to daily stress may constitute part of the liability to 
psychosis” (Myin-Germeys & van Os, 2007, p.420). Thus, the relationship between 
the aversive scale and a stressed state could plausibly be a better indicator of the 
scales ability at predicting enduring illness than the (lack of) relationship with a 
schizotypal state. Nonetheless, the relationship between susceptibility to a 
stressed state and the aversive scale provides evidence of the convergent validity 
(and in some regards predictive validity) of the measure at assessing psychotic 
vulnerability.  
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Discriminating between cannabis users  
The aversive scale of the CEQ displays good internal reliability in the three groups 
of cannabis users; a community sample (CSCU); those with self-reported 
depression (DD) and those with a self-reported psychotic disorder. This suggests 
that the scale is appropriate for use in both clinical and non-clinical populations. 
The results of the discriminant function analysis indicate that perhaps the optimum 
way to utilise the SPQ-b and the aversive scale is in a two-step process. First 
utilising the SPQ-b to identify psychopathology, then secondly utilising the 
aversive scale to identify those with a psychotic illness. As it is hoped that the 
measures under assessment may be utilised as a self-report predictor of psychotic 
vulnerability, it is necessary to adopt the most conservative approach. Thus, only 
the results from the Leave One Out (LOO) method will be discussed. Even with 
the optimum means of discriminating between participants described, only around 
a third of participants were correctly identified as having a self-reported psychotic 
diagnosis. This finding and the associated R2 values of the regression models 
(Sections 2.3.7-9) indicate that the variables under assessment only account for a 
small amount of variance in diagnosis. Thus, indicating that other factors may 
account for a large proportion of variance in the data. 
 
Schizophrenia has been associated with environmental risk factors such as: 
obstetric conditions (Byrne, et al., 2007), prenatal illness (Brown, Cohen, 
Greenwald, & Susser, 2000), childhood trauma (Heins et al., 2011), acquired brain 
injury (see Clarke et al., 2012), and urbanicity (Krabbendam & van Os, 2005) 
amongst others. Feasibly, hundreds of genetic SNP may each confer a small 
additive risk (Purcell et al., 2009) in what has been described as a “hyper-
complex” model (Sullivan, 2005, p212). If the various psycho-social and genetic 
risk factors had been considered in the current investigation they would have in all 
likelihood accounted for some of the variance in the data. The measuring and 
assessment of such a quantity of variables is implausible for most investigations, 
and the current investigation is not an exception.  Despite the myriad of factors 
that contribute to a risk of a diagnosis of a psychotic disorder, the psychotomimetic 
phenomenology documented in measures of schizotypy are thought to represent 
an expression of an individual’s genetic risk to the development of psychosis, the 
“schizophrenic phenotype” (Rado, 1960 p.87). The current investigation has 
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served to demonstrate that the psychotomimetic phenomenology assessed by the 
aversive scale may also reflect an expression of one or several genetic and 
psycho-social determinates of psychotic liability.  
 
A differential sensitivity to the psychotomimetic effects of cannabis expressed as 
psychotic like experience has been demonstrated in individuals diagnosed with 
psychotic illness (D’Souza et al., 2005), their first degree relatives (GROUP, 2011) 
and individuals prone to psychosis (Barkus, et al., 2006; Barkus & Lewis, 2008; 
Henquet et al., 2005; Mason et al, 2009; Stirling et al., 2008). The association 
between cannabis and schizophrenia may feasibly occur as a result of an 
interaction between genetic (Caspi et al., 2005) and/or psychosocial processes 
(Houston et al., 2008).  Moreover, cannabis is thought to be an independent 
developmental antecedent to schizophrenia (Arseneault et al., 2007). Thus, it 
would stand to reason that psychosis prone individuals may be identifiable by their 
response to cannabis. The current investigation has added further to this area of 
research by demonstrating that people with self-reported psychotic illness can be 
identified by their experiences with cannabis. This indicates that cannabis-induced 
experience may be one means by which psychotic vulnerability can be assessed.   
 
A differential sensitivity to the psychotomimetic effects of cannabis may represent 
one of several endophenotypes which may independently contribute to different 
pathways to psychotic illness (e.g. see Myin-Germeys & van Os, 2007).  This 
could plausibly indicate that the aversive scale might be incapable of identifying 
disorder that originates from vulnerability to other pathways. Those diagnosed with 
cannabis induced psychotic disorder have displayed significantly more aversive 
cannabis induced experiences (Stirling, 2011). Cannabis users who have been 
diagnosed with schizophrenia appear to be substantively different to their non-
cannabis using counterparts (Meijer et al., 2012). Moreover, around half of those 
diagnosed with a cannabis-induced psychotic disorder progress to develop a 
schizophrenia-spectrum disorder (Arendt et al., 2005). Thus, as opposed to 
assessing psychotic vulnerability per se, the aversive scale could plausibly be 
assessing the ‘psychotic vulnerability’ of the cannabinoid system. Identifying such 
sensitivity can have wide reaching implications by enabling the assessment of 
individual risk to cannabis. Moreover, given the relationship between the 
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endocannabinoid system and stress (see Section 1.7.4 pp. 91-95 & Sections 
3.3.3-4 pp. 217-29) aversive cannabis induced experiences could be reflective of a 
psychotic sensitivity to psychological stressors.  If this were the case the aversive 
scale may be useful in assessing allocation of stress reduction treatment in 
psychotic patients.  
 
4.4.3 Limitations  
The limitations of this investigation have already been discussed in depth in 
Sections 2.4.3 (pp. 155-57) and 3.4.3 (pp. 247-257) and will not be repeated here. 
However, there is a limitation specific to comparing the CEQ-b to the aversive 
scale of the CEQ. The items of the CEQ-b and the aversive scale are the same, 
except for an altered rubric. However, the time frame in which the items refer to is 
very different. The CEQ-b refers to events that have taken place over the last 24 
hours. However, the aversive scale of the CEQ refers to the participant’s ‘lifetime’ 
experience with cannabis. Although the CEQ-b can allow for inferences to be 
made about the aversive scales stability and validity, caution should be applied. At 
present there is not enough data to suggest what, if any, difference exists between 
these two measures in their assessment of psychosis vulnerability.  Nonetheless, 
it would be erroneous to assume that they were entirely equivocal. 
 
4.4.4 Conclusions 
This chapter has considered the data of two separate investigations. These data 
have provided information regarding the validity and reliability of the CEQ aversive 
scale as an assessment of psychotic vulnerability. This investigation has 
demonstrated both convergent and predictive validity of the CEQ-b, which 
plausibly infers validity of the aversive scale of the full CEQ. The cannabis induced 
experiences assessed by the CEQ-b appear to be influenced by both stable 
(between participants) and transient (within participant) effects.  This is a similar 
notion that has been discussed in relation to drug induced experiences since the 
1960s called the “set-setting theory” (Leary, 1966, p.84). The CEQ-b is reflecting 
both the innate vulnerability (‘mind-set’) and environmental stressors (setting) 
which constitute a risk for psychotic-like experience. This may indicate that the 
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aversive scale of the CEQ (full version) is assessing genetic and environmental 
risk factors. 
 
The aversive scale of the CEQ (full version) was a significant predictor of a 
stressed state in the ESM investigation. This indicates that the aversive scale may 
share a common or closely related construct with liability to stress reactivity. It has 
been proposed that altered emotional reactivity to stress may constitute an 
endophenotype for psychosis (Myin-Germeys & Van Os, 2007). Thus, perhaps 
aversive cannabis induced phenomena may be experienced more regularly in 
individuals with this particular propensity. This demonstrates convergent and 
predictive validity of the aversive scale as a predictor of psychotic vulnerability. 
 
This investigation has demonstrated that, by quantifying cannabis induced 
experience it is possible to discriminate between participants who have or have 
not been diagnosed with a psychotic illness. This indicates that cannabis-induced 
experiences may be an appropriate means to assess risk of psychotic 
vulnerability. These experiences did however only account for a small proportion 
of variance in the data. 
 
In assessment of psychotic liability; interviewing, psychiatric assessment, and 
genetic analyses are costly, often impractical and can be imprecise. Thus, one of 
the most common means to assess vulnerability is via self-report questionnaire 
such as the SPQ-b. However, assessments of schizotypy may highlight a gamut of 
(attenuated) symptomatology even if they originate from non-psychotic illness (see 
Section 2.4.2 pp. 147-54). This could feasibly indicate that conventional measures 
of psychosis proneness are not appropriate with cannabis using populations who 
have been diagnosed with-, or an increased risk of- non-psychotic illness. 
However, assessment of cannabis induced phenomena may circumvent this 
problem without increasing demands on resources. Cannabis consumption may 
allow for the assessment of vulnerability to environmental (psychotic) stressors, in 
a similar manner to the use of a tilt-table test in the diagnosis of syncope. 
 
The aversive scale of the CEQ has previously provided evidence of its concurrent 
and convergent validity with assessments of psychotic vulnerability (Stirling et al., 
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2008). Moreover, the CEQ has previously displayed good test-retest reliability 
(Stirling, unpublished data).  The aversive scale has now provided further 
evidence of its convergent validity (Sections 4.3.1 pp. 263-67 and 4.3.2 pp. 267-
69), discriminant validity (Section 4.3.4 pp.270-73), and predictive validity (Section 
4.3.2), as an assessment of psychotic vulnerability. Moreover, the aversive scale 
has demonstrated internal reliability in both clinical respondents and a community 
sample (section 4.3.3 pp. 269-70) and there is further evidence suggesting test-
retest reliability (section 4.3.1). 
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5. Summary of the main findings in relation to aims and 
implications 
This chapter serves to highlight the means by which each of the research chapters 
(Chapters 2, 3 & 4) individual aims have been fulfilled. This chapter also discusses 
how each respective chapter has contributed to accomplishing the overall aim of 
this body of research. It will also highlight to the reader some of the main 
implications of each of the individual chapters and the thesis as a whole. 
 
5.1 Chapter 2 
Four groups of participants were assessed on measures of schizotypy (SPQ-b) 
and cannabis induced phenomena (CEQ), where applicable. These groups of 
participants consisted of a community sample who were cannabis naïve (CSCN, n 
= 306); a community sample who were cannabis users (CSCU, n = 861); cannabis 
users with self-reported depression (DD, n = 85); cannabis users with a self-
reported psychotic disorder (PD, n = 48).  
 
In pairwise comparison the PD group scored significantly higher than the DD 
group on only one of the three SPQ-b subscales (cognitive-perceptual). The PD 
group had significantly more aversive cannabis experiences than both the DD 
group and the CSCU group. However, the DD group had significantly more 
appetitive cannabis experiences than both the PD group and CSCU group. The 
various regression models and the pairwise comparison contained within this 
chapter indicate that the cognitive-perceptual subscale of the SPQ-b and the 
aversive scale of the CEQ display evidence of convergent validity and specificity to 
assessment of psychotic vulnerability. 
 
5.1.1 Aims of Chapter 2 
1. To assess variance in schizotypal trait related to cannabis use and reported 
mental illness  
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2. To assess the presence of a differential sensitivity to the psychotomimetic 
effects of cannabis in those with psychotic illness  
3. To assess the utility of assessments of cannabis induced experience and 
schizotypal trait as predictors of psychotic illness in cannabis using 
populations 
 
The first aim of the chapter was acheived in Section 2.3.4 (pp.127-31), through 
pairwise comparison of the aforementioned groups of participants on assessments 
of schizotypy. The second aim of this chapter was fulfilled in Section 2.3.5 (pp. 
132-33) via pairwise comparison of the CSCU group, DD group, and PD group on 
the CEQ. A differential sensitivity of cannabis was observed, which feeds into the 
second aim of this thesis. The third aim was partially acheived in Section 2.3.5 (pp. 
131-33) via assessment of group differences in the CEQ. The analyses contained 
within Sections 2.3.6-8 (pp.134-45) also provide evidence towards aim 3. In these 
sections cannabis induced experiences and schizotypal trait were assessed within 
various regression models for their ability to significantly predict psychotic 
disorder. 
 
5.1.2 Implications of Chapter 2 
The SPQ-b subscales may not all equally contribute to an increased predisposition 
to psychosis in cannabis using populations and thus, future investigations should 
apply caution when assessing participant’s total score on the SPQ-b.  Moreover, 
the interpersonal and disorganised SPQ-b subscales may not be appropriate for 
the accurate assessment of psychosis proneness in cannabis using populations 
when other mental illness is present. Henceforth future investigations should 
consider other means of assessing psychotic vulnerability when conducting 
research with this population, such as by assessing differential sensitivity to 
cannabis. However, the cognitive-perceptual subscale of the SPQ-b and the 
aversive scale of the CEQ appear promising at discriminating between cannabis 
users who have increased psychotic liability and those with liability to other mental 
illness. These scales may prove useful in future investigations wishing to assess 
psychosis proneness in cannabis using populations.  
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This chapter has substantiated the notion of a differential sensitivity to the 
psychotomimetic effects of cannabis on the basis of psychotic vulnerability. 
Participants with self-reported psychotic disorder had significantly more aversive 
experiences than a community sample, and cannabis users with self-reported 
depression. Interestingly, a differential sensitivity in the subjective effects of 
cannabis was also elucidated in those with reported depression. Participants who 
reported experience of this disorder also had significantly more pleasurable effects 
of cannabis. A dysfunctional endocannabinoid system may play a role in the 
presentation of depression. This is evinced by the results of previous 
investigations (see Section 2.4.2 pp. 147 -54) and the results of this chapter, which 
revealed cannabis users with self-reported depression experiencing a differential 
sensitivity to appetitive cannabis induced phenomena. This may suggest an 
antidepressant effect of cannabis. However, the current investigation failed to 
establish if the appetitive cannabis experiences occurred whilst experiencing the 
symptoms of their mood disorder. Further investigation is necessary to establish if 
participants who are currently presenting with depressive symptomatology also 
frequently experience appetitive cannabis induced phenomena. This notion may 
be tested through an ESM study design with recreational/self-medicating cannabis 
users suffering with depression in order to assess the momentary relationship 
(temporal priority) between cannabis consumption, depressive symptomatology, 
and appetitive cannabis experience. 
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5.2 Chapter 3 
Chapter 3 considered the data from 36 healthy regular cannabis users applying an 
ESM study design. Over a two week period the participants completed multiple 
assessments of a stressed state, a calm state and a schizotypal state. Participants 
also completed items pertaining to their previous events and drug consumption. 
 
This investigation demonstrated methodological reactivity as displayed by 
frequency of data entry significantly and positively co-varying with schizotypal 
state. In various models a stressed state was also found to be a significant positive 
covariate of a schizotypal state, conversely, a calm state was a significant 
negative covariate of interpersonal schizotypal states. Cannabis consumption and 
quantity of cannabis consumed significantly increased scores on the calm scale. 
This finding could be taken as evidence in support of the drug conferring an 
anxiolytic effect. Cannabis consumption and quantity of cannabis consumed 
significantly predicted schizotypal states in the domains of interpersonal distortion 
and disorganisation. However, elevations in the disorganised domain of 
schizotypal state significantly predicted cannabis consumption. This indicates that 
elevations within this domain may be as a consequence of synergistic 
maintenance. However, cannabis appears to exert an independent effect on 
interpersonal distortions. Stress and cannabis consumption also significantly 
interacted to predict a schizotypal state.  
 
5.2.1 Aims of Chapter 3 
1. To assess whether schizotypy has state like components that are altered by 
cannabis intoxication  
2. To assess the evidence for temporal priority in the relationship between 
cannabis and psychotic experience in a naturalistic setting.  
3. To assess the effect of a stressed and calm state on psychotic-like states 
utilising a cannabis challenge to facilitate a model of psychosis. 
4. To assess factors which may influence the consumption of cannabis 
5. To assess the plausibility of an interaction between cannabis and 
psychological stressors on psychotic (like) experience  
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The first aim of this chapter is in part substantiated by the consideration of 
scatterplots of the participant’s scores on the SSQ (see Section 3.3.3 pp. 217-26 & 
Figure 9). Schizotypal states displayed both within and between participant 
variance. The first aim of this investigation is fulfilled in analyses contained within 
Section 3.3.3 in which cannabis consumption was shown to significantly predict 
schizotypal states.   
 
Analyses contained within Section 3.3.3 also served to accomplish aim 2, along 
with analyses contained within Section 3.3.6 (pp. 234-238). These analyses 
assessed whether cannabis consumption significantly predicted psychotic-like 
states and in-turn whether psychotic-like states significantly predicted cannabis 
consumption. Given the repeated measures study design these analyses were 
capable of establishing temporal priority. 
 
Analyses contained within Section 3.3.3 assisted to acheive the third aim of this 
investigation. The analyses contained in Section 3.3.3 assessed stressed and 
calm states as predictors of psychotic-like states. The data indicated that stressed 
states significantly increased schizotypal states, and calm states decreased 
interpersonal schizotypal states.  
 
Aim four was addressed by assessing variables which increase the O.R. of 
cannabis consumption (Section 3.3.6). These analyses assessed psychotic-like 
states and stressed states as predictors of cannabis consumption. The fourth aim 
was also attained by analyses contained within Section 3.3.5 (pp. 230-34) which 
investigated whether cannabis may serve to confer a beneficial effect on the 
participant’s perception of stressed or calm states. These analyses could be said 
to be assessing aspects of the self-medication hypothesis. 
 
Aim five of the investigation was addressed in Section 3.3.3 in which a cannabis 
stress interaction variable was assessed as a predictor of a psychotic-like state. 
The fifth aim of this investigation was reached by the analysis contained in Section 
3.3.4. (pp. 226-29) In this section participants that displayed the least and most 
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stressed states throughout the investigation were assessed independently for an 
effect of cannabis consumption on psychotic-like states. 
 
The first, second, fourth and fifth aims of this investigation contribute to the thesis’ 
first overall aim of adding to discussions of causality in the relationship between 
cannabis and psychosis. The first aim of this body of research is fulfilled through; 
the establishment of the temporal sequence of cannabis and psychotic-like states; 
establishing the presenece of a beneficial (possibly self-medicative) anxiolytic 
effect of cannabis; and providing supporting evidence of a plausible mechanism. 
 
5.2.2 Implications of Chapter 3 
This investigation has demonstrated some evidence of methodological reactivity, 
whereby the act of measurement in itself serves to alter the variable under 
assessment. This indicates that whilst undertaking future investigation with this 
population attention should be paid to both monitoring and attempting to diminish 
methodological reactivity. Nonetheless, the majority of the participants that 
initiated the investigation completed it and the majority of the equipment was 
returned. Thus, indicating that ESM research is a viable methodology with this 
population. 
 
Stressed states increase psychotomimetic experience and calm states 
independently decrease psychotomimetic experience. This may plausibly indicate 
stress reduction exercises as a useful approach in controlling psychotic symptoms. 
However, further investigation is required to understand whether the relationship 
between stress and psychotic experience displayed in this healthy sample has a 
similar effect in a clinical population.  
 
Cannabis consumption elevates schizotypal states which implicates a causal 
relationship between cannabis and psychotic illness. However, this appears 
restricted to ‘symptoms’ from within the interpersonal domain. There is still a need 
to assess whether such elevations in such schizotypal states translate to an 
increased risk of decompensating into psychotic disorder. Disorganised 
schizotypal states were both predicted by cannabis consumption and predicted 
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cannabis consumption. This may implicate both a self-medication type action, and 
a cannabis-psychosis causal action; a synergistic self-maintaining model. 
Intriguingly in Chapter 2 the community sample cannabis users and non-users 
were only differentiated by schizotypal traits within the disorganised domain. 
These findings, when combined, may indicate that psychotic-like states from within 
this domain are synergistically maintained (as evinced in the ESM investigation). 
However, the exacerbation of schizotypal traits within the community sample of 
cannabis users could indicate; permanent alteration as a consequence of 
cannabis; or attempts to self-medicate a pre-existing vulnerability / pathology. 
Nonetheless, cannabis appears highly related to both disorganised schizotypal 
state and trait. Further, investigations could seek to elucidate this relationship by 
conducting multi-staged research consisting of both ESM assessment of 
schizotypal state and longitudinal follow-up phases (similar to that described in 
Collip et al., 2013). To assess the persistence of the transient psychotomimetic 
effects of cannabis. 
 
This investigation has also provided some support for the ‘self-medication 
hypothesis’ cannabis appears to induce calm like states in the user. This could 
plausibly indicate that the cannabis users may use cannabis in an attempt to 
mitigate the effects of adverse psychological states. Nonetheless, cannabis 
appears to confer no benefit on psychotic-like symptoms, or stressed states. 
However, calm states attenuate interpersonal schizotypal states. This indicates 
that a proportion of the association between cannabis and schizophrenia could 
plausibly be as a consequence of self-medication. Future investigations attempting 
to establish causal inference should consider taking a measure of the anxiolytic 
effects of the drug. 
 
This investigation has elucidated an interaction effect between cannabis and 
stressed states. This could be the mechanism by which cannabis use could 
contribute to psychotic breakdown and excacerbate symptoms. However, further 
research is required to this effect. Nonetheless, this indicates that individuals at 
highest risk of psychotic illness should be advised against using cannabis as a 
stress reduction aid. 
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5.3 Chapter 4 
The aversive scale of the CEQ has demonstrated evidence of its convergent 
validity (Sections 4.3.1 pp. 263-67 and 4.3.2 pp. 267-69), discriminant validity 
(Section 4.3.4 pp. 270-73), and predictive validity (Section 4.3.2) for assessment 
of psychotic vulnerability. Moreover, the aversive scale has established internal 
reliability in both clinical respondents and a community sample (Section 4.3.3 
pp.269-70 ) and there is further evidence suggesting test-retest reliability (Section 
4.3.1).   
 
5.3.1 Aims of Chapter 4 
1. To assess evidence for the reliability of the aversive scale of the CEQ as an 
assessment of psychotic vulnerability. 
2. To assess evidence for the convergent, concurrent and predictive validity of 
the aversive scale of the CEQ. 
 
5.3.2 Implications of Chapter 4 
The data presented in this section suggests that the aversive scale of the CEQ is 
adept at assessing psychotic vulnerability. The psychotic vulnerability displayed 
however, may only be representative of one of several functional pathways to 
psychosis. This measure could feasibly be assessing the cannabinoid pathway to 
psychotic disorder. Nonetheless, the measure appears to reflect both genetic and 
environmental factors. Given that cannabis use is one of the few controllable risk 
factors there is a need to undertake a prospective cohort study assessing 
cannabis experiences as a predictor of psychotic illness. Such an endeavour may 
be utilised to reduce the incidence of psychosis in a population known to be at an 
increased risk. 
 
Cannabis is the most frequently consumed illicit drug. Thus, the assessment of 
cannabis induced phenomenology could represent an opportunity for the rapid and 
wide spread assessment of psychotic vulnerability. This thesis highlights the need 
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for a prospective cohort based study examining the predictive ability of the 
aversive scale at assessing vulnerability to psychosis.  
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5.4 Aims and implications of this thesis 
The thesis as a whole possessed two primary aims: 
1. To contribute to discussions relating to ‘causal inference’ in the relationship 
between cannabis and psychosis 
2. To assess the reliability and validity of a measure of psychotic vulnerability 
based on differential sensitivity to cannabis 
 
The first aim of this thesis is addressed in Chapter 3. Chapter 3 allowed for the 
assessment of temporality of numerous variables of interest. Within a continuum 
model of psychosis, analyses contained in Sections 3.3.3, 3.3.5, 3.3.6 assessed 
the validity of the; self-medication hypothesis; a causal model of association; and a 
synergistic model of association (see Section 1.6 pp. 61-79). Evidence supported 
the existence of all three of these models of association. In addition to temporality, 
the data considered within this chapter also allowed for the assessment of another 
aspect of causality, plausibility. The presence of a cannabis and stress interaction 
effect were assessed, with evidence found in support of the notion that such an 
effect may play a role in a plausible mechanism of decompensating. Thus, this 
thesis has served to contribute to discussions pertaining to; whether cannabis use 
causes psychotic illness; and the mechanism by which cannabis use may (interact 
with other factors to) cause psychotic illness. There is a paucity of research within 
this area which can establish temporality (Kimhy et al 2009), or assess the 
plausibility of a cannabis stress interaction effect (see Henquet et al., 2008). Thus, 
this investigation represents a significant contribution to knowledge.  
 
The second chapter helped to fulfil the second primary aim of this thesis. This 
chapter served to substantiate the notion of a differential sensitivity to the 
psychotomimetic effects of cannabis in those vulnerable to psychosis. Such a 
differential sensitivity to cannabis has only been demonstrated in a small number 
of investigations previously (see Section 2.1 pp. 102-05), and to the authors 
knowledge never previously utilising both a community sample control and clinical 
control (reported depression). Thus, such a finding contributes to this area of 
research. The data contained within the fourth chapter provided evidence of the 
validity and reliability of the aversive scale.  
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The aversive scale could plausibly represent psychotic sensitivity of the 
endocannabinoid system and / or psychotic sensitivity to psychological stressors. 
The ability to assess sensitivity of the endocannabinoid system is a worthwhile 
endeavour, as cannabis use is one of the few purported independent 
developmental antecedents of psychotic disorder which is preventable. 
Furthermore, if the aversive scale is assessing psychotic sensitivity to stress, the 
measure could be capable of identifying individuals who are likely to have the 
biggest diminution of psychotic symptomatology in response to stress reduction 
techniques. The investigations within this thesis and that of previous investigations 
(see Section 2.1) indicate that the aversive scale is appropriate for assessment of; 
psychotic vulnerability; and adverse (psychotic) reaction to cannabis. Therefore, 
the aversive scale may be useful in the future; in drug education programmes and 
risk assessment in recreational cannabis users; in screening for medicinal 
cannabis prescription; in screening for research trials with cannabinoids or other 
known psychotomimetics; and in the allocation of psychological intervention for 
cannabis dependence, and (possibly) stress-reduction in those with disorder or at 
ultra-high risk. Thus, the development of the aversive scale of the CEQ (and 
consequently this thesis) may have implications for research, education and 
clinical care. The development of a scale for assessment of psychotic vulnerability 
based on differential sensitivity to the psychotmimetic effects of cannabis is a 
significant contribution to this area of research.  
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7. APPENDICES 
Appendix 1 Principal component analysis of the cannabis experiences 
questionnaire 
Considering the data from a community sample of 892 cannabis users a principal 
component analysis (PCA) with oblimin rotation was performed on the cannabis 
experiences questionnaire. Any factor scoring an eigenvalue higher than two was 
retained in the model. As demonstrated by the associated scree plot a three factor 
solution emerged (Figure 13). 
 
Figure 13 
Scree plot of principal component analysis of the cannabis experiences 
questionnaire 
 
Any factor with a unique loading of 0.4 was retained in the model the putative 
names assigned are displayed in the associated pattern matrix with the full list of 
the CEQ items (Table 39). 
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Table 39 
Table the pattern matrix of a principal component analysis of the Cannabis 
Experiences Questionnaire 
 Aversive Appetitive Intoxicated 
Feeling happy -.490 .529 .167 
Being relaxed -.590 .428 .366 
Excited .005 .594 -.034 
Sleepy -.110 -.007 .573 
Energized -.051 .641 -.248 
Powerful .240 .513 -.186 
Laid back -.599 .428 .383 
Sentimental .046 .452 .196 
Felt all powerful, like you could do anything .241 .520 -.142 
Religious .278 .292 -.121 
Full of Plans -.018 .704 .070 
Ecstatic .014 .684 -.087 
Feel more creative -.144 .740 .104 
Able to understand the world better -.056 .650 .184 
Enhanced perceptual awareness .042 .548 .143 
Looking for excitement .066 .551 -.019 
Out of body experiences .469 .262 -.125 
Full of ideas -.026 .714 .095 
Obsessive (or fixed on something) .332 .363 .216 
Fearful .617 -.074 .143 
Angry .606 .180 -.066 
Paranoid .592 -.107 .230 
Uncomfortably sleepy .255 -.050 .374 
Anxious .694 -.143 .185 
Like there was something you had to do no matter 
what 
.386 .319 .039 
Depressed .616 -.003 .194 
Deluded .464 .248 .056 
Rapid flow of thoughts .237 .530 .128 
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Table 38 continued 
 Aversive Appetitive Intoxicated 
Threatened by unknown force .690 .017 .045 
Lethargic .038 .053 .547 
Sad .582 .037 .149 
Disturbed in your thinking .587 .003 .241 
Nervy .601 -.010 .239 
Speech becomes slurred .218 .117 .285 
Slowing of time .173 .130 .355 
Auditory hallucinations .467 .184 .044 
Visual hallucinations .499 .174 -.064 
Things not feel right on your skin .564 .052 .139 
Losing a sense of reality .451 .177 .228 
Feeling like you no longer know yourself .689 .005 .106 
Fearful that you are going mad .743 .007 .059 
Reduced level of consciousness .175 .066 .360 
Increased appetite -.110 .217 .466 
Disinhibition AE .312 .157 .335 
Don't want to do anything AE .069 -.076 .780 
Feel Generally slowed down AE .086 -.121 .817 
Loss of motivation AE .109 -.048 .740 
Feel that your thinking has been slowed down AE .187 -.117 .738 
Cannot concentrate AE .198 -.080 .698 
Slowing of time AE .199 -.035 .557 
Paranoid without reason AE .633 -.088 .285 
Suspicious without reason AE .635 -.031 .255 
Felt depersonalised AE .566 .028 .283 
Cannot remember events AE .046 .149 .255 
Have reduced attention AE .181 -.009 .670 
AE = After Effect    
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Appendix 2 An example of study advertisement in a virtual 
environment 
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Appendix 3 Study advertisement (hard copy) 
 
Help needed for a study by the Research Institute for 
Health and Social Change 
 
 
 
  
We in the Psychology Department at MMU, England are researching the 
relationship between cannabis and mental illness. We are looking for anyone over 
the age of 18, who has a history of mental health problems and who has used 
cannabis at least once to complete an anonymous questionnaire. 
  
The main aim of our research is to develop a tool which will help identify those 
who might be at risk to some of the adverse effects of cannabis. This tool could 
hopefully prevent, or delay some people becoming unwell. 
  
If you would like to take part or for further information, then please go to: 
www.hpsc.mmu.ac.uk/street-drugs-research 
 
At this time we are only interested in the recreational (or non-medically prescribed) 
use of natural (non-synthetic) cannabis products. If you have ONLY had 
experience of synthetic cannabis products (e.g. Spice), or medically prescribed 
natural cannabis products (e.g. Sativex) you would not be eligible to take part. 
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Appendix 4 Demographic information & mental health questionnaire 
1 Sex Female Male 
2 Age 
 
   
3 
I am currently psychologically 
well. 
Yes No 
4a 
I am currently receiving 
treatment for a nervous / 
psychological disorder. 
Yes No 
4b 
(If previous answer was YES) 
What nervous / psychological 
disorder(s) are you being 
treated for? 
 
 
 
 
 
5a 
I have received treatment for 
a psychological disorder in the 
past 
Yes No 
5b 
(If previous answer was YES) 
What nervous or 
psychological disorder(s) have 
you received treatment for? 
 
 
 
 
 
6a 
I am currently taking 
medication to treat a 
psychological disorder. 
Yes No 
6b 
(If previous answer was YES) 
What medication(s) are you 
currently taking? 
 
 
 
 
 
  
 
 
 
This questionnaire will ask for some basic information about yourself and your mental health. Any 
responses that you give will be treated in the strictest confidence. Please circle or fill in the boxes 
where appropriate. 
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7a 
I have been prescribed 
medication to treat a 
psychological in the past that 
I am not currently taking. 
Yes No 
7b 
(If previous answer was YES) 
Please give the name(s) of the 
medication that you were 
prescribed. 
 
 
 
 
 
8 
If you are/were taking 
medication, did/do you take 
your medication as often as 
the doctor or pharmacist told 
you to? 
(please circle one of the boxes 
or complete the ‘other’ 
option) 
Rarely 
or 
never 
From 
time to 
time 
Sometimes Yes 
and sometimes 
No 
More 
often 
than 
not 
Always or 
almost 
always 
Other:__________________________________ 
9a 
Are you currently receiving 
treatment for a nervous or 
psychological disorder that is 
not medication? 
Yes No 
9b 
(If previous answer was YES) 
What (none medication) 
treatment are you currently 
receiving? 
 
 
 
 
 
10a 
Have you ever received 
treatment for a nervous or 
psychological disorder that 
was not medication? 
Yes No 
10b 
(If previous answer was YES) 
Please indicate what 
treatment you have received 
for a psychological disorder 
that was not medication. 
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Appendix 5 Checklist of ‘other drugs’ 
  
342 | P a g e  
 
343 | P a g e  
 
Appendix 6 Screen shot: Participant Information Sheet 
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Appendix 7 Screen shot: Context of the investigation 
 
346 | P a g e  
 
Appendix 8 Screen shot: Participant information about the study 
ethics 
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Appendix 9 Screen shot displaying researcher contact details 
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Appendix 10 Screen shot displaying consent form 
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Appendix 11 Screen shot displaying questionnaire ‘pop up’ 
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Appendix 12 Tests of normality on participant characteristics 
 
Table 40  
Showing tests of normality on participant characteristics  
 
 n Skewness Kurtosis 
Kolmogorov-Smirnov 
 D DF p- value 
PD 
Frequency of use 40 0.82 -0.63 0.230 40 <.001 
Weekly Expenditure 45 -0.37 -1.655 0.202 45 <.001 
Age of first use 48 2.718 13.016 0.169 48 <.001 
Age 48 0.756 -0.390 0.142 48 .017 
Number of lifetime uses 48 4.759 21.624 0.538 47 <.001 
DD 
Frequency of use 79 1.21 0.40 0.333 79 <.001 
Weekly Expenditure 85 -0.294 -1.494 0.229 85 <.001 
Age of first use 85 1.596 3.799 0.166 85 <.001 
Age 85 1.166 1.092 0.145 85 <.001 
Number of lifetime uses 77 9.220 85.0 0.428 77 <.001 
CSCU 
Frequency of use 845 0.072 -1.08 0.159 845 <.001 
Weekly Expenditure 685 0.606 -1.24 0.257 685 <.001 
Age 861 2.643 8.533 0.239 861 <.001 
 
Appendix 13 Tests of homogeneity of variance in participant 
characteristics 
 
  
Table 41 
S  w    L     ’         f           y  f             p      p                    
 DF F P - value 
Frequency of use 2 961 1.147 .318 
Weekly Expenditure 2 812 5.199 .006 
Age of first use 1 31 2.727 .101 
Age 2 991 36.581 <.001 
Number of lifetime uses 1 122 1.206 .274 
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Appendix 14 Tests of normality on the SPQ-b 
Table 42  
Showing tests of homogeneity of variance on the SPQ-b 
 
 
Skewness Kurtosis 
Kolmogorov-Smirnov 
 D DF p- value 
PD 
Cognitive-perceptual -0.279 -0.564 0.203 48 <.001 
Interpersonal -0.335 -1.098 0.159 48 .004 
Disorganised -0.12 -1 0.152 48 .007 
SPQ-b Total -0.238 -0.885 0.142 48 .017 
DD 
Cognitive-perceptual -0.33 -1.031 0.143 85 <.001 
Interpersonal -0.33 -1.031 0.165 85 <.001 
Disorganised 0.041 -1.078 0.147 85 <.001 
SPQ-b Total 0.06 -0.709 0.07 85 .20 
CSCU 
Cognitive-perceptual 0.592 -0.416 0.149 861 <.001 
Interpersonal 0.583 -0.712 0.163 861 <.001 
Disorganised 0.578 -0.717 0.182 861 <.001 
SPQ-b Total 0.624 -0.244 0.102 861 <.001 
CSCN 
Cognitive-perceptual 0.627 -0.439 0.149 306 <.001 
Interpersonal 0.488 -0.439 0.135 306 <.001 
Disorganised 0.933 -0.022 0.206 306 <.001 
SPQ-b Total 0.676 -0.083 0.135 306 <.001 
 
Appendix 15 Tests of homogeneity of variance on the SPQ-b 
Table 43 
S  w    L     ’         f           y  f             the SPQ-b 
 DF F p- value 
Cognitive-perceptual 3 1296 0.508 .68 
Interpersonal 3 1296 0.685 .56 
Disorganised 3 1296 0.860 .46 
SPQ-b Total 3 1296 1.252 .29 
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Appendix 16 Tests of normality on the CEQ 
Table 44  
Showing tests of homogeneity of variance on the CEQ 
 
 
Skewness Kurtosis 
Kolmogorov-Smirnov 
 D DF p- value 
PD 
Aversive 0.896 -0.044 0.137 48 .024 
Appetitive 0.67 -0.626 0.194 48 <.001 
Intoxicated 0.422 -0.623 0.145 48 .013 
DD 
Aversive 1.568 2.813 0.154 85 <.001 
Appetitive -0.185 -0.053 0.069 85 .20 
Intoxicated 0.584 0.012 0.099 85 .039 
CSCU 
Aversive 1.27 1.138 0.146 861 <.001 
Appetitive 0.214 0.203 0.056 861 <.001 
Intoxicated 0.203 -0.716 0.07 861 <.001 
 
Appendix 17 Tests of homogeneity of variance on the CEQ 
Table 45 
S  w    L     ’         f           y  of variance on the CEQ 
 DF F p- value 
Aversive 2 991 7.030 .001 
Appetitive 2 991 5.134 .006 
Intoxicated 2 991 3.563 .029 
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Appendix 18 Tests of multicolinearity variance proportion tables SPQ-
b 
Table 46 
Showing variance proportion table of the SPQ-b total and the aversive and 
intoxicated scales 
Dimension Eigenvalue Condition Index 
Variance proportions 
Constant SPQ-b Aversive Intoxicated 
1 3.421 1.0 .01 .02 .02 .01 
2 0.295 3.407 .13 .08 .68 .00 
3 0.197 4.168 .10 .80 .01 .18 
4 0.087 6.260 .75 .11 .29 .81 
 
Appendix 19 Tests of multicolinearity variance inflation factors SPQ-b 
Table 47 
Showing variance inflation factors of the SPQ-b total and the aversive and 
intoxicated scales 
 Tolerance VIF 
SPQ-b .844 1.184 
Aversive .625 1.600 
Intoxicated .682 1.467 
 
Appendix 20 Tests of multicolinearity variance proportion tables SPQ-
b subscales 
Table 48 
Showing variance proportion table of the SPQ-b subscales and the aversive and 
intoxicated scales 
Dimension Eigenvalue 
Condition 
Index 
Variance proportions 
Constant 
Cog-
Per 
Inter Dis Aversive Intoxicated 
1 4.834 1.000 .01 .01 .01 .01 .01 .01 
2 0.403 3.463 .00 .02 .15 .15 .27 .06 
3 0.269 4.241 .27 .04 .00 .07 .38 .06 
4 0.206 4.839 .00 .68 .50 .00 .07 .00 
5 0.198 4.938 .01 .24 .33 .77 .00 .01 
6 0.089 7.379 .71 .01 .01 .00 .28 .86 
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Appendix 21 Tests of multicolinearity variance inflation factors SPQ-b 
subscales 
Table 49 
Showing variance inflation factors of the SPQ-b total and the aversive and 
intoxicated scales 
 Tolerance VIF 
Cognitive-perceptual .617 1.620 
Interpersonal .681 1.468 
Disorganised .669 1.495 
Aversive .692 1.445 
Intoxicated .659 1.517 
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Appendix 22 ESM study advertisement 
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Appendix 23 How to guide part 1 
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Appendix 24 How to guide part 2 
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Appendix 25 Schizotypal States Questionnaire items  
This is an example of the SSQ items however please note these were displayed on a mobile device 
not paper format. 
  
  Strongly 
disagree 
disagree Neutral Agree Strongly 
Agree 
Right now I feel: People would think me aloof           
 Unseen forces are around me           
 My behaviour is unusual           
 Other people can read my mind           
 Things have special meanings 
for me 
          
 Rather bizarre           
 I should be wary of others           
 That if I spoke, I’d seem 
vague/elusive 
          
 Threatened/put down           
 Others are looking at me oddly           
 Uneasy about being with others           
 Astrology and fortune telling 
make sense 
          
 I could use words in an odd 
way 
          
 I don’t want to reveal much 
about myself 
          
 I want to keep in the 
background 
          
 I can hear things others cannot           
 people are taking advantage of 
me 
          
 I cannot get close to others           
 I’m a rather odd unusual 
person 
          
 I cannot express myself clearly           
 uneasy just talking           
 I should keep my feelings 
private 
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Appendix 26 Concurrent States Questionnaire items  
This is an example of the SSQ items however please note these were displayed on a mobile device 
not paper format. 
 
Right now I am feeling:  
  Not at all a bit so so quite a lot very 
much so 
chilled out           
 on edge           
 Calm           
 Worried           
 Content           
 anxious           
 Relaxed           
 concerned           
 Happy           
 agitated           
 Stressed           
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Appendix 27 ESM Participant information sheet 
 Participant Information Sheet 
 
Study title: Momentary assessment of aversive cannabis experiences, a schizotypal 
state and perceived stress 
 
Researchers: Rohan Morris, John Cavill, Chris Wibberley, and Laura Brown 
(Manchester Metropolitan University) 
 
Invitation: We would like to invite you to take part in our research study. Before you decide, we 
would like you to understand why the research is being done and what it would involve for you. One 
of our research team will be available to go through the information sheet with you (if you so wish) 
and answer any questions you may have. We’d suggest this should take about 20 minutes. Talk to 
others about the study if you wish.  
 
What is the purpose of the study? To be able to look at the relationship between people’s 
experiences with cannabis, their experiences which are related to an aspect of personality known as 
schizotypy (schizotypal state), and how stressed a person feels. It is hoped that this study will 
provide data that will enable us to identify people who are at the greatest risk of experiencing some 
of the negative psychological effects of cannabis. 
 
Why have I been invited? We are trying to recruit 60 people who are over the age of 18 and are 
current cannabis users. You have been invited because we believe that you may be eligible to 
participate. 
 
Do I have to take part? It is entirely up to you to decide whether or not to take part in the study. We 
will be available to describe the study and go through the information sheet with you. If you agree to 
take part we will ask you to sign a consent form, however (as with our previous research in this area) 
you do not have to use your real name. You are free to withdraw (leave) at any time, without giving a 
reason. 
 
What will happen to me if I take part? Initially you will be asked to complete two questionnaires; 
one looking at your past experiences with cannabis (the cannabis experiences questionnaire) and 
the other measuring your score on a personality trait known as schizotypy (schizotypal personality 
questionnaire). After you have completed these questionnaires you will be asked to meet with one of 
the researchers. This can be done at a time and location at your convenience, and will take 
approximately 30 minutes. The researcher will explain in detail exactly what is required of you for the 
next stage of the study, answer any questions that you may have, and loan you the necessary 
equipment.  
 
The second stage will involve you carrying a mobile device around with you for a period of two 
weeks. The mobile device will prompt you at various times completing a short questionnaire on the 
mobile device. You will be requested to complete the questions 6 times a day when prompted by a 
signal from the mobile device. This phase will last for a period of two weeks and will require on 
average between 10 and 20 minutes per day. 
 
Expenses and payments: 
As a thank you for those that complete the second phase of the study (inputting data on a daily basis 
into a mobile device) we will give you £20 (in Love2Shop gift vouchers) upon completion of the 
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study and return of the mobile device. In addition the mobile device will be pre-loaded with £10 
mobile phone credit and 400 text messages for you to use, this is to ensure you can contact a 
member of the research team free of charge. However, will not be able to cover any associated costs 
which you may incur including, but not exclusive to, your time, and electricity consumption (as the 
mobile device will require charging).  
 
What will I have to do? 
For the first phase simply answer our questionnaires and return them (or submit it if in an electronic 
format). For the second phase for the most part you will continue with your typical routine. You will 
receive a prompt on your mobile device at random times (except for times that you have indicated 
you will be unavailable e.g. when you are asleep). After you have received the prompt we request 
that you use the device to access our questionnaire and respond to the questions presented. 
 
What are the possible disadvantages and risks of taking part? 
The associated risks of taking part are very low. You will be requested to complete a questionnaire 
containing items relating to your experiences of drug use. There is a small possibility that some 
participants might find this mildly distressing, for instance by being asked to focus on feelings that 
you found unpleasant.  
 
Another possible disadvantage of taking part in this research is that some participants may find the 
methodology intrusive. As the study may require a response at a random time point it may distract 
you from your normal daily activity. However, you will not be expected to respond if you are 
unavailable (e.g. in a meeting or a class) or if it would be dangerous to do so (e.g. whilst driving). 
Furthermore, if you are unavailable and wish to not be disturbed you can always put the device on to 
a silent or vibrate only setting, or alternatively turn the device off. 
 
What are the possible benefits of taking part? 
For you personally, probably none, although our work may alert you to some of the dangers of using 
cannabis, and make you think about the wisdom of continuing to use it if you are concerned that it 
might be doing you harm.  In the wider context, you will have the satisfaction of having contributed to 
our research efforts which have the ultimate goal of having practical health benefits for cannabis 
users.  
 
What will happen when the research study ends? 
When the study ends we will arrange a convenient time and location to meet with you and collect the 
mobile device from you. 
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the researchers 
who will do their best to answer you questions (see contact details beneath). If you remain unhappy 
and wish to complain formally you can do this by contacting John Cavill on 0161 247 2867 or 
j.cavill@mmu.ac.uk 
 
Will my taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be handled in the 
strictest confidence. Only the named researchers will have access to any identifying information you 
have supplied us. However, it is not necessary for you to use your real name. Identifying information 
and contact details will be stored separately from your data on password-protected computer, which 
is kept in a locked office. Data will be sent to our secure server which is physically located on the 
university campus. Our IT team regularly update security to prevent any malicious access to our 
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server. Once downloaded from the server data will be stored on a password-protected computer (in 
a locked office) that only the researchers will have access to.  
 
What will happen if I don’t want to carry on with the study? You can withdraw from the study at 
any time during participation. Additionally if you so wish we can destroy any data that you have 
already submitted to us up to a two week period after your completion. 
 
What will happen to the results? 
To acknowledge the time and effort our participants put into our research we will always endeavour 
to publish our findings. By publishing our research our participants can have a direct impact on 
scientific knowledge and understanding. In any publications produced from this research it will not be 
possible to identify you or any other participant in this study. 
 
Who is funding the research? 
This research is being funded by the Research Institute for Health and Social Change, Manchester 
Metropolitan University (MMU), and is being supported by the Department of Psychology, MMU. 
 
Who has reviewed this study? 
This study has been reviewed and approved by the MMU faculty of Health, Psychology and Social 
Care ethics committee. 
 
Thank you for taking the time to read this,  
Rohan Morris 
Department of Psychology 
Elizabeth Gaskell 
Manchester Metropolitan University 
Hathersage Rd 
M13 OJA 
0161 247 2415  
R.Morris@mmu.ac.uk 
 
Please note we are in no way responsible for or connected with any of the organisations 
beneath: 
 
 
If you have any concerns about drug addiction or want information about drugs, then 
please contact one of the following organisations who may be able to provide you with 
help and support: 
 
Talk to Frank-  http://www.talktofrank.com/ or 0800 77 66 00 
Drugs Line- http://www.drugsline.org/ or 0808 1 606 606  
Erowid- http://www.erowid.org/ 
 
If you have any concerns about mental health problems or want further information about 
mental health issues, then please contact one of the following organisations who may be 
able to provide you with help and support: 
 
www.makingspace.co.uk 
www.mentalhealth.org.uk 
www.rethink.org or 0845 456 0455 
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www.sane.org.uk or 0845 767 8000 
 
Appendix 28 ESM Participant consent form 
 
Momentary assessment of aversive cannabis experiences, a 
schizotypal state and perceived stress  
 
CONSENT FORM 
 I confirm that I have read and understood the information sheet for the 
project with the above title. 
 
 I understand that my agreement to take part in the research is voluntary 
and that I am free to withdraw from the research, without giving any reason. 
 
 I also understand that I am free to withdraw any data I may have submitted 
at any point during my participation and two weeks after my participation in 
this research. 
 
 I understand that any information given to the research team will remain 
confidential and that my anonymity will be protected. 
 
 I give my consent for the data I provide to be analysed and am aware that 
the results of such an analysis may be reproduced in any report or 
publication of the research. However, this will not be in any way in which I 
may be identified. 
 
I agree to take part in the research 
 
Date    ________________________________ 
 
Participant signature 
(May use pseudonym) ________________________________ 
 
 
Contact details  ________________________________ 
 
________________________________ 
 
   ________________________________ 
(phone number, email or address) 
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Appendix 29 Validating the ESM items 
Validating measures of a schizotypal state 
Please note for the validation items (the PSI and WSI) no system of pro-rating was 
adopted hence the N varies from analysis to analysis. 
Table 50 
R        f   P      ’                   p  y                   p b  w              
the PSI and SSQ administered at Day 0 of the investigation.  
  SSQ total SSQ Cog SSQ Dis SSQ Int 
Cronbach’s Alpha  α=0.91 α=0.79 α=0.76 α=0.88 
PSI total 
N 
r 
p 
 
51 
.626 
<.0001 
51 
.445 
.001 
52 
1.000 
<.0001 
52 
.567 
<.0001 
PSI DT 
N 
r 
p 
 
51 
.473 
<.001 
51 
.501 
<.001 
52 
.258 
.064 
52 
.338 
.014 
PSI PD 
N 
r 
p 
 
51 
.5632 
<.0001 
51 
.462 
<.001 
52 
.478 
<.001 
52 
.508 
<.001 
PSI CD 
N 
r 
p 
 
51 
.460 
<.001 
51 
.247 
.080 
52 
.482 
<.001 
52 
.471 
.003 
PSI An 
N 
r 
p 
 
51 
.448 
.001 
51 
.237 
.094 
52 
.354 
.01 
52 
.162 
.251 
PSI Ma 
N 
r 
p 
 
51 
.354 
.011 
51 
.262 
.063 
52 
.332 
.016 
52 
.279 
.045 
PSI Pa 
N 
r 
p 
 
51 
.500 
<.001 
51 
.310 
.027 
52 
.303 
.029 
52 
.448 
<.001 
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Table 51 
R        f   P      ’                   p  y                   p b  w                
re-test of the PSI and SSQ administered at day 4 of the investigation.  
  SSQ total SSQ Dis SSQ Cog SSQ Int 
PSI total 
n 
r 
p 
 
37 
.818 
<.0001 
37 
.772 
<.0001 
38 
.737 
<.0001 
38 
.772 
<.0001 
PSI DT 
n 
r 
p 
 
37 
.553 
<.001 
37 
.496 
.002 
38 
.639 
<.0001 
38 
.452 
.004 
PSI PD 
n 
r 
p 
 
37 
.638 
<.0001 
37 
.560 
<.001 
38 
0.702 
<.0001 
38 
0.547 
<.001 
PSI CD 
n 
r 
p 
 
37 
.719 
<.0001 
37 
.756 
<.0001 
38 
.582 
<.001 
38 
.620 
<.0001 
PSI An 
n 
r 
p 
 
37 
.543 
<.001 
37 
.447 
.006 
38 
.391 
.015 
38 
.655 
<.0001 
PSI Ma 
n 
r 
p 
 
37 
.690 
<.0001 
37 
.664 
<.0001 
38 
.641 
<.0001 
38 
.643 
<.0001 
PSI Pa 
n 
r 
p 
 
37 
.806 
<.0001 
37 
.744 
<.0001 
38 
.599 
<.001 
38 
.789 
<.0001 
 
Validating momentary measures of stress 
Prior to analysis the relationship between the two proposed scales/sub-scales of 
the CSQ had not been assessed as a consequence two scoring approaches were 
adopted. One approach was to consider the two scales as related along a 
continuum, i.e. feelings of calmness are the opposite to feelings of stress. Another 
approach was to consider the two constructs as independent, i.e. feeling calm and 
feeling stress are not related and could co-occur. Therefore, the CSQ was 
consider as a sum of the six items pertaining to stress, and the five items 
pertaining to calmness (with scores reversed), referred to herein as CSQ total. The 
CSQ was also considered as consisting of two independent scales, the six items 
assessing stress and the five items assessing calmness referred to as CSQ Stress 
and CSQ Calm. 
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The CSQ total was assessed as a predictor on the outcome variables of WSI 
Event (Table 52) and WSI Impact (Table 53). The CSQ total did not predict scores 
on the WSI Event scale. However, the predictor accounted for a significant 
increase on the WSI Impact, (b = 0.11, 95% CI 0.05 to 0.17, p < .001), a one unit 
increase on the CSQ total predicted an increase of 0.11 in the outcome variable. 
These results demonstrate evidence of convergent validity between the CSQ total 
and the impact of stressful events. 
 
Table 52 
Parameter estimates for multilevel model of the event scale of the Weekly Stress 
Inventory (outcome) as a function of scores on the CSQ total  
Fixed effect (intercept, 
slopes) 
Estimate (SE) Z
 
P
 
95% CI 
Lower Upper 
Intercept 11.684 0.821 14.23 <.001 10.075 13.293 
CSQ total 0.017 0.009 1.90 .057 -0.0005 0.032 
       
Random effects ([co-
]variances) 
 Estimate (SE) ICC (%) 95% CI 
Lower Upper 
Level 1 Intercept 4.411 0.582 87.628 3.406 5.712 
 Residual 1.657 0.037  1.587 1.731 
 
Table 53 
Parameter estimates for multilevel model of the impact scale of the Weekly Stress 
Inventory (outcome) as a function of scores on the CSQ total  
Fixed effect (intercept, 
slopes) 
Estimate (SE) Z
 
P
 
95% CI 
Lower Upper 
Intercept 21.509 2.504 8.59 <.001 16.602 26.417 
CSQ total 0.109 0.029 3.69 <.001 0.051 0.166 
       
Random effects ([co-
]variances) 
 Estimate (SE) ICC (%) 95% CI 
Lower Upper 
Level 1 Intercept 13.446 1.777 85.244% 10.378 17.422 
 Residual 5.594 0.123  5.358 5.841 
 
Despite the relationship between the CSQ total and the WSI Impact it is still 
necessary to assess the relationship between the CSQ Calm and CSQ Stress 
items. The effects of CSQ Calm and CSQ Stress were considered simultaneously 
as predictors of scores on the WSI Event and WSI Impact. There was no 
significant effect of CSQ Calm and CSQ Stress on WSI Event (see Table 54). 
There was also no significant effect of CSQ Calm on WSI Impact, however, CSQ 
Stress was a significant predictor of the scale (b = 0.21, 95% CI 0.07 to 0.35, p = 
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.004). A one unit increase in the CSQ Stress scale predicted an increase of 0.21 
on the WSI Impact scale (see Table 55). 
Table 54 
Parameter estimates for multilevel model of the event scale of the Weekly Stress 
Inventory (outcome) as a function of scores on the CSQ calm and CSQ Stress scales  
Fixed effect (intercept, 
slopes) 
Estimate (SE) Z
 
P
 
95% CI 
Lower Upper 
Intercept 11.683 0.821 14.23 <.001 10.074 13.292 
CSQ Calm -0.014 0.019 -0.72 .475 -0.051 0.024 
CSQ Stress 0.020 0.021 0.93 .352 -0.022 0.062 
       
Random effects ([co-
]variances) 
 Estimate (SE) ICC (%) 95% CI 
Lower Upper 
Level 1 Intercept 4.411 0.582 87.628 3.406 5.712 
 Residual 1.657 0.037  1.587 1.731 
 
Table 55 
Parameter estimates for multilevel model of the impact scale of the Weekly Stress 
Inventory (outcome) as a function of scores on the CSQ calm and CSQ Stress scales  
Fixed effect (intercept, 
slopes) 
Estimate (SE) Z
 
P
 
95% CI 
Lower Upper 
Intercept 21.514 2.493 8.63 <.001 16.628 26.399 
CSQ Calm -0.023 0.065 -0.36 .719 -0.150 0.103 
CSQ Stress 0.207 0.072 2.86 .004 0.065 0.348 
       
Random effects ([co-
]variances) 
 Estimate (SE) ICC (%) 95% CI 
Lower Upper 
Level 1 Intercept 13.385 1.769 85.153 10.330 17.344 
 Residual 5.589 0.123  5.353 5.836 
 
The findings outlined above demonstrate evidence of the independence of 
concurrent experiences of calmness and concurrent experiences of stress. The 
fact that CSQ Stress was capable of distinguishing stressful weeks, and CSQ 
Calm was not is testimony to the fact.  
 
Validating event related items  
To assess an appropriate means of scoring the items ER, SE and PE two 
approaches were adopted. One approach was to consider the normalised (Z-
score) of the three items as related along a continuum, i.e. stressful events have 
an antagonistic relationship with pleasurable events. This approach consists of the 
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addition of standardised scores for ER (reversed), PE (reversed), and SE, referred 
to herein as the Events Questionnaire (EQ).  Another approach is to consider the 
two constructs as independent, i.e. pleasurable events and stressful events are 
not related and could co-occur within one event. This approach consists of ER, 
PE, and SE being considered independent factors. EQ was not a significant 
predictor of the WSI Event scale (see Table 56). Neither was there a significant 
effect of EQ on WSI Impact (see Table 57). 
 
Table 56 
Parameter estimates for multilevel model of the event scale of the Weekly Stress 
Inventory (outcome) as a function of scores on the Events Questionnaire  
Fixed effect 
(intercept, 
slopes) 
Estimate (SE) Z
 
P
 
95% CI 
Lower Upper 
Intercept 11.734 0.838 14.00 <.001 10.091 13.377 
EQ 0.054 0.040 1.33 .182 -0.025 0.133 
Time 0.002 0.001 1.47 .142 -0.0005 0.004 
Random 
effects ([co-
]variances) 
 Estimate (SE) ICC (%) 95% CI 
Lower Upper 
Level 1 Intercept 4.493 0.596 88.781 3.464 5.827 
 Residual 1.597 0.048  1.506 1.694 
 
Table 57 
Parameter estimates for multilevel model of the impact scale of the Weekly Stress 
Inventory (outcome) as a function of scores on the Events Questionnaire  
Fixed effect 
(intercept, 
slopes) 
Estimate (SE) Z
 
P
 
95% CI 
Lower Upper 
Intercept 21.665 2.610 8.30 .000 16.550 26.780 
EQ 0.212 0.140 1.51 .130 -0.062 0.486 
Time 0.007 0.004 2.02 .044 0.0002 0.015 
Random 
effects ([co-
]variances) 
 Estimate (SE) ICC (%) 95% CI 
Lower Upper 
Level 1 Intercept 13.971 1.858 86.356 10.766 18.130 
 Residual 5.553 0.167  5.236 5.889 
 
In the consideration of the items ER, SE and PE as independent constructs none 
of the variables significantly predicted scores on the WSI event scale (see Table 
58 & 59), neither, did they significantly predict scores on the WSI Impact scale. 
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Table 58 
Parameter estimates for multilevel model of the event scale of the Weekly Stress 
Inventory (outcome) as a function of Pleasurable Events, Stressful Events and an 
Event Rating 
Fixed effect (intercept, 
slopes) 
Estimate (SE) Z
 
P
 
95% CI 
Lower Upper 
Intercept 11.735 0.8400 13.97 <.001 10.089 13.382 
Event Rating (ER) -0.101 0.091 -1.12 .264 -0.279 0.077 
Stressful Events (SE) 0.054 0.102 0.52 .601 -0.147 0.254 
Pleasurable Events (PE) 0.088 0.111 0.79 .427 -0.130 0.307 
Time 0.001 0.001 1.27 .204 -0.0007 0.003 
Random effects ([co-
]variances) 
 Estimate (SE) ICC (%) 95% CI 
Lower Upper 
Level 1 Intercept 4.502 0.597 88.84 3.471 5.839 
 Residual 1.596 0.048  1.505 1.692 
 
Table 59 
Parameter estimates for multilevel model of the impact scale of the Weekly Stress 
Inventory (outcome) as a function of Pleasurable Events, Stressful Events and an 
Event Rating 
Fixed effect (intercept, 
slopes) 
Estimate (SE) Z
 
P
 
95% CI 
Lower Upper 
Intercept 21.68 2.613 8.30 <.001 16.559 26.801 
Event Rating (ER) -0.344 0.315 -1.09 .275 -0.963 0.274 
Stressful Events (SE) 0.254 0.356 0.72 .475 -0.443 0.951 
Pleasurable Events (PE) 0.473 0.387 1.22 .221 -0.285 1.232 
Time 0.006 0.004 1.72 .085 -0.0009 0.014 
Random effects ([co-
]variances) 
 Estimate (SE) ICC (%) 95% CI 
Lower Upper 
Level 1 Intercept 13.986 1.860 86.419 10.777 18.149 
 Residual 5.544 0.166  5.228 5.880 
 
The inability of aforementioned items to reliably predict scores on the WSI may 
have occurred for several reasons. One possibility is that the items developed for 
the purposes of this investigation do not possess construct validity and as a 
consequence no convergent validity was observed. PE and ER are not directly 
pertaining to stressful events and as consequence it could be viewed as 
unremarkable their inability to predict stressful weeks.   The lack of relationship 
between SE and WSI Event score perhaps may be indicative of cultural 
differences between the current sample and the sample which was used in the 
creation of the WSI. The WSI was developed in the United States of America, item 
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retention was based on the item being endorsed by at least 10% of the sample 
(Brantley, Jones, Boudreaux & Catz, 1997). Perhaps, in using a measure 
developed in another culture some of the daily minor stressors experienced may 
be different. 
 
The validity of the aforementioned items can be assessed through means other 
than the WSI. It would be anticipated that stressful events would predict 
concurrent stressed states and pleasurable events would predict concurrent calm 
states. Consequently, the effect of EQ, ER, SE, and PE were estimated as 
predictors of the CSQ scales.  
 
EQ was capable of significantly predicting scores on the CSQ stress scale (b = 
0.75, 95% CI 0.65 to 0.84, p < .001) each unit increase on the independent 
variable predicted an increase of 0.75 on the outcome variable. EQ was also a 
significant predictor of CSQ Calm (b = -0.98, 95% CI -1.10 to -0.87, p < .001) for 
each unit increase on EQ there was a decrease of 0.98 on the dependent variable. 
This finding provides further evidence of convergent validity; the Events 
Questionnaire is capable of predicting stressed and calm states. 
 
  
Table 60 
Parameter estimates for multilevel model of the CSQ Stress scale (outcome) as a 
function of scores on the Events Questionnaire  
Fixed effect 
(intercept, 
slopes) 
Estimate (SE) Z
 
P
 
95% CI 
Lower Upper 
Intercept 2.334 0.373 6.26 <.001 1.604 3.064 
EQ 0.748 0.049 15.31 <.001 0.652 0.844 
Time 0.0009 0.001 0.78 .434 -0.001 0.003 
       
Random 
effects ([co-
]variances) 
 Estimate (SE) ICC (%) 95% CI 
Lower Upper 
Level 1 Intercept 4.154 1.193 44.011 2.600 7.498 
Level 2 Intercept 2.862 0.361 28.522 2.234 3.665 
 Residual 2.756 0.176  2.431 3.124 
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Table 61 
Parameter estimates for multilevel model of the CSQ Calm scale (outcome) as a 
function of scores on the Events Questionnaire  
Fixed effect 
(intercept, 
slopes) 
Estimate (SE) Z
 
p
 
95% CI 
Lower Upper 
Intercept 12.935 0.559 23.13 <.001 11.839 14.031 
EQ -0.984 0.060 -16.40 <.001 -1.101 -0.866 
Time -0.003 0.001 -2.48 .013 -0.006 -0.0007 
       
Random 
effects ([co-
]variances) 
 Estimate (SE) ICC (%) 95% CI 
Lower Upper 
Level 1 Intercept 10.631 2.639 60.729 6.535 17.293 
Level 2 Intercept 2.057 0.379 11.751 1.434 2.952 
 Residual 4.817 0.309  4.248 5.463 
 
As discussed previously it is necessary to evaluate the independence of stressful 
and pleasurable events, consequently the items ER, PE, and SE, were tested as 
predictors of CSQ Stress and CSQ Calm. Both ER (b = -0.42, 95% CI -0.59 to -
0.24, p < .001) and SE predicted (b = 2.03, 95% CI  1.78 to 2.27, p < .001) 
significant changes on the CSQ Stress. A one unit increase in ER resulted in a 
decrease of 0.42 units of the CSQ stress and a unit increase in SE resulted in a 
2.03 unit increase in the outcome variable. PE did not significantly predict scores 
on the CSQ Stress. However, all explanatory variables assessed were significant 
predictors of scores on CSQ Calm.  A one unit increase in ER resulted in an 
increase of 0.67 units of the CSQ Calm (b = 0.67, 95% CI 0.43 to 0.90, p < .001), 
a unit increase in SE resulted in a 1.78 unit decrease in the outcome variable (b = 
-1.78, 95% CI -2.10 to -1.46, p < .001), and a unit increase in PE equated to an 
increase of 0.73 (b = 0.73, 95% CI 0.47 to 1.0006, p < .001).  
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Table 62 
Parameter estimates for multilevel model of scores on the CSQ Stress scale 
(outcome) as a function of Pleasurable Events, Stressful Events and an Event Rating  
Fixed effect (intercept, 
slopes) 
Estimate (SE) Z
 
P
 
95% CI 
Lower Upper 
Intercept 2.371 0.342 6.93 <.001 1.701 3.042 
Event Rating (ER) -0.416 0.090 -4.63 <.001 -0.592 -0.240 
Stressful Events (SE) 2.027 0.125 16.18 <.001 1.782 2.273 
Pleasurable Events (PE) -0.136 0.103 -1.32 .187 -0.339 0.066 
Time -0.001 0.001 -0.94 .346 -0.003 0.001 
       
Random effects ([co-
]variances) 
 Estimate (SE) ICC (%) 95% CI 
Lower Upper 
Level 1 Intercept 3.690 1.021 42.333 2.145 6.348 
Level 2 Intercept 2.630 0.330 30.173 2.056 3.364 
 Residual 2.397 0.154  2.113 2.719 
 
Table 63 
Parameter estimates for multilevel model of scores on the CSQ Calm scale 
(outcome) as a function of Pleasurable Events, Stressful Events and an Event Rating  
CSQ Calm 
Fixed effect (intercept, 
slopes) 
Estimate (SE) Z
 
P
 
95% CI 
Lower Upper 
Intercept 12.920 0.554 23.34 <.001 11.834 14.005 
Event Rating (ER) 0.670 0.120 5.59 <.001 0.435 0.904 
Stressful Events (SE) -1.781 0.163 -10.93 <.001 -2.101 -1.462 
Pleasurable Events 
(PE) 
0.733 0.137 5.37 <.001 0.465 1.0006 
Time -0.003 0.001 -2.01 .045 -0.006 -0.00006 
       
Random effects ([co-
]variances) 
 Estimate (SE) ICC (%) 95% CI 
Lower Upper 
Level 1 Intercept 10.415 2.590 60.614 6.397 16.955 
Level 2 Intercept 2.054 0.380 11.957 1.429 2.953 
 Residual 4.713 0.304  4.153 5.348 
 
The results displayed in Tables 62 and 63 provide evidence of convergent validity 
between measures of concurrent stress and pleasure and previous stressful and 
pleasurable events. The anchors assigned to the ER item, incorporating both ‘very 
pleasant’ (0) and ‘very unpleasant’ (4) may have attempted to assess two 
constructs with one item. However, the ability of ER to predict scores on both the 
CSQ Calm and CSQ Stress in the direction anticipated suggests that perhaps the 
item is assessing one construct which is a correlate of both stress and pleasure; 
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event evaluation. The results displayed in Table 62 can also help make inferences 
about the independence of stressful events and pleasurable events. SE were 
capable of significantly predicting scores on the CSQ Stress, however, PE had no 
such effect. The non-significant finding indicates that there is no relationship 
between previous pleasurable events and concurrent feelings of stress. 
 
The independence of stress and pleasure 
Some of the analyses outlined in this appendix provide evidence for the 
independence of feelings of stress and feelings of calm. Concurrent feelings of 
stress (CSQ stress) predicted scores on the WSI Impact scale. However, no such 
significant relationship was observed with concurrent feelings of calm (CSQ calm). 
If CSQ Stress and CSQ Calm were pertaining to the same underlying factor one 
would expect the variables to both exert an influence on the same outcome 
variable. SE and ER were capable of predicting scores on the CSQ Stress scale, 
however, PE did not have a significant relationship. Despite this EQ significantly 
predicted concurrent states of calm and stress. Furthermore, SE significantly 
reduced and PE significantly increased scores on the CSQ Calm, thus seemingly 
displaying an antagonistic relationship. It is possible to further evaluate the 
independence of the items, however, this is unlikely to yield any definitive 
answers. Furthermore, such an analysis is beyond the scope of this current study.  
As there is (some) evidence suggesting that the CSQ total and EQ are potentially 
assessing more than one independent constructs, for the purposes of this body of 
research, the scales will be considered as assessing independent constructs. 
Considering the constructs as independent even if they are assessing one 
underlying concept will not typically result in the loss of any information. The 
instance where information loss may occur, would be in the case of collinearity. 
However, within the MLM the variables are assessed for collinearity and any that 
are deemed to be are omitted from the model. The alternative approach would be 
to encounter the possibility of utilising composite scores of two (or more) unrelated 
concepts, if this were to occur the variables would cease to assess a construct and 
would  instead assess a mean of two independent scores, resulting in the loss of 
meaning (information). Consequently, CSQ Stress and CSQ Calm are considered 
as independent, as are ER, SE, and PE. 
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Appendix 30 quantity of cannabis consumed predicting SSQ total 
 
  
Table 64 
Parameter estimates for multilevel model of schizotypal state (outcome) as a 
function of states of stress, states of calm, stressful events, pleasurable events, 
quantity of cannabis consumed and a cannabis -stress interaction 
Fixed effect 
(intercept, 
slopes) 
 Estimate (SE) Z
 
p
 
95% CI 
 Lower Upper 
Intercept  14.141 1.813 7.80 <.001 10.589 17.694 
CSQ Stress  0.689 0.091 7.58 <.001 0.511 0.867 
CSQ Calm  -0.071 0.071 -0.99 .320 -0.211 0.069 
Event Rating 
(ER) 
 -0.120 0.210 -0.57 .569 -0.532 0.292 
Stressful Events 
(SE) 
 -0.081 0.333 -0.24 .807 -0.735 0.572 
Pleasurable 
Events (PE) 
 0.327 0.252 1.30 .194 -0.166 0.820 
Cannabis 
Quantity 
Between 2.939 2.190 1.34 .180 -1.353 7.231 
Within 0.439 0.160 2.74 .006 0.125 0.754 
Caffeine  0.140 0.186 0.75 .451 -0.225 0.506 
Tobacco  -0.269 0.229 -1.17 .241 -0.19 0.180 
Alcohol  0.208 0.214 0.97 .331 -0.211 0.628 
Time  -0.006 0.003 -2.17 .030 -0.010 -0.001 
Random effects 
([co-]variances) 
  Estimate (SE) ICC (%) 95% CI 
 Lower Upper 
Level 1  Intercept 114.706 27.779 83.440 71.359 184.385 
Level 2  Intercept 10.134 1.450 7.372 7.656 13.415 
  Residual 12.632 0.831  11.103 14.371 
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Appendix 31 quantity of cannabis predicting interpersonal psychotic 
like states 
 
  
Table 65 
Parameter estimates for multilevel model of interpersonal distortions (outcome) 
as a function of states of stress, states of calm, stressful events, pleasurable 
events, quantity of cannabis consumed and a cannabis -stress interaction 
Fixed effect 
(intercept, slopes) 
 Estimate (SE) Z
 
p
 
95% CI 
 Lower Upper 
Intercept  6.063 0.767 7.90 <.001 4.559 7.566 
CSQ Stress  0.279 0.050 5.62 <.001 0.181 0.376 
CSQ Calm  -0.093 0.039 -2.39 .017 -0.170 -0.017 
Event Rating (ER)  0.035 0.116 0.30 .765 -0.193 0.262 
Stressful Events 
(SE) 
 -0.030 0.183 -0.17 .869 -0.389 0.329 
Pleasurable 
Events (PE) 
 -0.180 0.138 -1.30 .192 -0.451 0.091 
Cannabis 
Quantity 
Between 0.698 0.927 0.75 .451 -1.118 2.515 
Within 0.245 0.088 2.77 .006 0.071 0.418 
Caffeine  0.076 0.103 0.74 .459 -0.125 0.278 
Tobacco  -0.151 0.126 -1.19 .233 -0.398 0.097 
Alcohol  0.048 0.118 0.40 .686 -0.184 0.279 
Time  -0.002 0.001 -1.35 .178 -0.005 0.001 
Random effects 
([co-]variances) 
  Estimate (SE) ICC (%) 95% CI 
 Lower Upper 
Level 1  Intercept 20.270 4.992 75.298 12.508 32.847 
Level 2  Intercept 2.730 0.427 10.143 2.010 3.709 
  Residual 3.919 0.261  3.439 4.663 
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Appendix 32 quantity of cannabis predicting disorganised psychotic 
like states 
 
  
Table 66 
Parameter estimates for multilevel model of distortions of disorganisation 
(outcome) as a function of states of stress, states of calm, stressful events, 
pleasurable events, quantity of cannabis consumed and a cannabis-stress 
interaction 
Fixed effect 
(intercept, slopes) 
 Estimate (SE) Z
 
P
 
95% CI 
Lower Upper 
Intercept  4.105 0.548 7.49 <.001 3.030 5.180 
CSQ Stress  0.195 0.032 6.18 <.001 0.133 0.257 
CSQ Calm  -0.011 0.025 -0.43 .667 -0.060 0.038 
Event Rating (ER)  -0.142 0.075 -1.90 .057 -0.288 0.004 
Stressful Events 
(SE) 
 -0.035 0.117 -0.30 .765 -0.265 0.195 
Pleasurable 
Events (PE) 
 0.298 0.089 3.37 .001 0.125 0.472 
Cannabis 
Quantity 
Between 1.171 0.662 1.77 .077 -0.127 2.470 
Within 0.156 0.057 2.75 .006 0.045 0.267 
Caffeine  0.080 0.066 1.21 .226 -0.049 0.210 
Tobacco  -0.053 0.081 -0.65 .514 -0.212 0.106 
Alcohol  0.160 0.076 2.10 .036 0.011 0.308 
Time  -0.003 0.001 -3.06 .002 -0.005 -0.001 
Random effects 
([co-]variances) 
  Estimate (SE) ICC (%) 95% CI 
 Lower Upper 
Level 1  Intercept 10.444 2.539 79.781 6.485 16.820 
Level 2  Intercept 1.004 0.171 7.667 0.719 1.401 
  Residual 1.643 0.111  1.440 1.875 
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Appendix 33 quantity of cannabis predicting calm states 
 
  
Table 67 
Parameter estimates for multilevel model of states of calm (outcome) as a function of 
schizotypal state, stress, stressful events, pleasurable events, and quantity of 
cannabis consumed 
Fixed effect 
(intercept, slopes) 
 Estimate (SE) Z
 
P
 
95% CI 
 Lower Upper 
Intercept  13.084 0.491 26.64 <.001 12.122 14.047 
SSQ Total  -0.025 0.017 -1.42 .156 -0.058 0.009 
CSQ Stress  -0.552 0.042 12.99 <.001 -0.635 -0.468 
Event Rating (ER)  0.391 0.109 3.60 <.001 0.178 0.605 
Stressful Events 
(SE) 
 -0.568 0.169 -3.35 .001 -0.900 -0.236 
Pleasurable 
Events (PE) 
 0.503 0.127 3.96 <.001 0.254 0.751 
Cannabis 
Quantity 
Between 0.570 0.594 0.96 .337 -0.595 1.736 
Within 0.231 0.083 2.77 .006 0.068 0.394 
Caffeine  -0.028 0.097 -0.29 .772 -0.218 0.162 
Tobacco  -0.373 0.119 -0.31 .753 -0.270 0.195 
Alcohol  0.069 0.111 0.62 .537 -0.150 0.287 
Time  -0.004 0.001 -2.75 .006 -0.006 -0.001 
Random effects 
([co-]variances) 
  Estimate (SE) ICC (%) 95% CI 
 Lower Upper 
Level 1  Intercept 8.102 2.020 59.606 4.888 13.134 
Level 2  Intercept 1.779 0.316 13.233 1.256 2.519 
  Residual 3.651 0.239  3.210 4.152 
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Appendix 34 CEQ-b as a predictor of a schizotypal state 
Table 68 
Parameter estimates for multilevel model of schizotypal state (outcome) as a 
function of states of stress, states of calm, stressful events, pleasurable events, 
cannabis consumption per se, a cannabis -stress interaction, and aversive cannabis 
experiences 
 
Fixed effect (intercept, 
slopes) 
Estimate (SE) Z
 
P
 
95% CI 
Lower Upper 
Intercept 14.337 1.783 8.04 <.001 10.842 17.830 
CSQ Stress 0.403 0.106 3.82 <.001 0.196 0.610 
CSQ Calm -0.099 0.075 -1.32 .186 -0.245 0.048 
Event Rating (ER) -0.076 0.232 -0.33 .743 -0.530 0.378 
Stressful Events (SE) 0.116 0.363 0.32 .748 -0.595 0.827 
Pleasurable Events 
(PE) 
0.716 0.267 2.68 .007 0.191 1.240 
CEQ-b 0.286 0.066 4.32 <.001 0.156 0.416 
Cannabis Consumed 0.940 0.384 2.45 .014 0.188 1.693 
Cannabis X Stress 0.433 0.092 4.69 <.001 0.252 0.613 
Caffeine -0.027 0.202 -0.13 .895 -0.422 0.369 
Tobacco -0.395 0.258 -1.53 .125 -0.901 0.110 
Alcohol -0.118 0.239 -0.49 .623 -0.586 0.351 
Time -0.004 0.003 -1.44 .150 -0.010 0.001 
Random effects ([co-
]variances) 
 Estimate (SE) ICC (%) 
95% CI 
Lower Upper 
Level 1 Intercept 110.735 27.118 84.219 68.523 178.951 
Level 2 Intercept 8.716 1.449 6.629 6.292 12.072 
 Residual 12.033 0.846  10.485 13.811 
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Appendix 35 Time lagged CEQ-b as a predictor of a schizotypal state 
Table 69 
Parameter estimates for multilevel model of schizotypal state (outcome) as a 
function of states of stress, states of calm, stressful events, pleasurable events, 
cannabis consumption per se, a cannabis -stress interaction, and aversive cannabis 
experiences from the previous day  
Fixed effect (intercept, 
slopes) 
Estimate (SE) Z
 
P
 
95% CI 
Lower Upper 
Intercept 13.277 1.807 7.35 <.001 9.735 16.818 
CSQ Stress 0.485 0.117 4.13 <.001 0.255 0.715 
CSQ Calm -0.115 0.084 -1.37 .170 -0.279 0.049 
Event Rating (ER) -0.019 0.268 -0.07 .944 -0.544 0.507 
Stressful Events (SE) -0.307 0.417 -0.74 .462 -1.124 0.510 
Pleasurable Events 
(PE) 
0.410 0.316 1.30 .195 -0.209 1.029 
CEQ-b T-1 0.232 0.057 4.09 <.001 0.121 0.342 
Cannabis Consumed 1.135 0.432 2.63 .009 0.288 1.981 
Cannabis X Stress 0.470 0.097 4.83 <.001 0.279 0.661 
Caffeine -0.028 0.230 -0.12 .903 -0.478 0.422 
Tobacco -0.504 0.300 -1.68 .093 -1.091 0.084 
Alcohol 0.102 0.297 0.34 .732 -0.480 0.684 
Time -0.005 0.003 -1.53 .126 -0.011 0.001 
Random effects ([co-
]variances) 
 Estimate (SE) ICC (%) 95% CI 
Lower Upper 
Level 1 Intercept 109.284 27.721 84.777 66.472 179.670 
Level 2 Intercept 6.895 1.414 5.349 4.613 10.308 
 Residual 12.729 1.001  10.911 14.850 
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Appendix 35 Aversive scale as a predictor of a schizotypal state 
 
 
  
Table 70 
Parameter estimates for multilevel model of schizotypal state (outcome) as a 
function of Aversive cannabis experiences, and cannabis consumption per se  
Fixed effect (intercept, 
slopes) 
Estimate (SE) Z
 
P
 
95% CI 
Lower Upper 
Intercept 14.328 1.957 7.32 <.001 10.492 18.164 
Aversive scale 0.088 0.234 0.37 .708 -0.371 0.547 
Cannabis consumed 0.814 0.357 2.28 .023 0.114 1.514 
Caffeine 0.140 0.198 0.70 .481 -0.249 0.528 
Tobacco 0.097 0.243 0.40 .689 -0.379 0.574 
Alcohol 0.272 0.224 1.21 .225 -0.167 0.710 
Time -0.005 0.003 -1.93 .054 -0.010 0.0001 
Random effects ([co-
]variances) 
 Estimate (SE) ICC (%) 95% CI 
Lower Upper 
Level 1 Intercept 135.050 32.61 82.847 84.131 216.785 
Level 2 Intercept 13.111 1.710 8.043 10.153 16.930 
 Residual 14.851 0.909  13.172 16.744 
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Appendix 36 Internal reliability of the aversive scale 
 
Table 71 
Table displaying internal reliability of aversive cannabis experiences  
 Cronbach’s α if item 
deleted 
 CSCU DD PD 
Out of body experiences .932 .919 .936 
Feeling fearful .929 .910 .935 
Angry .930 .916 .940 
Paranoid .928 .912 .934 
Anxious for no reason .927 .911 .934 
Depressed .928 .913 .937 
Deluded (believing in something which afterwards you knew not to be 
true) 
.931 .914 .934 
Feeling threatened by an unknown force .928 .912 .934 
Sad .929 .914 .937 
Disturbed in your thinking .928 .910 .933 
Nervy .927 .914 .937 
Hearing things other people couldn’t hear (auditory hallucinations) .931 .915 .940 
Having visions (like visual hallucinations) .931 .918 .941 
Things not feeling ‘right’ on your skin or in your body .929 .911 .936 
Losing your sense of reality .930 .912 .938 
Feeling like you no longer know yourself .927 .912 .934 
Fearful that you are going crazy/mad .927 .910 .933 
Paranoid without reason (AE) .927 .911 .933 
Suspicious of people, events or things without reason (AE) .927 .910 .934 
Feeling depersonalised (AE) .928 .915 .935 
 
